"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,GB,B,GB 2598974 B,002-248-413-724-595,2023-02-15,2023,GB 202100477 A,2021-01-14,GB 202014672 A;;GB 202018040 A,2020-09-17,Shoring system for aircraft and the like,,DANIEL COUGHLIN;;SUPPORT AIR LTD,DANIEL COUGHLIN,,https://lens.org/002-248-413-724-595,Granted Patent,no,4,0,7,7,0,B64F1/22;;B64F5/40;;B64F5/40;;B64F5/60,B64F5/40;;B64F5/60,,0,0,,,,ACTIVE
2,DE,B,DE 1022599 B,027-194-117-624-422,1958-01-16,1958,DE D0015897 A,1953-09-07,US 1022599X A,1952-09-09,Halterung fuer einen UEberhitzer mit haengenden Rohrschlangen eines Strahlungsdampferzeugers,,BABCOCK & WILCOX DAMPFKESSEL,COUGHLIN DANIEL,,https://lens.org/027-194-117-624-422,Patent Application,no,3,3,1,1,0,F22B37/20;;F22B37/24;;F22B37/205,,,0,0,,,,DISCONTINUED
3,GB,B,GB 2598973 B,114-342-614-819-672,2022-11-02,2022,GB 202018040 A,2020-11-17,GB 202014672 A,2020-09-17,Shoring system for aircraft and the like,,DANIEL COUGHLIN;;SUPPORT AIR LTD,DANIEL COUGHLIN,,https://lens.org/114-342-614-819-672,Granted Patent,no,5,0,7,7,0,B64F1/22;;B64F5/40;;B64F5/40;;B64F5/60,B64F1/22;;B64F5/10;;B64F5/40,,0,0,,,,ACTIVE
4,GB,A,GB 2598973 A,069-149-076-039-550,2022-03-23,2022,GB 202018040 A,2020-11-17,GB 202014672 A,2020-09-17,Shoring system for aircraft and the like,"A support cradle 200 for an aircraft fuselage shoring system comprises two lateral arm sections 220 hingedly attached to opposing ends of a central cradle section 210. The arm sections swivel between a first position forming a cradle shape and a second position where the arms pivot away from the central section and form a shallower profile. The arm sections 220 may be actuated manually or remotely, with hydraulic, pneumatic or electric drive units, such as pistons. The central section may comprise forklift tine through-holes. Also disclosed is a cradle base unit 100 comprising an adjustable lifting mechanism, having a horizontal support beam 111 with vertically extending guide rails 135 at opposing ends, a cradle support section with legs slidably engaged with the rails, and a central beam with releasable attachment means for engaging with an aircraft cradle. Stackable modular supports (300, Figure 3B) may be installed beneath the cradle.",DANIEL COUGHLIN;;SUPPORT AIR LTD,DANIEL COUGHLIN,,https://lens.org/069-149-076-039-550,Patent Application,no,5,0,7,7,0,B64F1/22;;B64F5/40;;B64F5/40;;B64F5/60,B64F1/22;;B64F5/10;;B64F5/40,,0,0,,,,ACTIVE
5,GB,A,GB 2598974 A,152-125-843-832-86X,2022-03-23,2022,GB 202100477 A,2021-01-14,GB 202014672 A;;GB 202018040 A,2020-09-17,Shoring system for aircraft and the like,"A shoring system for an aircraft comprising a top segment, and at least one lower segment. The plurality of segments are of substantially the same shape and graduated different sizes. The top segment is smallest and bottom segment is largest. The segments are nested within one another in a storage configuration and stacked on top of one another in a deployed configuration. An aircraft support cradle (210, figure 5) is releasably attachable to the top segment (e.g. via a hydraulic piston or driven threaded shaft). Preferably aluminium segments have triangular top and bottom plates. The segments may fit one within another to form a pyramid like structure for compact storage with reduced footprint. Forklift tines may pass through the segments. Two shoring systems may support a single cradle (figure 7).",DANIEL COUGHLIN;;SUPPORT AIR LTD,DANIEL COUGHLIN,,https://lens.org/152-125-843-832-86X,Patent Application,no,4,0,7,7,0,B64F1/22;;B64F5/40;;B64F5/40;;B64F5/60,B64F5/40;;B64F5/60,,0,0,,,,ACTIVE
6,US,A,US 736940 A,078-351-522-876-953,1903-08-25,1903,US 1902/0128610 A,1902-10-24,US 1902/0128610 A,1902-10-24,AUTOMATIC WATER-FEED AND SAFETY APPARATUS FOR STEAM-BOILERS.,,COUGHLIN OWEN JOHN;;COUGHLIN DANIEL,COUGHLIN OWEN JOHN;;COUGHLIN DANIEL,,https://lens.org/078-351-522-876-953,Granted Patent,no,0,0,1,1,0,F22D11/00;;F22D11/00,,,0,0,,,,EXPIRED
7,US,A1,US 2009/0308884 A1,173-291-730-355-855,2009-12-17,2009,US 13710208 A,2008-06-11,US 13710208 A,2008-06-11,Method and Apparatus for Dispensing Treats,A dispensing device that can store a plurality of treats and sequentially release a singe treat is provided. The dispensing device includes a housing and a reservoir in the housing for holding treats to be dispensed. A dispenser is moveable from a first position to a second position to sequentially release treats from the reservoir. An actuating mechanism is provided for actuating the dispenser. The dispensing device also includes a receptacle that is accessible from the exterior of the housing. A passageway is provided for treats to travel from the reservoir to the receptacle.,COUGHLIN DANIEL P;;COUGHLIN MARY C,COUGHLIN DANIEL P;;COUGHLIN MARY C,,https://lens.org/173-291-730-355-855,Patent Application,yes,14,13,1,2,0,G07F11/14;;G07F11/34;;G07F11/44;;G07F11/52;;G07F11/14;;G07F11/44;;G07F11/34;;G07F11/52,G07F11/00;;B65H3/00;;G07F11/42,221/15;;221/265;;221/258;;221/1,0,0,,,,DISCONTINUED
8,US,A1,US 2010/0065577 A1,003-579-403-569-483,2010-03-18,2010,US 60309409 A,2009-10-21,US 60309409 A;;US 13710208 A;;US 10756208 P,2008-06-11,Apparatus for Dispensing Treats,A dispensing device that can store a plurality of treats and sequentially release a single treat is provided. The dispensing device includes a housing and a reservoir in the housing for holding treats to be dispensed. A dispenser is moveable from a first position to a second position to sequentially release treats from the reservoir. The dispensing device also includes a receptacle that is accessible from the exterior of the housing. A passageway is provided for treats to travel from the reservoir to the receptacle.,COUGHLIN DANIEL P;;COUGHLIN MARY C,COUGHLIN DANIEL P;;COUGHLIN MARY C,,https://lens.org/003-579-403-569-483,Patent Application,yes,23,16,1,2,0,G07F11/24;;G07F11/24;;G07F11/32;;G07F11/32;;G07F11/44;;G07F11/44,B65D83/04,221/277,0,0,,,,DISCONTINUED
9,US,A,US 2018839 A,089-387-769-718-424,1935-10-29,1935,US 66518533 A,1933-04-08,US 66518533 A,1933-04-08,Machine for sealing wire in a wooden member,,JAYDEL NOVELTY MANUFACTURERS I,DANIEL COUGHLIN JOSEPH,,https://lens.org/089-387-769-718-424,Granted Patent,no,0,5,1,1,0,B21F45/004;;Y10T29/5343;;Y10T29/5147;;Y10T29/5343;;Y10T29/5147;;B21F45/004,B21F45/00,,0,0,,,,EXPIRED
10,WO,A1,WO 1995/034314 A1,110-361-760-673-235,1995-12-21,1995,US 9507462 W,1995-06-13,US 25977594 A,1994-06-14,A RESIN FOR USE IN SOLID PHASE SYNTHESIS FOR THE PREPARATION OF PEPTIDE HYDRAZIDES,"The present invention is directed to a handle for use on a solid phase resin for peptide synthesis. In particular, the invention relates to a 2-methoxy-4-alkoxy-benzyloxycarbonyl hydrazide handle to provide a useful resin for solid phase synthesis. The handle provides for Fmoc peptide synthesis, followed by cleavage of a side chain-protected petpide hydrazide under mild conditions. The invention further relates to side chain-protected peptide hydrazides, in which the protecting groups are those used in Fmoc synthesis.",CYTOGEN CORP,COUGHLIN DANIEL J,,https://lens.org/110-361-760-673-235,Patent Application,yes,1,1,2,2,0,C07K1/042;;Y02P20/55,C07K1/04,,1,1,034-682-059-103-261,10.1021/jo01295a026,"J. ORG. CHEM., Volume 45, No. 7, issued 1980, WILLIAM F. DeGRADO et al., ""Polymer-Bound Oxime Esters as Supports for Solid-Phase Peptide Synthesis. Preparation of Protected Peptide Fragments"", pages 1295-1300.",PENDING
11,WO,A1,WO 2014/053897 A1,000-051-794-174-651,2014-04-10,2014,IB 2013002162 W,2013-09-30,US 201261708289 P,2012-10-01,METHOD FOR THE PURIFICATION OF DECITABINE,"A method of preparing purified decitabine comprises mixing crude decitabine with solvent, such as dimethylacetamide, to form a solution or suspension and forming the purified decitabine from the solution or suspension. The forming step comprises adding a anti-solvent, such as ethanol, to the solution or suspension. The forming step may further comprise after adding ethanol to provide a mixture of dimethylacetamide and ethanol : cooling the mixture; isolating the solid decitabine present in the cooled mixture; and evaporating residual dimethylacetamide and ethanol from the solid decitabine to provide the purified decitabine. The mixture of dimethylacetamide and ethanol may be heated. The purification method preferably results in decitabine having a ratio of the β-anomer of decitabine to the α-anomer of decitabine of at least about 99.9: 0.1.",JOHNSON MATTHEY PLC,COUGHLIN DANIEL JAMES,,https://lens.org/000-051-794-174-651,Patent Application,yes,6,0,4,4,0,C07H1/06;;C07H1/06;;C07H19/12;;C07H19/12,C07H1/06;;C07H19/12,,0,0,,,,PENDING
12,US,A,US 2757649 A,074-730-973-432-15X,1956-08-07,1956,US 30865152 A,1952-09-09,US 30865152 A,1952-09-09,Fluid heater with guided convection elements,,BABCOCK & WILCOX CO,COUGHLIN DANIEL T,,https://lens.org/074-730-973-432-15X,Granted Patent,no,7,13,1,1,0,F22B37/202;;F22B37/202,F22B37/20,,0,0,,,,EXPIRED
13,US,A1,US 2016/0168182 A1,010-880-136-217-219,2016-06-16,2016,US 201615053549 A,2016-02-25,US 201615053549 A;;US 201314041562 A;;US 201261708289 P,2012-10-01,METHOD FOR THE PURIFICATION OF DECITABINE,"A method of preparing purified decitabine comprises mixing crude decitabine with solvent, such as dimethylacetamide, to form a solution or suspension and forming the purified decitabine from the solution or suspension. The forming step comprises adding an anti-solvent, such as ethanol, to the solution or suspension. The forming step may further comprise after adding ethanol to provide a mixture of dimethylacetamide and ethanol: cooling the mixture; isolating the solid decitabine present in the cooled mixture; and evaporating residual dimethylacetamide and ethanol from the solid decitabine to provide the purified decitabine. The mixture of dimethylacetamide and ethanol may be heated. The purification method preferably results in decitabine having a ratio of the β-anomer of decitabine to the α-anomer of decitabine of at least about 99.9:0.1.",JOHNSON MATTHEY PLC,COUGHLIN DANIEL JAMES,JOHNSON MATTHEY PUBLIC LIMITED COMPANY (2012-10-23);;MACFARLAN SMITH LIMITED (2022-09-30),https://lens.org/010-880-136-217-219,Patent Application,yes,0,0,4,4,0,C07H1/06;;C07H1/06;;C07H19/12;;C07H19/12,C07H1/06;;C07H19/12,,0,0,,,,ACTIVE
14,US,A1,US 2014/0094598 A1,097-410-354-320-361,2014-04-03,2014,US 201314041562 A,2013-09-30,US 201314041562 A;;US 201261708289 P,2012-10-01,METHOD FOR THE PURIFICATION OF DECITABINE,"A method of preparing purified decitabine comprises mixing crude decitabine with solvent, such as dimethylacetamide, to form a solution or suspension and forming the purified decitabine from the solution or suspension. The forming step comprises adding an anti-solvent, such as ethanol, to the solution or suspension. The forming step may further comprise after adding ethanol to provide a mixture of dimethylacetamide and ethanol: cooling the mixture; isolating the solid decitabine present in the cooled mixture; and evaporating residual dimethylacetamide and ethanol from the solid decitabine to provide the purified decitabine. The mixture of dimethylacetamide and ethanol may be heated. The purification method preferably results in decitabine having a ratio of the β-anomer of decitabine to the α-anomer of decitabine of at least about 99.9:0.1.",JOHNSON MATTHEY PLC,COUGHLIN DANIEL JAMES,JOHNSON MATTHEY PUBLIC LIMITED COMPANY (2014-01-28),https://lens.org/097-410-354-320-361,Patent Application,yes,1,0,4,4,0,C07H1/06;;C07H1/06;;C07H19/12;;C07H19/12,C07H1/06;;C07H19/12,536/28.3,0,0,,,,DISCONTINUED
15,US,B2,US 10011626 B2,108-271-489-507-262,2018-07-03,2018,US 201615053549 A,2016-02-25,US 201615053549 A;;US 201314041562 A;;US 201261708289 P,2012-10-01,Method for the purification of decitabine,"A method of preparing purified decitabine comprises mixing crude decitabine with solvent, such as dimethylacetamide, to form a solution or suspension and forming the purified decitabine from the solution or suspension. The forming step comprises adding an anti-solvent, such as ethanol, to the solution or suspension. The forming step may further comprise after adding ethanol to provide a mixture of dimethylacetamide and ethanol: cooling the mixture; isolating the solid decitabine present in the cooled mixture; and evaporating residual dimethylacetamide and ethanol from the solid decitabine to provide the purified decitabine. The mixture of dimethylacetamide and ethanol may be heated. The purification method preferably results in decitabine having a ratio of the β-anomer of decitabine to the α-anomer of decitabine of at least about 99.9:0.1.",JOHNSON MATTHEY PLC,COUGHLIN DANIEL JAMES,JOHNSON MATTHEY PUBLIC LIMITED COMPANY (2012-10-23);;MACFARLAN SMITH LIMITED (2022-09-30),https://lens.org/108-271-489-507-262,Granted Patent,yes,8,0,4,4,0,C07H1/06;;C07H1/06;;C07H19/12;;C07H19/12,C07H1/06;;C07H19/12,,1,0,,,"International Search Report for International Application No. PCT/IB2013/002162 dated Dec. 12, 2013 and Written Opinion.",ACTIVE
16,GB,A,GB 191412023 A,019-097-192-809-473,1914-07-09,1914,GB 191412023D A,1914-05-15,GB 191412023T A,1914-05-15,Improvements in Egg Beaters and the like.,"12,023. Coughlin, J. D. May 15. Egg-beaters.-A device for beating eggs and for like operations comprises a perforated base-plate 10 and a beater 21 formed as a conical helix with perforations and projections. The beater 21 is carried by a spindle 13 journaled in the plate 10. The lower part of the spindle 13 is threaded to receive a nut to secure the beater 21, and the upper part is square. The topmost part of the spindle 13 is twisted so as to serve as a screw and be rotated by reciprocating the handle 15. The handle 15 is attached to the spindle 13 by means of a spring 17, which normally retains the handle at the top of the spindle.",COUGHLIN JOSEPH DANIEL,COUGHLIN JOSEPH DANIEL,,https://lens.org/019-097-192-809-473,Patent Application,no,0,0,1,1,0,A47J43/1068,A47J43/10,,0,0,,,,DISCONTINUED
17,CA,A,CA 413775 A,048-444-101-395-515,1943-07-13,1943,CA 413775D A,,CA 413775T A,,CUTTING TOOL HOLDER,,COUGHLIN DANIEL JOSEF,COUGHLIN DANIEL JOSEF,,https://lens.org/048-444-101-395-515,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
18,CA,A,CA 542629 A,061-342-731-988-140,1957-06-25,1957,CA 542629D A,,CA 542629T A,,FLUID HEATER WITH GUIDED CONVECTION ELEMENTS,,BABCOCK WILCOX & GOLDIE MCCULL,COUGHLIN DANIEL T,,https://lens.org/061-342-731-988-140,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
19,US,A,US 2345462 A,186-832-675-295-335,1944-03-28,1944,US 42002541 A,1941-11-21,SE 553968X A,1940-11-29,Cutting tool holder,,JOSEF COUGHLIN DANIEL,JOSEF COUGHLIN DANIEL,,https://lens.org/186-832-675-295-335,Granted Patent,no,0,3,2,2,0,B23C5/24;;Y10T407/28;;Y10T407/191;;Y10T407/1914;;Y10T408/907;;Y10T279/17;;B23B31/1078;;Y10T407/28;;Y10T407/191;;Y10T407/1914;;Y10T408/907;;Y10T279/17;;B23C5/24;;B23B31/1078,B23B31/02;;B23C5/24,,0,0,,,,EXPIRED
20,US,A,US 1437723 A,142-816-408-501-281,1922-12-05,1922,US 42008920 A,1920-10-28,US 42008920 A,1920-10-28,Theftproof electric-light bulb,,COUGHLIN DANIEL R,COUGHLIN DANIEL R,,https://lens.org/142-816-408-501-281,Granted Patent,no,0,4,1,1,0,H01K9/02;;F16B2200/69;;H01K9/02;;F16B2200/69,H01K9/02,,0,0,,,,EXPIRED
21,US,A1,US 2009/0021394 A1,044-089-141-137-212,2009-01-22,2009,US 4584308 A,2008-03-11,US 4584308 A;;US 95113607 P,2007-07-20,ALTAVIEW SYSTEM,"Telemetry signals and biometric telemetry signals are wirelessly transmitted from an athlete, driver, or other person over an audio/video link. The measurement stream from a sensor can be modulated and then fed into a transmitter's audio input or video input. The transmitter transmits a signal containing the measurement stream as well as audio and video streams. A demodulator recovers the measurement stream output by a receiver receiving the signal. The recovered measurement signal can then be passed to an interested party. For example, a heart rate measurement can be obtained from a driver or other athlete and displayed to a television audience.",COUGHLIN DANIEL J,COUGHLIN DANIEL J,,https://lens.org/044-089-141-137-212,Patent Application,yes,7,4,1,1,0,H04Q9/00;;H04Q9/00,H04Q9/00,340/870.07,0,0,,,,DISCONTINUED
22,US,A,US 1793160 A,021-267-589-693-174,1931-02-17,1931,US 24413528 A,1928-01-03,US 24413528 A,1928-01-03,Combination oil can and flash light,,FRENCH BATTERY COMPANY,COUGHLIN DANIEL R,,https://lens.org/021-267-589-693-174,Granted Patent,no,0,8,1,1,0,F16N3/04;;F21L4/005;;F16N3/04;;F21L4/005,F16N3/04,,0,0,,,,EXPIRED
23,AU,A,AU 1995/029021 A,104-108-021-867-136,1996-01-05,1996,AU 1995/029021 A,1995-06-13,US 25977594 A;;US 9507462 W,1994-06-14,A resin for use in solid phase synthesis for the preparation of peptide hydrazides,,CYTOGEN CORP,COUGHLIN DANIEL J,,https://lens.org/104-108-021-867-136,Patent Application,no,0,0,2,2,0,C07K1/042;;Y02P20/55,C07K1/04,,0,0,,,,PENDING
24,CA,A,CA 256050 A,115-773-816-220-036,1925-12-08,1925,CA 256050D A,,CA 256050T A,,THEFTPROOF ELECTRIC LIGHT BULB,,COUGHLIN DANIEL R,COUGHLIN DANIEL R,,https://lens.org/115-773-816-220-036,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
25,DE,D1,DE 69313272 D1,107-508-892-450-047,1997-09-25,1997,DE 69313272 T,1993-04-08,US 86637592 A;;US 9303208 W,1992-04-09,SUBSTITUIERTE THIOHARNSTOFFE ALS BIFUNKTIONELLE CHELATOREN,"PCT No. PCT/US93/03208 Sec. 371 Date Jun. 27, 1994 Sec. 102(e) Date Jun. 27, 1994 PCT Filed Apr. 8, 1993 PCT Pub. No. WO93/21151 PCT Pub. Date Oct. 28, 1993This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.",CYTOGEN CORP,COUGHLIN DANIEL;;BELINKA BENJAMIN,,https://lens.org/107-508-892-450-047,Granted Patent,no,0,0,12,12,0,A61K51/088;;A61K51/1093;;A61K2121/00;;A61K2123/00;;C07C335/22;;C07C337/06;;C07D207/452;;C07D213/71;;A61K51/082;;A61K47/50;;C07D207/452;;C07C335/22;;A61K2123/00;;C07D213/71;;A61K2121/00;;C07C337/06;;A61K51/1093;;A61K51/088;;A61K51/082;;A61K47/50,G01N33/58;;A61K39/44;;A61K47/48;;A61K51/00;;A61K51/08;;A61K51/10;;C07C335/06;;C07C335/14;;C07C335/16;;C07C335/22;;C07C337/06;;C07D207/44;;C07D207/452;;C07D213/34;;C07D213/71;;C09K3/00,,0,0,,,,EXPIRED
26,WO,A1,WO 2023/100110 A1,125-644-974-335-447,2023-06-08,2023,IB 2022061610 W,2022-11-30,US 202163264816 P,2021-12-02,PROCESS FOR PREPARING BRIVARACETAM,"The present invention is directed to a novel compound, (4R)-1-((S)-1-carboxypropyl)-2-oxo-4-propylpyrrolidine-3-carboxylic acid, which can be used as an intermediate in the preparation of brivaracetam. The invention is also directed to a process of preparing (4R)-1-((S)-1-carboxypropyl)-2-oxo-4-propylpyrrolidine-3-carboxylic acid. Further, the invention is directed to a process of preparing (S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanoic acid from (4R)-1-((S)-1-carboxypropyl)-2-oxo-4-propylpyrrolidine-3-carboxylic acid. (S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanoic acid can also be used in a process of preparing brivaracetam.",MACFARLAN SMITH LTD,COUGHLIN DANIEL;;WILT JEREMY,,https://lens.org/125-644-974-335-447,Patent Application,yes,6,0,1,1,0,C07D207/277;;C07D207/27,C07D207/277;;C07D207/27,,1,0,,,"KENDA ET AL., J. MED. CHEM., vol. 47, 2004, pages 530",PENDING
27,DE,T2,DE 69313272 T2,008-591-474-088-12X,1998-04-02,1998,DE 69313272 T,1993-04-08,US 86637592 A;;US 9303208 W,1992-04-09,SUBSTITUIERTE THIOHARNSTOFFE ALS BIFUNKTIONELLE CHELATOREN,"PCT No. PCT/US93/03208 Sec. 371 Date Jun. 27, 1994 Sec. 102(e) Date Jun. 27, 1994 PCT Filed Apr. 8, 1993 PCT Pub. No. WO93/21151 PCT Pub. Date Oct. 28, 1993This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.",CYTOGEN CORP,COUGHLIN DANIEL;;BELINKA BENJAMIN,,https://lens.org/008-591-474-088-12X,Granted Patent,no,0,0,12,12,0,A61K51/088;;A61K51/1093;;A61K2121/00;;A61K2123/00;;C07C335/22;;C07C337/06;;C07D207/452;;C07D213/71;;A61K51/082;;A61K47/50;;C07D207/452;;C07C335/22;;A61K2123/00;;C07D213/71;;A61K2121/00;;C07C337/06;;A61K51/1093;;A61K51/088;;A61K51/082;;A61K47/50,G01N33/58;;A61K39/44;;A61K47/48;;A61K51/00;;A61K51/08;;A61K51/10;;C07C335/06;;C07C335/14;;C07C335/16;;C07C335/22;;C07C337/06;;C07D207/44;;C07D207/452;;C07D213/34;;C07D213/71;;C09K3/00,,0,0,,,,EXPIRED
28,CA,A,CA 98323 A,181-675-254-469-394,1906-04-03,1906,CA 98323D A,1906-02-19,CA 98323T A,1906-02-19,CORK SCREW,,COUGHLIN JOSEPH DANIEL;;MCGRATH FREDERICK,COUGHLIN JOSEPH DANIEL;;MCGRATH FREDERICK,,https://lens.org/181-675-254-469-394,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
29,AT,B,AT 101560 B,189-143-908-577-647,1925-11-10,1925,AT 101560D A,1924-05-14,AT 101560T A,1924-05-14,Sicherung für elektrische Lampen gegen Diebstahl.,,KULP LESTER;;COUGHLIN DANIEL RICHARD,KULP LESTER;;COUGHLIN DANIEL RICHARD,,https://lens.org/189-143-908-577-647,Granted Patent,no,0,1,1,1,0,,,21F,0,0,,,,EXPIRED
30,GB,A,GB 190604452 A,123-252-649-746-423,1906-04-12,1906,GB 190604452D A,1906-02-23,GB 190604452T A,1906-02-23,Improvements in and relating to Cork-screws.,"4452. Coughlin, J. D., and McGrath, F. Feb. 23. Corkscrews; opening bottles &c. -Relates to corkscrews, particularly those adapted for advertising purposes. The corkscrew blank, Fig. 1, is stamped from flat metal, the tail portion 4 being at an angle with the head. This tail piece is coiled about the line a-a to form the screw. The head is formed with a thin edge 8 for removing crown corks, and with a pointed tip 9 for removing loops. In a modification, the head of the corkscrew is made cylindrical, being rolled from a rectangular blank. The screw portions of the corkscrews are provided with wooden sheaths, and advertising matter is placed on the sheaths and on the heads.",COUGHLIN JOSEPH DANIEL;;MCGRATH FREDERICK,COUGHLIN JOSEPH DANIEL;;MCGRATH FREDERICK,,https://lens.org/123-252-649-746-423,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
31,FR,A,FR 582149 A,131-729-660-557-880,1924-12-12,1924,FR 582149D A,1924-05-10,US 582149X A,1923-12-26,Perfectionnements aux dispositifs de verrouillage pour lampes électriques,,,KULP LESTER;;COUGHLIN DANIEL RICHARD,,https://lens.org/131-729-660-557-880,Granted Patent,no,0,0,2,2,0,H01K1/465,H01K1/46,,0,0,,,,EXPIRED
32,US,H,US H0001312 H,163-956-953-634-780,1994-05-03,1994,US 89051992 A,1992-05-28,US 89051992 A,1992-05-28,Method for the preparation of gyk-dtpa,"Disclosed herein is a novel method for preparing a DPTA tripeptide-chelator. In particular, a method for preparing GYK-DTPA is described. The method disclosed herein is an improvement over the known methods of preparation based on the cost and labor savings of the present invention. The present invention utilizes t-butyloxycarbonyl (Boc) protecting groups to facilitate the polypeptide-chelator production.",CYTOGEN CORPORATION,COUGHLIN DANIEL J;;WOOD RICHARD,CYTOGEN CORPORATION (1992-07-20),https://lens.org/163-956-953-634-780,Statutory Invention Registration,yes,10,24,1,1,0,C07K5/0806;;Y02P20/55;;C07K5/0806;;Y02P20/55,C07K5/083,530/331;;530/345,7,0,,,"Bodanszky, Int. J. Protein Res. (25) 449-474 (1985).;;Alvarez et al., Antibody-Mediated Delivery Systems, John D. Rodwell, Ed., Marcel Dekker, Inc., New York, ch. 10. pp. 306-309 (1988).;;Hnatowich et al., ""The Preparation and Labeling of DTPA-Coupled Albumin"", Int. J. Appl. Radiat. Isot. 33:327-332 (1982).;;Krejcarek et al., ""Covalent Attachment of Chelating Groups to Macromolecules"", Biochem. Biophys. Res. Comm. 77:581 (1977).;;Scheinberg et al., ""Tumor Imaging With Radioactive Metal Chelates Conjugated to Monoclonal Antibodies"", Sci. 215:1511-1513 (1982).;;Sundberg et al., ""Selective Binding of Metal Ions to Macromolecules Using Bifunctional Analogs of EDTA"", J. Med. Chem. 17:1304 (1974).;;Yeh et al., ""Decomposition Rates of Radiopharmaceutical Indium Chelates in Serum"", J. Radioanalytical Chem. 53:327 (1979).",EXPIRED
33,PH,A,PH 31639 A,077-160-474-561-050,1999-01-12,1999,PH 49252 A,1994-10-27,US 14559193 A,1993-11-04,Non-alkaline purification of aminophosphonic acids.,"A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100% are thus obtained.",CYTOGEN CORP,BELINKA BENJAMIN A;;COUGHLIN DANIEL J,,https://lens.org/077-160-474-561-050,Granted Patent,no,0,0,15,15,0,C07F9/025;;C07F9/3817;;C07F9/6524;;C07F9/6524;;C07F9/025;;C07F9/3817,C07F9/02;;C07F9/38;;C07D255/02;;C07F9/6524,,0,0,,,,EXPIRED
34,WO,A1,WO 2021/195671 A1,038-386-480-236-622,2021-09-30,2021,US 2021/0070320 W,2021-03-26,US 202063000931 P,2020-03-27,PROCESS FOR PREPARING TRIENTINE DIHYDROCHLORIDE,The present invention relates to a process for preparing trientine dihydrochloride as an active pharmaceutical ingredient (API). The present invention relates to a process for the preparation of trientine dihydrochloride with a pharmaceutical grade of purity. The invention also relates to novel intermediates used in the preparation of trientine dihydrochloride.,JOHNSON MATTHEY PLC;;COUGHLIN DANIEL J,COUGHLIN DANIEL J;;WILT JEREMY C,,https://lens.org/038-386-480-236-622,Patent Application,yes,1,0,2,2,0,C07C269/08;;C07C209/68;;C07C209/68,C07C209/68;;C07C211/13;;C07C269/08;;C07C271/20,,0,0,,,,PENDING
35,AU,A,AU 1994/078317 A,167-908-937-249-62X,1995-05-23,1995,AU 1994/078317 A,1994-09-15,US 14559193 A;;US 9410106 W,1993-11-04,Non-alkaline purification of aminophosphonic acids,"A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100% are thus obtained.",CYTOGEN CORP,BELINKA BENJAMIN A;;COUGHLIN DANIEL J,,https://lens.org/167-908-937-249-62X,Patent Application,no,0,0,15,15,0,C07F9/025;;C07F9/3817;;C07F9/6524;;C07F9/6524;;C07F9/025;;C07F9/3817,C07D255/02;;C07F9/02;;C07F9/38;;C07F9/6524,,0,0,,,,PENDING
36,WO,B1,WO 2007/145681 B1,142-163-684-626-616,2008-06-12,2008,US 2007/0003816 W,2007-02-09,US 45257206 A,2006-06-14,INFLATION NEEDLE,"An inflation needle for inflating an object such as a sports ball includes a tubular body having an attachment end configured for engagement with a fluid supply. The body fairs into a tubular probe extending along a longitudinal axis from a proximal end to a distal end configured for being inserted into the ball. A concavo-convex base extends radially outward from the body and towards the distal end, terminating at a periphery spaced radially from the probe, the base being configured to engage the object upon insertion of the probe therein. The inflation needle is a unitary, molded polymeric component.",VOORHIES PATRICIA COUGHLIN;;MARLOWE DANIEL R,VOORHIES PATRICIA COUGHLIN;;MARLOWE DANIEL R,,https://lens.org/142-163-684-626-616,Patent Application,no,0,0,7,9,0,A63B41/12;;A63B41/12;;Y10T29/494;;Y10T29/494;;Y10T137/3724;;Y10T137/3724,B65B1/04,,0,0,,,,PENDING
37,CN,A,CN 101208314 A,040-032-043-658-927,2008-06-25,2008,CN 200680023047 A,2006-04-26,US 2006/0016059 W;;US 67520205 P,2005-04-26,Benzisoxazole piperazine compounds and methods of use thereof,,HYPNION INC,DANIEL COUGHLIN;;KAZUMI SHIOSAKI;;MICHAEL SOLOMON,,https://lens.org/040-032-043-658-927,Patent Application,no,0,1,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,ACTIVE
38,US,A1,US 2003/0232583 A1,185-635-736-032-602,2003-12-18,2003,US 17287302 A,2002-06-14,US 17287302 A,2002-06-14,Apparatus for superpolishing the inside surface of a seam of a continuous photoreceptor belt,"
   Apparatus is provided for superpolishing the inside diameter surface of a seam of a flexible continuous photoreceptor belt. The apparatus includes (a) spaced apart support rollers for supporting the inside surface of the flexible continuous photoreceptor belt into a loop having strands, including a seam strand, between adjacent rollers; (b) a polishing machine mounted adjacent the seam strand, the polishing machine having: (i) polishing forms defining a path for the seam strand; (ii) a rotatable drum for supporting and carrying a polishing media material against the inside surface of the seam on the seam strand, (iii) sets of pinch rolls for clamping the seam strand and straddling the seam thereon; (iv) polishing media material mounted over the rotatable drum and through the path between the polishing forms for contacting the inside surface of the seam; and (v) a reciprocating superpolishing head for reciprocating relative to a width of the flexible continuous belt and a length of the seam, thereby simultaneously (x) reciprocating the superpolishing head in contact with the inside surface of the seam along the length thereof, (y) moving the seam with the sets of pinch rolls, and (z) rotating the drum for move the polishing media material in polishing contact with the inside surface of the seam and across a width of the seam to achieve required random superpolishing motion against the inside surface of the seam. 
",XEROX CORP,MASTRO PAUL F;;COUGHLIN DANIEL L,XEROX CORPORATION (2002-06-11),https://lens.org/185-635-736-032-602,Patent Application,yes,8,0,2,2,0,B24B21/02;;B24B35/00;;B29C66/032;;B29C66/2272;;B29L2031/709;;B29L2031/764;;G03G5/10;;B29C65/56;;B29C66/1142;;B29C66/4322;;B29C66/4324;;B29C66/49;;B29C66/032;;B24B21/02;;B29L2031/764;;B24B35/00;;B29C66/2272;;B29L2031/709;;G03G5/10;;B29C66/1142;;B29C66/4322;;B29C66/4324;;B29C65/56;;B29C66/49,B24B21/02;;B24B35/00;;B29C65/00;;G03G5/10,451/109;;156/502;;156/154,0,0,,,,EXPIRED
39,US,A,US 5140104 A,133-139-851-007-550,1992-08-18,1992,US 42637489 A,1989-10-24,US 42637489 A;;US 35631582 A;;US 65037584 A;;US 86103786 A,1982-03-09,Amine derivatives of folic acid analogs,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;RODWELL JOHN D,,https://lens.org/133-139-851-007-550,Granted Patent,yes,29,131,1,90,0,A61K41/0042;;A61K41/0042;;A61K41/0057;;A61K41/0057;;A61K47/68;;A61K47/68;;A61K47/6803;;A61K47/6803;;A61K47/6889;;A61K47/6889;;A61K51/10;;A61K51/10;;A61K51/1093;;A61K51/1093;;A61K2121/00;;A61K2121/00;;C07K5/0804;;C07K5/0804;;G01N33/531;;G01N33/531;;G01N33/54353;;G01N33/54353,A61K41/00;;A61K47/48;;A61K51/10;;C07K5/083;;G01N33/531;;G01N33/543,530/330;;544/260,39,32,097-106-737-528-892;;035-365-737-785-474;;030-695-376-183-100;;031-542-023-008-39X;;138-049-764-544-270;;058-248-900-440-161;;006-530-116-700-399;;162-766-551-165-818;;029-355-433-223-855;;075-889-605-642-840;;133-572-190-866-899;;053-977-872-012-335;;034-144-941-661-246;;013-367-834-212-265;;016-132-221-527-857;;053-367-492-376-059;;015-905-644-328-679;;037-576-359-715-69X;;044-471-993-527-613;;032-327-260-001-487;;112-350-446-844-955;;026-239-711-372-07X;;037-987-949-965-097;;038-699-074-248-473;;090-802-635-099-729;;100-521-187-523-433;;006-392-791-860-123;;061-708-320-333-821;;055-631-723-799-490;;039-266-207-397-847;;008-338-316-745-754;;118-897-675-236-176,10.1021/jm50001a021;;3872941;;10.1021/jm00137a016;;6787199;;10.1021/jm00144a016;;6796689;;6467187;;7248938;;7057425;;10.1021/jm00344a018;;6836297;;10.1126/science.6836297;;7397692;;5353111;;10.1021/bi00839a042;;7207595;;10.1038/290145a0;;7217674;;10.1021/bi00690a015;;241376;;10.1016/s0021-9258(18)70223-8;;13641238;;10.1126/science.6115471;;6115471;;10.1093/jnci/61.3.657;;80453;;6996002;;10.1016/0163-7258(80)90010-8;;10.1038/265407a0;;834290;;6163457;;10.1016/0005-2736(81)90532-0;;10.1016/s0021-9258(19)70595-x;;7410345;;10.1002/ijc.2910240414;;393637;;10.1002/0471264180.or002.08;;10.1016/s0021-9258(17)30016-9;;571437;;7442804;;10.1038/288602a0;;7284322;;10.1021/bi00517a043;;6185591;;10.4049/jimmunol.130.3.1473;;10.1021/ja00505a043;;365720;;10.1016/0161-5890(78)90003-2;;7252257;;10.1111/1523-1747.ep12479235;;7023363;;10.1146/annurev.bi.50.070181.002245;;10.1042/bj1630219;;869924;;pmc1164687;;196922;;10.1016/0014-5793(77)80423-7;;10.1016/0165-2478(84)90008-7;;6394473,"Chemical Abstracts, (No.: 33729n), 1989.;;Rosowsky et al., J. Med. Chem., 23: (5), pp. 660 667 (1985).;;Rosowsky et al., J. Med. Chem., 24: (5), pp. 559 567 (1981).;;Rosowsky et al., J. Med. Chem., 24: (12), pp. 1450 1455 (1981).;;Burnstein et al., J. Med. Chem., 20: (7), pp. 950 956 (1977).;;Uadia et al., Cancer Research, 44: pp. 4263 4266 (1984).;;Kulkarni et al., Cancer Research, 41: pp. 2700 2706 (1981).;;Piper et al., J. Med. Chem., 25: (2), pp. 182 187 (1982).;;Anderson and Parrish, Science, 220:524 527 (1983).;;Bale et al., Cancer Research, 40:2965 2972 (1980).;;Bing, Biochemistry, 8:4503 4510 (1969).;;Blythman et al., Nature, 290: 145 146 (1981).;;Bunton, in Oxidation in Organic Chemistry, vol. I, Widberg, ed., Academic Press, New York, p. 365 (1965).;;Caporale et al., J. Immunol., 126:1963 1965 (1981).;;Cooper, Biochemistry, 14:4245 4251 (1975).;;Cooper et al., J. Biol. Chem., 234:445 448 (1959).;;Davis and Preston, Science, 213:1358 1388 (1981).;;Dougherty et al., in Porphyrin Photosensitization, Kessel and Dougherty eds., Plenum Publishing Corp., N.Y., pp. 3 13 (1983).;;Ghose et al., J. Natl. Cancer Inst., 61(3):657 676 (1978).;;Gregoriadis, Pharmac. Ther., 10:103 118 (1980).;;Gregoriadis, Nature, 265:407 411 (1977).;;Heath et al., Biochim Biophys. Acta., 640:66 81 (1981).;;Huang et al., J. Biol. Chem., 255(17):8015 8018 (1980).;;Hurwitz et al., Int. J. Cancer, 24:461 470 (1979).;;Jackson, Periodic Acid Oxidations in Organic Reactions, vol., pp. 341 375 (1944).;;Jentoff and Dearborn, J. Biol. Chem., 254:4359 4365 (1979).;;Lesserman et al., Nature, 288:602 604 (1980).;;March, in Advanced Organic Chemistry: Reactions; Mechanisms and Structures, McGraw Hill Co., N.Y., pp. 824 825 (1978).;;Martin et al., Biochem., 20:4229 4238 (1981).;;Mew et al., J. Immunol., 130:1473 1477 (1983).;;Mitra and Lawton, J. Amer. Chem. Soc., 101:3097 3110 (1979).;;Murayama et al., Immunochem., 15:523 528 (1978).;;Parrish, J. Investig. Dermatol., 77:45 50 (1981).;;Reid and Porter, Ann. Rev. Biochem., 50:433 464 (1981).;;Rowland, in Targeted Drugs, Goldberg ed., Interscience Publications, N.Y., pp. 57 72 (1983).;;Sims et al., Biochem. J., 163:219 227 (1977).;;Stanworth and Turner, in Handbook of Experimental Immunology, vol. I, 2d ed. Weir, ed. Blackwell Scientific Publications, London, Chapter 10 (1973).;;Willan et al., FEBS Lett., 80:133 136 (1977).;;O Shannessy et al., 1984, Immunology Lett., 8:273 277.",EXPIRED
40,US,A1,US 2023/0192591 A1,130-994-264-939-992,2023-06-22,2023,US 202117907512 A,2021-03-26,US 202117907512 A;;US 202063000931 P;;US 2021/0070320 W,2020-03-27,PROCESS FOR PREPARING TRIENTINE DIHYDROCHLORIDE,The present invention relates to a process for preparing trientine dihydrochloride as an active pharmaceutical ingredient (API). The present invention relates to a process for the preparation of trientine dihydrochloride with a pharmaceutical grade of purity. The invention also relates to novel intermediates used in the preparation of trientine dihydrochloride.,COUGHLIN DANIEL J;;MACFARLAN SMITH LTD,COUGHLIN DANIEL J;;WILT JEREMY C,,https://lens.org/130-994-264-939-992,Patent Application,yes,0,0,2,2,0,C07C269/08;;C07C209/68;;C07C209/68,C07C209/68,,0,0,,,,PENDING
41,WO,A3,WO 2007/145681 A3,075-799-245-488-173,2008-04-24,2008,US 2007/0003816 W,2007-02-09,US 45257206 A,2006-06-14,INFLATION NEEDLE,"An inflation needle for inflating an object such as a sports ball includes a tubular body having an attachment end configured for engagement with a fluid supply. The body fairs into a tubular probe extending along a longitudinal axis from a proximal end to a distal end configured for being inserted into the ball. A concavo-convex base extends radially outward from the body and towards the distal end, terminating at a periphery spaced radially from the probe, the base being configured to engage the object upon insertion of the probe therein. The inflation needle is a unitary, molded polymeric component.",VOORHIES PATRICIA COUGHLIN;;MARLOWE DANIEL R,VOORHIES PATRICIA COUGHLIN;;MARLOWE DANIEL R,,https://lens.org/075-799-245-488-173,Search Report,yes,3,0,7,9,0,A63B41/12;;A63B41/12;;Y10T29/494;;Y10T29/494;;Y10T137/3724;;Y10T137/3724,B65B1/04,,0,0,,,,PENDING
42,WO,A2,WO 2007/145681 A2,061-918-266-892-643,2007-12-21,2007,US 2007/0003816 W,2007-02-09,US 45257206 A,2006-06-14,INFLATION NEEDLE,"An inflation needle for inflating an object such as a sports ball includes a tubular body having an attachment end configured for engagement with a fluid supply. The body fairs into a tubular probe extending along a longitudinal axis from a proximal end to a distal end configured for being inserted into the ball. A concavo-convex base extends radially outward from the body and towards the distal end, terminating at a periphery spaced radially from the probe, the base being configured to engage the object upon insertion of the probe therein. The inflation needle is a unitary, molded polymeric component.",VOORHIES PATRICIA COUGHLIN;;MARLOWE DANIEL R,VOORHIES PATRICIA COUGHLIN;;MARLOWE DANIEL R,,https://lens.org/061-918-266-892-643,Patent Application,yes,0,1,7,9,0,A63B41/12;;A63B41/12;;Y10T29/494;;Y10T29/494;;Y10T137/3724;;Y10T137/3724,F15B1/08,,0,0,,,,PENDING
43,EP,A4,EP 0724576 A4,172-336-318-814-140,1997-02-12,1997,EP 94929152 A,1994-09-15,US 9410106 W;;US 14559193 A,1993-11-04,NON-ALKALINE PURIFICATION OF AMINOPHOSPHONIC ACIDS,"A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100% are thus obtained.",CYTOGEN CORP,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J,,https://lens.org/172-336-318-814-140,Search Report,no,4,0,15,15,0,C07F9/025;;C07F9/3817;;C07F9/6524;;C07F9/6524;;C07F9/025;;C07F9/3817,C07D255/02;;C07F9/02;;C07F9/38;;C07F9/6524,,0,0,,,,EXPIRED
44,AT,T1,AT E214705 T1,032-906-080-308-824,2002-04-15,2002,AT 94929152 T,1994-09-15,US 14559193 A;;US 9410106 W,1993-11-04,NICHTALKALISCHE REINIGUNG VON AMINOPHOSPHONSÄUREN,"A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100% are thus obtained.",CYTOGEN CORP,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J,,https://lens.org/032-906-080-308-824,Granted Patent,no,0,0,15,15,0,C07F9/025;;C07F9/3817;;C07F9/6524;;C07F9/6524;;C07F9/025;;C07F9/3817,C07D255/02;;C07F9/02;;C07F9/38;;C07F9/6524,,0,0,,,,DISCONTINUED
45,AT,T1,AT E157084 T1,106-209-423-202-888,1997-09-15,1997,AT 93911594 T,1993-04-08,US 86637592 A,1992-04-09,SUBSTITUIERTE THIOHARNSTOFFE ALS BIFUNKTIONELLE CHELATOREN,"PCT No. PCT/US93/03208 Sec. 371 Date Jun. 27, 1994 Sec. 102(e) Date Jun. 27, 1994 PCT Filed Apr. 8, 1993 PCT Pub. No. WO93/21151 PCT Pub. Date Oct. 28, 1993This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.",CYTOGEN CORP,COUGHLIN DANIEL J;;BELINKA BENJAMIN A JR,,https://lens.org/106-209-423-202-888,Granted Patent,no,0,0,12,12,0,A61K51/088;;A61K51/1093;;A61K2121/00;;A61K2123/00;;C07C335/22;;C07C337/06;;C07D207/452;;C07D213/71;;A61K51/082;;A61K47/50;;C07D207/452;;C07C335/22;;A61K2123/00;;C07D213/71;;A61K2121/00;;C07C337/06;;A61K51/1093;;A61K51/088;;A61K51/082;;A61K47/50,G01N33/58;;A61K39/44;;A61K47/48;;A61K51/00;;A61K51/08;;A61K51/10;;C07C335/06;;C07C335/14;;C07C335/16;;C07C335/22;;C07C337/06;;C07D207/44;;C07D207/452;;C07D213/34;;C07D213/71;;C09K3/00,,0,0,,,,EXPIRED
46,WO,A1,WO 1995/012586 A1,004-431-038-060-544,1995-05-11,1995,US 9410106 W,1994-09-15,US 14559193 A,1993-11-04,NON-ALKALINE PURIFICATION OF AMINOPHOSPHONIC ACIDS,"A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100 % are thus obtained.",CYTOGEN CORP,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J,,https://lens.org/004-431-038-060-544,Patent Application,yes,3,1,15,15,0,C07F9/025;;C07F9/3817;;C07F9/6524;;C07F9/6524;;C07F9/025;;C07F9/3817,C07F9/02;;C07F9/38;;C07D255/02;;C07F9/6524,,0,0,,,,PATENTED
47,US,B2,US 6916232 B2,050-361-738-790-49X,2005-07-12,2005,US 17287302 A,2002-06-14,US 17287302 A,2002-06-14,Apparatus for superpolishing the inside surface of a seam of a continuous photoreceptor belt,"Apparatus is provided for superpolishing the inside diameter surface of a seam of a flexible continuous photoreceptor belt. The apparatus includes (a) spaced apart support rollers for supporting the inside surface of the flexible continuous photoreceptor belt into a loop having strands, including a seam strand, between adjacent rollers; (b) a polishing machine mounted adjacent the seam strand, the polishing machine having: (i) polishing forms defining a path for the seam strand; (ii) a rotatable drum for supporting and carrying a polishing media material against the inside surface of the seam on the seam strand, (iii) sets of pinch rolls for clamping the seam strand and straddling the seam thereon; (iv) polishing media material mounted over the rotatable drum and through the path between the polishing forms for contacting the inside surface of the seam; and (v) a reciprocating superpolishing head for reciprocating relative to a width of the flexible continuous belt and a length of the seam, thereby simultaneously (x) reciprocating the superpolishing head in contact with the inside surface of the seam along the length thereof, (y) moving the seam with the sets of pinch rolls, and (z) rotating the drum for move the polishing media material in polishing contact with the inside surface of the seam and across a width of the seam to achieve required random superpolishing motion against the inside surface of the seam.",XEROX CORP,MASTRO PAUL F;;COUGHLIN JR DANIEL L,XEROX CORPORATION (2002-06-11),https://lens.org/050-361-738-790-49X,Granted Patent,yes,8,2,2,2,0,B24B21/02;;B24B35/00;;B29C66/032;;B29C66/2272;;B29L2031/709;;B29L2031/764;;G03G5/10;;B29C65/56;;B29C66/1142;;B29C66/4322;;B29C66/4324;;B29C66/49;;B29C66/032;;B24B21/02;;B29L2031/764;;B24B35/00;;B29C66/2272;;B29L2031/709;;G03G5/10;;B29C66/1142;;B29C66/4322;;B29C66/4324;;B29C65/56;;B29C66/49,B24B21/02;;B24B35/00;;B29C65/00;;G03G5/10,451/109;;451/184;;451/212;;451/218;;451/306,0,0,,,,EXPIRED
48,US,A1,US 2009/0317156 A1,112-850-682-550-116,2009-12-24,2009,US 14488408 A,2008-06-24,US 14488408 A,2008-06-24,SELECTIVE POLISHING OF FUSER MEMBERS,"A method of forming and a resulting selectively polished fuser member. The method includes selectively polishing that portion of the fuser member surface not subject to rapid natural wear. The method further includes polishing both a surface region subject to rapid sheet edge wear and a surface region not subject to rapid sheet edge wear, and polishing the surface region not subject to rapid sheet edge wear more than the surface region subject to rapid sheet edge wear. The rapid natural wear corresponds to sheet edge wear on the fuser member surface.",XEROX CORP,COUGHLIN JR DANIEL L;;FINN PATRICK J,XEROX CORPORATION (2008-06-23),https://lens.org/112-850-682-550-116,Patent Application,yes,2,0,2,2,0,G03G15/2053;;Y10T428/3154;;Y10T428/3154;;G03G15/2053,G03G15/20,399/333,0,0,,,,INACTIVE
49,US,A,US 5495042 A,125-067-169-764-081,1996-02-27,1996,US 14559193 A,1993-11-04,US 14559193 A,1993-11-04,Non-alkaline purification of aminophosphonic acids,"A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100% are thus obtained.",CYTOGEN CORP,BELINKA JR BENJAMIN A;;COUGHLIN DANIEL J,CYTOGEN CORPORATION (1993-12-01),https://lens.org/125-067-169-764-081,Granted Patent,yes,22,28,15,15,0,C07F9/025;;C07F9/3817;;C07F9/6524;;C07F9/6524;;C07F9/025;;C07F9/3817,C07F9/02;;C07D255/02;;C07F9/38;;C07F9/6524,562/14;;540/474;;562/12,4,2,030-399-997-199-504;;065-231-280-389-846,10.1021/ic00152a012;;10.1080/03086648308080472,"Ault, Techniques and Experiments for Organic Chemistry , 4th ed., Allyn & Bacon, Inc., Boston (1983), pp. 44 46, 50.;;Inorganic Chemistry, vol. 22, 1983, pp. 1478 1482, E. N. Rizkalla, et al., Nuclear Magnetic Resonance Study of Ethylenediaminetetrakis(methylenephosphonic acid) and Some Metal Complexes .;;Phosphorus and Sulfur, 1983, vol. 16, pp. 233 238, Derek Redmore, et al., Novel Magnetic N,N bis(methylene) bisphosponic Acids of , Diamines. Preparation and Characterization of (2 aminoethyl)imino bis(methylene) bisphosphonic acid and (6 aminohexyl)imino bis(methylene bisphosphonic acid .;;Journal of Isotopes, vol. 5, No. 2, May 1992, pp. 72 76, Yang Zhi, et al., Preparation of Yttrium 90 EDTMP for Bone Tumor Treatment , (abstract only).",EXPIRED
50,ES,T3,ES 2109495 T3,091-329-985-538-969,1998-01-16,1998,ES 93911594 T,1993-04-08,US 86637592 A,1992-04-09,TIOUREAS SUSTITUIDAS UTILIZADAS COMO AGENTES QUELANTES BIFUNCIONALES.,"PCT No. PCT/US93/03208 Sec. 371 Date Jun. 27, 1994 Sec. 102(e) Date Jun. 27, 1994 PCT Filed Apr. 8, 1993 PCT Pub. No. WO93/21151 PCT Pub. Date Oct. 28, 1993This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.",CYTOGEN CORP,COUGHLIN DANIEL J;;BELINKA BENJAMIN A JR,,https://lens.org/091-329-985-538-969,Granted Patent,no,0,0,12,12,0,A61K51/088;;A61K51/1093;;A61K2121/00;;A61K2123/00;;C07C335/22;;C07C337/06;;C07D207/452;;C07D213/71;;A61K51/082;;A61K47/50;;C07D207/452;;C07C335/22;;A61K2123/00;;C07D213/71;;A61K2121/00;;C07C337/06;;A61K51/1093;;A61K51/088;;A61K51/082;;A61K47/50,G01N33/58;;A61K39/44;;A61K47/48;;A61K51/00;;A61K51/08;;A61K51/10;;C07C335/06;;C07C335/14;;C07C335/16;;C07C335/22;;C07C337/06;;C07D207/44;;C07D207/452;;C07D213/34;;C07D213/71;;C09K3/00,,0,0,,,,EXPIRED
51,US,A,US 5585468 A,101-027-208-034-704,1996-12-17,1996,US 20419794 A,1994-06-27,US 20419794 A;;US 86637592 A;;US 9303208 W,1992-04-09,Substituted thioureas as bifunctional chelators,"This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.",CYTOGEN CORP,COUGHLIN DANIEL J;;BELINKA JR BENJAMIN A,CYTOGEN CORPORATION (1994-04-20),https://lens.org/101-027-208-034-704,Granted Patent,yes,13,18,12,12,0,A61K51/088;;A61K51/1093;;A61K2121/00;;A61K2123/00;;C07C335/22;;C07C337/06;;C07D207/452;;C07D213/71;;A61K51/082;;A61K47/50;;C07D207/452;;C07C335/22;;A61K2123/00;;C07D213/71;;A61K2121/00;;C07C337/06;;A61K51/1093;;A61K51/088;;A61K51/082;;A61K47/50,A61K39/44;;A61K47/48;;A61K51/00;;A61K51/08;;G01N33/58;;A61K51/10;;C07C335/06;;C07C335/14;;C07C335/16;;C07C335/22;;C07C337/06;;C07D207/44;;C07D207/452;;C07D213/34;;C07D213/71;;C09K3/00,534/14;;534/14;;534/10;;530/300;;530/391.5;;530/408;;564/18;;564/23;;564/26;;564/28;;556/45;;556/64;;556/85;;556/110;;556/118;;560/18;;562/432;;536/26.6;;552/502;;552/504,18,14,016-606-045-126-078;;180-750-634-162-600;;033-893-528-815-223;;114-533-678-415-708;;108-603-154-328-455;;004-375-770-011-889;;025-681-938-968-762;;133-719-973-344-505;;023-275-088-197-255;;024-282-261-448-508;;007-247-499-969-67X;;012-968-148-734-706;;025-824-099-847-876;;037-541-240-623-536,10.1016/s0047-0740(86)80003-1;;3710705;;3585492;;pmc436876;;6681615;;10.1172/jci110778;;2654090;;10.1016/0883-2897(89)90192-x;;3375252;;pmc280353;;10.1073/pnas.85.11.4025;;7400835;;10.1080/00397917908060950;;10.1016/0040-4039(88)85126-8;;10.1016/s0040-4039(00)99604-7;;10.1021/ed062p965;;1838699;;10.1021/bc00011a007;;7160402;;10.1007/bf00571648;;10.1016/0076-6879(89)69054-4;;2716524;;10.1021/jm00080a022;;1732553,"Arano, Y. et al., Bifunctional Chelating Agents for Tc 99m labeled Monoclonal Antibodies , IAEA CN 45/68, 143 151, (1985).;;Arano et al., Synthesis and Evaluation of a New Bifunctional Chelating Agent for 99m Tc Labeling Proteins:p Carboxyethylphenylglyoxal di(N methylthiosemicarbazone) , In. J. Nucl. Med. Biol. 12:425 430, 1986.;;Arano et al., Techneitum 99m Labeled Monoclonal Antibody With Preserved Immunoreactivity and High In Vivo Stability , J. Nucl. Med. 28:1027 1033 (1987).;;Collen et al., Thrombolysis with human extrinsic (tissue type) plasminogen activator in Rabbits with experimental jugular vein thrombosis , J. Clin. Invest. 71368 376 (1983).;;Eckelman et al., Three Approaches to Radiolabeling Antibodies with 99m Tc , Nucl. Med. Biol. 16(2):171 176 (1989).;;Fitzberg, et al., Specific and Stable Labeling of Antibodies with Technetium 99m With a Diamide Dithiolate Chelating Agent , Proc. Natl. Acad. Sci. U.S.A. 85: 4025 4029 (1988).;;Huang et al., Detection of bacterial endocarditis with Technetium 99m labeled antistaphyloccoccal antibody , J. Nucl. Med. 21:783 786 (1980).;;Hull, An improved preparation of O phenylenedi isothiocyanate , Synthetic Commun. 9:477 481 (1979).;;Kopunec et al., Reaction of Pertechnetate With Thiourea in the Nitric Acid Solutions , Radiochem. Radioanal. Lett. 29:171 178 (1977).;;Lever et al., Synthesis of a Novel Bifunctional Chelate Designed for Labeling Proteins With Technetium 99m , Tetrahedron Letters 29(26):3219 3222 (1988).;;Misra et al., Synthesis of a Novel Diaminodithiol Ligand for Labeling Proteiuns and Small Molecules With Technetium 99m , Tetrahedron Letters 30(15):1885 1888 (1989).;;Pinkerton et al., Bioinorganic activity of technetium pharmaceuticals , J. Chem. Educ. 62:965 973 (1985).;;Rhodes et al., in Tumor Imaging , Burchiel and Rhodes, eds., Masson: New York, pp. 111 123, (1982).;;Schwartz et al., Preparation of Hydrazino Modified Proteins and Their Use for the Synthesis of 99m Tc Protein Conjugates , Biconjugate Chem. 2:333 336 (1991).;;Sundrehagen, Formation of 99m Tc immunoglobulin G complexes free from radio colloids, quality controlled by radioimmunoelectrophoresis , Eur. J. Nucl. Med. 7:549 552 (1982).;;Wensel et al., Bifunctional Chelating Agents for Binding Metal Ions to Proteins , in Radioimmunoimaging and Radioimmunotherapy, Burchiek and Rhodes (eds.), Elsevier Science Publishing, Inc., pp. 185 196 (1983).;;Zucker, Platelet aggregation measured by the photometric method Meth. Enzymol., 169:117 133 (1989).;;Cullen, Ernest, et al. Bis Basic Substituted Diaminobenzobisthiazoles As Potential Antiarthritic Agents , J. Med. Chem. (35) 350 361, 1992.",EXPIRED
52,EP,B1,EP 0635001 B1,128-128-478-027-275,1997-08-20,1997,EP 93911594 A,1993-04-08,US 86637592 A;;US 9303208 W,1992-04-09,SUBSTITUTED THIOUREAS AS BIFUNCTIONAL CHELATORS,"PCT No. PCT/US93/03208 Sec. 371 Date Jun. 27, 1994 Sec. 102(e) Date Jun. 27, 1994 PCT Filed Apr. 8, 1993 PCT Pub. No. WO93/21151 PCT Pub. Date Oct. 28, 1993This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.",CYTOGEN CORP,COUGHLIN DANIEL J;;BELINKA BENJAMIN A JR,,https://lens.org/128-128-478-027-275,Granted Patent,yes,3,0,12,12,0,A61K51/088;;A61K51/1093;;A61K2121/00;;A61K2123/00;;C07C335/22;;C07C337/06;;C07D207/452;;C07D213/71;;A61K51/082;;A61K47/50;;C07D207/452;;C07C335/22;;A61K2123/00;;C07D213/71;;A61K2121/00;;C07C337/06;;A61K51/1093;;A61K51/088;;A61K51/082;;A61K47/50,G01N33/58;;A61K39/44;;A61K47/48;;A61K51/00;;A61K51/08;;A61K51/10;;C07C335/06;;C07C335/14;;C07C335/16;;C07C335/22;;C07C337/06;;C07D207/44;;C07D207/452;;C07D213/34;;C07D213/71;;C09K3/00,,2,0,,,"JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 2, 24 January 1992, Washington, DC, US, pages 350-361, E. CULLEN et al, ""Bis basic substituted diaminobenzobisthiazoles as potential antiarthritic agents2;;JOURNAL OF ORGANIC CHEMISTRY, vol. 27, no. 6, 12 June 1962, Washington, DC, US, pages 2214-2217, E. LEIBER et al, ""Diisothiocyanates and derivatives""",EXPIRED
53,BR,A,BR 9501850 A,176-392-522-798-960,1995-12-12,1995,BR 9501850 A,1995-04-28,US 23599794 A,1994-05-02,Dispositivo localizador,,XEROX CORP,MAXFIELD DAVID E JR;;COUGHLIN DANIEL L,,https://lens.org/176-392-522-798-960,Patent Application,no,0,0,4,4,0,B21D22/04;;B21D22/04;;B21D39/03;;B21D39/03;;F16B17/008;;F16B17/008;;Y10T29/49895;;Y10T29/49895;;Y10T403/1624;;Y10T403/1624,B21D22/04;;B21D39/03;;F16B17/00,,0,0,,,,EXPIRED
54,CA,A1,CA 2117770 A1,005-150-319-489-852,1993-10-28,1993,CA 2117770 A,1993-04-08,US 86637592 A,1992-04-09,SUBSTITUTED THIOUREAS AS BIFUNCTIONAL CHELATORS,"2117770 9321151 PCTABS00027 This invention relates to chelating agents of formula (I), in which L is a linker; D is an alkyl backbone, cyclic alkyl backbone or aryl backbone group substituted with the NHCSNHR groups: and R is hydrogen or a substituent of general formula (1) in which a = 0 or 1; b = 0-10; c = 0 or 1; if c = 1, Y = S, O or H2; d = 0-2; e = 0-10; and Z = H, N+(R')3X-, SO3H, CO2H, OH, H2PO3; in which X- is a counterion such as a halide or an acid anion and R' is a C1 to C4 lower alkyl, useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.",CYTOGEN CORP,COUGHLIN DANIEL J;;BELINKA BENJAMIN A JR,,https://lens.org/005-150-319-489-852,Patent Application,no,0,0,12,12,0,A61K51/088;;A61K51/1093;;A61K2121/00;;A61K2123/00;;C07C335/22;;C07C337/06;;C07D207/452;;C07D213/71;;A61K51/082;;A61K47/50;;C07D207/452;;C07C335/22;;A61K2123/00;;C07D213/71;;A61K2121/00;;C07C337/06;;A61K51/1093;;A61K51/088;;A61K51/082;;A61K47/50,G01N33/58;;A61K39/44;;A61K47/48;;A61K51/00;;A61K51/08;;A61K51/10;;C07C335/06;;C07C335/14;;C07C335/16;;C07C335/22;;C07C337/06;;C07D207/44;;C07D207/452;;C07D213/34;;C07D213/71;;C09K3/00,,0,0,,,,DISCONTINUED
55,US,A,US 5326856 A,076-901-516-405-048,1994-07-05,1994,US 86637592 A,1992-04-09,US 86637592 A,1992-04-09,Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding,"This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, isothiocyanate derived thiocarbonyls for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.",CYTOGEN CORP,COUGHLIN DANIEL J;;BELINKA JR BENJAMIN A,CYTOGEN CORPORATION A CORPORATION OF DELAWARE (1992-06-03),https://lens.org/076-901-516-405-048,Granted Patent,yes,20,119,12,12,0,A61K51/088;;A61K51/1093;;A61K2121/00;;A61K2123/00;;C07C335/22;;C07C337/06;;C07D207/452;;C07D213/71;;A61K51/082;;A61K47/50;;C07D207/452;;C07C335/22;;A61K2123/00;;C07D213/71;;A61K2121/00;;C07C337/06;;A61K51/1093;;A61K51/088;;A61K51/082;;A61K47/50,A61K39/44;;A61K47/48;;A61K51/00;;A61K51/08;;G01N33/58;;A61K51/10;;C07C335/06;;C07C335/14;;C07C335/16;;C07C335/22;;C07C337/06;;C07D207/44;;C07D207/452;;C07D213/34;;C07D213/71;;C09K3/00,534/14;;534/10;;530/300;;530/391.5;;530/408;;564/18;;564/23;;564/26;;564/27;;564/28;;556/45;;556/64;;556/81;;556/110;;556/118;;560/18;;562/432;;536/26.6;;552/502;;552/504,21,16,016-606-045-126-078;;180-750-634-162-600;;033-893-528-815-223;;114-533-678-415-708;;108-603-154-328-455;;004-375-770-011-889;;025-681-938-968-762;;133-719-973-344-505;;023-275-088-197-255;;024-282-261-448-508;;007-247-499-969-67X;;012-968-148-734-706;;025-824-099-847-876;;037-541-240-623-536;;016-123-081-923-529;;016-606-045-126-078,10.1016/s0047-0740(86)80003-1;;3710705;;3585492;;pmc436876;;6681615;;10.1172/jci110778;;2654090;;10.1016/0883-2897(89)90192-x;;3375252;;pmc280353;;10.1073/pnas.85.11.4025;;7400835;;10.1080/00397917908060950;;10.1016/0040-4039(88)85126-8;;10.1016/s0040-4039(00)99604-7;;10.1021/ed062p965;;1838699;;10.1021/bc00011a007;;7160402;;10.1007/bf00571648;;10.1016/0076-6879(89)69054-4;;2716524;;10.1021/jm00080a022;;1732553;;3021660;;10.1016/0883-2889(86)90077-8;;10.1016/s0047-0740(86)80003-1;;3710705,"Arano et al., Synthesis and Evaluation of a New Bifunctional Chelating Agent for 99m Tc Labeling Proteins: p Carboxyethylphenylglyoxal di(N methylthiosemicarbazone) , Int. J. Nucl. Med. Biol. 12:425 430 (1986).;;Arano et al., Technetium 99m Labeled Monoclonal Antibody With Preserved Immunoreactivity and High In Vivo Stability , J. Nucl. Med. 28:1027 1033 (1987).;;Collen et al., Thrombolysis with human extrinsic (tissue type) plasinogen activator in Rabbits with experimental jugular vein thrombosis , J. Clin. Invest. 71:368 376 (1983).;;Eckelman et al., Three Approaches to Radiolabeling Antibodies with 99m Tc , Nucl. Med. Biol., 16(2):171 176 (1989).;;Fritzberg, et al., Specific and Stable Labeling of Antibodies With Technetium 99m With a Diamide Dithiolate Chelating Agent , Proc. Natl. Acad. Sci. U.S.A. 85:4025 4029 (1988).;;Huang et al., Detection of bacterial endocarditis with Technetium 99m labeled antistaphylococcal antibody , J. Nucl. Med. 21:783 786 (1980).;;Hull, An Improved preparation of O phenylenedi isothiocyanate , Synthetic Commun. 9:477 481 (1979).;;Kopunec et al., Reaction of Pertechnetate With Thiourea in the Nitric Acid Solutions , Radiochem. Radioanal. Lett. 29:171 178 (1977).;;Lever et al., Synthesis of a Novel Bifunctional Chelate Designed for Labeling Proteins With Technetium 99mn , Tetrahedron Letters 29 (26):3219 3222 (1988).;;Misra et al., Synthesis of a Novel Diaminodithiol Ligand for Labeling Proteins and Small Molecules With Technetium 99m , Tetrahedron Lett., 30(15): 1885 1888 (1989).;;Pinkerton et al., Bioinorganic activity of technetium pharmaceuticals , J. Chem. Educ. 62:965 973 (1985).;;Rhodes et al., in Tumor Imaging , Burchiel and Rhodes, eds., Masson: New York, pp. 111 123, (1982).;;Schwartz et al., Preparation of Hydrazino Modified Proteins and Their Use for the Synthesis of 99m Tc Protein Conjugates , Bioconjugate Chem. 2:333 336 (1991).;;Sundrehagen, Formation of 99m Tc immunoglobulin G complexes free from radiocolloids, quality controlled by radioimmunoelectrophoresis , Eur. J. Nucl. Med. 7:549 552 (1982).;;Wensel et al., Bifunctional Chelating Agents for Binding Metal Ions to Proteins , in Radioimmunoimaging and Radioimmunotherapy, Burchiek and Rhodes (eds.), Elsevier Science Publishing, Inc., pp. 185 196 (1983).;;Zucker, Platelet aggregation measured by the photometric method , Meth. Enzymol. 169:117 133 (1989).;;E. Leiber et al., Diisothiocyanates and Derivatives , Journal of Organic Chemistry, vol. 27, No. 6, Jun. 12, 1962, pp. 2214 2217.;;E. Cullen et al., Bis Basic Substituted Diaminobenzobisthiazoles as Potential Antiarthritic Agents , Journal of Medicinal Chemistry, vol. 35, No.2, Jan. 24, 1992, pp. 350 361.;;Y. Arano et al., Bifunctional Chelating Agents For 99Tcm Labelled Monoclonal Antibodies , IAE A CN 45/68, pp. 143 151.;;Y. Arano et al., In the Procurement of Stabel 99mTc Labeled Protein Using Bifunctional Chelating Agents , Appl. Radiat. Isot., vol. 37, No. 7, pp. 587 592, 1986.;;Arano et al., Synthesis and Evaluation of a New Bifunctional Chelating Agent for Tc 99m Labeling Proteins: p Carboxyethylphenylglyoxal di(N methylthiosemicarbazone) , Int J. Nucl. Med. Biol., 12: 425 430 (1986).",EXPIRED
56,CA,A1,CA 2175221 A1,198-956-606-264-957,1995-05-11,1995,CA 2175221 A,1994-09-15,US 14559193 A;;US 9410106 W,1993-11-04,Non-Alkaline Purification of Aminophosphonic Acids,"A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100% are thus obtained.",CYTOGEN CORP,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J,,https://lens.org/198-956-606-264-957,Patent Application,no,0,0,15,15,0,C07F9/025;;C07F9/3817;;C07F9/6524;;C07F9/6524;;C07F9/025;;C07F9/3817,C07D255/02;;C07F9/02;;C07F9/38;;C07F9/6524,,0,0,,,,EXPIRED
57,EP,B1,EP 0724576 B1,090-584-148-685-648,2002-03-20,2002,EP 94929152 A,1994-09-15,US 9410106 W;;US 14559193 A,1993-11-04,NON-ALKALINE PURIFICATION OF AMINOPHOSPHONIC ACIDS,"A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100% are thus obtained.",CYTOGEN CORP,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J,,https://lens.org/090-584-148-685-648,Granted Patent,yes,4,5,15,15,0,C07F9/025;;C07F9/3817;;C07F9/6524;;C07F9/6524;;C07F9/025;;C07F9/3817,C07D255/02;;C07F9/02;;C07F9/38;;C07F9/6524,,0,0,,,,EXPIRED
58,WO,A1,WO 2015/195478 A1,142-639-371-833-674,2015-12-23,2015,US 2015/0035558 W,2015-06-12,US 201462012701 P,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,"Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R 1 and R 2 are individually selected from hydrogen, alkyl, substituted or aikyl; n = 0, 1, or 2; Y = NR 3 R 4 , QR 5 , or SR 5 , where R 3 and R 4 are individually selected from acyl or su!fonyl, and where R 5 is aryi or heteroaryi, or heterocyclic; and Ar is an aryl, heteroaryl, or heterocyclic compound.",JOHNSON MATTHEY PLC;;COUGHLIN DANIEL,COUGHLIN DANIEL;;WILT JEREMY;;GOU DA-MING,,https://lens.org/142-639-371-833-674,Patent Application,yes,2,1,17,17,0,C07D311/06;;C07D215/22;;C07D413/04;;C07D239/88;;C07D241/04;;C07D471/12;;C07D487/12;;C07D209/52;;C07C39/00;;C07D519/00;;C07D417/08;;C07D261/20;;C07D209/56;;C07D417/12;;C07D215/227;;C07D401/12;;C07D403/12;;C07D275/06;;C07D311/20;;C07D413/12;;C07D413/14;;C07D519/00;;C07D417/08;;C07D261/20;;C07D209/56;;C07D417/12;;C07D215/227;;C07D401/12;;C07D403/12;;C07D275/06;;C07D311/20;;C07D413/12;;C07C39/00;;C07D311/06;;C07D215/22;;C07D413/04;;C07D239/88;;C07D241/04;;C07D471/12;;C07D487/12;;C07D209/52;;C07D413/14,C07D417/12;;C07C39/00;;C07D209/52;;C07D215/22;;C07D239/88;;C07D241/04;;C07D275/06;;C07D311/06;;C07D413/04;;C07D413/12;;C07D471/12;;C07D487/12,,8,5,004-043-978-302-81X;;067-395-301-650-737;;066-962-151-006-947;;076-944-497-354-029;;031-383-047-746-877,10.1002/hlca.19670500528;;10.1002/prac.19753170610;;10.1002/zfch.19890290213;;10.1002/bbpc.19830871210;;10.1016/j.bmcl.2014.01.070;;24582477,"CHERBULIEZ ET AL.: ""148. Recherches sur la formation et la transformation des esters LXXV[1]"", HELVETICA CHIMICA ACTA, vol. 50, 1967, pages 1440 - 1452, XP002742557;;GERHARD W. FISCHER ET AL: ""Reaktivitaet und Toxizitaet cyclischer Schwefelsaeur eester"", JOURNAL FUER PRAKTISCHE CHEMIE, vol. 317, no. 6, 1975, DE, pages 943 - 952, XP055203634, ISSN: 0021-8383, DOI: 10.1002/prac.19753170610;;DOLENSKI ET AL.: ""Molécules amphiphiles électroréductibles. Etude de la réduction en milieux de sulfates d'omega-(4-acétylphénoxy)alkyle"", BULL.SOC. CHIM. FR., vol. 133, 1996, pages 235 - 242, XP009185494;;LICHTENBERGER ET AL.: ""N° 204. Sur les sulfates de diols"", BULL. SOC. CHIM. FR., 1948, pages 1002 - 1012, XP009185493;;HÄSSNER ET AL.: ""EI-Massenspektrometrie N-monosulfoalkyl-substituierte Cyanine"", ZEITSCHRIFT FÜR CHEMIE, vol. 29, no. 2, 1989, pages 65 - 66, XP001525976;;NAGAMURA ET AL.: ""Novel effect of man-made molecular assemblies on photoinduced charge separation.4.Synthetic bilayer membrane of amphipathic viologen as an efficient electron collector in photosensitized redox reactions"", BERICHTE DER BUNSENGESELLSCHAFT, PHYSICAL CHEMISTRY CHEMICAL PHYSICS, vol. 87, no. 12, 1983, pages 1129 - 1133, XP009185495;;JIA JIAN-MIN ET AL: ""Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 6, 15 February 2014 (2014-02-15), pages 1557 - 1561, XP028625276, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2014.01.070;;PAI ET AL.: ""Synthesis of novel analogs 3,4-dihydro-1H-quinolin-2-one derivatives as typical antidepressant, sedative and anti-Parkinson agents"", HETEROCYCLIC LETTERS, vol. 2, no. 1, 2012, pages 117 - 128, XP002742558",PENDING
59,EP,A1,EP 0724576 A1,037-322-140-362-148,1996-08-07,1996,EP 94929152 A,1994-09-15,US 9410106 W;;US 14559193 A,1993-11-04,NON-ALKALINE PURIFICATION OF AMINOPHOSPHONIC ACIDS,"A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100% are thus obtained.",CYTOGEN CORP,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J,,https://lens.org/037-322-140-362-148,Patent Application,yes,0,0,15,15,0,C07F9/025;;C07F9/3817;;C07F9/6524;;C07F9/6524;;C07F9/025;;C07F9/3817,C07D255/02;;C07F9/02;;C07F9/38;;C07F9/6524,,0,0,,,,EXPIRED
60,BR,A,BR 9407990 A,061-211-593-505-285,1996-12-03,1996,BR 9407990 A,1994-09-15,US 14559193 A;;US 9410106 W,1993-11-04,Purificaçao nao alcalina de ácidos aminofosfônicos,"A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100% are thus obtained.",CYTOGEN CORP,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J,,https://lens.org/061-211-593-505-285,Patent Application,no,0,0,15,15,0,C07F9/025;;C07F9/3817;;C07F9/6524;;C07F9/6524;;C07F9/025;;C07F9/3817,C07D255/02;;C07F9/02;;C07F9/38;;C07F9/6524,,0,0,,,,DISCONTINUED
61,CA,C,CA 2175221 C,142-268-229-766-140,2000-01-18,2000,CA 2175221 A,1994-09-15,US 14559193 A;;US 9410106 W,1993-11-04,NON-ALKALINE PURIFICATION OF AMINOPHOSPHONIC ACIDS,"A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100 % are thus obtained.",,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J,,https://lens.org/142-268-229-766-140,Granted Patent,no,0,0,15,15,0,C07F9/025;;C07F9/3817;;C07F9/6524;;C07F9/6524;;C07F9/025;;C07F9/3817,C07D255/02;;C07F9/02;;C07F9/38;;C07F9/6524,,0,0,,,,EXPIRED
62,US,A,US 5527885 A,001-300-619-835-310,1996-06-18,1996,US 26844594 A,1994-06-30,US 26844594 A;;US 86637592 A,1992-04-09,Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding,"This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, isothiocyanate derived thiocarbonyls for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.",CYTOGEN CORP,COUGHLIN DANIEL J;;BELINKA JR BENJAMIN A,,https://lens.org/001-300-619-835-310,Granted Patent,yes,15,44,12,12,0,A61K51/088;;A61K51/1093;;A61K2121/00;;A61K2123/00;;C07C335/22;;C07C337/06;;C07D207/452;;C07D213/71;;A61K51/082;;A61K47/50;;C07D207/452;;C07C335/22;;A61K2123/00;;C07D213/71;;A61K2121/00;;C07C337/06;;A61K51/1093;;A61K51/088;;A61K51/082;;A61K47/50,A61K39/44;;A61K47/48;;A61K51/00;;G01N33/58;;A61K51/08;;A61K51/10;;C07C335/06;;C07C335/14;;C07C335/16;;C07C335/22;;C07C337/06;;C07D207/44;;C07D207/452;;C07D213/34;;C07D213/71;;C09K3/00,534/14;;534/10;;530/391.3;;530/391.5,16,13,016-606-045-126-078;;180-750-634-162-600;;033-893-528-815-223;;114-533-678-415-708;;108-603-154-328-455;;004-375-770-011-889;;025-681-938-968-762;;133-719-973-344-505;;024-282-261-448-508;;007-247-499-969-67X;;012-968-148-734-706;;025-824-099-847-876;;023-275-088-197-255,10.1016/s0047-0740(86)80003-1;;3710705;;3585492;;pmc436876;;6681615;;10.1172/jci110778;;2654090;;10.1016/0883-2897(89)90192-x;;3375252;;pmc280353;;10.1073/pnas.85.11.4025;;7400835;;10.1080/00397917908060950;;10.1016/0040-4039(88)85126-8;;10.1021/ed062p965;;1838699;;10.1021/bc00011a007;;7160402;;10.1007/bf00571648;;10.1016/0076-6879(89)69054-4;;2716524;;10.1016/s0040-4039(00)99604-7,"Arano et al., Synthesis and Evaluation of a New Bifunctional Chelating Agent for 99m Tc Labeling Proteins: p Carboxyethylphenylglyoxal di(N methylthiosemicarbazone) , Int. J. Nucl. Med. Biol. 12:425 430 (1986)***.;;Arano et al., Technetium 99m Labeled Monoclonal Antibody With Preserved Immunoreactivity and High In Vivo Stability , J. Nucl. Med. 28:1027 1033 (1987)***.;;Collen et al., Thrombolysis with human extrinsic (tissue type) plasinogen activator in Rabbits with experimental jugular vein thrombosis , J. Clin. Invest. 71:368 376 (1983).;;Eckelman et al., Three Approaches to Radiolabeling Antibodies with 99m Tc , Nucl. Med. Biol., 16(2):171 176 (1989).;;Fritzberg, et al., Specific and Stable Labeling of Antibodies with Technetium 99m with a Diamide Dithiolate Chelating Agent , Proc. Natl. Acad. Sci. U.S.A. 85:4025 4029 (1988).;;Huang et al., Detection of bacterial endocarditis with Technetium 99m labeled antistaphylococcal antibody , J. Nucl. Med. 21:783 786 (1980).;;Hull, An improved preparation of O phenylenedi isothiocyanate , Synthetic Commun. 9:477 481 (1979).;;Kopunec et al., Reaction of Pertechnetate With Thiourea in the Nitric Acid Solutions , Radiochem. Radioanal. Lett. 29:171 178 (1977).;;Lever et al., Synthesis of a Novel Bifunctional Chelate Designed for Labeling Proteins With Technetium 99m , Tetrahedron Letters, 2(26):3219 3222 (1988).;;Pinkerton et al., Bioinorganic activity of technetium pharmaceuticals , J. Chem. Educ. 62:965 973 (1985).;;Rhodes et al., in Tumor Imaging , Burchiel and Rhodes, eds., Masson: New York, pp. 111 123, (1982).;;Schwartz et al., Preparation of Hydrazino Modified Proteins and Their Use for the Synthesis of 99m Tc Protein Conjugates Bioconjugate Chem. 2:333 336 (1991).;;Sundrehagen, Formation of 99m Tc immunoglobulin G complexes free from radiocolloids, quality controlled by radioimmunoelectrophoresis , Eur. J. Nucl. Med. 7:549 552 (1982).;;Wensel et al., Bifunctional Chelating Agents for Binding Metal Ions to Proteins , in Radioimmunoimaging and Radioimmunotherapy, Burchiek and Rhodes (eds.), Elsevier Science Publishing, Inc., pp. 185 196 (1983).;;Zucker, Platelet aggregation measured by the photometric method , Meth. Enzymol. 169:117 133 (1989).;;Misra et al., Synthesis of a Novel Diaminodithiol Ligand for Labeling Proteins and Small Molecules With Technetium 99m , Tetrahedron Lett., 30(15): 1885 1888 (1989).",EXPIRED
63,EP,A1,EP 0635001 A1,166-015-713-799-847,1995-01-25,1995,EP 93911594 A,1993-04-08,US 86637592 A;;US 9303208 W,1992-04-09,SUBSTITUTED THIOUREAS AS BIFUNCTIONAL CHELATORS.,"PCT No. PCT/US93/03208 Sec. 371 Date Jun. 27, 1994 Sec. 102(e) Date Jun. 27, 1994 PCT Filed Apr. 8, 1993 PCT Pub. No. WO93/21151 PCT Pub. Date Oct. 28, 1993This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.",CYTOGEN CORP,COUGHLIN DANIEL J;;BELINKA BENJAMIN A JR,,https://lens.org/166-015-713-799-847,Patent Application,yes,0,0,12,12,0,A61K51/088;;A61K51/1093;;A61K2121/00;;A61K2123/00;;C07C335/22;;C07C337/06;;C07D207/452;;C07D213/71;;A61K51/082;;A61K47/50;;C07D207/452;;C07C335/22;;A61K2123/00;;C07D213/71;;A61K2121/00;;C07C337/06;;A61K51/1093;;A61K51/088;;A61K51/082;;A61K47/50,G01N33/58;;A61K39/44;;A61K47/48;;A61K51/00;;A61K51/08;;A61K51/10;;C07C335/06;;C07C335/14;;C07C335/16;;C07C335/22;;C07C337/06;;C07D207/44;;C07D207/452;;C07D213/34;;C07D213/71;;C09K3/00,,0,0,,,,EXPIRED
64,WO,A1,WO 1993/021151 A1,150-604-548-204-129,1993-10-28,1993,US 9303208 W,1993-04-08,US 86637592 A,1992-04-09,SUBSTITUTED THIOUREAS AS BIFUNCTIONAL CHELATORS,"This invention relates to chelating agents of formula (I), in which L is a linker; D is an alkyl backbone, cyclic alkyl backbone or aryl backbone group substituted with the NHCSNHR groups: and R is hydrogen or a substituent of general formula (1) in which a = 0 or 1; b = 0-10; c = 0 or 1; if c = 1, Y = S, O or H2; d = 0-2; e = 0-10; and Z = H, N+(R')3X-, SO3H, CO2H, OH, H2PO3; in which X- is a counterion such as a halide or an acid anion and R' is a C¿1? to C4 lower alkyl, useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.",CYTOGEN CORP;;COUGHLIN DANIEL J;;BELINKA BENJAMIN A JR,COUGHLIN DANIEL J;;BELINKA BENJAMIN A JR,,https://lens.org/150-604-548-204-129,Patent Application,yes,3,11,12,12,0,A61K51/088;;A61K51/1093;;A61K2121/00;;A61K2123/00;;C07C335/22;;C07C337/06;;C07D207/452;;C07D213/71;;A61K51/082;;A61K47/50;;C07D207/452;;C07C335/22;;A61K2123/00;;C07D213/71;;A61K2121/00;;C07C337/06;;A61K51/1093;;A61K51/088;;A61K51/082;;A61K47/50,A61K39/44;;A61K47/48;;A61K51/00;;A61K51/08;;G01N33/58;;A61K51/10;;C07C335/06;;C07C335/14;;C07C335/16;;C07C335/22;;C07C337/06;;C07D207/44;;C07D207/452;;C07D213/34;;C07D213/71;;C09K3/00,,2,1,037-541-240-623-536,10.1021/jm00080a022;;1732553,"JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 2, 24 January 1992, Washington, DC, US, pages 350 - 361 E. CULLEN, ET AL.: 'Bis basic substituted diaminobenzobisthiazoles as potential antiarthritic agents';;JOURNAL OF ORGANIC CHEMISTRY, vol. 27, no. 6, 12 June 1962, Washington, DC, US, pages 2214 - 2217 E. LEIBER, ET AL.: 'Diisothiocyanates and derivatives' cited in the application",PATENTED
65,US,B2,US 8097339 B2,045-961-926-156-400,2012-01-17,2012,US 14488408 A,2008-06-24,US 14488408 A,2008-06-24,Selective polishing of fuser members,"A method of forming and a resulting selectively polished fuser member. The method includes selectively polishing that portion of the fuser member surface not subject to rapid natural wear. The method further includes polishing both a surface region subject to rapid sheet edge wear and a surface region not subject to rapid sheet edge wear, and polishing the surface region not subject to rapid sheet edge wear more than the surface region subject to rapid sheet edge wear. The rapid natural wear corresponds to sheet edge wear on the fuser member surface.",COUGHLIN JR DANIEL L;;FINN PATRICK J;;XEROX CORP,COUGHLIN JR DANIEL L;;FINN PATRICK J,XEROX CORPORATION (2008-06-23),https://lens.org/045-961-926-156-400,Granted Patent,yes,2,0,2,2,0,G03G15/2053;;Y10T428/3154;;Y10T428/3154;;G03G15/2053,G03G15/20,428/421;;399/279;;399/330;;399/333;;451/28,0,0,,,,INACTIVE
66,WO,A1,WO 2017/184915 A1,001-503-720-961-485,2017-10-26,2017,US 2017/0028721 W,2017-04-21,US 201662325572 P,2016-04-21,LIQUID DISPENSER FOR A SINK FAUCET,"A faucet integrated liquid dispensing system which includes a faucet and a liquid dispensing system. The faucet includes a faucet body, a spout for dispensing water from the faucet, and a dispenser compartment positioned within an interior of the faucet body. The liquid dispenser system includes a dispenser cartridge configured to contain a liquid and positionable within the dispenser compartment of the faucet, one or more fluid lines in fluid communication with the dispenser cartridge, and a dispenser button. Activating the dispenser button provides dispensing of the liquid from the dispenser cartridge through a spout of the faucet.",HUNTER INNOVATIONS LLC,ZAVODNICK DANIEL S;;ZAVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,,https://lens.org/001-503-720-961-485,Patent Application,yes,6,3,1,1,0,A47K5/12;;A47K2005/1218;;E03C1/046,E03C1/046;;A47K5/12;;B05B1/18;;B05B7/04;;B05B7/24,,0,0,,,,PENDING
67,US,A1,US 2016/0356027 A1,174-354-311-107-496,2016-12-08,2016,US 201615174056 A,2016-06-06,US 201615174056 A;;US 201562230433 P;;US 201562219774 P;;US 201662276491 P,2015-06-06,FAUCET ASSEMBLY FIXTURE,"A faucet assembly device which includes an adapter having a bolt with an axially extending internally threaded bore, and an anchor tab which extends axially from the bolt and includes a radially extending protrusion is disclosed. The adapter is configured to rotatably mechanically couple to an outer surface of a faucet fixture and mount the faucet fixture through a hole in a barrier such as a countertop or sink from a faucet side of the barrier so that the anchor tab may hold the faucet fixture securely on the barrier. The device may also include an alignment tool which allows measurement of a thickness of the barrier and provides alignment of the adapter on the faucet fixture at a position corresponding to the thickness of the barrier. Also disclosed are kits which include the adapter and alignment tool, and methods of use of the devices and kits.",ZAVODNICK DANIEL S;;ZAVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,ZAVODNICK DANIEL S;;ZAVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,HUNTER INNOVATIONS LLC (2018-06-15);;ZAVODNICK JOANN (2019-12-31);;ZAVODNICK ALAN (2019-12-31);;ZAVODNICK DANIEL S (2019-12-31),https://lens.org/174-354-311-107-496,Patent Application,yes,11,1,8,8,0,E03C1/0401;;E03C1/0401;;E03C1/0402;;E03C1/0402;;F16B13/0808;;F16B19/008;;F16B37/043;;F16B37/043,E03C1/04,,0,0,,,,ACTIVE
68,US,A,US 5642641 A,027-510-427-401-074,1997-07-01,1997,US 65337696 A,1996-05-21,US 65337696 A;;US 23599794 A,1994-05-02,Dome shaped extruded location feature tool for making the location feature and method for locating adjoining plates using the location feature,A locating feature comprises a plate and a protrusion extending outwardly from the plate. The protrusion includes a substantially linear portion extending from the plate and a dome shaped portion extending from the linear portion.,XEROX CORP,MAXFIELD JR DAVID E;;COUGHLIN JR DANIEL L,,https://lens.org/027-510-427-401-074,Granted Patent,yes,27,33,4,4,0,B21D22/04;;B21D22/04;;B21D39/03;;B21D39/03;;F16B17/008;;F16B17/008;;Y10T29/49895;;Y10T29/49895;;Y10T403/1624;;Y10T403/1624,B21D22/04;;B21D39/03;;F16B17/00,72/358;;72/379.2;;72/377;;72/412;;72/352;;29/464;;52/789.1;;403/14;;411/504,0,0,,,,EXPIRED
69,US,B2,US 10030369 B2,079-233-862-570-562,2018-07-24,2018,US 201615174056 A,2016-06-06,US 201615174056 A;;US 201562230433 P;;US 201562219774 P;;US 201662276491 P,2015-06-06,Faucet assembly fixture,"A faucet assembly device which includes an adapter having a bolt with an axially extending internally threaded bore, and an anchor tab which extends axially from the bolt and includes a radially extending protrusion is disclosed. The adapter is configured to rotatably mechanically couple to an outer surface of a faucet fixture and mount the faucet fixture through a hole in a barrier such as a countertop or sink from a faucet side of the barrier so that the anchor tab may hold the faucet fixture securely on the barrier. The device may also include an alignment tool which allows measurement of a thickness of the barrier and provides alignment of the adapter on the faucet fixture at a position corresponding to the thickness of the barrier. Also disclosed are kits which include the adapter and alignment tool, and methods of use of the devices and kits.",ZAVODNICK DANIEL S;;ZAVODNICK ALAN;;COUGHLIN MATTHEW PATRICK;;HUNTER INNOVATIONS LLC,ZAVODNICK DANIEL S;;ZAVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,HUNTER INNOVATIONS LLC (2018-06-15);;ZAVODNICK JOANN (2019-12-31);;ZAVODNICK DANIEL S (2019-12-31);;ZAVODNICK ALAN (2019-12-31),https://lens.org/079-233-862-570-562,Granted Patent,yes,46,0,8,8,0,E03C1/0401;;E03C1/0401;;E03C1/0402;;E03C1/0402;;F16B13/0808;;F16B19/008;;F16B37/043;;F16B37/043,E03C1/042;;E03C1/04;;F16B13/08;;F16B19/00;;F16B37/04,,0,0,,,,ACTIVE
70,WO,A1,WO 2016/200724 A1,114-914-516-341-338,2016-12-15,2016,US 2016/0035992 W,2016-06-06,US 201562230433 P;;US 201562219774 P;;US 201662276491 P,2015-06-06,FAUCET ASSEMBLY FIXTURE,"A faucet assembly device which includes an adapter having a bolt with an axially extending internally threaded bore, and an anchor tab which extends axially from the bolt and includes a radially extending protrusion is disclosed. The adapter is configured to rotatably mechanically couple to an outer surface of a faucet fixture and mount the faucet fixture through a hole in a barrier such as a countertop or sink from a faucet side of the barrier so that the anchor tab may hold the faucet fixture securely on the barrier. The device may also include an alignment tool which allows measurement of a thickness of the barrier and provides alignment of the adapter on the faucet fixture at a position corresponding to the thickness of the barrier. Also disclosed are kits which include the adapter and alignment tool, and methods of use of the devices and kits.",ZAVODNICK DANIEL S;;ZAVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,ZAVODNICK DANIEL S;;ZAVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,,https://lens.org/114-914-516-341-338,Patent Application,yes,5,0,8,8,0,E03C1/0401;;E03C1/0401;;E03C1/0402;;E03C1/0402;;F16B13/0808;;F16B19/008;;F16B37/043;;F16B37/043,E03C1/04;;E03C1/00;;E03C1/042;;F16K21/00;;F16L3/12,,0,0,,,,PENDING
71,CA,A1,CA 3026831 A1,043-247-728-942-004,2016-12-15,2016,CA 3026831 A,2016-06-06,US 201562230433 P;;US 201562219774 P;;US 201662276491 P;;US 2016/0035999 W,2015-06-06,TENSION-BASED MECHANICAL COUPLING DEVICE,"A mechanical-coupling device is described. The mechanical-coupling device includes a toggle bolt with a fixture in a bolt head that remateably mechanically couples to an attachment tool. The device may further include an anchor nut having an anchor wing or tab. During mechanical coupling of the anchor nut to the bolt with a mounting material, such as a wall, countertop or sink, between the bolt head and the anchor nut, the fixture may convey a pulling force, from the attachment tool, that results in fixing a position of the anchor nut with the anchor wing or tab in a deployed position. Moreover, the fixture may convey a rotational torque, from the attachment tool, about a symmetry axis of the bolt that rotates the bolt relative to the fixed position of the anchor nut so that a distance between the bolt head and the anchor nut decreases.",ZAVODNICK DANIEL S;;ZOVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,ZAVODNICK DANIEL S;;ZOVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,,https://lens.org/043-247-728-942-004,Patent Application,no,0,0,8,8,0,E03C1/0401;;E03C1/0401;;E03C1/0402;;E03C1/0402;;F16B13/0808;;F16B19/008;;F16B37/043;;F16B37/043,F16B13/08;;F16B13/04;;F16B21/06;;F16B21/07;;F16B37/04,,0,0,,,,DISCONTINUED
72,US,B2,US 10364556 B2,015-593-381-058-258,2019-07-30,2019,US 201615174252 A,2016-06-06,US 201615174252 A;;US 201562230433 P;;US 201562219774 P;;US 201662276491 P,2015-06-06,Tension-based mechanical coupling device,"A mechanical-coupling device is described. The mechanical-coupling device includes a toggle bolt with a fixture in a bolt head that remateably mechanically couples to an attachment tool. The device may further include an anchor nut having an anchor wing or tab. During mechanical coupling of the anchor nut to the bolt with a mounting material, such as a wall, countertop or sink, between the bolt head and the anchor nut, the fixture may convey a pulling force, from the attachment tool, that results in fixing a position of the anchor nut with the anchor wing or tab in a deployed position. Moreover, the fixture may convey a rotational torque, from the attachment tool, about a symmetry axis of the bolt that rotates the bolt relative to the fixed position of the anchor nut so that a distance between the bolt head and the anchor nut decreases.",ZAVODNICK DANIEL S;;ZAVODNICK ALAN;;COUGHLIN MATTHEW PATRICK;;HUNTER INNOVATIONS LLC,ZAVODNICK DANIEL S;;ZAVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,HUNTER INNOVATIONS LLC (2019-06-04);;ZAVODNICK JOANN (2019-12-31);;ZAVODNICK DANIEL S (2019-12-31);;ZAVODNICK ALAN (2019-12-31),https://lens.org/015-593-381-058-258,Granted Patent,yes,49,3,8,8,0,E03C1/0401;;E03C1/0401;;E03C1/0402;;E03C1/0402;;F16B13/0808;;F16B19/008;;F16B37/043;;F16B37/043,F16B21/00;;E03C1/04;;F16B13/08;;F16B19/00;;F16B37/04,,0,0,,,,ACTIVE
73,US,B2,US 7691446 B2,081-723-041-014-212,2010-04-06,2010,US 87915307 A,2007-07-16,US 87915307 A,2007-07-16,High temperature silicone processing of fuser structure,This is a process to restore compression set properties of a silicone rubber fuser structure that has been damaged during the coating of the silicone with Teflon; Teflon is a registered trademark of DuPont. This restoration is achieved by re-baking the coated fuser roll at temperatures of 175° C. to 275° C. This will improve the compression set and will give the fuser structure improved life and provide better image quality.,XEROX CORP,IRVING DAVID C;;COUGHLIN DANIEL L;;FINN PATRICK,XEROX CORPORATION (2007-07-11),https://lens.org/081-723-041-014-212,Granted Patent,yes,3,0,2,2,0,G03G15/2057;;Y10T428/139;;Y10T428/1386;;Y10T428/254;;Y10T428/3154;;Y10T428/31663;;Y10T428/249974;;Y10T428/139;;Y10T428/1386;;Y10T428/254;;Y10T428/3154;;Y10T428/31663;;Y10T428/249974;;G03G15/2057,B05D3/02,427/372.2;;427/374;;427/379;;427/384;;428/36.8;;428/36.9;;428/313.9;;428/327;;428/421;;428/447,0,0,,,,INACTIVE
74,US,A1,US 2016/0356297 A1,164-575-920-980-06X,2016-12-08,2016,US 201615174252 A,2016-06-06,US 201615174252 A;;US 201562230433 P;;US 201562219774 P;;US 201662276491 P,2015-06-06,TENSION-BASED MECHANICAL COUPLING DEVICE,"A mechanical-coupling device is described. The mechanical-coupling device includes a toggle bolt with a fixture in a bolt head that remateably mechanically couples to an attachment tool. The device may further include an anchor nut having an anchor wing or tab. During mechanical coupling of the anchor nut to the bolt with a mounting material, such as a wall, countertop or sink, between the bolt head and the anchor nut, the fixture may convey a pulling force, from the attachment tool, that results in fixing a position of the anchor nut with the anchor wing or tab in a deployed position. Moreover, the fixture may convey a rotational torque, from the attachment tool, about a symmetry axis of the bolt that rotates the bolt relative to the fixed position of the anchor nut so that a distance between the bolt head and the anchor nut decreases.",ZAVODNICK DANIEL S;;ZAVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,ZAVODNICK DANIEL S;;ZAVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,HUNTER INNOVATIONS LLC (2019-06-04);;ZAVODNICK JOANN (2019-12-31);;ZAVODNICK DANIEL S (2019-12-31);;ZAVODNICK ALAN (2019-12-31),https://lens.org/164-575-920-980-06X,Patent Application,yes,0,4,8,8,0,E03C1/0401;;E03C1/0401;;E03C1/0402;;E03C1/0402;;F16B13/0808;;F16B19/008;;F16B37/043;;F16B37/043,F16B13/08;;F16B19/00,,0,0,,,,ACTIVE
75,WO,A1,WO 2016/200725 A1,143-389-311-811-542,2016-12-15,2016,US 2016/0035999 W,2016-06-06,US 201662276491 P;;US 201562219774 P;;US 201562230433 P,2015-06-06,TENSION-BASED MECHANICAL COUPLING DEVICE,"A mechanical-coupling device is described. The mechanical-coupling device includes a toggle bolt with a fixture in a bolt head that remateably mechanically couples to an attachment tool. The device may further include an anchor nut having an anchor wing or tab. During mechanical coupling of the anchor nut to the bolt with a mounting material, such as a wall, countertop or sink, between the bolt head and the anchor nut, the fixture may convey a pulling force, from the attachment tool, that results in fixing a position of the anchor nut with the anchor wing or tab in a deployed position. Moreover, the fixture may convey a rotational torque, from the attachment tool, about a symmetry axis of the bolt that rotates the bolt relative to the fixed position of the anchor nut so that a distance between the bolt head and the anchor nut decreases.",ZAVODNICK DANIEL S;;ZOVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,ZAVODNICK DANIEL S;;ZOVODNICK ALAN;;COUGHLIN MATTHEW PATRICK,,https://lens.org/143-389-311-811-542,Patent Application,yes,5,0,8,8,0,E03C1/0401;;E03C1/0401;;E03C1/0402;;E03C1/0402;;F16B13/0808;;F16B19/008;;F16B37/043;;F16B37/043,F16B13/08;;F16B13/04;;F16B21/06;;F16B21/07;;F16B37/04,,0,0,,,,PENDING
76,US,A1,US 2018/0328009 A1,157-225-256-725-090,2018-11-15,2018,US 201816040810 A,2018-07-20,US 201816040810 A;;US 201615174056 A;;US 201562230433 P;;US 201562219774 P;;US 201662276491 P,2015-06-06,FAUCET ASSEMBLY FIXTURE,"A faucet assembly device which includes an adapter having a bolt with an axially extending internally threaded bore, and an anchor tab which extends axially from the bolt and includes a radially extending protrusion is disclosed. The adapter is configured to rotatably mechanically couple to an outer surface of a faucet fixture and mount the faucet fixture through a hole in a barrier such as a countertop or sink from a faucet side of the barrier so that the anchor tab may hold the faucet fixture securely on the barrier. The device may also include an alignment tool which allows measurement of a thickness of the barrier and provides alignment of the adapter on the faucet fixture at a position corresponding to the thickness of the barrier. Also disclosed are kits which include the adapter and alignment tool, and methods of use of the devices and kits.",ZAVODNIK DANIEL S;;ZAVODNIK ALAN;;COUGHLIN MATTHEW PATRICK,ZAVODNIK DANIEL S;;ZAVODNIK ALAN;;COUGHLIN MATTHEW PATRICK,ZAVODNICK JOANN (2019-12-31);;ZAVODNICK ALAN (2019-12-31);;ZAVODNICK DANIEL S (2019-12-31),https://lens.org/157-225-256-725-090,Patent Application,yes,0,0,8,8,0,E03C1/0401;;E03C1/0401;;E03C1/0402;;E03C1/0402;;F16B13/0808;;F16B19/008;;F16B37/043;;F16B37/043,E03C1/04;;F16B13/08;;F16B19/00;;F16B37/04,,0,0,,,,DISCONTINUED
77,EP,A1,EP 0680792 A1,175-634-886-570-126,1995-11-08,1995,EP 95302960 A,1995-05-01,US 23599794 A,1994-05-02,Dome shaped extruded location feature.,A locating feature comprises a plate (42) and a protrusion (40) extending outwardly from the plate. The protrusion includes a substantially linear portion (44) extending from the plate and a dome shaped portion (50) extending from the linear portion.,XEROX CORP,MAXFIELD DAVID E JR;;COUGHLIN DANIEL L JR,,https://lens.org/175-634-886-570-126,Patent Application,yes,5,3,4,4,0,B21D22/04;;B21D22/04;;B21D39/03;;B21D39/03;;F16B17/008;;F16B17/008;;Y10T29/49895;;Y10T29/49895;;Y10T403/1624;;Y10T403/1624,B21D22/04;;B21D39/03;;F16B17/00,,0,0,,,,DISCONTINUED
78,HR,T1,HR P20201638 T1,064-002-328-725-971,2021-03-05,2021,HR P20201638 T,2020-10-12,US 201462012701 P;;EP 15731459 A;;US 2015/0035558 W,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,,JOHNSON MATTHEY PLC,COUGHLIN DANIEL;;WILT JEREMY;;GOU DA-MING;;COLLIER STEVEN,,https://lens.org/064-002-328-725-971,Granted Patent,no,0,0,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07D417/12;;C07C39/00;;C07D209/52;;C07D215/22;;C07D239/88;;C07D241/04;;C07D275/06;;C07D311/06;;C07D413/04;;C07D413/12;;C07D471/12;;C07D487/12,,0,0,,,,ACTIVE
79,DE,D1,DE 68911397 D1,139-050-608-208-763,1994-01-27,1994,DE 68911397 T,1989-06-06,US 20379388 A,1988-06-07,Radiohalogenierte Verbindungen für Markierung von spezifischen Stellen.,,CYTOGEN CORP,COUGHLIN DANIEL JAMES;;BELINKA BENJAMIN A;;ALVAREZ VERNON LEON,,https://lens.org/139-050-608-208-763,Granted Patent,no,0,0,11,11,0,A61K51/1051;;A61K51/1063;;A61K2121/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61K51/1051;;A61K51/1063;;A61K2121/00,A61K39/395;;A61K51/00;;A61K51/10;;A61P31/04;;A61P31/12;;A61P35/00;;C07B59/00;;C07C215/00;;C07C215/76;;C07C217/00;;C07C217/84;;C07C243/00;;C07C243/22;;C07C243/38;;C07K1/113;;C07K14/00;;C07K14/705;;C07K16/00,,0,0,,,,EXPIRED
80,US,A1,US 2015/0361099 A1,195-240-205-012-502,2015-12-17,2015,US 201514737599 A,2015-06-12,US 201514737599 A;;US 201462012701 P,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,"Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R 1 and R 2 are individually selected from hydrogen, alkyl, substituted or alkyl; n=0, 1, or 2; Y=NR 3 R 4 , OR 5 , or SR 5 , where R 3 and R 4 are individually selected from acyl or sulfonyl, and where R 5 is aryl or heteroaryl, or heterocyclic; and Ar is an aryl, heteroaryl, or heterocyclic compound.",JOHNSON MATTHEY PLC,COUGHLIN DANIEL J;;WILT JEREMY C;;GOU DA-MING,JOHNSON MATTHEY PUBLIC LIMITED COMPANY (2016-03-15);;MACFARLAN SMITH LIMITED (2022-09-30),https://lens.org/195-240-205-012-502,Patent Application,yes,1,2,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07D519/00;;C07D209/56;;C07D215/227;;C07D261/20;;C07D275/06;;C07D311/20;;C07D401/12;;C07D403/12;;C07D413/12;;C07D417/08;;C07D417/12,,0,0,,,,ACTIVE
81,AT,T1,AT E98630 T1,011-696-543-128-949,1994-01-15,1994,AT 89401557 T,1989-06-06,EP 89401557 A;;US 20379388 A,1988-06-07,RADIOHALOGENIERTE VERBINDUNGEN FUER MARKIERUNG VON SPEZIFISCHEN STELLEN.,,CYTOGEN CORP,COUGHLIN DANIEL JAMES;;BELINKA BENJAMIN A;;ALVAREZ VERNON LEON,,https://lens.org/011-696-543-128-949,Granted Patent,no,0,0,11,11,0,A61K51/1051;;A61K51/1063;;A61K2121/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61K51/1051;;A61K51/1063;;A61K2121/00,A61K39/395;;A61K51/00;;A61K51/10;;A61P31/04;;A61P31/12;;A61P35/00;;C07B59/00;;C07C215/00;;C07C215/76;;C07C217/00;;C07C217/84;;C07C243/00;;C07C243/22;;C07C243/38;;C07K1/113;;C07K14/00;;C07K14/705;;C07K16/00,,0,0,,,,DISCONTINUED
82,AU,A,AU 1989/037728 A,055-425-262-120-563,1990-01-05,1990,AU 1989/037728 A,1989-06-06,US 20379388 A,1988-06-07,RADIOHALOGENATED COMPOUNDS FOR SITE SPECIFIC LABELING,,CYTOGEN CORP,COUGHLIN DANIEL J;;BELINKA BENJAMIN A;;ALVAREZ VERNON L,,https://lens.org/055-425-262-120-563,Patent Application,no,0,0,11,11,0,A61K51/1051;;A61K51/1063;;A61K2121/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61K51/1051;;A61K51/1063;;A61K2121/00,A61K39/395;;A61K51/00;;A61K51/10;;A61P31/04;;A61P31/12;;A61P35/00;;C07B59/00;;C07C215/00;;C07C215/76;;C07C217/00;;C07C217/84;;C07C243/00;;C07C243/22;;C07C243/38;;C07K1/113;;C07K14/00;;C07K14/705;;C07K16/00,,0,0,,,,PENDING
83,AU,A1,AU 2010/232496 A1,043-548-978-761-213,2011-11-24,2011,AU 2010/232496 A,2010-04-02,US 16614309 P;;US 2010/0029809 W,2009-04-02,Compositions of cholinesterase inhibitors,"The present invention is directed to compositions, methods of use, and processes for the synthesis related to 3-(()-l-(dimethylamino)ethyl)phenyl methyl-(()- 1 -phenylpropan-2 yl)carbamate, and its pharmaceutically acceptable salt forms, including the hydrogen fumarate salt. The present invention also relates to a novel form polymorph of 3-(()-l- (dimethylamino)ethyl)phenyl methyl-(()- 1 -phenylpropan-2 yl)carbamate, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.",COLUCID PHARMACEUTICALS INC,SHOUCHENG DU;;ANDERSEN MARC W;;DANIEL COUGHLIN;;ALEXANDER KOLCHINSKI,,https://lens.org/043-548-978-761-213,Patent Application,no,0,0,6,6,0,C07C57/15;;C07C271/44;;A61P1/00;;A61P25/00;;A61P25/16;;A61P25/28;;A61P25/34;;A61P27/06;;A61P9/10;;C07C271/44;;C07C57/15,A61K31/221;;A61P25/00;;A61P25/28,,0,0,,,,DISCONTINUED
84,EP,A1,EP 0348261 A1,019-700-505-828-127,1989-12-27,1989,EP 89401557 A,1989-06-06,US 20379388 A,1988-06-07,Radiohalogenated compounds for site specific labeling.,"Radiohalogenated compounds which are useful as intermediates for preparing radiohalogenated antibody conjugates in which the radiohalogenated compound is site specifically attached to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. Methods for making the compounds and the antibody conjugates as well as methods of use of the same are also disclosed.  ",CYTOGEN CORP,COUGHLIN DANIEL JAMES;;BELINKA BENJAMIN A;;ALVAREZ VERNON LEON,,https://lens.org/019-700-505-828-127,Patent Application,yes,3,1,11,11,0,A61K51/1051;;A61K51/1063;;A61K2121/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61K51/1051;;A61K51/1063;;A61K2121/00,A61K39/395;;A61K51/00;;A61K51/10;;A61P31/04;;A61P31/12;;A61P35/00;;C07B59/00;;C07C215/00;;C07C215/76;;C07C217/00;;C07C217/84;;C07C243/00;;C07C243/22;;C07C243/38;;C07K1/113;;C07K14/00;;C07K14/705;;C07K16/00,,2,2,101-133-297-153-391;;001-840-214-108-665,10.1021/jo00211a044;;10.1021/jm00264a023;;4715002,"The Journal of Organic Chemistry, Vol. 50, No. 11, May 31, 1985, pages 1988-1990, American Chemical Society; N.D. HEINDEL et al.: ""Prosthetic group radioiodination at ""No Carrier Added"" levels of carbonyl-containing molecules"", whole article.;;The Journal of Medicinal Chemistry, Vol. 16, No. 6, June 1973, pages 684-687, R.E. COUNSELL et al.: ""Potential organ or tumor imaging agents. 11. Radioiodinated tyramines"", whole article.",EXPIRED
85,DE,T2,DE 68911397 T2,104-589-132-292-216,1994-05-26,1994,DE 68911397 T,1989-06-06,US 20379388 A,1988-06-07,Radiohalogenierte Verbindungen für Markierung von spezifischen Stellen.,,CYTOGEN CORP,COUGHLIN DANIEL JAMES;;BELINKA BENJAMIN A;;ALVAREZ VERNON LEON,,https://lens.org/104-589-132-292-216,Granted Patent,no,0,0,11,11,0,A61K51/1051;;A61K51/1063;;A61K2121/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61K51/1051;;A61K51/1063;;A61K2121/00,A61K39/395;;A61K51/00;;A61K51/10;;A61P31/04;;A61P31/12;;A61P35/00;;C07B59/00;;C07C215/00;;C07C215/76;;C07C217/00;;C07C217/84;;C07C243/00;;C07C243/22;;C07C243/38;;C07K1/113;;C07K14/00;;C07K14/705;;C07K16/00,,0,0,,,,EXPIRED
86,WO,A3,WO 2010/115124 A3,148-668-377-133-960,2011-02-24,2011,US 2010/0029809 W,2010-04-02,US 16614309 P,2009-04-02,COMPOSITIONS OF CHOLINESTERASE INHIBITORS,"The present invention is directed to compositions, methods of use, and processes for the synthesis related to 3-(( S )-l-(dimethylamino)ethyl)phenyl methyl-(( R )- 1 -phenylpropan-2 yl)carbamate, and its pharmaceutically acceptable salt forms, including the hydrogen fumarate salt. The present invention also relates to a novel form polymorph of 3-(( S )-l- (dimethylamino)ethyl)phenyl methyl-(( R )- 1 -phenylpropan-2 yl)carbamate, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.",COLUCID PHARMACEUTICALS INC;;DU SHOUCHENG;;ANDERSEN MARC W;;COUGHLIN DANIEL;;KOLCHINSKI ALEXANDER,DU SHOUCHENG;;ANDERSEN MARC W;;COUGHLIN DANIEL;;KOLCHINSKI ALEXANDER,,https://lens.org/148-668-377-133-960,Search Report,yes,3,0,6,6,0,C07C57/15;;C07C271/44;;A61P1/00;;A61P25/00;;A61P25/16;;A61P25/28;;A61P25/34;;A61P27/06;;A61P9/10;;C07C271/44;;C07C57/15,A61K31/221;;A61P25/00;;A61P25/28,,1,1,018-481-310-187-389,10.1021/jm010914b;;11689067,"ANGELA RAMPA ET AL.: ""Acetylcholinesterase inhibitors: SAR and kinetic studies on omega- [N-methyl-N-(3-alkylcarbamoyloayphenylmethyl]aminoalkoxyaryl derivatives"", J MED. CHEM., vol. 44, 2001, pages 3810 - 3820, XP002297756",PENDING
87,ES,T3,ES 2062061 T3,006-887-887-358-722,1994-12-16,1994,ES 89401557 T,1989-06-06,US 20379388 A,1988-06-07,COMPUESTOS RADIOHALOGENADOS PARA EL MARCAJE ESPECIFICO DE SITIO.,LA INVENCION SE REFIERE A COMPUESTO RADIOHALOGENADOS QUE SON UTILES COMO COMPUESTOS INTERMEDIOS PARA PREPARAR CONJUGADOS DE ANTICUERPOS RADIOHALOGENADOS EN LOS QUE EL COMPUESTO RADIOHALOGENADO ESTA UNIDO ESPECIFICAMENTE POR UN PUNTO A UNA PORCION O UN FRAGMENTO DE ANTICUERPO. TAMBIEN INCLUYE LA INVENCION METODOS PARA LA PREPARACION DE LOS COMPUESTOS Y LOS CONJUGADOS DEL ANTICUERPO ASI COMO METODOS PARA SU EMPLEO.,CYTOGEN CORP,COUGHLIN DANIEL JAMES;;BELINKA BENJAMIN A;;ALVAREZ VERNON LEON,,https://lens.org/006-887-887-358-722,Granted Patent,no,0,0,11,11,0,A61K51/1051;;A61K51/1063;;A61K2121/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61K51/1051;;A61K51/1063;;A61K2121/00,A61K39/395;;A61K51/00;;A61K51/10;;A61P31/04;;A61P31/12;;A61P35/00;;C07B59/00;;C07C215/00;;C07C215/76;;C07C217/00;;C07C217/84;;C07C243/00;;C07C243/22;;C07C243/38;;C07K1/113;;C07K14/00;;C07K14/705;;C07K16/00,,0,0,,,,EXPIRED
88,US,A1,US 2004/0014402 A1,013-777-410-639-507,2004-01-22,2004,US 42732703 A,2003-05-01,US 42732703 A;;US 72315000 A,2000-11-27,"Method of finishing a belt seam using an abrasive finishing machine, a method of finishing a belt seam using an abrasive finishing machine having a plurality of finishing heads, and a method of finishing a belt seam using an abrasive finishing machine having first, second, third and fourth finishing heads","
   An imageable belt includes a seam that is finished using an abrasive finishing machine. The seam comprises a seam width with adhesive material disposed thereon. The finishing process includes an abrasive-finishing media with a finishing surface and a backer bar. The backer bar comprises a backer bar radius. The backer bar surface is positioned against the belt inner surface so that the belt outer surface contacts the finishing surface to define a finishing contact arc with respect to the backer bar radius. A tension, feed rate and pressure are applied to the finishing media. Using the finishing machine, the seam is then finished to remove the adhesive material. The finishing process results in a seam that is imageable. In one embodiment, the backer bar radius is adjusted so that the finishing contact arc covers the seam width. 
",XEROX CORP,MASTRO PAUL F;;COUGHLIN DANIEL L;;DIGRAVIO THOMAS L,XEROX CORPORATION (2003-09-03),https://lens.org/013-777-410-639-507,Patent Application,yes,12,0,2,4,0,B24B21/006;;B24B21/006;;B29C66/02245;;B29C66/02245;;B29C66/032;;B29C66/032;;B29L2031/709;;B29L2031/709;;B29L2031/764;;B29L2031/764,B24B21/00;;B29C65/00,451/59;;451/28,0,0,,,,EXPIRED
89,US,A1,US 2003/0031822 A1,127-056-887-032-183,2003-02-13,2003,US 26814502 A,2002-10-09,US 26814502 A;;US 72315000 A,2000-11-27,"Method of finishing a belt seam, an intermediate transfer belt finished in accordance with the same method, and a printing machine with an intermediate transfer belt finished in accordance with the same method","
   An intermediate transfer belt includes a seam that is finished using a finishing machine. The intermediate transfer belt comprises a belt outer surface and a belt inner surface. The seam comprises a seam outer surface of a seam width with adhesive material disposed thereon. The finishing process includes a finishing media with a finishing surface and a backer bar. The backer bar comprises a backer bar radius and a backer bar surface with a backer surface curvature based on the backer bar radius. The backer bar surface is positioned against the belt inner surface so that the belt outer surface contacts the finishing surface to define a finishing contact arc with respect to the backer bar radius. A tension, feed rate and pressure are applied to the finishing media. The backer bar radius is then adjusted so that the finishing contact arc covers the seam width. Using the finishing machine, the seam is then finished to remove the adhesive material. The backer bar radius is adjusted by any convenient means such as, for example, by grinding the backer bar. The finishing process results in a seam that is imageable. 
",XEROX CORP,MASTRO PAUL F;;COUGHLIN DANIEL L;;DIGRAVIO THOMAS L,,https://lens.org/127-056-887-032-183,Patent Application,yes,0,0,2,4,0,B24B21/006;;B29C66/02245;;B29C66/032;;B29L2031/709;;B29L2031/764;;Y10T428/192;;Y10T428/19;;Y10T428/192;;Y10T428/19;;B29C66/032;;B29L2031/709;;B29L2031/764;;B29C66/02245;;B24B21/006,B24B21/00;;B29C65/00,428/58,0,0,,,,DISCONTINUED
90,ES,T3,ES 2826603 T3,175-671-869-189-983,2021-05-18,2021,ES 15731459 T,2015-06-12,US 201462012701 P;;US 2015/0035558 W,2014-06-16,Procesos para la preparación de compuestos de arilpiperazina alquilada y arilpiperidina alquilada que incluyen productos intermedios novedosos,"Un proceso para la preparación de un compuesto de arilpiperazina alquilada de Fórmula (I): **(Ver fórmula)** en donde, R1 y R2 se seleccionan individualmente de hidrógeno, alquilo no sustituido y alquilo sustituido o R1 y R2 se conectan para formar un anillo cíclico de 5 a 8 carbonos; n es 0, 1 o 2; Y es NR3R4, OR5 o SR5, donde R3 y R4 se seleccionan individualmente de acilo o sulfonilo, en donde R3 y R4 se pueden conectar para formar un anillo cíclico o bicíclico sustituido o no sustituido y en donde R5 es arilo o heteroarilo, o heterocíclico; y Ar es un grupo arilo o heteroarilo; comprendiendo dicho proceso las etapas de: (i) alquilar YH con un sulfato cíclico de Fórmula (II) en presencia de una base para formar un compuesto de Fórmula (III), en donde Q es hidrógeno, un metal o una sal de amonio; **(Ver fórmula)** (ii) hidrolizar el compuesto de Fórmula (III) para formar un alcohol de Fórmula (IV); **(Ver fórmula)** (iii) convertir el compuesto de Fórmula (IV) para formar un agente alquilante de Fórmula (V) en donde GS es un grupo saliente; y **(Ver fórmula)** (iv) alquilar un compuesto de piperazina de Fórmula (VI) con el agente alquilante de Fórmula (V) para proporcionar la arilpiperazina alquilada de Fórmula (I) **(Ver fórmula)**",JOHNSON MATTHEY PLC,COUGHLIN DANIEL;;WILT JEREMY;;GOU DA-MING;;COLLIER STEVEN,,https://lens.org/175-671-869-189-983,Granted Patent,no,0,0,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07D417/12;;C07C39/00;;C07D209/52;;C07D215/22;;C07D239/88;;C07D241/04;;C07D275/06;;C07D311/06;;C07D413/04;;C07D413/12;;C07D471/12;;C07D487/12,,0,0,,,,ACTIVE
91,CA,C,CA 1318615 C,032-117-894-775-761,1993-06-01,1993,CA 601795 A,1989-06-05,US 20379388 A,1988-06-07,RADIOHALOGENATED COMPOUNDS FOR SITE SPECIFIC LABELING,ABSTRACT OF THE DISCLOSURE Radiohalogenated compounds which are useful as intermediates for preparing radiohalogenated antibody conjugates in which the radiohalogenated compound is site specifically attached to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. Methods for making the compounds and the antibody conjugates as well as methods of use of the same are also disclosed.,COUGHLIN DANIEL J,COUGHLIN DANIEL J;;BELINKA BENJAMIN A;;ALVAREZ VERNON L,,https://lens.org/032-117-894-775-761,Granted Patent,no,0,0,11,11,0,A61K51/1051;;A61K51/1063;;A61K2121/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61K51/1051;;A61K51/1063;;A61K2121/00,A61K39/395;;A61K51/00;;A61K51/10;;A61P31/04;;A61P31/12;;A61P35/00;;C07B59/00;;C07C215/00;;C07C215/76;;C07C217/00;;C07C217/84;;C07C243/00;;C07C243/22;;C07C243/38;;C07K1/113;;C07K14/00;;C07K14/705;;C07K16/00,D319500011   M;;1670041    S;;1670047    S;;1670139    S;;26005493   S;;26005911   S;;26006037   S,0,0,,,,EXPIRED
92,EP,A1,EP 3154967 A1,076-071-455-219-89X,2017-04-19,2017,EP 15731459 A,2015-06-12,US 201462012701 P;;US 2015/0035558 W,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,,JOHNSON MATTHEY PLC,COUGHLIN DANIEL;;WILT JEREMY;;GOU DA-MING;;COLLIER STEVEN,"MACFARLAN SMITH LIMITED; GB (2023-02-27);;MACFARLAN SMITH LIMITED, GB (2023-02-14)",https://lens.org/076-071-455-219-89X,Patent Application,yes,0,0,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07D417/12;;C07C39/00;;C07D209/52;;C07D215/22;;C07D239/88;;C07D241/04;;C07D275/06;;C07D311/06;;C07D413/04;;C07D413/12;;C07D471/12;;C07D487/12,,1,0,,,See references of WO 2015195478A1,ACTIVE
93,US,A,US 4966999 A,023-873-804-730-373,1990-10-30,1990,US 20379388 A,1988-06-07,US 20379388 A,1988-06-07,Radiohalogenated compounds for site specific labeling,"Radiohalogenated compounds which are useful as intermediates for preparing radiohalogenated antibody conjugates in which the radiohalogenated compound is site specifically attached to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. Methods for making the compounds and the antibody conjugates as well as methods of use of the same are also disclosed In particular, phenolic hydrazide and phenolic amine compounds are disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;BELINKA BENJAMIN A;;ALVAREZ VERNON L,CYTOGEN CORPORATION (1988-08-05),https://lens.org/023-873-804-730-373,Granted Patent,yes,7,45,11,11,0,A61K51/1051;;A61K51/1063;;A61K2121/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61K51/1051;;A61K51/1063;;A61K2121/00,A61K39/395;;A61K51/00;;A61K51/10;;A61P31/04;;A61P31/12;;A61P35/00;;C07B59/00;;C07C215/00;;C07C215/76;;C07C217/00;;C07C217/84;;C07C243/00;;C07C243/22;;C07C243/38;;C07K1/113;;C07K14/00;;C07K14/705;;C07K16/00,564/150;;564/390;;424/1.1;;424/85.91;;530/391;;530/405,6,0,,,"European Patent Application No. 86,303,757.8 to Wilbur, et al.;;Wilbur et al., J. Labelled Compd. Radiopharm. 23 (10 12): 1304 1306 (1986).;;Wilbur et al., Nucl. Med. 27(6):959 (1986).;;Hadley et al., J. Nucl. Med 28 (4 Suppl.): 725 (1987).;;Gersehngorn et al., in The Throid Gland: 81 121 (M. De Visscher ed. 1980).;;Powe, Hybridoma 5 (Suppl. 1): 539 542 (1986).",EXPIRED
94,US,A1,US 2010/0256229 A1,061-832-302-268-622,2010-10-07,2010,US 75356710 A,2010-04-02,US 75356710 A;;US 16614309 P,2009-04-02,COMPOSITIONS OF CHOLINESTERASE INHIBITORS,"The present invention is directed to compositions, methods of use, and processes for the synthesis related to 3-((S)-1-(dimethylamino)ethyl)phenyl methyl-((R)-1-phenylpropan-2 yl)carbamate, and its pharmaceutically acceptable salt forms, including the hydrogen fumarate salt. The present invention also relates to a novel form polymorph of 3-((S)-1-(dimethylamino)ethyl)phenylmethyl-((R)-1-phenylpropan-2 yl)carbamate, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.",COLUCID PHARMACEUTICALS INC,DU SHOUCHENG;;ANDERSEN MARC W;;COUGHLIN DANIEL;;KOLCHINSKI ALEXANDER,APTUIT (EDINBURGH) LTD (2010-06-07);;COLUCID PHARMACEUTICALS INC (2010-06-08),https://lens.org/061-832-302-268-622,Patent Application,yes,0,3,6,6,0,C07C57/15;;C07C271/44;;A61P1/00;;A61P25/00;;A61P25/16;;A61P25/28;;A61P25/34;;A61P27/06;;A61P9/10;;C07C271/44;;C07C57/15,A61K31/27;;A61P1/00;;A61P9/10;;A61P25/16;;A61P25/28;;A61P25/34;;A61P27/06;;C07C271/44,514/487;;560/32,0,0,,,,DISCONTINUED
95,SI,T1,SI 3154967 T1,071-194-698-419-51X,2020-11-30,2020,SI 201531384 T,2015-06-12,US 201462012701 P;;US 2015/0035558 W;;EP 15731459 A,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,,JOHNSON MATTHEY PLC,COUGHLIN DANIEL;;WILT JEREMY;;GOU DA-MING;;COLLIER STEVEN,,https://lens.org/071-194-698-419-51X,Granted Patent,no,0,0,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07D417/00;;C07C39/00;;C07D209/00;;C07D215/00;;C07D239/00;;C07D241/00;;C07D275/00;;C07D311/00;;C07D413/00;;C07D471/00;;C07D487/00,,0,0,,,,ACTIVE
96,US,A1,US 2003/0039791 A1,096-790-325-395-648,2003-02-27,2003,US 26814402 A,2002-10-09,US 26814402 A;;US 72315000 A,2000-11-27,"Method of finishing a belt seam, an intermediate transfer belt finished in accordance with the same method, and a printing machine with an intermediate transfer belt finished in accordance with the same method","
   An intermediate transfer belt includes a seam that is finished using a finishing machine. The intermediate transfer belt comprises a belt outer surface and a belt inner surface. The seam comprises a seam outer surface of a seam width with adhesive material disposed thereon. The finishing process includes a finishing media with a finishing surface and a backer bar. The backer bar comprises a backer bar radius and a backer bar surface with a backer surface curvature based on the backer bar radius. The backer bar surface is positioned against the belt inner surface so that the belt outer surface contacts the finishing surface to define a finishing contact arc with respect to the backer bar radius. A tension, feed rate and pressure are applied to the finishing media. The backer bar radius is then adjusted so that the finishing contact arc covers the seam width. Using the finishing machine, the seam is then finished to remove the adhesive material. The backer bar radius is adjusted by any convenient means such as, for example, by grinding the backer bar. The finishing process results in a seam that is imageable. 
",XEROX CORP,MASTRO PAUL F;;COUGHLIN DANIEL L;;DIGRAVIO THOMAS L,,https://lens.org/096-790-325-395-648,Patent Application,yes,0,1,2,4,0,B24B21/006;;B29C66/02245;;B29C66/032;;B29L2031/709;;B29L2031/764;;Y10T428/192;;Y10T428/19;;Y10T428/192;;Y10T428/19;;B29C66/032;;B29L2031/709;;B29L2031/764;;B29C66/02245;;B24B21/006,B24B21/00;;B29C65/00,428/57,0,0,,,,DISCONTINUED
97,US,A1,US 2009/0022897 A1,148-439-315-489-671,2009-01-22,2009,US 87915307 A,2007-07-16,US 87915307 A,2007-07-16,High temperature silicone processing of fuser structure,This is a process to restore compression set properties of a silicone rubber fuser structure that has been damaged during the coating of the silicone with Teflon; Teflon is a registered trademark of DuPont. This restoration is achieved by re-baking the coated fuser roll at temperatures of 175° C. to 275° C. This will improve the compression set and will give the fuser structure improved life and provide better image quality.,XEROX CORP,IRVING DAVID C;;COUGHLIN JR DANIEL L;;FINN PATRICK,XEROX CORPORATION (2007-07-11),https://lens.org/148-439-315-489-671,Patent Application,yes,3,1,2,2,0,G03G15/2057;;Y10T428/139;;Y10T428/1386;;Y10T428/254;;Y10T428/3154;;Y10T428/31663;;Y10T428/249974;;Y10T428/139;;Y10T428/1386;;Y10T428/254;;Y10T428/3154;;Y10T428/31663;;Y10T428/249974;;G03G15/2057,B05D3/02,427/372.2,0,0,,,,INACTIVE
98,EP,A2,EP 2413926 A2,107-233-164-220-411,2012-02-08,2012,EP 10759490 A,2010-04-02,US 2010/0029809 W;;US 16614309 P,2009-04-02,COMPOSITIONS OF CHOLINESTERASE INHIBITORS,,COLUCID PHARMACEUTICALS INC,DU SHOUCHENG;;ANDERSEN MARC W;;COUGHLIN DANIEL;;KOLCHINSKI ALEXANDER,,https://lens.org/107-233-164-220-411,Patent Application,yes,0,0,6,6,0,C07C57/15;;C07C271/44;;A61P1/00;;A61P25/00;;A61P25/16;;A61P25/28;;A61P25/34;;A61P27/06;;A61P9/10;;C07C271/44;;C07C57/15,A61K31/221;;A61P25/00;;A61P25/28,,0,0,,,,DISCONTINUED
99,US,A,US 5473784 A,048-330-517-453-98X,1995-12-12,1995,US 27718994 A,1994-07-19,US 27718994 A,1994-07-19,Body board,"A body board is provided having upper and lower plastic components defining an outer plastic shell having a hollow interior. The underside of the plastic shell defines a pair of runners which serve to space handholds disposed about the periphery of the body board from the ground on which the body board rests. A fiberglass reinforcement structure having upper and lower sheets is disposed within the hollow interior. The fiberglass sheets are bent or curved across the width of the body board to provide increased structural support for resistance to deflection or sagging of the body board when supporting a patient. The thickness of the upper and lower plastic shell components and the thickness of the upper and lower sheets of the fiberglass reinforcement structure are substantially uniform over a central x-ray region. Also, none of the upper and lower plastic shell components or the upper and lower fiberglass sheets extend vertically over any portion thereof disposed within the central x-ray region. Hence, x-rays passed through the x-ray region of the body board are absorbed by the body board substantially uniformly, without producing any lines of high density on x-ray film. The x-ray region may include the runners, and no lines of high density are realized at the runners despite the increased thickness at the runners. Identifying indicia may be formed in the underside of the outer plastic shell by a manner in which the indicia do not produce high density images on x-ray film.",ARIZONA E M S PRODUCTS INC,NIXON DRUE C;;SOULVIE DANIEL B;;COUGHLIN RICHARD T,ARIZONA E.M.S. PRODUCTS INC (1994-07-14),https://lens.org/048-330-517-453-98X,Granted Patent,yes,16,47,1,1,0,A61B6/0442;;A61G1/00;;A61G1/01;;A61G2210/50;;A61B6/0442;;A61G1/01;;A61G2210/50;;A61G1/00,A61B6/04;;A61G1/00;;A61G1/01,5/625;;5/601,0,0,,,,EXPIRED
100,PL,T3,PL 3154967 T3,071-698-848-939-06X,2021-01-11,2021,PL 15731459 T,2015-06-12,US 201462012701 P;;EP 15731459 A;;US 2015/0035558 W,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,,JOHNSON MATTHEY PLC,COUGHLIN DANIEL;;WILT JEREMY;;GOU DA-MING;;COLLIER STEVEN,,https://lens.org/071-698-848-939-06X,Patent Application,no,0,0,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07D417/12;;C07C39/00;;C07D209/52;;C07D215/22;;C07D239/88;;C07D241/04;;C07D275/06;;C07D311/06;;C07D413/04;;C07D413/12;;C07D471/12;;C07D487/12,,0,0,,,,PENDING
101,EP,B1,EP 3154967 B1,098-395-778-513-427,2020-07-29,2020,EP 15731459 A,2015-06-12,US 201462012701 P;;US 2015/0035558 W,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,,JOHNSON MATTHEY PLC,COUGHLIN DANIEL;;WILT JEREMY;;GOU DA-MING;;COLLIER STEVEN,"MACFARLAN SMITH LIMITED; GB (2023-02-27);;MACFARLAN SMITH LIMITED, GB (2023-02-14)",https://lens.org/098-395-778-513-427,Granted Patent,yes,2,0,17,17,0,C07D311/06;;C07D215/22;;C07D413/04;;C07D239/88;;C07D241/04;;C07D471/12;;C07D487/12;;C07D209/52;;C07C39/00;;C07D519/00;;C07D417/08;;C07D261/20;;C07D209/56;;C07D417/12;;C07D215/227;;C07D401/12;;C07D403/12;;C07D275/06;;C07D311/20;;C07D413/12;;C07D413/14;;C07D519/00;;C07D417/08;;C07D261/20;;C07D209/56;;C07D417/12;;C07D215/227;;C07D401/12;;C07D403/12;;C07D275/06;;C07D311/20;;C07D413/12;;C07C39/00;;C07D311/06;;C07D215/22;;C07D413/04;;C07D239/88;;C07D241/04;;C07D471/12;;C07D487/12;;C07D209/52;;C07D413/14,C07D417/12;;C07C39/00;;C07D209/52;;C07D215/22;;C07D239/88;;C07D241/04;;C07D275/06;;C07D311/06;;C07D413/04;;C07D413/12;;C07D471/12;;C07D487/12,,8,0,,,"CHERBULIEZ ET AL.: ""148. Recherches sur la formation et la transformation des esters LXXV[1]"", HELVETICA CHIMICA ACTA, vol. 50, 1967, pages 1440-1452, XP002742557,;;GERHARD W. FISCHER ET AL: ""Reaktivitaet und Toxizitaet cyclischer Schwefelsaeur eester"", JOURNAL FUER PRAKTISCHE CHEMIE, vol. 317, no. 6, 1975, pages 943-952, XP055203634, DE ISSN: 0021-8383, DOI: 10.1002/prac.19753170610;;DOLENSKI ET AL.: ""Molécules amphiphiles électroréductibles. Etude de la réduction en milieux de sulfates d'omega-(4-acétylphénoxy)alkyle"", BULL.SOC. CHIM. FR., vol. 133, 1996, pages 235-242, XP009185494,;;LICHTENBERGER ET AL.: ""N° 204. Sur les sulfates de diols"", BULL. SOC. CHIM. FR., 1948, pages 1002-1012, XP009185493,;;HÄSSNER ET AL.: ""EI-Massenspektrometrie N-monosulfoalkyl-substituierte Cyanine"", ZEITSCHRIFT FÜR CHEMIE, vol. 29, no. 2, 1989, pages 65-66, XP001525976,;;NAGAMURA ET AL.: ""Novel effect of man-made molecular assemblies on photoinduced charge separation.4.Synthetic bilayer membrane of amphipathic viologen as an efficient electron collector in photosensitized redox reactions"", BERICHTE DER BUNSENGESELLSCHAFT, PHYSICAL CHEMISTRY CHEMICAL PHYSICS, vol. 87, no. 12, 1983, pages 1129-1133, XP009185495,;;JIA JIAN-MIN ET AL: ""Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 6, 15 February 2014 (2014-02-15), pages 1557-1561, XP028625276, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2014.01.070;;PAI ET AL.: ""Synthesis of novel analogs 3,4-dihydro-1H-quinolin-2-one derivatives as typical antidepressant, sedative and anti-Parkinson agents"", HETEROCYCLIC LETTERS, vol. 2, no. 1, 2012, pages 117-128, XP002742558,",ACTIVE
102,WO,A2,WO 2010/115124 A2,025-937-396-491-23X,2010-10-07,2010,US 2010/0029809 W,2010-04-02,US 16614309 P,2009-04-02,COMPOSITIONS OF CHOLINESTERASE INHIBITORS,"The present invention is directed to compositions, methods of use, and processes for the synthesis related to 3-(( S )-l-(dimethylamino)ethyl)phenyl methyl-(( R )- 1 -phenylpropan-2 yl)carbamate, and its pharmaceutically acceptable salt forms, including the hydrogen fumarate salt. The present invention also relates to a novel form polymorph of 3-(( S )-l- (dimethylamino)ethyl)phenyl methyl-(( R )- 1 -phenylpropan-2 yl)carbamate, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.",COLUCID PHARMACEUTICALS INC;;DU SHOUCHENG;;ANDERSEN MARC W;;COUGHLIN DANIEL;;KOLCHINSKI ALEXANDER,DU SHOUCHENG;;ANDERSEN MARC W;;COUGHLIN DANIEL;;KOLCHINSKI ALEXANDER,,https://lens.org/025-937-396-491-23X,Patent Application,yes,0,0,6,6,0,C07C57/15;;C07C271/44;;A61P1/00;;A61P25/00;;A61P25/16;;A61P25/28;;A61P25/34;;A61P27/06;;A61P9/10;;C07C271/44;;C07C57/15,A61P25/00;;A61K31/221;;A61P25/28,,0,0,,,,PENDING
103,WO,A1,WO 1989/011876 A1,051-652-881-359-914,1989-12-14,1989,US 8902467 W,1989-06-06,US 20379388 A,1988-06-07,RADIOHALOGENATED COMPOUNDS FOR SITE SPECIFIC LABELING,Radiohalogenated compounds which are useful as intermediates for preparing radiohalogenated antibody conjugates in which the radiohalogenated compound is site specifically attached to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. Methods for making the compounds and the antibody conjugates as well as methods of use of the same are also disclosed.,CYTOGEN CORP,COUGHLIN DANIEL J;;BELINKA BENJAMIN A;;ALVAREZ VERNON L,,https://lens.org/051-652-881-359-914,Patent Application,yes,3,2,11,11,0,A61K51/1051;;A61K51/1063;;A61K2121/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61K51/1051;;A61K51/1063;;A61K2121/00,A61K39/395;;A61K51/00;;A61K51/10;;A61P31/04;;A61P31/12;;A61P35/00;;C07B59/00;;C07C215/00;;C07C215/76;;C07C217/00;;C07C217/84;;C07C243/00;;C07C243/22;;C07C243/38;;C07K1/113;;C07K14/00;;C07K14/705;;C07K16/00,,0,0,,,,PENDING
104,HU,T2,HU E052277 T2,075-582-555-437-016,2021-04-28,2021,HU E15731459 A,2015-06-12,US 201462012701 P,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,,JOHNSON MATTHEY PLC,COUGHLIN DANIEL;;WILT JEREMY;;GOU DA-MING;;COLLIER STEVEN,,https://lens.org/075-582-555-437-016,Amended Patent,no,0,0,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07C39/00,,0,0,,,,PENDING
105,EP,B1,EP 0348261 B1,123-436-680-982-228,1993-12-15,1993,EP 89401557 A,1989-06-06,US 20379388 A,1988-06-07,Radiohalogenated compounds for site specific labeling.,,CYTOGEN CORP,COUGHLIN DANIEL JAMES;;BELINKA BENJAMIN A;;ALVAREZ VERNON LEON,,https://lens.org/123-436-680-982-228,Granted Patent,yes,3,0,11,11,0,A61K51/1051;;A61K51/1063;;A61K2121/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61K51/1051;;A61K51/1063;;A61K2121/00,A61K39/395;;A61K51/00;;A61K51/10;;A61P31/04;;A61P31/12;;A61P35/00;;C07B59/00;;C07C215/00;;C07C215/76;;C07C217/00;;C07C217/84;;C07C243/00;;C07C243/22;;C07C243/38;;C07K1/113;;C07K14/00;;C07K14/705;;C07K16/00,,2,0,,,"THE JOURNAL OF ORGANIC CHEMISTRY, vol. 50, no. 11, May 31, 1985, pp. 1988-1990, American Chemical Society; N. D. HEINDEL et al, ""Prosthetic group radioiodination at ""No-Carrier Added"" levels of carbonyl-containing molecules"";;THE JOURNAL OF MEDICINAL CHEMISTRY, vol. 16, no. 6, June 1973, pp. 684-687; R. E. COUNSELL et al, ""Potential organ or tumor imaging agents. 11. Radioiodinated tyramines""",EXPIRED
106,CA,A1,CA 2930395 A1,061-650-999-768-119,2015-05-21,2015,CA 2930395 A,2014-11-12,US 201314078253 A;;US 201414253660 A;;US 2014/0065290 W,2013-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",VIZURI HEALTH SCIENCES LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,,https://lens.org/061-650-999-768-119,Patent Application,no,0,2,13,13,0,A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61P17/02;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;A61K9/0019;;A61K9/08;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K47/10;;A61K47/26;;A61K47/36;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024,A61K9/00;;A61K31/165,,0,0,,,,DISCONTINUED
107,AU,A2,AU 2013/341380 A2,070-834-717-187-977,2015-10-22,2015,AU 2013/341380 A,2013-11-12,US 201261725161 P;;US 2013/0069711 W,2012-11-12,"Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid","Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",API GENESIS LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,"VIZURI HEALTH SCIENCES LLC (2017-02-02);;PROPELLA THERAPEUTICS, INC. (2020-12-10)",https://lens.org/070-834-717-187-977,Patent Application,no,0,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/00,,0,0,,,,INACTIVE
108,WO,A2,WO 2008/083175 A2,090-867-491-764-01X,2008-07-10,2008,US 2007/0088852 W,2007-12-26,US 87714606 P;;US 67334107 A;;US 67399207 A,2006-12-26,ON A MOBILE DEVICE TRACKING USE OF SEARCH RESULTS DELIVERED TO THE MOBILE DEVICE,"A method implemented on a mobile device that includes speech recognition functionality involves: receiving an utterance that includes a search request from a user of the device; recognizing that the utterance includes a search request; sending a representation of the search request to a remote server over a wireless data connection; receiving information over the wireless data connection that is responsive to the search request; presenting the information on the mobile device; receiving an input from the user selecting an item present in the received information, the item identifying a remote resource; using the selected item to connect to the remote resource, the connection to the remote resource not involving the remote server; and sending to the remote server an indication that a connection was made to the resource identified by the selected item. The method further involves storing a log of the user's connection to remote resources and sending the log to the server.",VOICE SIGNAL TECHNOLOGIES INC;;EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/090-867-491-764-01X,Patent Application,yes,0,0,3,18,0,G10L15/26;;H04M2250/74;;G06F16/951;;G06F16/90335;;H04M1/72403;;H04M2250/74;;G10L15/26;;G06F16/90335;;G06F16/951;;H04M1/72403,H04M1/72403,,0,0,,,,PENDING
109,EP,A2,EP 2130359 A2,126-204-092-457-271,2009-12-09,2009,EP 07866025 A,2007-12-26,US 2007/0088847 W;;US 87714606 P;;US 67334107 A;;US 67398807 A,2006-12-26,INTEGRATED VOICE SEARCH COMMANDS FOR MOBILE COMMUNICATIONS DEVICES,,VOICE SIGNAL TECHNOLOGIES INC,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/126-204-092-457-271,Patent Application,yes,0,1,3,18,0,H04M3/4938;;H04M2201/40;;G10L2015/223;;G06F16/90332;;H04M1/72403,H04M1/72403;;H04M3/493,,0,0,,,,DISCONTINUED
110,CN,A,CN 101616915 A,006-141-934-209-340,2009-12-30,2009,CN 200780051766 A,2007-12-28,US 2007/0026457 W;;US 87776206 P,2006-12-28,Composition and methods for modulating a kinase cascade,The invention relates to compositions of N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl)acetamide (KX2-391) and methods for modulating one or more components of a kinase cascade.,KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G;;DANIEL COUGHLIN;;CODY JEREMY A;;JONATHAN GALE,,https://lens.org/006-141-934-209-340,Patent Application,no,1,7,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D413/12,,0,0,,,,ACTIVE
111,EP,A1,EP 3446680 A1,039-003-197-566-816,2019-02-27,2019,EP 18182795 A,2013-11-12,US 201261725161 P;;EP 13812219 A;;US 2013/0069711 W,2012-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.
",VIZURI HEALTH SCIENCES LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,"PROPELLA THERAPEUTICS, INC. (2020-12-09)",https://lens.org/039-003-197-566-816,Patent Application,yes,33,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/00;;A61K9/08;;A61K9/107;;A61K31/045;;A61P17/02;;A61P19/02,,5,5,035-822-081-026-563;;025-364-321-877-36X;;022-608-812-820-025;;023-204-558-598-46X;;093-117-581-767-974,21852280;;10.1093/bja/aer260;;pmc3169333;;9647450;;10.1097/00002508-199806000-00003;;2580718;;10.1016/0014-2999(85)90456-x;;10.1016/0167-0115(88)90046-8;;2452458;;7537589;;10.1111/j.1476-5381.1995.tb17177.x;;pmc1510027,"ANAND P; BLEY K: ""Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch"", BR J ANAESTH., vol. 107, no. 4, 2011, pages 490 - 502;;MARTIN HAUTKAPPE ET AL.: ""Review of the Effectiveness of Capsaicin for Painful Cutaneous Disorders and Neural Dysfunction"", CLIN. J. PAIN, vol. 14, 1998, pages 97 - 106, XP008165653, DOI: doi:10.1097/00002508-199806000-00003;;LUNDBERG ET AL.: ""Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin"", EUR. J. PHARMACOL., vol. 108, 1985, pages 315 - 319, XP025566186, DOI: doi:10.1016/0014-2999(85)90456-X;;MARTLING ET AL.: ""Calcitonin gene-related peptide and the lung: neuronal coexistence with substance P, release by capsaicin and vasodilatory effect"", REGUL. PEPT., vol. 20, 1988, pages 125 - 139, XP025209323, DOI: doi:10.1016/0167-0115(88)90046-8;;NEWBOLD ET AL.: ""An Investigation into the mechanism of capsaicin-induced edema in rabbit skin"", BRIT. J. OF PHARMA., vol. 114, 1995, pages 570 - 577",DISCONTINUED
112,WO,A3,WO 2008/083172 A3,060-578-232-805-199,2008-12-11,2008,US 2007/0088847 W,2007-12-26,US 87714606 P;;US 67334107 A;;US 67398807 A,2006-12-26,INTEGRATED VOICE SEARCH COMMANDS FOR MOBILE COMMUNICATIONS DEVICES,"A method implemented on a mobile device that includes speech recognition functionality involves presenting to a user of the mobile device a voice-control interface that supports two types of commands at a common level of the interface, the two types of commands including a first type and a second type, the first type being command and control commands and the second type being search request commands. The method further involves: receiving an utterance from the user that corresponds to a command of either of the first type or the second type; recognizing the utterance; if the received utterance is a command of the first type, performing a corresponding command and control function; and if the received utterance is a command of the second type, generating a representation of a corresponding search request and then using the representation to request a search that is responsive to the search request.",VOICE SIGNAL TECHNOLOGIES INC;;EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/060-578-232-805-199,Search Report,yes,4,0,3,18,0,H04M3/4938;;H04M2201/40;;G10L2015/223;;G06F16/90332;;H04M1/72403,H04M1/72403;;H04M3/493,,0,0,,,,PENDING
113,MX,A,MX 2018013715 A,077-008-156-922-379,2019-07-29,2019,MX 2018013715 A,2015-05-11,US 201261725161 P,2012-11-12,"AQUEOUS BASED CAPSAICINOID FORMULATIONS, AND TREATMENT IN COMBINATION WITH A CORTICOSTEROID.","Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",VIZURI HEALTH SCIENCES LLC,CHARLES A BIRBARA;;MARY COUGHLIN;;PHILIP J BIRBARA;;DANIEL BUCKS,,https://lens.org/077-008-156-922-379,Patent Application,no,0,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/00;;A61K31/085;;A61K9/08;;A61K9/107;;A61K31/045;;A61K31/05;;A61K31/165;;A61K31/573;;A61K31/738;;A61K45/06;;A61P17/02;;A61P19/02,,0,0,,,,PENDING
114,WO,A2,WO 2008/083176 A2,081-249-888-790-326,2008-07-10,2008,US 2007/0088856 W,2007-12-26,US 87714606 P;;US 67334107 A,2006-12-26,VOICE SEARCH-ENABLED MOBILE DEVICE,"Methods and devices for providing a user of a mobile communications device with mobile voice-mediated search capability. The methods and devices involve receiving an utterance from a user of the mobile device, the utterance including a search request; using the speech recognition functionality to recognize that the utterance includes a search request; as a result of recognizing that the utterance includes a search request, establishing a wireless data connection to a remote server; sending a representation of the search request to the remote server over the wireless data connection; receiving search results that are responsive to the search request; and presenting the search results on the mobile device.",VOICE SIGNAL TECHNOLOGIES INC;;EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/081-249-888-790-326,Patent Application,yes,1,1,5,18,0,G10L15/30;;H04M3/4931;;H04M7/0036;;H04M2250/74;;G06F16/957;;H04M1/72445;;H04M1/72403;;G06F16/957;;G10L15/30;;H04M3/4931;;H04M7/0036;;H04M2250/74;;H04M1/72403;;H04M1/72445,H04M1/72403;;H04M1/72445,,0,0,,,,PENDING
115,WO,A9,WO 2008/082637 A9,016-554-119-054-926,2008-09-18,2008,US 2007/0026457 W,2007-12-28,US 87776206 P,2006-12-28,COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE,The invention relates to compositions of N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl)acetamide (KX2-391) and methods for modulating one or more components of a kinase cascade.,KINEX PHARMACEUTICALS LLC;;HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN,,https://lens.org/016-554-119-054-926,Patent Application,no,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D413/12;;A61K31/5377;;A61P35/00,,0,0,,,,PENDING
116,WO,A3,WO 2008/083171 A3,093-040-536-508-639,2008-12-31,2008,US 2007/0088845 W,2007-12-26,US 87714606 P;;US 67334107 A;;US 67399507 A,2006-12-26,COLLECTION AND USE OF SIDE INFORMATION IN A MOBILE COMMUNICATION DEVICE WITH VOICE-MEDIATED SEARCH,"Methods and systems for providing voice-mediated search capability to a mobile communications device involve receiving a signal from the mobile device that includes a representation of a spoken search request from a user of the mobile device, using speech recognition software to convert the search request into a text search request, extracting side information contained implicitly within the received signal, using the extracted side information to assign the user to a category, sending the text search request and the user category to content providers, receiving from the content providers content that is responsive to the text search request and the user category, and sending to the mobile device search results that are based on content from content providers. The methods and systems further involve sending searches and user categories to advertising providers, and sending advertisements returned by the advertising providers to the mobile device along with the search results.",VOICE SIGNAL TECHNOLOGIES INC;;EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/093-040-536-508-639,Search Report,yes,3,0,3,18,0,G10L15/08;;G06F16/9535;;H04M1/72403;;G10L15/08;;G06F16/9535;;H04M1/72403,H04M1/72403;;H04M3/493,,0,0,,,,PENDING
117,US,A1,US 2008/0154608 A1,103-685-631-334-795,2008-06-26,2008,US 67399207 A,2007-02-12,US 67399207 A;;US 67334107 A;;US 87714606 P,2006-12-26,ON A MOBILE DEVICE TRACKING USE OF SEARCH RESULTS DELIVERED TO THE MOBILE DEVICE,"A method implemented on a mobile device that includes speech recognition functionality involves: receiving an utterance that includes a search request from a user of the device; recognizing that the utterance includes a search request; sending a representation of the search request to a remote server over a wireless data connection; receiving information over the wireless data connection that is responsive to the search request; presenting the information on the mobile device; receiving an input from the user selecting an item present in the received information, the item identifying a remote resource; using the selected item to connect to the remote resource, the connection to the remote resource not involving the remote server; and sending to the remote server an indication that a connection was made to the resource identified by the selected item. The method further involves storing a log of the user's connection to remote resources and sending the log to the server.",VOICE SIGNAL TECHNOLOGIES INC,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/103-685-631-334-795,Patent Application,yes,99,32,3,18,0,G10L15/26;;H04M2250/74;;G06F16/951;;G06F16/90335;;H04M1/72403;;H04M2250/74;;G10L15/26;;G06F16/90335;;G06F16/951;;H04M1/72403,G10L11/00;;H04M1/72403,704/270.1,0,0,,,,DISCONTINUED
118,MX,A,MX 2016006179 A,117-778-434-616-815,2016-10-26,2016,MX 2016006179 A,2014-11-12,US 201314078253 A;;US 201414253660 A;;US 2014/0065290 W,2013-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE.,"Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",VIZURI HEALTH SCIENCES LLC,BUCKS DANIEL;;BIRBARA PHILIP J;;CHARLES A BIRBARA;;MARY COUGHLIN,,https://lens.org/117-778-434-616-815,Patent Application,no,0,0,13,13,0,A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61P17/02;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;A61K9/0019;;A61K9/08;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K47/10;;A61K47/26;;A61K47/36;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024,A61K9/00;;A61K31/165,,0,0,,,,PENDING
119,WO,A2,WO 2008/083171 A2,008-960-999-614-98X,2008-07-10,2008,US 2007/0088845 W,2007-12-26,US 87714606 P;;US 67334107 A;;US 67399507 A,2006-12-26,COLLECTION AND USE OF SIDE INFORMATION IN VOICE-MEDIATED MOBILE SEARCH,"Methods and systems for providing voice-mediated search capability to a mobile communications device involve receiving a signal from the mobile device that includes a representation of a spoken search request from a user of the mobile device, using speech recognition software to convert the search request into a text search request, extracting side information contained implicitly within the received signal, using the extracted side information to assign the user to a category, sending the text search request and the user category to content providers, receiving from the content providers content that is responsive to the text search request and the user category, and sending to the mobile device search results that are based on content from content providers. The methods and systems further involve sending searches and user categories to advertising providers, and sending advertisements returned by the advertising providers to the mobile device along with the search results.",VOICE SIGNAL TECHNOLOGIES INC;;EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/008-960-999-614-98X,Patent Application,yes,0,0,3,18,0,G10L15/08;;G06F16/9535;;H04M1/72403;;G10L15/08;;G06F16/9535;;H04M1/72403,H04M1/72403,,0,0,,,,PENDING
120,CN,A,CN 105960230 A,051-618-246-402-021,2016-09-21,2016,CN 201480071773 A,2014-11-12,US 201314078253 A;;US 201414253660 A;;US 2014/0065290 W,2013-11-12,Aqueous based capsaicinoid formulations and methods of manufacture and use,"The invention discloses capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",VIZURI HEALTH SCIENCES LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,,https://lens.org/051-618-246-402-021,Patent Application,no,3,5,13,13,0,A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61P17/02;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;A61K9/0019;;A61K9/08;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K47/10;;A61K47/26;;A61K47/36;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024,A61K9/00;;A61K31/165,,1,0,,,"姚日生: ""《药用高分子材料》"", 30 April 2008, 化学工业出版社",INACTIVE
121,EP,A2,EP 2127339 A2,122-588-841-982-584,2009-12-02,2009,EP 07866028 A,2007-12-26,US 2007/0088850 W;;US 87714606 P;;US 67334107 A;;US 67399707 A,2006-12-26,LOCAL STORAGE AND USE OF SEARCH RESULTS FOR VOICE-ENABLED MOBILE COMMUNICATIONS DEVICES,,VOICE SIGNAL TECHNOLOGIES INC,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,"NUANCE COMMUNICATIONS, INC. (2013-01-09)",https://lens.org/122-588-841-982-584,Patent Application,yes,0,0,4,18,0,H04M2250/74;;G10L15/26;;H04M1/72403;;H04M2250/74;;G10L15/26;;H04M1/72403,H04M1/72403;;H04M3/493,,0,0,,,,DISCONTINUED
122,AU,B2,AU 2013/341380 B2,142-132-538-258-454,2018-04-26,2018,AU 2013/341380 A,2013-11-12,US 201261725161 P;;US 2013/0069711 W,2012-11-12,"Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid","Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",PROPELLA THERAPEUTICS INC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,"VIZURI HEALTH SCIENCES LLC (2017-02-02);;PROPELLA THERAPEUTICS, INC. (2020-12-10)",https://lens.org/142-132-538-258-454,Granted Patent,no,5,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/00,,0,0,,,,INACTIVE
123,WO,A1,WO 2008/082637 A1,136-257-043-657-746,2008-07-10,2008,US 2007/0026457 W,2007-12-28,US 87776206 P,2006-12-28,COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE,The invention relates to compositions of N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl)acetamide (KX2-391) and methods for modulating one or more components of a kinase cascade.,KINEX PHARMACEUTICALS LLC;;HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN,,https://lens.org/136-257-043-657-746,Patent Application,yes,4,30,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,A61K31/5377;;C07D413/12;;A61P35/00,,10,8,050-136-953-559-441;;090-907-195-606-66X;;008-506-871-340-22X;;014-281-294-082-381;;045-942-893-332-610;;133-545-268-130-061;;012-656-727-136-02X;;078-865-453-097-216,1605572;;10.1146/annurev.pa.32.040192.002113;;10.1146/annurev.pharmtox.32.1.377;;10.1042/bj3510095;;pmc1221339;;10.1042/0264-6021:3510095;;10998351;;10.1517/13543776.15.9.1183;;10.1038/84675;;11175854;;pmc33604;;10.1073/pnas.96.14.7697;;10393883;;pmc6757905;;12122079;;10.1523/jneurosci.22-14-06208.2002;;20026599;;pmc1171573;;10487754;;10.1093/emboj/18.18.5019;;10.1128/mcb.17.11.6427;;9343405;;pmc232495,"HIDAKA; KOBAYASHI, ANNU. REV. PHARMACOL. TOXICOL, vol. 32, 1992, pages 377 - 397;;DAVIES ET AL., BIOCHEM. J., vol. 351, 2000, pages 95 - 105;;PARANG; SUN, EXPERT OPIN. THER. PATENTS, vol. 15, 2005, pages 1183 - 1207;;FRAME, BIOCHIM. BIOPHYS. ACTA, vol. T602, 2002, pages 14 - 130;;PAUL, NATURE MEDICINE, vol. 7, no. 2, 2001, pages 222 - 227;;PARANG; SUN, EXPERT OPIN. THER. PATENTS, vol. 15, no. 9, 2005, pages 1183 - 1206;;YU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 7697 - 7704;;GUO ET AL., J. NEURO., vol. 22, 2002, pages 6208 - 6217;;KLEIN ET AL., EMBO J., vol. 18, 1999, pages 5019 - 5027;;KLEIN ET AL., MOL. CELL. BIOL., vol. 17, 1997, pages 6427 - 6436",PENDING
124,KR,A,KR 20150084996 A,048-445-422-647-255,2015-07-22,2015,KR 20157015545 A,2013-11-12,US 201261725161 P,2012-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"포유동물의 통증을 치료/감소시키는데 이용될 수 있는 캡사이시노이드 제형 및 치료 방법이 여기에서 개시된다. 일반적으로, 투여는 분리된 부위에 연장된 시간 동안 통증 경감을 위하여 주입을 통하여 이루어진다. 제형은 약학적으로 허용가능한 비히클로 투여된다. 제형은 캡사이시노이드 투여의 작열 및 자통 효과를 감소시키는데 충분한 양으로 진통제를 포함한다. 본 발명은 또한 캡사이시노이드 투여 이전에 코르티코스테로이드를 투여하여 통증을 치료하는 방법을 포함한다.",API GENESIS LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,,https://lens.org/048-445-422-647-255,Patent Application,no,0,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/107;;A61K31/045;;A61K31/05;;A61K31/085;;A61K31/165;;A61K31/573;;A61K31/738;;A61K45/06,,0,0,,,,DISCONTINUED
125,MX,A,MX 2015005879 A,009-645-093-377-910,2016-02-05,2016,MX 2015005879 A,2013-11-12,US 201261725161 P;;US 2013/0069711 W,2012-11-12,"AQUEOUS BASED CAPSAICINOID FORMULATIONS, AND TREATMENT IN COMBINATION WITH A CORTICOSTEROID.","Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",API GENESIS LLC,BUCKS DANIEL;;BIRBARA PHILIP J;;BIRBARA CHARLES A;;COUGHLIN MARY,"MICROSOFT TECHNOLOGY LICENSING, LLC (2017-03-15)",https://lens.org/009-645-093-377-910,Patent Application,no,0,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/00,,0,0,,,,ACTIVE
126,WO,A3,WO 2008/083176 A3,017-631-770-242-603,2008-12-04,2008,US 2007/0088856 W,2007-12-26,US 87714606 P;;US 67334107 A,2006-12-26,VOICE SEARCH-ENABLED MOBILE DEVICE,"Methods and devices for providing a user of a mobile communications device with mobile voice-mediated search capability. The methods and devices involve receiving an utterance from a user of the mobile device, the utterance including a search request; using the speech recognition functionality to recognize that the utterance includes a search request; as a result of recognizing that the utterance includes a search request, establishing a wireless data connection to a remote server; sending a representation of the search request to the remote server over the wireless data connection; receiving search results that are responsive to the search request; and presenting the search results on the mobile device.",VOICE SIGNAL TECHNOLOGIES INC;;EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/017-631-770-242-603,Search Report,yes,6,0,5,18,0,G10L15/30;;H04M3/4931;;H04M7/0036;;H04M2250/74;;G06F16/957;;H04M1/72445;;H04M1/72403;;G06F16/957;;G10L15/30;;H04M3/4931;;H04M7/0036;;H04M2250/74;;H04M1/72403;;H04M1/72445,H04M1/72403;;H04M1/72445;;H04M3/493,,0,0,,,,PENDING
127,US,A1,US 2019/0142948 A1,138-692-880-897-13X,2019-05-16,2019,US 201916244896 A,2019-01-10,US 201916244896 A;;US 201414253660 A;;US 201314078253 A,2013-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",VIZURI HEALTH SCIENCES LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,VIZURI HEALTH SCIENCES LLC (2014-08-14);;PROPELLA THERAPEUTICS INC (2020-05-01),https://lens.org/138-692-880-897-13X,Patent Application,yes,0,0,13,13,0,A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61P17/02;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;A61K9/0019;;A61K9/08;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K47/10;;A61K47/26;;A61K47/36;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024,A61K47/36;;A61K9/00;;A61K31/045;;A61K31/05;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K45/06,,0,0,,,,DISCONTINUED
128,EP,B1,EP 2916817 B1,187-837-941-239-168,2018-09-12,2018,EP 13812219 A,2013-11-12,US 201261725161 P;;US 2013/0069711 W,2012-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,,VIZURI HEALTH SCIENCES LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,"PROPELLA THERAPEUTICS, INC., US (2021-01-15);;PROPELLA THERAPEUTICS, INC. (N.D.GES.D. STAATE, US (2020-12-16);;VIZURI HEALTH SCIENCES LLC (2017-03-08)",https://lens.org/187-837-941-239-168,Granted Patent,yes,5,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/08;;A61K31/045;;A61P23/02,,0,0,,,,ACTIVE
129,WO,A2,WO 2014/075084 A2,176-963-020-596-038,2014-05-15,2014,US 2013/0069711 W,2013-11-12,US 201261725161 P,2012-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",API GENESIS LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,,https://lens.org/176-963-020-596-038,Patent Application,yes,26,23,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/00,,5,5,035-822-081-026-563;;025-364-321-877-36X;;022-608-812-820-025;;023-204-558-598-46X;;093-117-581-767-974,21852280;;10.1093/bja/aer260;;pmc3169333;;9647450;;10.1097/00002508-199806000-00003;;2580718;;10.1016/0014-2999(85)90456-x;;10.1016/0167-0115(88)90046-8;;2452458;;7537589;;10.1111/j.1476-5381.1995.tb17177.x;;pmc1510027,"ANAND P; BLEY K.: ""Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch"", BR J ANAESTH., vol. 107, no. 4, 2011, pages 490 - 502;;MARTIN HAUTKAPPE ET AL.: ""Review of the Effectiveness of Capsaicin for Painful Cutaneous Disorders and Neural Dysfunction"", CLIN. J PAIN, vol. 14, 1998, pages 97 - 106;;LUNDBERG ET AL.: ""Co-existence ofsubstance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin"", EUR, J. PHARMACOL., vol. 108, 1985, pages 315 - 319;;MARTLING ET AL.: ""Calcitonin gene-related peptide and the lung: neuronal coexistence with substance P, release by capsaicin and vasodilatory effect"", REGUL. PEPT., vol. 20, 1988, pages 125 - 139;;NEWBOLD ET AL.: ""An Investigation into the mechanism of capsaicin-induced edema in rabbit skin"", BRIT. J. OF PHARMA., vol. 114, 1995, pages 570 - 577",PENDING
130,EP,A1,EP 0797131 A1,031-836-783-951-413,1997-09-24,1997,EP 97301274 A,1997-02-26,US 61929096 A,1996-03-18,Fuser roll core inner surface treatment,"A fuser roll (52) having a hollow metal core (49) with a roughened inner surface (49a) with improved radiation characteristics. The roughened inner surface diffusely scatters the radiation emitted from the fuser's heat source, which results in a longer heat source life and even heating of the fuser core (49). The inner surface (49a) is roughened by removing metal from the hollow core in processes such as grit blasting, etching and machining.",XEROX CORP,ANGOLD DOUGLAS W;;COUGHLIN JR DANIEL L;;MCGLYNN KEVIN M,,https://lens.org/031-836-783-951-413,Patent Application,yes,2,0,3,3,0,G03G15/2053,G03G15/20;;H05B3/00,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 008, no. 163 (P - 290) 27 July 1984 (1984-07-27);;PATENT ABSTRACTS OF JAPAN vol. 016, no. 402 (P - 1409) 25 August 1992 (1992-08-25)",DISCONTINUED
131,CA,A1,CA 2891218 A1,026-671-614-625-98X,2014-05-15,2014,CA 2891218 A,2013-11-12,US 201261725161 P;;US 2013/0069711 W,2012-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",API GENESIS LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,,https://lens.org/026-671-614-625-98X,Patent Application,no,0,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/00,,0,0,,,,DISCONTINUED
132,US,A1,US 2014/0142073 A1,077-263-381-903-981,2014-05-22,2014,US 201314078253 A,2013-11-12,US 201314078253 A;;US 201261725161 P,2012-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",API GENESIS LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,VIZURI HEALTH SCIENCES LLC (2016-11-15);;PROPELLA THERAPEUTICS INC (2020-05-01),https://lens.org/077-263-381-903-981,Patent Application,yes,4,8,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K31/05;;A61K31/573;;A61K31/165,514/171;;514/627,0,0,,,,DISCONTINUED
133,KR,A,KR 20200119351 A,112-600-088-261-678,2020-10-19,2020,KR 20207028806 A,2013-11-12,US 201261725161 P;;US 2013/0069711 W,2012-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"포유동물의 통증을 치료/감소시키는데 이용될 수 있는 캡사이시노이드 제형 및 치료 방법이 여기에서 개시된다. 일반적으로, 투여는 분리된 부위에 연장된 시간 동안 통증 경감을 위하여 주입을 통하여 이루어진다. 제형은 약학적으로 허용가능한 비히클로 투여된다. 제형은 캡사이시노이드 투여의 작열 및 자통 효과를 감소시키는데 충분한 양으로 진통제를 포함한다. 본 발명은 또한 캡사이시노이드 투여 이전에 코르티코스테로이드를 투여하여 통증을 치료하는 방법을 포함한다.",VIZURI HEALTH SCIENCES LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,,https://lens.org/112-600-088-261-678,Patent Application,no,0,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/08;;A61K9/00;;A61K9/107;;A61K31/045;;A61K31/05;;A61K31/085;;A61K31/165;;A61K31/573;;A61K31/738;;A61K45/06,,0,0,,,,DISCONTINUED
134,KR,A,KR 20160094952 A,127-404-504-068-938,2016-08-10,2016,KR 20167014539 A,2014-11-12,US 201314078253 A;;US 201414253660 A;;US 2014/0065290 W,2013-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"치료를 위한 캡사이시노이드 제형 및 방법은 포유동물의 통증을 치료/경감하는데 사용될 수 있도록 본 명세서에서 개시된다. 전형적으로, 투여는 분리된 부위에서 주입에 의하여 연장된 시간 동안 통증 경감을 제공한다. 제형은 약학적으로 허용되는 비히클로 투여된다. 제형은 캡사이시노이드 투여의 작열 및 통각과민 효과를 감소시키는 양으로 진통제를 포함한다. 본 발명은 또한 코르티코스테로이드를 투여하고 이어서 캡사이시노이드를 투여하여 통증을 치료하는 방법을 포함한다.",VIZURI HEALTH SCIENCES LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,,https://lens.org/127-404-504-068-938,Patent Application,no,1,0,13,13,0,A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61P17/02;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;A61K9/0019;;A61K9/08;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K47/10;;A61K47/26;;A61K47/36;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024,A61K9/08;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K47/10;;A61K47/26;;A61K47/36,,0,0,,,,ACTIVE
135,US,A1,US 2008/0154611 A1,079-661-608-837-138,2008-06-26,2008,US 67398807 A,2007-02-12,US 67398807 A;;US 67334107 A;;US 87714606 P,2006-12-26,INTEGRATED VOICE SEARCH COMMANDS FOR MOBILE COMMUNICATION DEVICES,"A method implemented on a mobile device that includes speech recognition functionality involves presenting to a user of the mobile device a voice-control interface that supports two types of commands at a common level of the interface, the two types of commands including a first type and a second type, the first type being command and control commands and the second type being search request commands. The method further involves: receiving an utterance from the user that corresponds to a command of either of the first type or the second type; recognizing the utterance; if the received utterance is a command of the first type, performing a corresponding command and control function; and if the received utterance is a command of the second type, generating a representation of a corresponding search request and then using the representation to request a search that is responsive to the search request.",VOICE SIGNAL TECHNOLOGIES INC,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/079-661-608-837-138,Patent Application,yes,99,63,5,18,0,G10L15/30;;H04M3/4931;;H04M7/0036;;H04M2250/74;;G06F16/957;;H04M1/72445;;H04M1/72403;;G06F16/957;;G10L15/30;;H04M3/4931;;H04M7/0036;;H04M2250/74;;H04M1/72403;;H04M1/72445,G10L21/00;;H04M1/72403;;H04M1/72445,704/275,0,0,,,,DISCONTINUED
136,WO,A2,WO 2008/083173 A2,120-630-249-208-331,2008-07-10,2008,US 2007/0088850 W,2007-12-26,US 87714606 P;;US 67334107 A;;US 67399707 A,2006-12-26,LOCAL STORAGE AND USE OF SEARCH RESULTS FOR VOICE-ENABLED MOBILE COMMUNICATIONS DEVICES,"A method implemented on a mobile device that includes speech recognition functionality involves: receiving an utterance from a user of the mobile device, the utterance including a spoken search request; recognizing that the utterance includes a spoken search request; sending a representation of the spoken search request to a remote server over a wireless data connection; receiving search results over the wireless data connection that are responsive to the search request; storing the results on the mobile device; receiving a subsequent search request; performing a subsequent search responsive to the subsequent search request to generate subsequent search results, the subsequent search including searching the stored search results; and presenting the subsequent results on the mobile device. The method also involves indexing the stored results according to the user's search request, enhancing the device's ability to recognize frequently requested searches, and pre-loading the device with results corresponding to certain frequently requested searches.",VOICE SIGNAL TECHNOLOGIES INC;;EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/120-630-249-208-331,Patent Application,yes,1,0,4,18,0,H04M2250/74;;G10L15/26;;H04M1/72403;;H04M2250/74;;G10L15/26;;H04M1/72403,H04M1/72403,,0,0,,,,PENDING
137,EP,B1,EP 3068373 B1,178-634-686-746-421,2021-06-23,2021,EP 14816464 A,2014-11-12,US 201314078253 A;;US 201414253660 A;;US 2014/0065290 W,2013-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,,PROPELLA THERAPEUTICS INC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,"PROPELLA THERAPEUTICS, INC. (2020-12-16)",https://lens.org/178-634-686-746-421,Granted Patent,yes,3,0,13,13,0,A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61P17/02;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;A61K9/0019;;A61K9/08;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K47/10;;A61K47/26;;A61K47/36;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024,A61K31/045;;A61K9/00;;A61K31/05;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K45/06;;A61K47/36;;A61P17/02;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00,,1,0,,,None,ACTIVE
138,AU,A1,AU 2013/341380 A1,068-332-667-433-647,2014-05-15,2014,AU 2013/341380 A,2013-11-12,US 201261725161 P;;US 2013/0069711 W,2012-11-12,"Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid",,API GENESIS LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,"VIZURI HEALTH SCIENCES LLC (2017-02-02);;PROPELLA THERAPEUTICS, INC. (2020-12-10)",https://lens.org/068-332-667-433-647,Patent Application,no,0,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,,,0,0,,,,INACTIVE
139,EP,A1,EP 3068373 A1,175-730-941-209-684,2016-09-21,2016,EP 14816464 A,2014-11-12,US 201314078253 A;;US 201414253660 A;;US 2014/0065290 W,2013-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,,VIZURI HEALTH SCIENCES LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,"PROPELLA THERAPEUTICS, INC. (2020-12-16)",https://lens.org/175-730-941-209-684,Patent Application,yes,0,0,13,13,0,A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61P17/02;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;A61K9/0019;;A61K9/08;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K47/10;;A61K47/26;;A61K47/36;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024,A61K31/165;;A61K9/00,,0,0,,,,ACTIVE
140,US,A1,US 2008/0154612 A1,008-209-292-209-031,2008-06-26,2008,US 67399707 A,2007-02-12,US 67399707 A;;US 67334107 A;;US 87714606 P,2006-12-26,Local storage and use of search results for voice-enabled mobile communications devices,"A method implemented on a mobile device that includes speech recognition functionality involves: receiving an utterance from a user of the mobile device, the utterance including a spoken search request; recognizing that the utterance includes a spoken search request; sending a representation of the spoken search request to a remote server over a wireless data connection; receiving search results over the wireless data connection that are responsive to the search request; storing the results on the mobile device; receiving a subsequent search request; performing a subsequent search responsive to the subsequent search request to generate subsequent search results, the subsequent search including searching the stored search results; and presenting the subsequent results on the mobile device. The method also involves indexing the stored results according to the user's search request, enhancing the device's ability to recognize frequently requested searches, and pre-loading the device with results corresponding to certain frequently requested searches.",VOICE SIGNAL TECHNOLOGIES INC,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,NUANCE COMMUNICATIONS INC (2007-05-14);;VOICE SIGNAL TECHNOLOGIES INC (2007-05-03),https://lens.org/008-209-292-209-031,Patent Application,yes,111,317,4,18,0,H04M2250/74;;G10L15/26;;H04M1/72403;;H04M2250/74;;G10L15/26;;H04M1/72403,G10L11/00;;H04M1/72403,704/275,0,0,,,,DISCONTINUED
141,BR,A,BR 9701317 A,033-450-788-724-544,1998-11-17,1998,BR 9701317 A,1997-03-17,US 61929096 A,1996-03-18,Processo para fazer um cilindro fusor para uma máquina de impressão eletrofotográfica,,XEROX CORP,MCGLYNN KEVIN M;;ANGOLD DOUGLAS W;;COUGHLIN DANIEL L JR,,https://lens.org/033-450-788-724-544,Patent Application,no,0,0,3,3,0,G03G15/2053,G03G15/20;;H05B3/00,,0,0,,,,DISCONTINUED
142,AU,A1,AU 2007/340350 A1,046-485-537-457-690,2008-07-10,2008,AU 2007/340350 A,2007-12-28,US 87776206 P;;US 2007/0026457 W,2006-12-28,Composition and Methods for Modulating a Kinase Cascade,,KINEX PHARMACEUTICALS LLC,CODY JEREMY A;;COUGHLIN DANIEL;;HANGAUER DAVID G;;GALE JONATHAN,"ATNX SPV, LLC (2023-03-16)",https://lens.org/046-485-537-457-690,Patent Application,no,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,A61K31/5377;;A61P35/00;;C07D413/12,,0,0,,,,ACTIVE
143,EP,A2,EP 2127340 A2,055-307-194-817-117,2009-12-02,2009,EP 07866034 A,2007-12-26,US 2007/0088856 W;;US 87714606 P;;US 67334107 A,2006-12-26,VOICE SEARCH-ENABLED MOBILE DEVICE,,VOICE SIGNAL TECHNOLOGIES INC,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,"NUANCE COMMUNICATIONS, INC. (2013-04-17);;NUANCE COMMUNICATION, INC. (2013-01-09)",https://lens.org/055-307-194-817-117,Patent Application,yes,0,0,5,18,0,G10L15/30;;H04M3/4931;;H04M7/0036;;H04M2250/74;;G06F16/957;;H04M1/72445;;H04M1/72403;;G06F16/957;;G10L15/30;;H04M3/4931;;H04M7/0036;;H04M2250/74;;H04M1/72403;;H04M1/72445,H04M1/72403;;H04M1/72445;;H04M3/493,,0,0,,,,DISCONTINUED
144,WO,A3,WO 2014/075084 A3,138-542-425-595-590,2014-07-10,2014,US 2013/0069711 W,2013-11-12,US 201261725161 P,2012-11-12,"AQUEOUS BASED CAPSAICINOID FORMULATIONS, AND TREATMENT IN COMBINATION WITH A CORTICOSTEROID","Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",API GENESIS LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,,https://lens.org/138-542-425-595-590,Search Report,yes,5,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/00,,0,0,,,,PENDING
145,US,A1,US 2008/0221102 A1,186-764-392-721-443,2008-09-11,2008,US 579207 A,2007-12-28,US 579207 A;;US 87776206 P,2006-12-28,Composition and methods for modulating a kinase cascade,The invention relates to compounds and methods for modulating one or more components of a kinase cascade.,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN,ATHENEX INC (2015-08-26);;ATNX SPV LLC (2022-06-29),https://lens.org/186-764-392-721-443,Patent Application,yes,9,8,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,A61K31/5377;;A61P31/00;;A61P35/04,514/235.5,0,0,,,,ACTIVE
146,US,A1,US 2008/0154870 A1,052-439-289-706-634,2008-06-26,2008,US 67399507 A,2007-02-12,US 67399507 A;;US 67334107 A;;US 87714606 P,2006-12-26,COLLECTION AND USE OF SIDE INFORMATION IN VOICE-MEDIATED MOBILE SEARCH,"Methods and systems for providing voice-mediated search capability to a mobile communications device involve receiving a signal from the mobile device that includes a representation of a spoken search request from a user of the mobile device, using speech recognition software to convert the search request into a text search request, extracting side information contained implicitly within the received signal, using the extracted side information to assign the user to a category, sending the text search request and the user category to content providers, receiving from the content providers content that is responsive to the text search request and the user category, and sending to the mobile device search results that are based on content from content providers. The methods and systems further involve sending searches and user categories to advertising providers, and sending advertisements returned by the advertising providers to the mobile device along with the search results.",VOICE SIGNAL TECHNOLOGIES INC,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,NUANCE COMMUNICATIONS INC (2007-05-14),https://lens.org/052-439-289-706-634,Patent Application,yes,99,116,3,18,0,G10L15/08;;G06F16/9535;;H04M1/72403;;G10L15/08;;G06F16/9535;;H04M1/72403,G06F17/30;;H04M1/72403;;G10L15/02,707/4;;704/235,0,0,,,,DISCONTINUED
147,WO,A3,WO 2008/083173 A3,067-434-572-953-464,2008-12-18,2008,US 2007/0088850 W,2007-12-26,US 87714606 P;;US 67334107 A;;US 67399707 A,2006-12-26,LOCAL STORAGE AND USE OF SEARCH RESULTS FOR VOICE-ENABLED MOBILE COMMUNICATIONS DEVICES,"A method implemented on a mobile device that includes speech recognition functionality involves: receiving an utterance from a user of the mobile device, the utterance including a spoken search request; recognizing that the utterance includes a spoken search request; sending a representation of the spoken search request to a remote server over a wireless data connection; receiving search results over the wireless data connection that are responsive to the search request; storing the results on the mobile device; receiving a subsequent search request; performing a subsequent search responsive to the subsequent search request to generate subsequent search results, the subsequent search including searching the stored search results; and presenting the subsequent results on the mobile device. The method also involves indexing the stored results according to the user's search request, enhancing the device's ability to recognize frequently requested searches, and pre-loading the device with results corresponding to certain frequently requested searches.",VOICE SIGNAL TECHNOLOGIES INC;;EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/067-434-572-953-464,Search Report,yes,3,0,4,18,0,H04M2250/74;;G10L15/26;;H04M1/72403;;H04M2250/74;;G10L15/26;;H04M1/72403,H04M1/72403;;H04M3/493,,0,0,,,,PENDING
148,WO,A3,WO 2008/083175 A3,114-359-560-979-46X,2008-12-24,2008,US 2007/0088852 W,2007-12-26,US 87714606 P;;US 67334107 A;;US 67399207 A,2006-12-26,ON A MOBILE DEVICE TRACKING USE OF SEARCH RESULTS DELIVERED TO THE MOBILE DEVICE,"A method implemented on a mobile device that includes speech recognition functionality involves: receiving an utterance that includes a search request from a user of the device; recognizing that the utterance includes a search request; sending a representation of the search request to a remote server over a wireless data connection; receiving information over the wireless data connection that is responsive to the search request; presenting the information on the mobile device; receiving an input from the user selecting an item present in the received information, the item identifying a remote resource; using the selected item to connect to the remote resource, the connection to the remote resource not involving the remote server; and sending to the remote server an indication that a connection was made to the resource identified by the selected item. The method further involves storing a log of the user's connection to remote resources and sending the log to the server.",VOICE SIGNAL TECHNOLOGIES INC;;EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/114-359-560-979-46X,Search Report,yes,4,0,3,18,0,G10L15/26;;H04M2250/74;;G06F16/951;;G06F16/90335;;H04M1/72403;;H04M2250/74;;G10L15/26;;G06F16/90335;;G06F16/951;;H04M1/72403,H04M1/72403;;H04M3/493,,0,0,,,,PENDING
149,MX,B,MX 362804 B,192-663-235-619-351,2019-02-14,2019,MX 2015005879 A,2013-11-12,US 201261725161 P;;US 2013/0069711 W,2012-11-12,"AQUEOUS BASED CAPSAICINOID FORMULATIONS, AND TREATMENT IN COMBINATION WITH A CORTICOSTEROID.","Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",VIZURI HEALTH SCIENCES LLC,BUCKS DANIEL;;BIRBARA PHILIP J;;BIRBARA CHARLES A;;COUGHLIN MARY,"MICROSOFT TECHNOLOGY LICENSING, LLC (2017-03-15)",https://lens.org/192-663-235-619-351,Granted Patent,no,0,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K31/165;;A61K9/08;;A61K31/045;;A61P23/02,,0,0,,,,ACTIVE
150,CN,A,CN 104230793 A,008-494-813-343-734,2014-12-24,2014,CN 201410363758 A,2007-12-28,US 87776206 P,2006-12-28,Composition and Methods for Modulating a Kinase Cascade,The invention relates to a composition and methods for modulating a minase cascade. The invention relates to compositions of N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl)acetamide (KX2-391) and methods for modulating one or more components of a kinase cascade.,KINEX PHARMACEUTICALS LLC,DAVID G HANGAUER;;DANIEL COUGHLIN;;JEREMY A CODY;;JONATHAN GALE,,https://lens.org/008-494-813-343-734,Patent Application,no,1,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D213/56,,0,0,,,,DISCONTINUED
151,AU,A2,AU 2007/340350 A2,073-990-545-936-292,2009-09-17,2009,AU 2007/340350 A,2007-12-28,US 87776206 P;;US 2007/0026457 W,2006-12-28,Composition and Methods for Modulating a Kinase Cascade,,KINEX PHARMACEUTICALS LLC,CODY JEREMY A;;COUGHLIN DANIEL;;HANGAUER DAVID G;;GALE JONATHAN,"ATNX SPV, LLC (2023-03-16)",https://lens.org/073-990-545-936-292,Patent Application,no,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,A61K31/5377;;A61P35/00;;C07D413/12,,0,0,,,,ACTIVE
152,US,A1,US 2015/0133561 A1,095-342-488-355-047,2015-05-14,2015,US 201414253660 A,2014-04-15,US 201414253660 A;;US 201314078253 A,2013-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",VIZURI HEALTH SCIENCES LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,VIZURI HEALTH SCIENCES LLC (2014-08-14);;PROPELLA THERAPEUTICS INC (2020-05-01),https://lens.org/095-342-488-355-047,Patent Application,yes,3,18,13,13,0,A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61P17/02;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;A61K9/0019;;A61K9/08;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K47/10;;A61K47/26;;A61K47/36;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024,A61K47/36;;A61K31/045;;A61K31/05;;A61K31/165;;A61K47/10;;A61K47/22,514/627,0,0,,,,DISCONTINUED
153,JP,A,JP H1010903 A,091-713-977-203-989,1998-01-16,1998,JP 5436097 A,1997-03-10,US 61929096 A,1996-03-18,MANUFACTURING OF FUSER ROLL,"PROBLEM TO BE SOLVED: To reduce the cost by removing the metal from an inner face of a fuser core, and coarsening the inner face of the hollow metallic fuser core, in lieu of the organic black paint coating on the inner face of the core, and to solve the problems on the treatment of a coating material, such as separating, blistering, sagging, flowing or the like, by reducing the dependency on a solvent. SOLUTION: An inner face of a fuser core 49 is coarsened by the grit glasting, or the mechaning or etching of a surface of a metal such as aluminium, copper or stainless steel. It is necessary that the inner surface is sufficiently coarsened, so that the diffused reflection of the infrared rays is performed on the inner face, without the high diffused reflection by the smooth metal surface. The value of the surface roughness is within 0.8-3.8 micron, and the desired diffusion scattering characteristic can be obtained within 1.0-1.5 micron. The inner face of a fuser roll 52 is treated so that the optimum fuser operating condition can be obtained by the diffusion and the reflection of the radiation by the inner face of the core 49.",XEROX CORP,ANGOLD DOUGLAS W;;COUGHLIN JR DANIEL L;;MCGLYNN KEVIN M,,https://lens.org/091-713-977-203-989,Patent Application,no,0,1,3,3,0,G03G15/2053,G03G15/20;;H05B3/00,,0,0,,,,DISCONTINUED
154,WO,A2,WO 2008/083172 A2,105-892-972-475-320,2008-07-10,2008,US 2007/0088847 W,2007-12-26,US 87714606 P;;US 67334107 A;;US 67398807 A,2006-12-26,INTEGRATED VOICE SEARCH COMMANDS FOR MOBILE COMMUNICATIONS DEVICES,"A method implemented on a mobile device that includes speech recognition functionality involves presenting to a user of the mobile device a voice-control interface that supports two types of commands at a common level of the interface, the two types of commands including a first type and a second type, the first type being command and control commands and the second type being search request commands. The method further involves: receiving an utterance from the user that corresponds to a command of either of the first type or the second type; recognizing the utterance; if the received utterance is a command of the first type, performing a corresponding command and control function; and if the received utterance is a command of the second type, generating a representation of a corresponding search request and then using the representation to request a search that is responsive to the search request.",VOICE SIGNAL TECHNOLOGIES INC;;EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,,https://lens.org/105-892-972-475-320,Patent Application,yes,0,1,3,18,0,H04M3/4938;;H04M2201/40;;G10L2015/223;;G06F16/90332;;H04M1/72403,H04M1/72403,,0,0,,,,PENDING
155,US,A1,US 2008/0153465 A1,107-205-622-139-779,2008-06-26,2008,US 67334107 A,2007-02-09,US 67334107 A;;US 87714606 P,2006-12-26,VOICE SEARCH-ENABLED MOBILE DEVICE,"Methods and devices for providing a user of a mobile communications device with mobile voice-mediated search capability. The methods and devices involve receiving an utterance from a user of the mobile device, the utterance including a search request; using the speech recognition functionality to recognize that the utterance includes a search request; as a result of recognizing that the utterance includes a search request, establishing a wireless data connection to a remote server; sending a representation of the search request to the remote server over the wireless data connection; receiving search results that are responsive to the search request; and presenting the search results on the mobile device.",VOICE SIGNAL TECHNOLOGIES INC,EVERMANN GUNNAR;;ROTH DANIEL L;;GILLICK LAURENCE S;;COUGHLIN JAMES,NUANCE COMMUNICATIONS INC (2007-05-14);;VOICE SIGNAL TECHNOLOGIES INC (2007-05-03),https://lens.org/107-205-622-139-779,Patent Application,yes,99,64,5,18,0,G10L15/30;;H04M3/4931;;H04M7/0036;;H04M2250/74;;G06F16/957;;H04M1/72445;;H04M1/72403;;G06F16/957;;G10L15/30;;H04M3/4931;;H04M7/0036;;H04M2250/74;;H04M1/72403;;H04M1/72445,G10L21/00;;H04M1/72403;;H04M1/72445;;H04Q7/22,455/414.1;;700/94;;704/201,0,0,,,,DISCONTINUED
156,US,A1,US 2019/0022110 A1,153-361-412-508-540,2019-01-24,2019,US 201816045782 A,2018-07-26,US 201816045782 A;;US 201314078253 A;;US 201261725161 P,2012-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",VIZURI HEALTH SCIENCES LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,PROPELLA THERAPEUTICS INC (2020-05-01),https://lens.org/153-361-412-508-540,Patent Application,yes,0,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K31/573;;A61K9/00;;A61K9/08;;A61K9/107;;A61K31/045;;A61K31/05;;A61K31/085;;A61K31/165;;A61K31/738;;A61K45/06,,0,0,,,,DISCONTINUED
157,EP,A2,EP 2916817 A2,027-534-304-267-940,2015-09-16,2015,EP 13812219 A,2013-11-12,US 201261725161 P;;US 2013/0069711 W,2012-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,,API GENESIS LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,"PROPELLA THERAPEUTICS, INC., US (2021-01-15);;PROPELLA THERAPEUTICS, INC. (N.D.GES.D. STAATE, US (2020-12-16);;VIZURI HEALTH SCIENCES LLC (2017-03-08)",https://lens.org/027-534-304-267-940,Patent Application,yes,0,0,19,19,0,A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573;;A61K9/08;;A61K9/107;;A61K9/0019;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/05;;A61K31/738;;A61K31/573;;A61K45/06;;A61K9/0019;;A61K9/08;;A61K9/107;;A61K31/045;;A61K45/06;;A61K31/085;;A61K31/738;;A61P17/02;;A61P19/02;;A61K31/05;;A61K31/165;;A61K31/573,A61K9/00,,0,0,,,,ACTIVE
158,WO,A1,WO 2015/073577 A1,060-596-064-555-934,2015-05-21,2015,US 2014/0065290 W,2014-11-12,US 201414253660 A;;US 201314078253 A,2013-11-12,AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE,"Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid.",VIZURI HEALTH SCIENCES LLC,BIRBARA CHARLES A;;BIRBARA PHILIP J;;BUCKS DANIEL;;COUGHLIN MARY,,https://lens.org/060-596-064-555-934,Patent Application,yes,30,1,13,13,0,A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61P17/02;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;A61K9/0019;;A61K9/08;;A61K31/045;;A61K31/085;;A61K31/165;;A61K31/167;;A61K31/728;;A61K47/10;;A61K47/26;;A61K47/36;;A61K47/36;;A61K31/165;;A61K31/05;;A61K31/045;;A61K9/0019;;A61K45/06;;A61K31/085;;A61K31/167;;A61K31/728;;A61K9/0024,A61K9/00;;A61K31/165,,9,9,035-822-081-026-563;;025-364-321-877-36X;;084-999-414-478-666;;029-169-798-920-160;;062-638-149-720-850;;022-608-812-820-025;;023-204-558-598-46X;;093-117-581-767-974;;013-466-470-994-473,21852280;;10.1093/bja/aer260;;pmc3169333;;9647450;;10.1097/00002508-199806000-00003;;18279766;;10.1016/j.joca.2007.12.013;;10.1136/ard.52.11.817;;8250613;;pmc1005195;;8867645;;2580718;;10.1016/0014-2999(85)90456-x;;10.1016/0167-0115(88)90046-8;;2452458;;7537589;;10.1111/j.1476-5381.1995.tb17177.x;;pmc1510027;;10.1016/0304-3940(92)90908-p;;1436645,"ANAND P; BLEY K: ""Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch"", BR ANAESTH., vol. 107, no. 4, 2011, pages 490 - 502;;MARTIN HAUTKAPPE ET AL.: ""Review of the Effectiveness of Capsaicin far Painful Cutaneous Disorders and Neural Dysfunction"", CLIN. J PAIN, vol. /4, 1998, pages 97 - 106, XP008165653, DOI: doi:10.1097/00002508-199806000-00003;;ZHANG ET AL.: ""OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines"", OSTEOARTHRITIS CARTILAGE, vol. 16, 2008, pages 137 - 162, XP022472323, DOI: doi:10.1016/j.joca.2007.12.013;;GOTOH S ET AL.: ""Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats"", ANN RHEUM DIS, vol. 52, 1993, pages 817 - 822, XP008063686;;MOORE ET AL.: ""Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action"", INT J TISSUE REACT, vol. 17, 1995, pages 153 - 156, XP000603128;;LUNDBERG ET AL.: ""Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin"", EUR. J. PHARMACOL., vol. 108, 1985, pages 315 - 319, XP025566186, DOI: doi:10.1016/0014-2999(85)90456-X;;MARTLING ET AL.: ""Calcitonin gene-related peptide and the lung: neuronal coexistence with substance P, release by capsaicin and vasodilatory effect"", REGUL. PEPT., vol. 20, 1988, pages 125 - 139, XP025209323, DOI: doi:10.1016/0167-0115(88)90046-8;;NEWBOLD ET AL.: ""An Investigation into the mechanism of capsaicin-induced edema in rabbit skin"", BRIT. J. OF PHARMA., vol. 114, 1995, pages 570 - 577;;FERRELL ET AL., NEUROSCIENCE LETTERS, vol. 141, 1992, pages 259 - 261",PENDING
159,US,B2,US 6848978 B2,090-596-048-990-467,2005-02-01,2005,US 42732703 A,2003-05-01,US 42732703 A;;US 72315000 A,2000-11-27,"METHOD OF FINISHING A BELT SEAM USING AN ABRASIVE FINISHING MACHINE, A METHOD OF FINISHING A BELT SEAM USING AN ABRASIVE FINISHING MACHINE HAVING A PLURALITY OF FINISHING HEADS, AND A METHOD OF FINISHING A BELT SEAM USING AN ABRASIVE FINISHING MACHINE HAVING FIRST, SECOND, THIRD AND FOURTH FINISHING HEADS","An imageable belt includes a seam that is finished using an abrasive finishing machine. The seam comprises a seam width with adhesive material disposed thereon. The finishing process includes an abrasive finishing media with a finishing surface and a backer bar. The backer bar comprises a backer bar radius. The backer bar surface is positioned against the belt inner surface so that the belt outer surface contacts the finishing surface to define a finishing contact arc with respect to the backer bar radius. A tension, feed rate and pressure are applied to the finishing media. Using the finishing machine, the seam is then finished to remove the adhesive material. The finishing process results in a seam that is imageable. In one embodiment, the backer bar radius is adjusted so that the finishing contact arc covers the seam width.",XEROX CORP,MASTRO PAUL F;;COUGHLIN JR DANIEL L;;DIGRAVIO THOMAS L,XEROX CORPORATION (2003-09-03),https://lens.org/090-596-048-990-467,Granted Patent,yes,12,8,2,4,0,B24B21/006;;B24B21/006;;B29C66/02245;;B29C66/02245;;B29C66/032;;B29C66/032;;B29L2031/709;;B29L2031/709;;B29L2031/764;;B29L2031/764,B24B21/00;;B29C65/00,451/51;;451/56;;451/59;;451/296,3,0,,,"Hammond Machinery Technical Bulletin No. FFP-1000A, Article entitled: ""Abrasive Belt Finishing of Skate Blades"".;;Hammond Machinery Technical Bulletin No. KP-570A, Article entitled: ""Chamfering Both Sides of Compressor Axial Plates"".;;Abrasive Engineering & Mfg. (AEM) Flyer, Entitled 700 Series Sanders, Abrasaplaners & Knife Planer/Sanders.",EXPIRED
160,US,A1,US 2020/0174763 A1,168-190-052-019-778,2020-06-04,2020,US 201816204594 A,2018-11-29,US 201816204594 A,2018-11-29,COMPILE-TIME FOLDING OF ASSUMED CONSTANT VALUES,"A computer-implemented method includes: selecting, by a computer device, a set of fields in a program which are marked as final fields to be treated as constants; adding, by the computer device, detection logic to the program, the detection logic including a process that detects writes to the final fields to be treated as constants; compiling, by the computer device, the program into compiled code; executing, by the computer device, the compiled code; detecting, by the computer device, a write to a first one of the final fields to be treated as constants; and transitioning, by the computer device, execution of the compiled code from the compiled code to an interpreter for processing by compensation code that operates on the first one of the final fields to be treated as constants.",IBM,CRAIK ANDREW JAMES;;COUGHLIN NICHOLAS JAMES;;CHAPMAN GRAHAM ALAN;;HEIDINGA DANIEL,,https://lens.org/168-190-052-019-778,Patent Application,yes,0,1,2,2,0,G06F8/443;;G06F9/4552;;G06F8/443;;G06F9/4552,G06F8/41;;G06F9/455,,0,0,,,,ACTIVE
161,US,A1,US 2018/0099982 A1,189-746-095-669-781,2018-04-12,2018,US 201715784585 A,2017-10-16,US 201715784585 A;;US 201514737599 A;;US 201462012701 P,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,"Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R 1 and R 2 are individually selected from hydrogen, alkyl, substituted or alkyl; n=0, 1, or 2; Y=NR 3 R 4 , OR 5 , or SR 5 , where R 3 and R 4 are individually selected from acyl or sulfonyl, and where R 5 is aryl or heteroaryl, or heterocyclic; and Ar is an aryl, heteroaryl, or heterocyclic compound.",JOHNSON MATTHEY PLC,COUGHLIN DANIEL J;;WILT JEREMY C;;GOU DA-MING;;COLLIER STEVEN,JOHNSON MATTHEY PUBLIC LIMITED COMPANY (2016-03-15);;MACFARLAN SMITH LIMITED (2022-09-30),https://lens.org/189-746-095-669-781,Patent Application,yes,0,0,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07D519/00;;C07C39/00;;C07D209/52;;C07D209/56;;C07D215/22;;C07D215/227;;C07D239/88;;C07D241/04;;C07D261/20;;C07D275/06;;C07D311/06;;C07D311/20;;C07D401/12;;C07D403/12;;C07D413/04;;C07D413/12;;C07D417/08;;C07D417/12;;C07D471/12;;C07D487/12,,0,0,,,,ACTIVE
162,US,B1,US 9957283 B1,096-380-990-507-361,2018-05-01,2018,US 201715784585 A,2017-10-16,US 201715784585 A;;US 201514737599 A;;US 201462012701 P,2014-06-16,Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates,"Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R 1 and R 2 are individually selected from hydrogen, alkyl, substituted or alkyl; n=0, 1, or 2; Y=NR 3 R 4 , OR 5 , or SR 5 , where R 3 and R 4 are individually selected from acyl or sulfonyl, and where R 5 is aryl or heteroaryl, or heterocyclic; and Ar is an aryl, heteroaryl, or heterocyclic compound.",JOHNSON MATTHEY PLC,COUGHLIN DANIEL J;;WILT JEREMY C;;GOU DA-MING;;COLLIER STEVEN,JOHNSON MATTHEY PUBLIC LIMITED COMPANY (2016-03-15);;MACFARLAN SMITH LIMITED (2022-09-30),https://lens.org/096-380-990-507-361,Granted Patent,yes,31,0,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07D239/88;;C07C39/00;;C07D209/52;;C07D209/56;;C07D215/22;;C07D215/227;;C07D241/04;;C07D261/20;;C07D275/06;;C07D311/06;;C07D311/20;;C07D401/12;;C07D403/12;;C07D413/04;;C07D413/12;;C07D417/08;;C07D417/12;;C07D471/12;;C07D487/12;;C07D519/00,,8,3,004-043-978-302-81X;;031-383-047-746-877;;076-944-497-354-029,10.1002/hlca.19670500528;;10.1016/j.bmcl.2014.01.070;;24582477;;10.1002/bbpc.19830871210,"Cherbuliez et al., “148. Recherches sur la Formation et la Transformation des esters LXXV[1]”, Helvetica Chimica Acta, 1967(50) pp. 1440-1452 (English Summary Included).;;Dolenski et al., “Molecules Amphiphiles Electroreductibles. Etude de la Reductio en Milieux de Sulfates d'omega-(4-acetylphenoxy)alkyle”, Bull. Soc. Chim. Fr. 1996 (133) pp. 235-242 (English Summary Included).;;Fischer et al., “Reaktivitaet und Toxizitaet Cyclischer Schwefelsaeur Eester”, Journal Fuer Praktische Chemie 1975(317)6 pp. 943-952 (English Abstract Included).;;Hassner et al., “El-Massenspektrometrie N-monosulfoalkyl-substituierte Cyanine”, Zeitschrift Fur Chemie 1989(29)2 pp. 65-66 (English Translated Included).;;Jia et al., “Synthesis and Evaluation of a Novel Class Hsp90 Inhibitors Containing 1-phenylpiperazine Scaffold”, Bioorganic & Med. Chem. Letters 2014(24)6 pp. 1557-1561.;;Lichtenberger, et al., “No 204. Sur Les Sulfates de Diols”, Bull. Soc. Chim. Fr. 1948 pp. 1002-1012 (English Abstract Included).;;Nagamura et al., “Novel effect of Man-Made Molecular Assemblies on Photoinduced Charge Separation. 4.Synthetic Bilayer Membrane of Amphipathic Viologen as an Efficient Electron Collector in Photosensitized Redox Reactions”, Ber. Bunsenges. Phys. Chem. 1983(87)12 pp. 1129-1133.;;Pai et al., “Synthesis of Novel Analogs 3,4-dihydro-1H-1uinolin-2-one Derivatives as Typical Antidepressant, Sedative and Anti-Parksinson Agents”, Heterocyclic Letters 2012(2)1 pp. 117-128.",ACTIVE
163,TW,A,TW 200827354 A,116-199-858-059-298,2008-07-01,2008,TW 95149416 A,2006-12-28,US 87776206 P,2006-12-28,Composition and methods for modulating a kinase cascade,The invention relates to compounds and methods for modulating one or more components of a kinase cascade.,KINEX PHARMACEUTICALS LLC,HANGAUER JR DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN,,https://lens.org/116-199-858-059-298,Patent of Addition,no,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,A61K31/5377;;C07D413/12;;A61P35/00,,0,0,,,,ACTIVE
164,WO,A1,WO 2008/144045 A1,083-290-071-163-907,2008-11-27,2008,US 2008/0006419 W,2008-05-19,US 93075807 P;;US 579207 A,2007-05-17,PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF,"The invention relates to compositions comprising 2-(5-(4-(2- morpholinoethoxy)phenyl)pyτidin-2-yl)--V-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-<4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-ΛΛbenzylacetainide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.",KINEX PHARMACEUTICALS LLC;;HANGAUER DAVID G JR;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN,HANGAUER DAVID G JR;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN,,https://lens.org/083-290-071-163-907,Patent Application,yes,1,7,16,64,0,C07D213/56;;A61P19/10;;A61P27/16;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00,C07D213/56;;A61K31/44;;A61P35/00,,0,0,,,,PENDING
165,AU,A,AU 1994/079568 A,157-592-306-144-716,1995-04-18,1995,AU 1994/079568 A,1994-09-28,US 12735193 A;;US 9410589 W,1993-09-28,Metal-binding targeted polypeptide constructs,,CYTOGEN CORP,BELINKA BENJAMIN A;;COUGHLIN DANIEL J;;ALVAREZ VERNON LEON;;WOOD RICHARD,,https://lens.org/157-592-306-144-716,Patent Application,no,0,0,9,9,0,A61K49/085;;A61K49/122;;A61K49/14;;A61K51/088;;A61K2121/00;;A61K2123/00;;A61K49/122;;A61K49/14;;A61K2121/00;;A61K49/085;;A61K2123/00;;A61K51/088,A61K49/08;;A61K51/08,,0,0,,,,PENDING
166,US,A1,US 2008/0287436 A1,176-563-638-509-87X,2008-11-20,2008,US 15405608 A,2008-05-19,US 15405608 A;;US 579207 A;;US 93075807 P,2007-05-17,Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof,"The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.",HANGAUER JR DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN,HANGAUER JR DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN,ATHENEX INC (2015-08-26);;ATNX SPV LLC (2022-06-29),https://lens.org/176-563-638-509-87X,Patent Application,yes,15,13,4,64,0,A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/02;;A61P37/06;;C07D413/12;;C07D413/12,A61K31/5377;;C07D413/12,514/235.5;;544/124,0,0,,,,ACTIVE
167,CA,A1,CA 2951917 A1,174-447-729-761-367,2015-12-23,2015,CA 2951917 A,2015-06-12,US 201462012701 P;;US 2015/0035558 W,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,"Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R1 and R2 are individually selected from hydrogen, alkyl, substituted or aikyl; n= 0, 1, or 2; Y = NR3R4, QR5, or SR5, where R3 and R4 are individually selected from acyl or su!fonyl, and where R5 is aryi or heteroaryi, or heterocyclic; and Ar is an aryl, heteroaryl, or heterocyclic compound.",JOHNSON MATTHEY PLC,COUGHLIN DANIEL J;;WILT JEREMY C;;GOU DA-MING;;COLLIER STEVEN,,https://lens.org/174-447-729-761-367,Patent Application,no,0,0,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07D275/06;;C07D417/12,,0,0,,,,ACTIVE
168,US,A1,US 2018/0312530 A1,012-172-489-650-11X,2018-11-01,2018,US 201815958645 A,2018-04-20,US 201815958645 A;;US 201715784585 A;;US 201514737599 A;;US 201462012701 P,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,"Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R 1 and R 2 are individually selected from hydrogen, alkyl, substituted or alkyl; n=0, 1, or 2; Y=NR 3 R 4 , OR 5 , or SR 5 , where R 3 and R 4 are individually selected from acyl or sulfonyl, and where R 5 is aryl or heteroaryl, or heterocyclic; and Ar is an aryl, heteroaryl, or heterocyclic compound.",JOHNSON MATTHEY PLC,COUGHLIN DANIEL J;;WILT JEREMY C;;GOU DA-MING;;COLLIER STEVEN,,https://lens.org/012-172-489-650-11X,Patent Application,yes,0,0,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07D519/00;;C07C39/00;;C07D209/52;;C07D209/56;;C07D215/22;;C07D215/227;;C07D239/88;;C07D241/04;;C07D261/20;;C07D275/06;;C07D311/06;;C07D311/20;;C07D401/12;;C07D403/12;;C07D413/04;;C07D413/12;;C07D417/08;;C07D417/12;;C07D471/12;;C07D487/12,,0,0,,,,DISCONTINUED
169,US,B2,US 10936290 B2,073-414-157-962-282,2021-03-02,2021,US 201816204594 A,2018-11-29,US 201816204594 A,2018-11-29,Compile-time folding of assumed constant values,"A computer-implemented method includes: selecting, by a computer device, a set of fields in a program which are marked as final fields to be treated as constants; adding, by the computer device, detection logic to the program, the detection logic including a process that detects writes to the final fields to be treated as constants; compiling, by the computer device, the program into compiled code; executing, by the computer device, the compiled code; detecting, by the computer device, a write to a first one of the final fields to be treated as constants; and transitioning, by the computer device, execution of the compiled code from the compiled code to an interpreter for processing by compensation code that operates on the first one of the final fields to be treated as constants.",IBM,CRAIK ANDREW JAMES;;COUGHLIN NICHOLAS JAMES;;CHAPMAN GRAHAM ALAN;;HEIDINGA DANIEL,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-11-28),https://lens.org/073-414-157-962-282,Granted Patent,yes,8,0,2,2,0,G06F8/443;;G06F9/4552;;G06F8/443;;G06F9/4552,G06F8/41;;G06F9/455,,2,1,052-152-063-024-042,10.6028/nist.sp.800-145,"Rodriguez-Cando et al., “Automatic Microbenchmark Generation to Prevent Dead Code Elimination and Constant Folding”, ASE 2016, Sep. 3-7, 2016, Singapore, Singapore, http://dx.doi.org/10.1145/2970276.2970346, 12 pages.;;Mell et al., “The NIST Definition of Cloud Computing”, NIST, Special Publication 800-145, Sep. 2011, 7 pages.",ACTIVE
170,CA,C,CA 2951917 C,076-262-882-512-531,2019-09-24,2019,CA 2951917 A,2015-06-12,US 201462012701 P;;US 2015/0035558 W,2014-06-16,PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES,"Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R1 and R2 are individually selected from hydrogen, alkyl, substituted or aikyl; n= 0, 1, or 2; Y = NR3R4, QR5, or SR5, where R3 and R4 are individually selected from acyl or su!fonyl, and where R5 is aryi or heteroaryi, or heterocyclic; and Ar is an aryl, heteroaryl, or heterocyclic compound.",JOHNSON MATTHEY PLC,COUGHLIN DANIEL J;;WILT JEREMY C;;GOU DA-MING;;COLLIER STEVEN,,https://lens.org/076-262-882-512-531,Granted Patent,no,0,0,17,17,0,C07D311/06;;C07D215/22;;C07D413/04;;C07D239/88;;C07D241/04;;C07D471/12;;C07D487/12;;C07D209/52;;C07C39/00;;C07D519/00;;C07D417/08;;C07D261/20;;C07D209/56;;C07D417/12;;C07D215/227;;C07D401/12;;C07D403/12;;C07D275/06;;C07D311/20;;C07D413/12;;C07D413/14;;C07D519/00;;C07D417/08;;C07D261/20;;C07D209/56;;C07D417/12;;C07D215/227;;C07D401/12;;C07D403/12;;C07D275/06;;C07D311/20;;C07D413/12;;C07C39/00;;C07D311/06;;C07D215/22;;C07D413/04;;C07D239/88;;C07D241/04;;C07D471/12;;C07D487/12;;C07D209/52;;C07D413/14,C07D275/06;;C07D417/12,,0,0,,,,ACTIVE
171,US,B2,US 9790237 B2,191-680-979-268-230,2017-10-17,2017,US 201514737599 A,2015-06-12,US 201514737599 A;;US 201462012701 P,2014-06-16,Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates,"Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R 1 and R 2 are individually selected from hydrogen, alkyl, substituted or alkyl; n=0, 1, or 2; Y=NR 3 R 4 , OR 5 , or SR 5 , where R 3 and R 4 are individually selected from acyl or sulfonyl, and where R 5 is aryl or heteroaryl, or heterocyclic; and Ar is an aryl, heteroaryl, or heterocyclic compound.",JOHNSON MATTHEY PLC,COUGHLIN DANIEL J;;WILT JEREMY C;;GOU DA-MING;;COLLIER STEVEN,JOHNSON MATTHEY PUBLIC LIMITED COMPANY (2016-03-15);;MACFARLAN SMITH LIMITED (2022-09-30),https://lens.org/191-680-979-268-230,Granted Patent,yes,31,0,17,17,0,C07D519/00;;C07D519/00;;C07C39/00;;C07C39/00;;C07D209/52;;C07D209/52;;C07D209/56;;C07D209/56;;C07D215/22;;C07D215/22;;C07D215/227;;C07D215/227;;C07D239/88;;C07D239/88;;C07D241/04;;C07D241/04;;C07D261/20;;C07D261/20;;C07D275/06;;C07D275/06;;C07D311/06;;C07D311/06;;C07D311/20;;C07D311/20;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D413/04;;C07D413/04;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14;;C07D417/08;;C07D417/08;;C07D417/12;;C07D417/12;;C07D471/12;;C07D471/12;;C07D487/12;;C07D487/12,C07D417/12;;C07C39/00;;C07D209/52;;C07D209/56;;C07D215/22;;C07D215/227;;C07D239/88;;C07D241/04;;C07D261/20;;C07D275/06;;C07D295/135;;C07D311/06;;C07D311/20;;C07D401/12;;C07D403/12;;C07D409/12;;C07D413/04;;C07D413/12;;C07D417/08;;C07D471/08;;C07D471/12;;C07D487/12;;C07D519/00,,8,3,004-043-978-302-81X;;076-944-497-354-029;;031-383-047-746-877,10.1002/hlca.19670500528;;10.1002/bbpc.19830871210;;10.1016/j.bmcl.2014.01.070;;24582477,"Cherbuliez et al., “148. Recherches sur la Formation et la Transformation des esters LXXV[1]”, Helvetica Chimica Acta, 1967(50) pp. 1440-1452 (English Summary Included).;;Dolenski et al., “Molecules Amphiphiles Electroreductibles. Etude de la Reductio en Milieux de Sulfates d'omega-(4-acetylphenoxy)alkyle”, Bull. Soc. Chim. Fr. 1996 (133) pp. 235-242 (English Summary Included).;;Nagamura et al., “Novel effect of Man-Made Molecular Assemblies on Photoinduced Charge Separation. 4.Synthetic Bilayer Membrane of Amphipathic Viologen as an Efficient Electron Collector in Photosensitized Redox Reactions”, Ber. Bunsenges. Phys. Chem. 1983(87)12 pp. 1129-1133.;;Jia et al., “Synthesis and Evaluation of a Novel Class Hsp90 Inhibitors Containing 1-phenylpiperazine Scaffold”, Bioorganic & Med. Chem. Letters 2014(24)6 pp. 1557-1561.;;Pai et al., “Synthesis of Novel Analogs 3,4-dihydro-1H-1uinolin-2-one Derivatives as Typical Antidepressant, Sedative and Anti-Parksinson Agents”, Heterocyclic Letters 2012(2)1 pp. 117-128.;;Fischer et al., “Reaktivitaet and Toxizitaet Cyclischer Schwefelsaeur Fester”, Journal Fuer Praktische Chemie 1975 (317)6 pp. 943-952 (English Abstract Included).;;Lichtenberger, et al., “No 204. Sur Les Sulfates de Diols”, Bull. Soc. Chim. Fr. 1948 pp. 1002-1012 (English Abstract Included).;;Hassner et al., “El-Massenspektrometrie N-monosulfoalkyl-substituierte Cyanine”, Zeitschrift Fur Chemie 1989(29)2 pp. 65-66 (English Translated Included).",ACTIVE
172,AT,T1,AT E461925 T1,085-034-410-181-991,2010-04-15,2010,AT 06751667 T,2006-04-26,US 67520205 P;;US 2006/0016059 W,2005-04-26,BENZISOXAZOLPIPERIDINVERBINDUNGEN UND VERFAHREN ZU DEREN ANWENDUNG,,HYPNION INC,WHITE JAMES;;COUGHLIN DANIEL;;EDGAR DALE;;SOLOMON MICHAEL;;HANGAUER DAVID;;SHIOSAKI KAZUMI,,https://lens.org/085-034-410-181-991,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,,,0,0,,,,ACTIVE
173,CA,C,CA 2673974 C,149-275-347-924-955,2017-01-17,2017,CA 2673974 A,2007-12-28,US 87776206 P;;US 2007/0026457 W,2006-12-28,COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE,The invention relates to compositions of N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl)acetamide (KX2-391) and methods for modulating one or more components of a kinase cascade.,KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS,,https://lens.org/149-275-347-924-955,Granted Patent,no,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D413/12;;A61K31/5377;;A61P35/00,,0,0,,,,ACTIVE
174,CA,C,CA 1330378 C,031-181-936-609-711,1994-06-21,1994,CA 536091 A,1987-04-30,US 86103786 A,1986-05-08,AMINE DERIVATIVES OF FOLIC ACID ANALOGS,"ABSTRACT OF THE DISCLOSURE Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;RADCLIFFE ROBERT D;;LOPES ANTHONY D;;RODWELL JOHN D,,https://lens.org/031-181-936-609-711,Granted Patent,no,0,0,17,90,0,A61K47/6889;;A61K47/6803,C07D239/95;;A61K39/00;;A61K39/395;;A61K47/48;;C07D471/00;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,D353000051   M;;1670139    S;;26002421   S,0,0,,,,EXPIRED
175,US,A,US 5449761 A,048-531-803-160-169,1995-09-12,1995,US 12735193 A,1993-09-28,US 12735193 A,1993-09-28,Metal-binding targeted polypeptide constructs,"This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, ""B"" is a hydrocarbon backbone, ""P"" is a polypeptide capable of targeting particular cells, tissues or organs of the body, ""A"" may be the group --NR'--NR""-- or the group --NR'--NR""--L-- in which L may be an aliphatic or aromatic linker group, R, R' and R"" may be the same or different and may be hydrogen or an aliphatic group, m is an integer .gtoreq.2, provided that the groups R, R', R', L and ""P"" of a given chain may be the same or different from the groups R, R', R"", L and ""P"" of another chain, n is an integer .gtoreq.0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.",CYTOGEN CORP,BELINKA JR BENJAMIN A;;COUGHLIN DANIEL J;;ALVAREZ VERNON L;;WOOD RICHARD,CYTOGEN CORPORATION (1993-09-23),https://lens.org/048-531-803-160-169,Granted Patent,yes,20,84,9,9,56,A61K49/085;;A61K49/122;;A61K49/14;;A61K51/088;;A61K2121/00;;A61K2123/00;;A61K49/122;;A61K49/14;;A61K2121/00;;A61K49/085;;A61K2123/00;;A61K51/088,A61K49/08;;A61K51/08,534/10;;534/14;;534/15;;530/300;;530/326;;530/327;;530/328;;530/399;;530/408;;564/18;;564/23;;564/26;;564/27;;564/28,9,8,016-606-045-126-078;;032-943-863-544-199;;128-298-129-167-095;;094-309-285-165-090;;037-541-240-623-536;;024-282-261-448-508;;180-750-634-162-600;;037-541-240-623-536,10.1016/s0047-0740(86)80003-1;;3710705;;10.1016/s0140-6736(89)91258-0;;1975618;;10.1056/nejm199011013231805;;2170840;;10.1021/jm00080a022;;1732553;;10.1021/ed062p965;;3585492;;10.1021/jm00080a022;;1732553,"Int. J. Nucl. Med. Biol., vol. 12, No. 6, pp. 425 430, Yashushi Arano, et al., Synthesis And Evaluation Of A New Bifunctional Chelating Agent For 99m Tc Labeling Proteins: p Carboxyethyl Phenylglyoxaldi(N Methylthiosemicarbazone) .;;The Lancet, Feb. 4, 1989, E. P. Krenning, et al., Localisation Of Endocrine Related Tumours With Radioiodinated Analogue Of Somatostatin , pp. 242 244.;;The Journal of Nuclear Medicine, vol. 31, No. 9, Sep. 1990, Willem H. Bakker, et al., Receptor Scintigraphy With A Radioiodinated Somatostatin Analogue: Radiolabeling, Purification, Biologic Activity, And In Vivo Application In Animals , pp. 1501 1509.;;The New England Journal of Medicine, vol. 323, No. 18, S. W. J. Lamberts, et al., Nov. 1, 1990, Somatostatin Receptor Imaging In The Localization Of Endocrine Tumors , pp. 1246 1249.;;Journal of Medicinal Chemistry, vol. 35, No. 2, Jan. 24, 1992, Ernest Cullen, et al., BIS Basic Substituted Diaminobenzobisthiazoles As Potential Antiarthritic Agents , pp. 350 361.;;Journal of Chemical Education, vol. 62, No. 11, Nov. 1985, Thomas C. Pinkerton, et al., Bioinorganic Activity Of Technetium Radiopharmaceuticals , pp. 965 973.;;Radiochem. Radioanal. Letters 29(4), pp. 171 178, 1977, R. Kopunec, et al., Reaction Of Pertechnetate With Thiourea In The Nitric Acid Solutions .;;The Journal of Nuclear Medicine, vol. 28, No. 6, Jun. 1987, Yasushi Arano, et al., Technetium 99m Labeled Monoclonal Antibody With Preserved Immunoreactivity And High In Vivo Stability , pp. 1027 1033.;;Cullen et al., J. Med. Chem., vol. 35(2), Jan. 24, 1992, pp. 350 361.",EXPIRED
176,AU,A,AU 1987/073590 A,122-839-870-674-277,1987-12-01,1987,AU 1987/073590 A,1987-05-01,US 86103786 A,1986-05-08,ANTIBODY CONJUGATES OF AMINE DERIVATIVES OF FOLIC ACID ANALOGS,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;RADCLIFFE ROBERT D;;LOPES ANTHONY DWIGHT;;RODWELL JOHN D,,https://lens.org/122-839-870-674-277,Patent Application,no,0,2,17,90,0,A61K47/6889;;A61K47/6803,C07D239/95;;A61K39/00;;A61K39/395;;A61K47/48;;C07D471/00;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,0,0,,,,DISCONTINUED
177,US,A1,US 2008/0187691 A1,141-920-392-666-180,2008-08-07,2008,US 67215607 A,2007-02-07,US 67215607 A,2007-02-07,Rapid Ink Drying Papers,"Papers are provided which exhibit rapid ink setting and ink drying. These papers include a topcoat layer, and a penultimate coating layer that draws ink through the topcoat layer. In some implementations, the penultimate coating layer includes a high internal pore volume filler, and/or has a fine external pigment pore structure.",WARREN S D CO,OSGOOD ALONZO K;;MASIA STEVEN L;;COUGHLIN DANIEL R;;COLEMAN PHILLIP S,S.D. WARREN COMPANY (2007-04-10),https://lens.org/141-920-392-666-180,Patent Application,yes,3,10,4,4,0,D21H19/82;;D21H19/82,B41M5/50;;B41M5/00,428/32.32;;428/32.1;;428/32.34;;428/32.35,0,0,,,,DISCONTINUED
178,EP,B1,EP 2114934 B1,166-937-332-820-578,2015-10-21,2015,EP 07863295 A,2007-12-28,US 2007/0026457 W;;US 87776206 P,2006-12-28,COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE,,KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS,"ATHENEX, INC. (2016-01-13);;ATNX SPV, LLC; US (2023-07-17);;ATHENEX, INC.; US (2016-01-26);;ATNX SPV, LLC, BUFFALO, US (2023-03-01);;ATHENEX, INC. (N. D. GES. D. STAATES DELAWARE), US (2016-05-31);;KINEX PHARMACEUTICALS, LLC (2012-05-23);;ATNX SPV, LLC (2023-06-12)",https://lens.org/166-937-332-820-578,Granted Patent,yes,1,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D413/12;;A61K31/5377;;A61P35/00,,0,0,,,,ACTIVE
179,DK,A,DK 5188 A,180-070-509-320-56X,1988-04-15,1988,DK 5188 A,1988-01-07,US 86103786 A;;US 8700992 W,1986-05-08,"ANTISTOF-FOLINSYREANALOGKONJUGAT, DETS FREMSTILLING, SAMT VED FREMSTILLINGEN ANVENDELIGT MELLEMPRODUKT OG FREMSTILLING DERAF","Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;RADCLIFFE ROBERT D;;LOPES ANTHONY DWIGHT;;RODWELL JOHN D,,https://lens.org/180-070-509-320-56X,Patent Application,no,0,0,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;C07D239/95;;A61K39/395;;A61K47/48;;C07D471/00;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,0,0,,,,EXPIRED
180,EP,A3,EP 0251455 A3,044-868-111-680-794,1990-09-05,1990,EP 87304093 A,1987-05-07,US 86103786 A,1986-05-08,ANTIBODY CONJUGATES OF AMINE DERIVATIVES OF FOLIC ACID ANALOGS,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORPORATION,"COUGHLIN, DANIEL J.;;LOPEZ, ANTHONY DWIGHT;;RADCLIFFE, ROBERT D.;;RODWELL, JOHN D.",,https://lens.org/044-868-111-680-794,Search Report,yes,7,0,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;A61K39/395;;A61K47/48;;C07D239/95;;C07D471/00;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,2,2,058-248-900-440-161;;030-695-376-183-100,7057425;;10.1021/jm00344a018;;10.1021/jm00144a016;;6796689,"CHEMICAL ABSTRACTS, Vol. 96, No. 7, 15 February 1982, page 19, column 1, Abstract No. 45865j, Columbus, Ohio, US; J.R. PIPER et al.: ""Syntheses of alpha- and gamma-substituted amides, peptides, and esters of methotrexate and their evaluation as inhibitors of folate metabolism"", & Journal of Medicinal Chemistry, Vol. 25, No. 2, 1982, pages 182-187 (Cat. D).;;CHEMICAL ABSTRACTS, Vol. 96, No. 1, 4 January 1982, page 33, column 1, Abstract No. 402q, Columbus, Ohio, US; A. ROSOWSKY et al.: ""Methotrexate analogs. 14. Synthesis of new gamma-substituted derivatives as dihydrofolate reductase inhibitors and potential anticancer agents"", & Journal of Medicinal Chemistry, Vol. 24, No. 12, 1981, pages 1450-1455.",EXPIRED
181,FI,A0,FI 880059 A0,073-444-386-014-435,1988-01-07,1988,FI 880059 A,1988-01-07,US 86103786 A;;US 8700992 W,1986-05-08,FOERFARANDE FOER FRAMSTAELLNING AV ANTIKROPPKONJUGATER AV FOLSYRAANALOGERS AMINDERIVAT.,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;RADCLIFFE ROBERT D;;LOPES ANTHONY DWIGHT;;RODWELL JOHN D,,https://lens.org/073-444-386-014-435,Patent Application,no,0,0,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;C07D239/95;;A61K39/395;;A61K47/48;;C07D471/00;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,0,0,,,,DISCONTINUED
182,AT,T1,AT E105484 T1,132-838-545-128-115,1994-05-15,1994,AT 87304093 T,1987-05-07,EP 87304093 A;;US 86103786 A,1986-05-08,AMINDERIVATE VON FOLSAEURE ANALOGEN.,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT D;;RODWELL JOHN D,,https://lens.org/132-838-545-128-115,Granted Patent,no,0,0,17,90,0,A61K47/6889;;A61K47/6803,C07D239/95;;A61K39/00;;A61K39/395;;A61K47/48;;C07D471/00;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,0,0,,,,EXPIRED
183,DE,D1,DE 3789788 D1,062-101-435-824-482,1994-06-16,1994,DE 3789788 T,1987-05-07,US 86103786 A,1986-05-08,Aminderivate von Folsäure Analogen.,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT D;;RODWELL JOHN D,,https://lens.org/062-101-435-824-482,Granted Patent,no,0,0,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;A61K39/395;;A61K47/48;;C07D471/00;;C07D239/95;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,0,0,,,,EXPIRED
184,FI,A,FI 880059 A,074-613-803-745-345,1988-01-07,1988,FI 880059 A,1988-01-07,US 86103786 A;;US 8700992 W,1986-05-08,FOERFARANDE FOER FRAMSTAELLNING AV ANTIKROPPKONJUGATER AV FOLSYRAANALOGERS AMINDERIVAT.,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;RADCLIFFE ROBERT D;;LOPES ANTHONY DWIGHT;;RODWELL JOHN D,,https://lens.org/074-613-803-745-345,Patent Application,no,0,0,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;C07D239/95;;A61K39/395;;A61K47/48;;C07D471/00;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,0,0,,,,DISCONTINUED
185,WO,A1,WO 2008/097883 A1,141-407-218-718-603,2008-08-14,2008,US 2008/0052883 W,2008-02-04,US 67215607 A,2007-02-07,RAPID INK DRYING PAPERS,"Papers are provided which exhibit rapid ink setting and ink drying. These papers include a topcoat layer, and a penultimate coating layer that draws ink through the topcoat layer. In some implementations, the penultimate coating layer includes a high internal pore volume filler, and/or has a fine external pigment pore structure.",WARREN S D CO;;OSGOOD ALONZO K;;MASIA STEVEN L;;COUGHLIN DANIEL R;;COLEMAN PHILLIP S,OSGOOD ALONZO K;;MASIA STEVEN L;;COUGHLIN DANIEL R;;COLEMAN PHILLIP S,,https://lens.org/141-407-218-718-603,Patent Application,yes,6,0,4,4,0,D21H19/82;;D21H19/82,D21H19/82,,0,0,,,,PENDING
186,US,A1,US 2007/0004752 A1,012-945-700-811-372,2007-01-04,2007,US 41285606 A,2006-04-26,US 41285606 A;;US 67520205 P,2005-04-26,Benzisoxazole piperazine compounds and methods of use thereof,The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep.,COUGHLIN DANIEL;;WHITE JAMES;;SHIOSAKI KAZUMI;;HANGAUER DAVID;;SOLOMON MICHAEL;;EDGAR DALE,COUGHLIN DANIEL;;WHITE JAMES;;SHIOSAKI KAZUMI;;HANGAUER DAVID;;SOLOMON MICHAEL;;EDGAR DALE,HYPNION INC (2007-04-03),https://lens.org/012-945-700-811-372,Patent Application,yes,7,8,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,A61K31/496;;C07D413/04,514/254.04;;544/368,0,0,,,,INACTIVE
187,DK,D0,DK 5188 D0,090-483-934-658-29X,1988-01-07,1988,DK 5188 A,1988-01-07,US 86103786 A;;US 8700992 W,1986-05-08,"ANTISTOF-FOLINSYREANALOGKONJUGAT, DETS FREMSTILLING, SAMT VED FREMSTILLINGEN ANVENDELIGT MELLEMPRODUKT OG FREMSTILLING DERAF","Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;RADCLIFFE ROBERT D;;LOPES ANTHONY DWIGHT;;RODWELL JOHN D,,https://lens.org/090-483-934-658-29X,Patent Application,no,0,0,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;C07D239/95;;A61K39/395;;A61K47/48;;C07D471/00;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,0,0,,,,EXPIRED
188,ES,T3,ES 2051738 T3,015-384-987-516-080,1994-07-01,1994,ES 87304093 T,1987-05-07,US 86103786 A,1986-05-08,DERIVADOS AMINICOS DE COMPUESTOS ANALOGOS A ACIDO FOLICO.,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT D;;RODWELL JOHN D,,https://lens.org/015-384-987-516-080,Granted Patent,no,0,0,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;A61K39/395;;A61K47/48;;C07D471/00;;C07D239/95;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,0,0,,,,EXPIRED
189,AU,A1,AU 2014/200559 A1,126-237-039-065-00X,2014-02-20,2014,AU 2014/200559 A,2014-01-31,AU 2007/340350 A;;AU 2014/200559 A,2007-12-28,Composition and Methods for Modulating a Kinase Cascade,The invention relates to compositions of N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin -2-yl)acetamide (KX2-391) and methods for modulating one or more components of a kinase cascade.,KINEX PHARMACEUTICALS,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS,"ATNX SPV, LLC (2023-03-16)",https://lens.org/126-237-039-065-00X,Patent Application,no,0,0,2,2,0,,C07D413/12;;A61K31/5377;;A61P35/00,,0,0,,,,ACTIVE
190,AT,T1,AT E458717 T1,126-958-108-765-086,2010-03-15,2010,AT 02804907 T,2002-12-17,US 34095301 P;;EP 0214355 W,2001-12-19,BETA-AMINO-ALPHA-CYANOACRYLATE UND DEREN VERWENDUNG ALS HERBIZIDE,,BASF SE,EVERSON ALBERT;;COUGHLIN DANIEL;;GUACIARO MICHAEL;;FLEMING LINDA;;MARAVETZ LESTER;;HUPPATZ JOHN,,https://lens.org/126-958-108-765-086,Granted Patent,no,0,0,13,13,0,A01N37/42;;A01N37/44;;A01N43/08;;A01N43/16;;A01N43/18;;C07C255/23;;C07C255/30;;C07C255/31;;C07C323/60;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C255/23;;A01N43/18;;C07D307/16;;C07C323/60;;C07D309/04;;A01N37/42;;C07D309/06;;A01N37/44;;C07C255/31;;C07D307/14;;A01N43/16;;C07C255/30;;A01N43/08;;C07C2601/02;;C07C2601/14;;C07C2601/08,C07D335/02;;A01N37/42;;A01N37/44;;A01N41/12;;A01N43/08;;A01N43/16;;A01N43/18;;C07C253/30;;C07C255/23;;C07C255/30;;C07C323/58;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06,,0,0,,,,EXPIRED
191,CN,B,CN 101616915 B,185-418-838-051-352,2014-12-17,2014,CN 200780051766 A,2007-12-28,US 2007/0026457 W;;US 87776206 P,2006-12-28,Composition and methods for modulating a kinase cascade,,KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;D PATRA,,https://lens.org/185-418-838-051-352,Granted Patent,no,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D413/12;;A61K31/5377;;A61P35/00,,0,0,,,,ACTIVE
192,WO,A1,WO 1987/006837 A1,031-419-366-700-261,1987-11-19,1987,US 8700992 W,1987-05-01,US 86103786 A,1986-05-08,ANTIBODY CONJUGATES OF AMINE DERIVATIVES OF FOLIC ACID ANALOGS,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment. The conjugates retain substantially the same immunospecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;RADCLIFFE ROBERT D;;LOPES ANTHONY DWIGHT;;RODWELL JOHN D,,https://lens.org/031-419-366-700-261,Patent Application,yes,1,13,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;A61K39/395;;A61K47/48;;C07D239/95;;C07D471/00;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,C3H HHX2          HHX2;;C3H H510          HHX2;;C3H H514          HHX2;;C3H H521          HHX2;;U1S S1313,5,5,138-049-764-544-270;;014-287-421-339-731;;005-334-346-125-348;;031-542-023-008-39X;;079-827-705-689-031,7248938;;87219;;10.1021/bi00578a014;;7191812;;10.1016/0014-5793(80)81026-x;;6467187;;pmc344852;;10.1073/pnas.81.5.1445;;6369328,"CANCER RESEARCH, Volume 41, issued July 1981, (Washington, D.C.), KULKERNI et al., ""Covalent Binding of Methotrexate to Immunoglobulins and the Effect of Antibody-Linked Drug on Tumor Growth In Vivo"", pages 2700-2706.;;BIOCHEMISTRY, Volume 18, Number 11, issued 1979, (London, England), KARUSH et al., ""Interaction of a Bivalent Ligand with IgM Anti-Lactose Antibody"", pages 2226-2231.;;FEBS LETTERS, Volume 119, Number 1, issued September 1980, (Amsterdam, The Netherlands), MONSIGNY et al., ""Preparation and Biological Properties of a Covalent Antitumor Drug-Arm-Carrier (DAC Conjugate)"".;;CANCER RESEARCH, Volume 44, issued October 1984, (Washington, D.C.), UADIA et al., ""Tumor and Tissue Distribution of a Methotrexate-Anti-EL4 Immunoglobulin Conjugate in EL4 Lymphoma-Bearing Mice"", pages 4263-4266.;;PROC. NATL. ACAD. SCI. U.S.A., Vol. 81, issued March 1984, (Washington, D.C.), SHEN et al., ""Selective Killing of a Fc-Receptor-Bearing Tumor Cells Through Endocytosis of a Drug Carrying Immune Complex"", pages 1445-1447.",PENDING
193,CN,A,CN 102657656 A,036-245-276-642-621,2012-09-12,2012,CN 201210109836 A,2007-12-28,US 87776206 P,2006-12-28,Composition and methods for modulating a kinase cascade,"The invention relates to ccompositions comprising N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide (KX2-391), and methods for modulating one or more components of a kinase cascade.",KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G;;DANIEL COUGHLIN;;CODY JEREMY A;;JONATHAN GALE;;DEBASIS PATRA,,https://lens.org/036-245-276-642-621,Patent Application,no,1,1,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,A61K31/5377;;A61P3/04;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06,,0,0,,,,DISCONTINUED
194,EP,A1,EP 2118367 A1,143-094-772-106-303,2009-11-18,2009,EP 08728895 A,2008-02-04,US 2008/0052883 W;;US 67215607 A,2007-02-07,RAPID INK DRYING PAPERS,,WARREN S D CO,OSGOOD ALONZO K;;MASIA STEVEN L;;COUGHLIN DANIEL R;;COLEMAN PHILLIP S,,https://lens.org/143-094-772-106-303,Patent Application,yes,0,0,4,4,0,D21H19/82;;D21H19/82,D21H19/82,,1,0,,,See references of WO 2008097883A1,DISCONTINUED
195,CA,A1,CA 2172625 A1,018-109-648-725-446,1995-04-06,1995,CA 2172625 A,1994-09-28,US 12735193 A,1993-09-28,METAL-BINDING TARGETED POLYPEPTIDE CONSTRUCTS,"This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metalbinding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of formula (I), in which, ""B"" is a hydrocarbon backbone, ""P"" is polypeptide capable of targeting particular cells, tissues or organs of the body, ""A"" may be the group -NR' -NR"" - or the group -NR' -NR"" -L- in which L may be an aliphatic or aromatic linker group, R, R', and R"" may be the same or different and may be hydrogen or an aliphatic group, m is an integer 2, provided that the groups R, R', R"", L and ""P"" of a given chain may be the same or different from the groups R, R', R"", L and ""P"" of another chain, n is an integer 0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.",CYTOGEN CORP,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J;;ALVAREZ VERNON LEON;;WOOD RICHARD,,https://lens.org/018-109-648-725-446,Patent Application,no,0,0,9,9,0,A61K49/085;;A61K49/122;;A61K49/14;;A61K51/088;;A61K2121/00;;A61K2123/00;;A61K49/122;;A61K49/14;;A61K2121/00;;A61K49/085;;A61K2123/00;;A61K51/088,A61K49/08;;A61K51/08,,0,0,,,,DISCONTINUED
196,DE,T2,DE 3789788 T2,054-586-801-319-063,1994-08-18,1994,DE 3789788 T,1987-05-07,US 86103786 A,1986-05-08,Aminderivate von Folsäure Analogen.,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT D;;RODWELL JOHN D,,https://lens.org/054-586-801-319-063,Granted Patent,no,0,0,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;A61K39/395;;A61K47/48;;C07D471/00;;C07D239/95;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,0,0,,,,EXPIRED
197,EP,A1,EP 0721353 A1,011-711-278-790-503,1996-07-17,1996,EP 94930452 A,1994-09-28,US 12735193 A;;US 9410589 W,1993-09-28,METAL-BINDING TARGETED POLYPEPTIDE CONSTRUCTS,,CYTOGEN CORP,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J;;ALVAREZ VERNON LEON;;WOOD RICHARD,,https://lens.org/011-711-278-790-503,Patent Application,yes,0,0,9,9,0,A61K49/085;;A61K49/122;;A61K49/14;;A61K51/088;;A61K2121/00;;A61K2123/00;;A61K49/122;;A61K49/14;;A61K2121/00;;A61K49/085;;A61K2123/00;;A61K51/088,A61K49/08;;A61K51/08,,0,0,,,,DISCONTINUED
198,AT,T1,AT E459621 T1,047-705-289-653-817,2010-03-15,2010,AT 06751665 T,2006-04-26,US 67520205 P;;US 2006/0016057 W,2005-04-26,BENZISOXAZOLPIPERIDINVERBINDUNGEN UND VERFAHREN ZU DEREN ANWENDUNG,,HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES;;SHIOSAKI KAZUMI;;HANGAUER DAVID;;SOLOMON MICHAEL;;EDGAR DALE,,https://lens.org/047-705-289-653-817,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,,,0,0,,,,INACTIVE
199,ES,T3,ES 2559687 T3,095-649-175-024-235,2016-02-15,2016,ES 07863295 T,2007-12-28,US 87776206 P;;US 2007/0026457 W,2006-12-28,Composición y métodos para modular una cascada de cinasa,Un procedimiento para preparar 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-N-bencilacetamida que comprende la etapa de: hacer reaccionar 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)acetato de metilo con bencilamina para dar 2-(5-(4-(2- morfolinoetoxi)fenil)piridin-2-il)-N-bencilacetamida.,ATHENEX INC,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS,,https://lens.org/095-649-175-024-235,Granted Patent,no,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D413/12;;A61K31/5377;;A61P35/00,,0,0,,,,ACTIVE
200,US,A,US 3254910 A,001-466-052-832-759,1966-06-07,1966,US 28465663 A,1963-05-31,US 28465663 A,1963-05-31,Flexible expansion pipe joint,,BABCOCK & WILCOX CO,POOLE ARTHUR J;;BILLY JOHN S;;COUGHLIN DANIEL T;;PATTERSON GORDON A,,https://lens.org/001-466-052-832-759,Granted Patent,no,17,9,1,1,0,F16L51/021;;F16L51/021,F16L51/02,,0,0,,,,EXPIRED
201,EP,A1,EP 2114934 A1,022-354-247-519-696,2009-11-11,2009,EP 07863295 A,2007-12-28,US 2007/0026457 W;;US 87776206 P,2006-12-28,COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE,,KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS,"ATHENEX, INC. (2016-01-13);;ATNX SPV, LLC; US (2023-07-17);;ATHENEX, INC.; US (2016-01-26);;ATNX SPV, LLC, BUFFALO, US (2023-03-01);;ATHENEX, INC. (N. D. GES. D. STAATES DELAWARE), US (2016-05-31);;KINEX PHARMACEUTICALS, LLC (2012-05-23);;ATNX SPV, LLC (2023-06-12)",https://lens.org/022-354-247-519-696,Patent Application,yes,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D413/12;;A61K31/5377;;A61P35/00,,0,0,,,,ACTIVE
202,ZA,B,ZA 873305 B,051-062-263-336-598,1987-11-02,1987,ZA 873305 A,1987-05-08,US 86103786 A,1986-05-08,ANTIBODY CONJUGATES OF AMINE DERIVATIVES OF FOLIC ACID ANALOGS,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORPORATION,DANIEL J. COUGHLIN;;ROBERT D. RADCLIFFE;;ANTHONY DWIGHT LOPES;;JOHN D. RODWELL,,https://lens.org/051-062-263-336-598,Granted Patent,no,0,0,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;A61K39/395;;C07D239/95;;A61K47/48;;C07D471/00;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,0,0,,,,EXPIRED
203,DK,A,DK 51189 A,121-090-610-092-029,1989-02-03,1989,DK 51189 A,1989-02-03,US 5844087 A;;US 19954988 A;;US 8801909 W,1987-06-05,"AMINDERIVATER AF ANTHACYCLINANTIBIOTIKA, ANTISTOFKONJUGATER DERAF SAMT DISSES FREMSTILLING OG ANVENDELSE","Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING DALTON H;;LOPES ANTHONY DWIGTH;;COUGHLIN DANIEL J;;RADCLIFFE ROBERT DAVID,,https://lens.org/121-090-610-092-029,Patent Application,no,0,0,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,0,0,,,,DISCONTINUED
204,US,A,US 5593656 A,171-049-181-100-084,1997-01-14,1997,US 48722195 A,1995-06-07,US 48722195 A;;US 12735193 A,1993-09-28,Metal-binding targeted polypeptide constructs,"This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, ""B"" is a hydrocarbon backbone, ""P"" is a polypeptide capable of targeting particular cells, tissues or organs of the body, ""A"" may be the group --NR'--NR""-- or the group --NR'--NR""--L-- in which L may be an aliphatic or aromatic linker group, R, R', and R"" may be the same or different and may be hydrogen or an aliphatic group, m is an integer.gtoreq.2, provided that the groups R, R', R"", L and ""P"" of a given chain may be the same or different from the groups R, R', R"", L and ""P"" of another chain, n is an integer.gtoreq.0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.",CYTOGEN CORP,BELINKA JR BENJAMIN A;;COUGHLIN DANIEL J;;ALVAREZ VERNON L;;WOOD RICHARD,,https://lens.org/171-049-181-100-084,Granted Patent,yes,23,18,9,9,56,A61K49/085;;A61K49/122;;A61K49/14;;A61K51/088;;A61K2121/00;;A61K2123/00;;A61K49/122;;A61K49/14;;A61K2121/00;;A61K49/085;;A61K2123/00;;A61K51/088,A61K49/08;;A61K51/08,424/1.69;;424/9.1;;424/9.3;;424/9.4;;534/10;;534/14;;534/15;;530/300;;530/324;;530/325;;530/326;;530/327;;530/328;;530/329;;530/330,18,13,016-606-045-126-078;;180-750-634-162-600;;128-298-129-167-095;;150-800-376-204-04X;;037-541-240-623-536;;048-323-342-433-77X;;021-524-763-108-909;;022-154-442-385-885;;108-717-593-270-043;;094-309-285-165-090;;106-655-176-540-969;;129-210-791-439-654;;038-447-130-884-626,10.1016/s0047-0740(86)80003-1;;3710705;;3585492;;1975618;;10.1073/pnas.78.5.3199;;6789331;;pmc319528;;10.1021/jm00080a022;;1732553;;10.1021/jo01041a040;;2404341;;10.1016/s0001-2998(05)80173-4;;2746136;;10.1007/bf01646868;;10.1201/9780429278822-2;;10.1056/nejm199011013231805;;2170840;;10.1021/jo01053a509;;3542202;;3100031,"Arano et al., Int. J. Nucl. Med Biol. (1986) 12(6):425 430.;;Arano et al., J. Nucl. Med. (1987) 28:1027.;;Bakker, W. H., et al., J. Nucl. Med. (1990) 21:1501 1509.;;Colcher et al., Proc. Natl. Acad. Sci. U.S.A. (1981) 78:3199 3203.;;Cullen et al., J. Med. Chem., vol. 35(2), Jan. 24, 1992, pp. 350 361.;;D Angeli et al., J. Org. Chem. (1963) 28:1596 1600.;;Dswanjee, Seminar in Nuclear Medicine (1990) 20:5 27.;;Granowska et al., Int. J. Colorect. Dis. (1989) 4:97 108.;;Hull, Synthetic Commun. (1979) 9:477 481.;;Kl o pping and van der Kerk, Rec. Trav. Chim. (1951) 70:949 961.;;Kopunec et al., Radiochem, Radioanal. Lett. (1977) 29:171.;;Krenning, E. P., et al., Lancet (1989) 242 245.;;Lamb and Kramer, Commercial Production of Radioisotopes for Nuclear Medicine, In Radiotracers For Medical Applications, vol. 1, Rayudu (Ed.), CRC Press, Inc., Boca Raton, pp. 17 62.;;Lamberts, S. W. J., et al., N. Eng. J. Med. (1990) 323:1246 1249.;;Lieber and Slutkin, J. Org. Chem. (1962) 27:2214 2217.;;Pinkerton et al., J. Chem. Ed. (1985) 62:965.;;Prehn, Richmond T. et al. Cancer Res. (1987) 47:927 932.;;Sunkard, Prasad S. et al. Cancer Res. (1987) 47:933 935.",EXPIRED
205,CN,A,CN 101631913 A,037-437-408-609-552,2010-01-20,2010,CN 200880004335 A,2008-02-04,US 67215607 A,2007-02-07,Rapid ink drying papers,"Papers are provided which exhibit rapid ink setting and ink drying. These papers include a topcoat layer, and a penultimate coating layer that draws ink through the topcoat layer. In some implementations, the penultimate coating layer includes a high internal pore volume filler, and/or has a fine external pigment pore structure.",WARREN S D CO,OSGOOD ALONZO K;;MASIA STEVEN L;;COUGHLIN DANIEL R;;COLEMAN PHILLIP S,,https://lens.org/037-437-408-609-552,Patent Application,no,0,2,4,4,0,D21H19/82;;D21H19/82,D21H19/82,,0,0,,,,DISCONTINUED
206,WO,A1,WO 1995/009013 A1,131-738-015-508-896,1995-04-06,1995,US 9410589 W,1994-09-28,US 12735193 A,1993-09-28,METAL-BINDING TARGETED POLYPEPTIDE CONSTRUCTS,"This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of formula (I), in which, 'B' is a hydrocarbon backbone, 'P' is polypeptide capable of targeting particular cells, tissues or organs of the body, 'A' may be the group -NR' -NR' - or the group -NR' -NR' -L- in which L may be an aliphatic or aromatic linker group, R, R', and R' may be the same or different and may be hydrogen or an aliphatic group, m is an integer ≥ 2, provided that the groups R, R', R', L and 'P' of a given chain may be the same or different from the groups R, R', R', L and 'P' of another chain, n is an integer ≥ 0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.",CYTOGEN CORP,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J;;ALVAREZ VERNON LEON;;WOOD RICHARD,,https://lens.org/131-738-015-508-896,Patent Application,yes,2,9,9,9,0,A61K49/085;;A61K49/122;;A61K49/14;;A61K51/088;;A61K2121/00;;A61K2123/00;;A61K49/122;;A61K49/14;;A61K2121/00;;A61K49/085;;A61K2123/00;;A61K51/088,A61K49/08;;A61K51/08,,2,1,037-541-240-623-536,10.1021/jm00080a022;;1732553,"JOURNAL OF MEDICINAL CHEMISTRY, Vol. 35, 04 January 1992, CULLEN et al., ""Bis Basic Substituted Diaminobenzobisthiazoles as Potential Antiarthritic Agents"", pp. 350-361.;;See also references of EP 0721353A4",PENDING
207,HK,A1,HK 1136570 A1,037-196-651-934-836,2010-07-02,2010,HK 10103982 A,2010-04-22,US 2007/0026457 W;;US 87776206 P,2006-12-28,COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE,,ATHENEX INC,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS,,https://lens.org/037-196-651-934-836,Patent Application,no,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D/;;A61K/;;A61P/,,0,0,,,,PENDING
208,DK,T3,DK 2114934 T3,167-189-242-868-135,2016-01-25,2016,DK 07863295 T,2007-12-28,US 87776206 P;;US 2007/0026457 W,2006-12-28,SAMMENSÆTNING OG FREMGANGSMÅDER TIL MODULERING AF EN KINASEKASKADE,,ATHENEX INC,COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;HANGAUER DAVID G;;PATRA DEBASIS,,https://lens.org/167-189-242-868-135,Granted Patent,no,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D413/12;;A61K31/5377;;A61P35/00,,0,0,,,,ACTIVE
209,DK,D0,DK 51189 D0,183-257-919-885-183,1989-02-03,1989,DK 51189 A,1989-02-03,US 5844087 A;;US 19954988 A;;US 8801909 W,1987-06-05,"AMINDERIVATER AF ANTHACYCLINANTIBIOTIKA, ANTISTOFKONJUGATER DERAF SAMT DISSES FREMSTILLING OG ANVENDELSE","Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING DALTON H;;LOPES ANTHONY DWIGTH;;COUGHLIN DANIEL J;;RADCLIFFE ROBERT DAVID,,https://lens.org/183-257-919-885-183,Patent Application,no,0,0,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,0,0,,,,DISCONTINUED
210,AU,B2,AU 2007/340350 B2,022-677-842-817-010,2014-02-20,2014,AU 2007/340350 A,2007-12-28,US 87776206 P;;US 2007/0026457 W,2006-12-28,Composition and Methods for Modulating a Kinase Cascade,The invention relates to compositions of N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl)acetamide (KX2-391) and methods for modulating one or more components of a kinase cascade.,ATNX SPV LLC,CODY JEREMY A;;COUGHLIN DANIEL;;HANGAUER DAVID G;;GALE JONATHAN;;PATRA DEBASIS,"ATNX SPV, LLC (2023-03-16)",https://lens.org/022-677-842-817-010,Granted Patent,no,1,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D413/12;;A61K31/5377;;A61P35/00,,0,0,,,,ACTIVE
211,EP,B1,EP 0251455 B1,024-452-289-964-749,1994-05-11,1994,EP 87304093 A,1987-05-07,US 86103786 A,1986-05-08,Amine derivatives of folic acid analogs.,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT D;;RODWELL JOHN D,,https://lens.org/024-452-289-964-749,Granted Patent,yes,0,3,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;A61K39/395;;A61K47/48;;C07D471/00;;C07D239/95;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,2,0,,,"CHEMICAL ABSTRACTS, vol. 96, no. 7, 15 February 1982, Columbus, OH (US); J.R. PIPER et al., p. 19, no. 45865j#;;CHEMICAL ABSTRACTS, vol. 96, no. 1, 04 January 1982, Columbus, OH (US); A. ROSOWSKY et al., p. 33, no. 402q#",EXPIRED
212,EP,A2,EP 0251455 A2,040-421-715-203-757,1988-01-07,1988,EP 87304093 A,1987-05-07,US 86103786 A,1986-05-08,Amine derivatives of folic acid analogs.,"Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,COUGHLIN DANIEL J;;LOPEZ ANTHONY DWIGHT;;RADCLIFFE ROBERT D;;RODWELL JOHN D,,https://lens.org/040-421-715-203-757,Patent Application,yes,0,25,17,90,0,A61K47/6889;;A61K47/6803,A61K39/00;;A61K39/395;;A61K47/48;;C07D239/95;;C07D471/00;;C07D471/04;;C07D475/00;;C07D475/02;;C07D475/04;;C07D475/08;;G01N33/531;;G01N33/532,,0,0,,,,EXPIRED
213,AU,B2,AU 2014/200559 B2,105-502-829-975-131,2016-05-26,2016,AU 2014/200559 A,2014-01-31,AU 2007/340350 A;;AU 2014/200559 A,2007-12-28,Composition and Methods for Modulating a Kinase Cascade,The invention relates to compositions of N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin -2-yl)acetamide (KX2-391) and methods for modulating one or more components of a kinase cascade.,ATNX SPV LLC,HANGAUER DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS,"ATNX SPV, LLC (2023-03-16)",https://lens.org/105-502-829-975-131,Granted Patent,no,1,0,2,2,0,,C07D413/12;;A61K31/5377;;A61P35/00,,0,0,,,,ACTIVE
214,CA,A1,CA 2673974 A1,143-337-558-268-030,2008-07-10,2008,CA 2673974 A,2007-12-28,US 87776206 P;;US 2007/0026457 W,2006-12-28,COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE,The invention relates to compositions of N-benzyl-2-(5-(4-(2- morpholinoe thoxy)phenyl)pyridin-2-yl)acetamide (KX2-391) and methods for modulating one or more components of a kinase cascade.,KINEX PHARMACEUTICALS LLC,GALE JONATHAN;;CODY JEREMY A;;COUGHLIN DANIEL;;HANGAUER DAVID G;;PATRA DEBASIS,,https://lens.org/143-337-558-268-030,Patent Application,no,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D413/12;;A61K31/5377;;A61P35/00,,0,0,,,,ACTIVE
215,EP,A4,EP 0721353 A4,165-684-114-981-905,1998-12-30,1998,EP 94930452 A,1994-09-28,US 12735193 A;;US 9410589 W,1993-09-28,METAL-BINDING TARGETED POLYPEPTIDE CONSTRUCTS,,CYTOGEN CORP,BELINKA BENJAMIN A JR;;COUGHLIN DANIEL J;;ALVAREZ VERNON LEON;;WOOD RICHARD,,https://lens.org/165-684-114-981-905,Search Report,no,1,0,9,9,0,A61K49/085;;A61K49/122;;A61K49/14;;A61K51/088;;A61K2121/00;;A61K2123/00;;A61K49/122;;A61K49/14;;A61K2121/00;;A61K49/085;;A61K2123/00;;A61K51/088,A61K49/08;;A61K51/08,,0,0,,,,DISCONTINUED
216,US,B1,US 11461816 B1,189-681-274-840-180,2022-10-04,2022,US 202016839961 A,2020-04-03,US 202016839961 A;;US 201816019816 A,2018-06-27,Healthcare provider bill validation,"A system for validation of healthcare provider bills includes obtaining an image of the bill on a mobile device which uses optical character recognition to resolve the patient identity, provider identity and amount due as alphanumeric characters. The system also receives adjudicated claims data from insurance companies in a non-standardized format. A claims conversion server converts the adjudicated claims data to a standardized machine-readable format. The standardized adjudicated claims data and provider bill are validated against each other in real-time so the patient can make payment in an accurate amount without having to first receive and decipher an EOB form.",RED CARD PAYMENT SYSTEMS LLC;;ZELIS HEALTHCARE LLC,FRENS JEREMY L;;COUGHLIN PATRICK J;;HINDEN PETER J;;BATTISTA DANIEL M,ZELIS HEALTHCARE LLC (2020-08-18),https://lens.org/189-681-274-840-180,Granted Patent,yes,40,2,1,2,0,G06F16/5846;;G06F16/909;;G06Q20/102;;G06Q40/08;;G06Q10/10;;G06Q30/0185;;G06Q30/04;;G06Q50/265;;G06F16/258;;G16H40/20;;G16H10/60;;G06Q30/04;;G06Q40/08;;G06Q10/10;;G06Q20/4014;;G06Q20/42;;G06Q50/265;;G16H10/60;;G06Q20/14;;G06Q30/0185;;G06F16/258;;G06F16/2365;;G16H40/20;;G06V30/414,G06Q30/04;;G06F16/23;;G06F16/25;;G06Q10/10;;G06Q20/14;;G06Q20/40;;G06Q20/42;;G06Q30/00;;G06Q40/08;;G06Q50/26;;G06V30/414;;G16H10/60;;G16H40/20,,0,0,,,,ACTIVE
217,US,A,US 5609847 A,166-423-090-484-058,1997-03-11,1997,US 48037095 A,1995-06-07,US 48037095 A;;US 12735193 A,1993-09-28,Treatment methods using metal-binding targeted polypeptide constructs,"The invention relates to a method of treating a patient in need thereof, including a need for diagnosis or treatment, comprising the administration of a metal complex of a polypeptide construct. The construct comprises a compound of the formula (I): ##STR1## in which, ""B"" is a hydrocarbon backbone, ""P"" is a polypeptide capable of targeting particular-cells, tissues or organs of the body, ""A"" may be the group --NR'--NR""-- or the group --NR'--NR""--L-- in which L may be an aliphatic or aromatic linker group, R, R', and R"" may be the same or different and may be hydrogen or an aliphatic group, m is an integer .gtoreq.2, provided that the groups R, R', R"", L and ""P"" of a given chain may be the same or different from the groups R, R', R"", L and ""P"" of another chain, n is an integer .gtoreq.0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.",CYTOGEN CORP,BELINKA JR BENJAMIN A;;COUGHLIN DANIEL J;;ALVAREZ VERNON L;;WOOD RICHARD,,https://lens.org/166-423-090-484-058,Granted Patent,yes,23,12,9,9,56,A61K49/085;;A61K49/122;;A61K49/14;;A61K51/088;;A61K2121/00;;A61K2123/00;;A61K49/122;;A61K49/14;;A61K2121/00;;A61K49/085;;A61K2123/00;;A61K51/088,A61K49/08;;A61K51/08,424/1.69;;530/300;;530/311;;424/1.11;;424/9.1;;534/10,18,9,016-606-045-126-078;;180-750-634-162-600;;150-800-376-204-04X;;037-541-240-623-536;;048-323-342-433-77X;;022-154-442-385-885;;094-309-285-165-090;;106-655-176-540-969;;129-210-791-439-654,10.1016/s0047-0740(86)80003-1;;3710705;;3585492;;10.1073/pnas.78.5.3199;;6789331;;pmc319528;;10.1021/jm00080a022;;1732553;;10.1021/jo01041a040;;2746136;;10.1007/bf01646868;;10.1056/nejm199011013231805;;2170840;;10.1021/jo01053a509;;3542202,"Arano et al., Int. J. Nucl. Med. Biol. (1986) 12(6):425 430 month not available.;;Arano et al., J. Nucl. Med. (1987) 28:1027 month not available.;;Bakker, W. H., et al., J. Nucl. Med. (1990) 21:1501 1509 month not available.;;Colcher et al., Proc. Natl. Acad. Sci. U.S.A. (1981) 78:3199 3203 month not available.;;Cullen et al., J. Med. Chem. , vol. 35(2), Jan. 24, 1992, pp. 350 361 month not available.;;D Angeli et al., J. Org. Chem. (1963) 28:1596 1600 month not available.;;Dswanjee, Seminar in Nuclear Medicine (1990) 20:5 27 month not available.;;Granowska et al., Int. J. Colorect. Dis. (1989) 4:97 108 month not available.;;Hull, Synthetic Commun. (1979) 9:477 481 month not available.;;Kl o pping and van der Kerk, Rec. Trav. Chim. (1951) 70:949 961 month not available.;;Kopunec et al., Radiochem, Radioanal. Lett. (1977) 29:171 month not available.;;Krenning, E. P., et al., Lancet (1989) 242 245 month not available.;;Lamb and Kramer, Commercial Production of Radioisotopes for Nuclear Medicine, In Radiotracers For Medical Applications , vol. 1, Rayudu (Ed.), CRC Press, Inc., Boca Raton, pp. 17 62, 1989 month not available.;;Lamberts, S. W. J., et al., N. Eng. J. Med. (1990) 323:1246 1249 month not available.;;Lieber and Slutkin, J. Org. Chem. (1962) 27:2214 2217 month not available.;;Pinkerton et al., J. Chem. Ed. (1985) 62:965 month not available.;;Prehn, Richmond T. et al. Cancer Res. (1987) 47:927 932 month not available.;;Sunkard, Prasad S. et al. Cancer Res. (1987) 47:933 935 month not available.",EXPIRED
218,US,B1,US 10664921 B1,080-328-041-064-213,2020-05-26,2020,US 201816019816 A,2018-06-27,US 201816019816 A,2018-06-27,Healthcare provider bill validation and payment,"A system for validation of healthcare provider bills includes obtaining an image of the bill on a mobile device which uses optical character recognition to resolve the patient, provider and amount due as alphanumeric characters. This collection of data is cross-referenced against an explanation of benefits (EOB) generated by a third-party administrator which relays the portion of the healthcare provider bill covered by insurance versus what is the patient's responsibility. The EOB and provider bill are validated against each other so the patient can make payment in an accurate amount.",RED CARD PAYMENT SYSTEMS LLC,FRENS JEREMY L;;COUGHLIN PATRICK J;;HINDEN PETER J;;BATTISTA DANIEL M,ZELIS HEALTHCARE LLC (2020-09-03);;RED-CARD PAYMENT SYSTEMS LLC (2018-06-27),https://lens.org/080-328-041-064-213,Granted Patent,yes,40,4,1,2,0,G06Q40/08;;G06F16/909;;G06F16/5846;;G06Q20/102;;G06V20/63;;G06V30/10;;G06V30/142;;G06Q40/08;;G06Q20/102;;G06Q20/40;;G06F16/33;;G06V30/418;;G06V30/142;;G06V30/10;;G06V20/63,G06Q40/08;;G06F16/33;;G06Q20/10;;G06Q20/40;;G06V30/10;;G06V30/142,,0,0,,,,ACTIVE
219,US,A,US 5578288 A,175-209-472-797-147,1996-11-26,1996,US 48036795 A,1995-06-07,US 48036795 A;;US 12735193 A,1993-09-28,Metal-binding targeted polypeptide constructs,"This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, ""B"" is a hydrocarbon backbone, ""P"" is a polypeptide capable of targeting particular cells, tissues or organs of the body, ""A"" may be the group --NR'--NR""-- or the group --NR'-- NR""--L-- in which L may be an aliphatic or aromatic linker group, R, R', and R"" may be the same or different and may be hydrogen or an aliphatic group, m is an integer.gtoreq.2, provided that the groups R, R', R"", L and ""P"" of a given chain may be the same or different from the groups R, R', R"", L and ""P"" of another chain, n is an integer.gtoreq.0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.",CYTOGEN CORP,BELINKA JR BENJAMIN A;;COUGHLIN DANIEL J;;ALVAREZ VERNON L;;WOOD RICHARD,,https://lens.org/175-209-472-797-147,Granted Patent,yes,22,11,9,9,56,A61K49/085;;A61K49/122;;A61K49/14;;A61K51/088;;A61K2121/00;;A61K2123/00;;A61K49/122;;A61K49/14;;A61K2121/00;;A61K49/085;;A61K2123/00;;A61K51/088,A61K49/08;;A61K51/08,424/1.69;;530/300;;530/328;;530/326;;530/327;;534/10;;534/14;;424/1.11,18,13,016-606-045-126-078;;180-750-634-162-600;;128-298-129-167-095;;150-800-376-204-04X;;037-541-240-623-536;;048-323-342-433-77X;;021-524-763-108-909;;022-154-442-385-885;;108-717-593-270-043;;094-309-285-165-090;;106-655-176-540-969;;129-210-791-439-654;;038-447-130-884-626,10.1016/s0047-0740(86)80003-1;;3710705;;3585492;;1975618;;10.1073/pnas.78.5.3199;;6789331;;pmc319528;;10.1021/jm00080a022;;1732553;;10.1021/jo01041a040;;2404341;;10.1016/s0001-2998(05)80173-4;;2746136;;10.1007/bf01646868;;10.1201/9780429278822-2;;10.1056/nejm199011013231805;;2170840;;10.1021/jo01053a509;;3542202;;3100031,"Arano et al., Int. J. Nucl. Med. Biol. (1986) 12(6):425 430.;;Arano et al., J. Nucl. Med. (1987) 28:1027.;;Bakker, W. H., et al., J. Nucl. Med. (1990) 21:1501 1509.;;Colcher et al., Proc. Natl. Acad. Sci. U.S.A. (1981) 78:3199 3203.;;Cullen et al., J. Med. Chem. , vol. 35(2), Jan. 24, 1992, pp. 350 361.;;D Angeli et al., J. Org. Chem. (1963) 28:1596 1600.;;Dswanjee, Seminar in Nuclear Medicine (1990) 20:5 27.;;Granowska et al., Int. J. Colorect. Dis. (1989) 4:97 108.;;Hull, Synthetic Commun. (1979) 9:477 481.;;Kl o pping and van der Kerk, Rec. Trav. Chim. (1951) 70:949 961.;;Kopunec et al., Radiochem, Radioanal. Lett. (1977) 29:171.;;Krenning, E. P., et al., Lancet (1989) 242 245.;;Lamb and Kramer, Commercial Production of Radioisotopes for Nuclear Medicine , In Radiotracers For Medical Applications , vol. 1, Rayudu (Ed.), CRC Press, Inc., Boca Raton, pp. 17 62.;;Lamberts, S. W. J., et al., N. Eng. J. Med. (1990) 323:1246 1249.;;Lieber and Slutkin, J. Org. Chem. (1962) 27:2214 2217.;;Pinkerton et al., J. Chem. Ed. (1985) 62:965.;;Prehn, Richmond T. et al. Cancer Res. (1987) 47:927 932.;;Sunkard, Prasad S. et al. Cancer Res. (1987) 47:933 935.",EXPIRED
220,JP,A,JP 2016222733 A,161-955-188-104-717,2016-12-28,2016,JP 2016197091 A,2016-10-05,US 87776206 P,2006-12-28,COMPOSITIONS AND METHODS FOR MODULATING KINASE CASCADE,"PROBLEM TO BE SOLVED: To provide compositions and methods for modulating a kinase cascade.SOLUTION: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (KX2-391), and methods for modulating one or more components of a kinase cascade. Compounds of the invention are useful in modulation of a component of a kinase signaling cascade. Some compounds may be useful in modulation of two or more components of a kinase signaling cascade. The compounds of the present invention are useful as pharmaceutical agents. The compounds of the invention may be useful for modulating regulation of a kinase which may be involved in a normal cellular signal transduction pathway (e.g., cell growth, differentiation, survival, adhesion, migration, etc.), or a kinase involved in a disease or disorder.SELECTED DRAWING: None",ATHENEX INC,DAVID G HANGAUER JR;;DANIEL COUGHLIN;;CODY JEREMY A;;JONATHAN GALE;;DEBASIS PATRA,,https://lens.org/161-955-188-104-717,Patent Application,no,1,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,A61K31/5377;;A61P1/04;;A61P9/00;;A61P11/00;;A61P15/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P35/04;;A61P43/00,,0,0,,,,DISCONTINUED
221,WO,A1,WO 2014/138740 A1,120-666-845-784-508,2014-09-12,2014,US 2014/0022716 W,2014-03-10,US 201361774756 P,2013-03-08,PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHIC FORMS OF HYDROCODONE BENZOIC ACID ENOL ESTER AND PROCESSES FOR MAKING SAME,"Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.",JOHNSON MATTHEY PLC;;MCCASTLE SHANAY M,HEINRICH BRIAN W;;DA-MING GOU;;MAHMOUD MIRMEHRABI;;PAUL BERNHARD;;COUGHLIN DANIEL JAMES,,https://lens.org/120-666-845-784-508,Patent Application,yes,3,3,8,8,0,A61K31/485;;C07D489/04;;C07D489/02;;A61K31/485;;C07D489/04;;C07B2200/13;;C07D489/02,A01N37/36,,0,0,,,,PENDING
222,JP,A,JP 2014037439 A,113-677-594-510-835,2014-02-27,2014,JP 2013241606 A,2013-11-22,US 87776206 P,2006-12-28,COMPOSITION AND METHOD FOR REGULATING KINASE CASCADE,"PROBLEM TO BE SOLVED: To provide a composition and a method for regulating kinase cascade.SOLUTION: The present invention relates to a composition of N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridine-2-yl)acetamide (KX2-391) and to a method for regulating one or more components of kinase cascade. The compound of the present invention is useful in modulation of a component of kinase signaling cascade. Some compounds may be useful in modulation of two or more components of kinase signaling cascade. The compound of the present invention is useful as a pharmaceutical. The compound of the present invention may be useful for regulating kinase possibly involved in a normal cell signaling path (for example, cell proliferation, differentiation, survival, adhesion, movement and the like) or kinase involved in sickness or a disease.",KINEX PHARMACEUTICALS LLC,DAVID G HANGAUER JR;;DANIEL COUGHLIN;;CODY JEREMY A;;JONATHAN GALE;;DEBASIS PATRA,,https://lens.org/113-677-594-510-835,Patent Application,no,0,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,A61K31/5377;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P31/04;;A61P31/10;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P43/00,,0,0,,,,DISCONTINUED
223,US,B2,US 7851470 B2,174-062-587-166-812,2010-12-14,2010,US 579207 A,2007-12-28,US 579207 A;;US 87776206 P,2006-12-28,Composition and methods for modulating a kinase cascade,The invention relates to compounds and methods for modulating one or more components of a kinase cascade.,KINEX PHARMACEUTICALS LLC,HANGAUER JR DAVID G;;COUGHLIN DANIEL;;GALE JONATHAN;;CODY JEREMY A;;PATRA DEBASIS,ATHENEX INC (2015-08-26);;ATNX SPV LLC (2022-06-29),https://lens.org/174-062-587-166-812,Granted Patent,yes,24,28,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,A61K31/535,514/235.5,18,17,093-514-661-071-28X;;014-892-315-361-770;;024-246-415-334-792;;013-644-197-083-407;;029-742-983-481-795;;133-545-268-130-061;;014-944-545-982-558;;017-937-967-857-021;;041-703-940-947-068;;085-441-379-277-757;;083-766-165-487-727;;016-856-688-460-880;;008-506-871-340-22X;;014-281-294-082-381;;196-137-673-224-806;;045-942-893-332-610;;059-992-524-705-606,5748697;;10.1021/jm00311a010;;15362850;;10.1021/bi0495073;;11102447;;10.1074/jbc.m008368200;;12020799;;10.1016/s0304-419x(02)00040-9;;10.1126/science.286.5439.531;;10521349;;pmc6757905;;12122079;;10.1523/jneurosci.22-14-06208.2002;;20026599;;10.1021/jm049876x;;15369401;;1875332;;10.1021/jm00112a001;;9544425;;10.1023/a:1005960822365;;10.1002/chin.200429087;;10.1021/jm00023a009;;7473597;;14739300;;10.1074/jbc.m311032200;;10.1517/13543776.15.9.1183;;10.1038/84675;;11175854;;10.1021/cen-v081n008.p032;;pmc33604;;10.1073/pnas.96.14.7697;;10393883;;10.1016/j.bmcl.2003.11.079;;15013006,"Cain et al., ""Potential Antitumor Agents. IX. Bisquaternary Salts"", J. Med. Chem., 11(5):963-966 (1968).;;Davidson et al., ""Discovery and characterization of a substrate selective p38alpha inhibitor"", Biochemistry, 43:11658-11671 (2004).;;Duong et al., ""Inhibition of osteoclast function by adenovirus expressing Antisense protein-tyrosine kinase 2"", J. Biol. Chem., 276(10):7484-7492 (2001).;;Frame, M.C., ""Src in cancer:deregulation and consequences for cell behaviour"", Biochem. Biophys. Acta, 1602:114-130 (2002).;;Golub et al., ""Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring"", Science, 286:531-537 (1999).;;Guo et al., ""Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia"", J. Neurosci., 22(14):6208-6217 (2002).;;Hadjeri et al., ""Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones"". J. Med. Chem., 47:4964-4970 (2004).;;Huff, J.R., ""HIV Protease: A Novel Chemotherapeutic Target for AIDS"", J. Med. Chem., 34(8):2305-2314 (1991).;;Lala et al., ""Role of nitric oxide in tumor progression: Lessons from experimental tumors"", Cancer Metastasis Rev., 17(1):91-106 (1998).;;Liechti et al., ""Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor"", Eur. J. Med. Chem., 39(1):11-26 (2004).;;Million et al., ""Inhibition of the EGF-stimulated cellular proliferation of ER 22 cells by hydroxybiphenyl derivatives"", J. Med. Chem., 38(23):4693-4703 (1995).;;Miyazaki et al., ""Src kinase activity is essential for osteoclast function"", J. Biol. Chem., 279(17):17660-17666 (2004).;;Parang et al., ""Recent advances in the discovery of Src kinase inhibitors"", Expert Opin. Ther. Patents, 15(9):1183-1207 (2005).;;Paul et al., ""Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke"", Nat. Med., 7(2):222-227 (2001).;;Rouhi, A.M., ""The right stuff: From research and development to the clinic, getting drug crystals right is full of pitfalls"", Chem. Eng. News, pp. 32-35 (2003).;;U.S. Pharmacopia #23, National Formulary #18, pp. 1843-1844 (1995).;;Yu et al., ""Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors"", Proc. Natl. Acad. Sci. USA, 96:7697-7704 (1999).;;Zhang et al., ""Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs"", Bioorg. Med. Chem. Lett., 14(4):983-987 (2004).",ACTIVE
224,TW,B,TW I457336 B,020-039-561-410-362,2014-10-21,2014,TW 95149416 A,2006-12-28,US 87776206 P,2006-12-28,Composition and methods for modulating a kinase cascade,,KINEX PHARMACEUTICALS LLC,HANGAUER JR DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS,,https://lens.org/020-039-561-410-362,Granted Patent,no,1,0,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,,,0,0,,,,ACTIVE
225,JP,A,JP 2015232050 A,039-860-462-104-185,2015-12-24,2015,JP 2015189232 A,2015-09-28,US 87776206 P,2006-12-28,COMPOSITION AND METHOD FOR REGULATING KINASE CASCADE,"PROBLEM TO BE SOLVED: To provide a composition and a method for regulating kinase cascade.SOLUTION: The present invention relates to a composition of N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridine-2-yl)acetamide (KX2-391) and to a method for regulating one or more components of kinase cascade. The compound of the present invention is useful in modulation of a component of kinase signaling cascade. Some compounds may be useful in modulation of two or more components of kinase signaling cascade. The compound of the present invention is useful as a pharmaceutical. The compound of the present invention may be useful for regulating kinase possibly involved in a normal cell signaling path (for example, cell proliferation, differentiation, survival, adhesion, movement and the like) or kinase involved in sickness or a disease.",ATHENEX INC,DAVID G HANGAUER JR;;DANIEL COUGHLIN;;CODY JEREMY A;;JONATHAN GALE;;DEBASIS PATRA,,https://lens.org/039-860-462-104-185,Patent Application,no,8,1,25,64,0,C07D213/56;;C07D413/12;;A61P1/04;;A61P11/00;;A61P15/00;;A61P17/06;;A61P19/10;;A61P25/04;;A61P27/02;;A61P27/16;;A61P3/10;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P3/04;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D413/12,C07D213/40,,0,0,,,,ACTIVE
226,US,A1,US 2016/0039837 A1,039-746-931-757-850,2016-02-11,2016,US 201414773628 A,2014-03-10,US 201414773628 A;;US 201361774756 P;;US 2014/0022716 W,2013-03-08,Pharmaceutically Acceptable Salts and Polymorphic Forms of Hydrocodone Benzoic Acid Enol Ester and Processes for Making Same,"Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.",JOHNSON MATTHEY PLC,HEINRICH BRIAN W;;GOU DA-MING;;MIRMEHRABI MAHMOUD;;PAUL BERNHARD;;COUGHLIN DANIEL JAMES,JOHNSON MATTHEY PUBLIC LIMITED COMPANY (2017-01-10);;MACFARLAN SMITH LIMITED (2022-09-30);;KEMPHARM INC (2017-04-12),https://lens.org/039-746-931-757-850,Patent Application,yes,0,4,8,8,0,A61K31/485;;C07D489/04;;C07D489/02;;A61K31/485;;C07D489/04;;C07B2200/13;;C07D489/02,C07D489/04;;A61K31/485;;C07D489/02,,0,0,,,,ACTIVE
227,US,B2,US 9815844 B2,072-854-675-263-302,2017-11-14,2017,US 201414773628 A,2014-03-10,US 201414773628 A;;US 201361774756 P;;US 2014/0022716 W,2013-03-08,Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same,"Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.",KEMPHARM INC,HEINRICH BRIAN W;;GOU DA-MING;;MIRMEHRABI MAHMOUD;;PAUL BERNHARD;;COUGHLIN DANIEL JAMES,JOHNSON MATTHEY PUBLIC LIMITED COMPANY (2017-01-10);;MACFARLAN SMITH LIMITED (2022-09-30);;KEMPHARM INC (2017-04-12),https://lens.org/072-854-675-263-302,Granted Patent,yes,9,0,8,8,0,A61K31/485;;C07D489/04;;C07D489/02;;A61K31/485;;C07D489/04;;C07B2200/13;;C07D489/02,A01N43/42;;A61K31/44;;A61K31/485;;C07D489/02;;C07D489/04,,0,0,,,,ACTIVE
228,EP,A1,EP 4000678 A1,099-931-954-182-499,2022-05-25,2022,EP 21218126 A,2017-03-03,US 201662303361 P;;US 201662328560 P;;US 201662365770 P;;US 201762448546 P;;EP 17760948 A;;US 2017/0020791 W,2016-03-03,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,"The present invention relates to a drainage system, comprising a tube configured for insertion into a body of a subject, wherein the tube defines a tube relief lumen and tube drainage lumen which are fluidly coupled to one another via an opening defined within a proximal portion of the tube, wherein the tube relief lumen and tube drainage lumen extend through the proximal portion separately from one another such that the opening is in proximity to one or more drainage openings defined along the tube, whereby the opening is positioned within the body of the subject when the tube is inserted into the body during use, and further comprising a tube relief lumen valve in fluid communication with the tube relief lumen such that a pressure differential is formed between an ambient pressure and the tube relief lumen, wherein the tube relief lumen valve is configured to close at a first pressure differential and to open at a second pressure differential which is different from the first pressure differential.",ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,,https://lens.org/099-931-954-182-499,Patent Application,yes,3,0,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M27/00;;A61M1/00,,0,0,,,,PENDING
229,AU,B2,AU 2017/228404 B2,028-300-158-736-378,2021-05-13,2021,AU 2017/228404 A,2017-03-03,US 201662328560 P;;US 201762448546 P;;US 201662303361 P;;US 201662365770 P;;US 2017/0020791 W,2016-03-03,Devices and methods for managing chest drainage,"Disclosed is a chest drainage system which reduces or eliminates pooling of blood/liquid and/or clogging/clotting in the drainage tube and/or chest tube, and provides objective and accurate measures of drained fluid volume and chest air leak. The chest drainage system continuously monitors chest tube and drainage tube status and clears pooled liquid in the drainage tube, and/or a clogged chest tube when necessary to restore negative pressure to the chest.",ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,,https://lens.org/028-300-158-736-378,Granted Patent,no,1,0,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M27/00;;A61M1/00,,0,0,,,,ACTIVE
230,AU,A1,AU 2017/228404 A1,038-755-227-088-129,2018-09-27,2018,AU 2017/228404 A,2017-03-03,US 201662328560 P;;US 201762448546 P;;US 201662303361 P;;US 201662365770 P;;US 2017/0020791 W,2016-03-03,Devices and methods for managing chest drainage,"Disclosed is a chest drainage system which reduces or eliminates pooling of blood/liquid and/or clogging/clotting in the drainage tube and/or chest tube, and provides objective and accurate measures of drained fluid volume and chest air leak. The chest drainage system continuously monitors chest tube and drainage tube status and clears pooled liquid in the drainage tube, and/or a clogged chest tube when necessary to restore negative pressure to the chest.",ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,,https://lens.org/038-755-227-088-129,Patent Application,no,0,0,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M27/00;;A61M1/00,,0,0,,,,ACTIVE
231,WO,A2,WO 2017/152125 A2,073-275-386-395-210,2017-09-08,2017,US 2017/0020791 W,2017-03-03,US 201662303361 P;;US 201662328560 P;;US 201662365770 P;;US 201762448546 P,2016-03-03,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,"Disclosed is a chest drainage system which reduces or eliminates pooling of blood/liquid and/or clogging/clotting in the drainage tube and/or chest tube, and provides objective and accurate measures of drained fluid volume and chest air leak. The chest drainage system continuously monitors chest tube and drainage tube status and clears pooled liquid in the drainage tube, and/or a clogged chest tube when necessary to restore negative pressure to the chest.",ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,,https://lens.org/073-275-386-395-210,Patent Application,yes,0,7,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M25/14,,0,0,,,,PENDING
232,WO,A3,WO 2017/152125 A3,189-750-767-741-398,2017-10-12,2017,US 2017/0020791 W,2017-03-03,US 201662303361 P;;US 201662328560 P;;US 201662365770 P;;US 201762448546 P,2016-03-03,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,"Disclosed is a chest drainage system which reduces or eliminates pooling of blood/liquid and/or clogging/clotting in the drainage tube and/or chest tube, and provides objective and accurate measures of drained fluid volume and chest air leak. The chest drainage system continuously monitors chest tube and drainage tube status and clears pooled liquid in the drainage tube, and/or a clogged chest tube when necessary to restore negative pressure to the chest.",ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,,https://lens.org/189-750-767-741-398,Search Report,yes,7,0,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M27/00;;A61M1/00,,0,0,,,,PENDING
233,GB,A,GB 2513804 A,027-876-718-602-251,2014-11-05,2014,GB 201415295 A,2013-03-01,US 201261605627 P;;US 2013/0028723 W,2012-03-01,Multi-Phase Operation With Single Phase Control,"A multi-phase control system having multi-phase operation with single phase control includes a main control module, a lineman module, and an add-on lineman module. The main control module and the lineman module control, automatically or manually, the first phase and first phase tap changer of a multi-phase system. The add-on lineman module and the main control module control, automatically or manually, additional phases of the multi-phase system. In certain example embodiments, the multi-phase control system detects when a line voltage of an additional phase is de-energized and allows the tap changer of the additional phase to be powered by a line voltage of the first phase. In certain example embodiments, the tap changer of a de-energized phase is powered by an external power supply.",COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;BRENNY TIMOTHY;;KROMREY TIMOTHY M,,https://lens.org/027-876-718-602-251,Patent Application,no,5,0,11,11,0,H02J3/1878;;G05F1/14;;Y02E40/30;;G05F1/12;;G05F1/153;;G05F1/12;;G05F1/14;;H02J3/1878;;Y02E40/30,G05F1/153;;G05F1/12,,0,0,,,,ACTIVE
234,EP,A4,EP 3407956 A4,164-251-907-932-724,2019-09-18,2019,EP 17760948 A,2017-03-03,US 201662303361 P;;US 201662328560 P;;US 201662365770 P;;US 201762448546 P;;US 2017/0020791 W,2016-03-03,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,,ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,,https://lens.org/164-251-907-932-724,Search Report,no,4,0,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M27/00;;A61M1/00,,0,0,,,,ACTIVE
235,US,B2,US 10265442 B2,152-478-924-589-367,2019-04-23,2019,US 201715840487 A,2017-12-13,US 201715840487 A;;US 2017/0020791 W;;US 201662303361 P;;US 201662328560 P;;US 201662365770 P;;US 201762448546 P,2016-03-03,Devices and methods for managing chest drainage,"Disclosed is a chest drainage system which reduces or eliminates pooling of blood/liquid and/or clogging/clotting in the drainage tube and/or chest tube, and provides objective and accurate measures of drained fluid volume and chest air leak. The chest drainage system continuously monitors chest tube and drainage tube status and clears pooled liquid in the drainage tube, and/or a clogged chest tube when necessary to restore negative pressure to the chest.",ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,ESCULON LLC (2017-06-02),https://lens.org/152-478-924-589-367,Granted Patent,yes,8,6,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M1/00;;A61M31/00;;A61M37/00;;B65B1/04;;B67C3/16,,0,0,,,,ACTIVE
236,EP,A2,EP 3407956 A2,026-468-587-164-589,2018-12-05,2018,EP 17760948 A,2017-03-03,US 201662303361 P;;US 201662328560 P;;US 201662365770 P;;US 201762448546 P;;US 2017/0020791 W,2016-03-03,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,,ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,,https://lens.org/026-468-587-164-589,Patent Application,yes,0,0,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M27/00;;A61M1/00,,0,0,,,,ACTIVE
237,US,A1,US 2019/0201596 A1,130-617-382-261-461,2019-07-04,2019,US 201916297198 A,2019-03-08,US 201916297198 A;;US 201715840487 A;;US 2017/0020791 W;;US 201662303361 P;;US 201662328560 P;;US 201662365770 P;;US 201762448546 P,2016-03-03,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,"Disclosed is a chest drainage system which reduces or eliminates pooling of blood/liquid and/or clogging/clotting in the drainage tube and/or chest tube, and provides objective and accurate measures of drained fluid volume and chest air leak. The chest drainage system continuously monitors chest tube and drainage tube status and clears pooled liquid in the drainage tube, and/or a clogged chest tube when necessary to restore negative pressure to the chest.",ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,ESCULON LLC (2017-06-02),https://lens.org/130-617-382-261-461,Patent Application,yes,0,4,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M1/00,,0,0,,,,PENDING
238,EP,B1,EP 3407956 B1,154-037-980-674-776,2022-02-09,2022,EP 17760948 A,2017-03-03,US 201662303361 P;;US 201662328560 P;;US 201662365770 P;;US 201762448546 P;;US 2017/0020791 W,2016-03-03,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,,ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,,https://lens.org/154-037-980-674-776,Granted Patent,yes,11,0,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M27/00;;A61M1/00,,0,0,,,,ACTIVE
239,JP,A,JP 2021118897 A,073-631-218-404-489,2021-08-12,2021,JP 2021076123 A,2021-04-28,US 201662303361 P;;US 201662328560 P;;US 201662365770 P;;US 201762448546 P,2016-03-03,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,"To provide a chest drainage system which reduces or eliminates pooling of blood/liquid and/or clogging/clotting in a drainage tube and/or chest tube, and provide objective and accurate measurements of drained fluid volume and chest air leak.SOLUTION: The chest drainage system continuously monitors the status of a chest tube and a drainage tube and clears pooled liquid in the drainage tube, and/or a clogged chest tube, when it is necessary to restore negative pressure on the chest.SELECTED DRAWING: Figure 3",ESCULON LLC,EVAN S LUXON;;DANIEL R BURNETT;;RANDY PRESTON;;RYAN COUGHLIN;;MARK ZIEGLER;;DEREK WALLIN,,https://lens.org/073-631-218-404-489,Patent Application,no,4,0,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M1/00,,0,0,,,,ACTIVE
240,US,A1,US 2018/0104391 A1,065-851-725-684-678,2018-04-19,2018,US 201715840487 A,2017-12-13,US 201715840487 A;;US 2017/0020791 W;;US 201662303361 P;;US 201662328560 P;;US 201662365770 P;;US 201762448546 P,2016-03-03,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,"Disclosed is a chest drainage system which reduces or eliminates pooling of blood/liquid and/or clogging/clotting in the drainage tube and/or chest tube, and provides objective and accurate measures of drained fluid volume and chest air leak. The chest drainage system continuously monitors chest tube and drainage tube status and clears pooled liquid in the drainage tube, and/or a clogged chest tube when necessary to restore negative pressure to the chest.",ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,ESCULON LLC (2017-06-02),https://lens.org/065-851-725-684-678,Patent Application,yes,7,19,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M1/00,,0,0,,,,ACTIVE
241,CA,A1,CA 3016065 A1,142-308-725-553-332,2017-09-08,2017,CA 3016065 A,2017-03-03,US 201662303361 P;;US 201662328560 P;;US 201662365770 P;;US 201762448546 P;;US 2017/0020791 W,2016-03-03,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,"Disclosed is a chest drainage system which reduces or eliminates pooling of blood/liquid and/or clogging/clotting in the drainage tube and/or chest tube, and provides objective and accurate measures of drained fluid volume and chest air leak. The chest drainage system continuously monitors chest tube and drainage tube status and clears pooled liquid in the drainage tube, and/or a clogged chest tube when necessary to restore negative pressure to the chest.",ESCULON LLC,LUXON EVAN S;;BURNETT DANIEL R;;PRESTON RANDY;;COUGHLIN RYAN;;ZIEGLER MARK;;WALLIN DEREK,,https://lens.org/142-308-725-553-332,Patent Application,no,0,0,18,18,0,A61M2205/3331;;A61M2210/101;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52;;A61M1/742;;A61M1/74;;A61M1/743;;A61M1/84;;A61M1/73;;A61M1/75;;A61M1/83;;A61M2210/101;;A61M2205/3331;;A61M1/743;;A61M1/74;;A61M1/84;;A61M1/742;;A61M1/83;;A61M1/73;;A61M1/75;;A61M2205/14;;A61M2205/15;;A61M2205/18;;A61M2205/3313;;A61M2205/3317;;A61M2205/3324;;A61M2205/3334;;A61M2205/3337;;A61M2205/3344;;A61M2205/52,A61M25/14;;A61M1/00,,0,0,,,,PENDING
242,GB,B,GB 2513804 B,147-073-887-147-116,2020-02-19,2020,GB 201415295 A,2013-03-01,US 201261605627 P;;US 2013/0028723 W,2012-03-01,Multi-Phase Operation With Single Phase Control,,EATON INTELLIGENT POWER LTD,DANIEL J DALEY;;CRAIG A COLOPY;;CHRISTOPHER J COUGHLIN;;TIMOTHY BRENNY;;TIMOTHY M KROMREY,,https://lens.org/147-073-887-147-116,Granted Patent,no,6,0,11,11,0,H02J3/1878;;G05F1/14;;Y02E40/30;;G05F1/12;;G05F1/153;;G05F1/12;;G05F1/14;;H02J3/1878;;Y02E40/30,G05F1/153;;G05F1/12,,0,0,,,,ACTIVE
243,US,A,US 5465138 A,102-212-799-833-84X,1995-11-07,1995,US 29747794 A,1994-08-29,US 29747794 A,1994-08-29,Development apparatus having a spincast roll assembly,"A development apparatus includes a housing defining a chamber holding a supply of two-component developer material including toner, and magnetizable carrier beads. The development apparatus also includes an increased reliability roller assembly within the housing for repeatably transporting a desired quantity of attracted developer material through a development zone. The roller assembly includes a first and a second preformed end cap sections each having a stub shaft portion and a cylindrical capping portion connected to the stub shaft portion and having an outer surface and assembly recesses formed into the outer surface. The roller assembly also includes a sleeve section connecting the first and the second preformed end cap sections, the sleeve section being spincast as a layer over each of the cylindrical capping portions, and into the assembly recesses of the end cap sections, so as to precisely and reliably assemble each capping portion, to the sleeve section.",XEROX CORP,JASKOWIAK TIMOTHY R;;COUGHLIN DANIEL L;;PEREZ JULIE A;;GILMORE III DANIEL R;;DIGRAVIO THOMAS L;;TAFT KEVIN H,XEROX CORPORATION (1994-08-24),https://lens.org/102-212-799-833-84X,Granted Patent,yes,7,12,2,2,0,F16C13/00;;F16C13/00;;G03G15/0806;;G03G15/0806;;G03G15/0921;;G03G15/0921;;G03G2215/0607;;G03G2215/0607;;G03G2215/0621;;G03G2215/0621;;G03G2215/0863;;G03G2215/0863;;Y10T29/49556;;Y10T29/49556;;Y10T29/49563;;Y10T29/49563,F16C13/00;;G03G15/08;;G03G15/09,355/245;;29/895.22;;29/895.32;;264/311;;492/47;;492/59,2,0,,,"Robert D. Bonham, Snap Together Magnet Core Assembly , Xerox Disclosure Journal, vol. 5, No. 3, May/Jun. 1980, p. 313.;;Robert D. Bonham, Neck Down Flow Form Mag Brush Roll & Core , Xerox Disclosure Journal, vol. 6, No. 1, Jan./Feb. 1981, p. 25.",EXPIRED
244,AT,T1,AT E122679 T1,155-218-104-975-594,1995-06-15,1995,AT 88401353 T,1988-06-03,US 5844087 A;;US 19954988 A,1987-06-05,AMIN-DERIVATE VON ANTHRACYCLIN-ANTIBIOTIKA.,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING DALTON H;;COUGHLIN DANIEL J;;RODWELL JOHN DENNIS;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT DAVID,,https://lens.org/155-218-104-975-594,Granted Patent,no,0,0,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,0,0,,,,DISCONTINUED
245,CA,A1,CA 2606471 A1,156-397-407-275-280,2006-11-02,2006,CA 2606471 A,2006-04-26,US 67520205 P;;US 2006/0016057 W,2005-04-26,BENZISOXAZOLE PIPERIDINE COMPOUNDS AND METHODS OF USE THEREOF,,HYPNION INC,EDGAR DALE M;;SOLOMON MICHAEL;;COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G,,https://lens.org/156-397-407-275-280,Patent Application,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D413/04;;A61K31/423;;A61K31/445,,0,0,,,,ACTIVE
246,AU,A1,AU 2013/225713 A1,170-312-490-165-18X,2014-09-18,2014,AU 2013/225713 A,2013-03-01,US 201261605627 P;;US 2013/0028723 W,2012-03-01,Multi-phase operation with single phase control,"A multi-phase control system having multi-phase operation with single phase control includes a main control module, a lineman module, and an add-on lineman module. The main control module and the lineman module control, automatically or manually, the first phase and first phase tap changer of a multi-phase system. The add-on lineman module and the main control module control, automatically or manually, additional phases of the multi-phase system. In certain example embodiments, the multi-phase control system detects when a line voltage of an additional phase is de-energized and allows the tap changer of the additional phase to be powered by a line voltage of the first phase. In certain example embodiments, the tap changer of a de-energized phase is powered by an external power supply.",COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;BRENNY TIMOTHY P;;KROMREY TIMOTHY M,EATON INTELLIGENT POWER LIMITED (2018-11-15),https://lens.org/170-312-490-165-18X,Patent Application,no,0,0,11,11,0,H02J3/1878;;G05F1/14;;Y02E40/30;;G05F1/12;;G05F1/153;;G05F1/12;;G05F1/14;;H02J3/1878;;Y02E40/30,G05F1/66;;G05F1/10,,0,0,,,,ACTIVE
247,NZ,A,NZ 629610 A,067-011-723-268-84X,2016-01-29,2016,NZ 62961013 A,2013-03-01,US 2013/0028723 W;;US 201261605627 P,2012-03-01,Multi-phase operation with single phase control,"A multi-phase operation voltage regulator controller is disclosed. The controller includes a main control module (100) with a processor (102), electronically-controlled switches, and a user interface. The main control module (100) is configured to automatically control a tap changer (150) of a lead phase of a multi-phase power system using the electronically-controlled switches in response to a first control signal of the processor (102). Coupled to the main control module (100) is a lineman module (104) with a mode switch and a tap change switch. The lineman module (104) is configured to manually control the tap changer (150) of the lead phase using the mode switch and tap change switch. An add-on lineman module (106) including second electronically-controlled switches, a second mode switch, and a second tap change switch automatically controls a tap changer (150) of a second phase using the second electronically-controlled switches in response to a second control signal of the processor (102). The main control module (100) is configured to automatically control a tap changer (150) of the second phase using the electronically-controlled switches in response to the second control signal from the processor (102).",COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;BRENNY TIMOTHY P;;KROMREY TIMOTHY M,,https://lens.org/067-011-723-268-84X,Patent Application,no,0,0,11,11,0,H02J3/1878;;G05F1/14;;Y02E40/30;;G05F1/12;;G05F1/153;;G05F1/12;;G05F1/14;;H02J3/1878;;Y02E40/30,G05F1/66;;G05F1/10,,0,0,,,,DISCONTINUED
248,EP,B1,EP 1877390 B1,114-612-392-226-413,2010-03-24,2010,EP 06751667 A,2006-04-26,US 2006/0016059 W;;US 67520205 P,2005-04-26,BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF,,HYPNION INC,WHITE JAMES F;;COUGHLIN DANIEL;;EDGAR DALE M;;SOLOMON MICHAEL;;HANGAUER DAVID G;;SHIOSAKI KAZUMI,"HYPNION, INC. (2009-10-21)",https://lens.org/114-612-392-226-413,Granted Patent,yes,2,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,1,0,,,"MARCELLO LEOPOLDO ET AL.: ""Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-ar yl-1-piperazinealkylamides,..."" JOURNAL OF MEDICINAL CHEMISTRY., vol. 47, no. 26, 2004, pages 6616-6624, XP002394594 USAMERICAN CHEMICAL SOCIETY. WASHINGTON.",ACTIVE
249,TW,A,TW 201445270 A,159-456-527-133-152,2014-12-01,2014,TW 102118269 A,2013-05-23,TW 102118269 A,2013-05-23,Multi-phase operation with single phase control,"A multi-phase control system having multi-phase operation with single phase control includes a main control module, a lineman module, and an add-on lineman module. The main control module and the lineman module control, automatically or manually, the first phase and first phase tap changer of a multi-phase system. The add-on lineman module and the main control module control, automatically or manually, additional phases of the multi-phase system. In certain example embodiments, the multi-phase control system detects when a line voltage of an additional phase is de-energized and allows the tap changer of the additional phase to be powered by a line voltage of the first phase. In certain example embodiments, the tap changer of a de-energized phase is powered by an external power supply.",COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;BRENNY TIMOTHY P;;KROMREY TIMOTHY M,,https://lens.org/159-456-527-133-152,Patent of Addition,no,0,0,1,1,0,Y02E40/50,G05F1/12;;H02J3/26,,0,0,,,,PENDING
250,BR,A2,BR 112019004469 A2,000-520-963-307-89X,2019-05-28,2019,BR 112019004469 A,2017-08-29,US 2017/0049013 W;;US 201662385069 P;;US 201615260588 A,2016-09-08,placa óssea de ângulo variável,"é descrita uma placa óssea que tem pelo menos um orifício de travamento de ângulo variável. o orifício de travamento de ângulo variável permite que uma âncora óssea que tem uma cabeça rosqueada seja conduzida para dentro do osso subjacente enquanto orientada em um ângulo em relação a um eixo geométrico de orifício central do orifício que está dentro de uma faixa de ângulos nos quais a cabeça é configurada para se encaixar de forma rosqueada com a pelo menos uma rosca da placa óssea. consequentemente, a âncora óssea pode ser acionada para dentro do osso subjacente até que a cabeça rosqueada se encaixe, por meio de rosqueamento, com a placa óssea dentro do orifício de travamento de ângulo variável.",DEPUY SYNTHES PRODUCTS INC,DYLAN JONES;;ERASMO A LOPEZ;;KRISTINA SNYDER;;ROBERT COUGHLIN;;SEUNG-KYU DANIEL KWAK;;TIMOTHY NICOLETTI,,https://lens.org/000-520-963-307-89X,Patent Application,no,0,0,12,12,0,A61B17/8014;;A61B17/8061;;A61B17/8605;;A61B17/8057;;A61B17/8061;;A61B17/8605;;A61B17/8014;;A61B17/8033;;A61B17/8057,A61B17/80,,0,0,,,,DISCONTINUED
251,US,A1,US 2008/0214539 A1,061-431-067-045-551,2008-09-04,2008,US 91274106 A,2006-04-26,US 91274106 A;;US 67520205 P;;US 2006/0016057 W,2005-04-26,Benzisoxazole Piperidine Compounds and Methods of Use Thereof,The invention includes benzisoxazole piperidine compositions and methods of using them for modulating sleep.,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,HYPNION INC (2007-04-03),https://lens.org/061-431-067-045-551,Patent Application,yes,6,2,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,A61K31/5377;;A61K31/454;;A61P25/20;;C07D401/04;;C07D413/14,514/233.8;;546/198;;544/129;;514/321,0,0,,,,INACTIVE
252,WO,A1,WO 2006/116615 A1,109-124-888-803-532,2006-11-02,2006,US 2006/0016059 W,2006-04-26,US 67520205 P;;US 2006/0016059 W,2005-04-26,BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF,The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep.,HYPNION INC;;COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,,https://lens.org/109-124-888-803-532,Patent Application,yes,3,0,3,37,0,C07D413/04,C07D261/20;;A61K31/423;;A61K31/496,,2,2,043-548-573-904-650;;043-548-573-904-650,15588097;;10.1021/jm049702f;;15588097;;10.1021/jm049702f,"MARCELLO LEOPOLDO ET AL.: ""Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides,..."", JOURNAL OF MEDICINAL CHEMISTRY., vol. 47, no. 26, 2004, USAMERICAN CHEMICAL SOCIETY. WASHINGTON., pages 6616 - 6624, XP002394594;;MARCELLO ET AL., J. MED. CHEM., vol. 47, no. 26, 2004, pages 6616 - 6624",PENDING
253,GR,T3,GR 3017120 T3,137-063-714-950-419,1995-11-30,1995,GR 950402239 T,1995-08-16,US 5844087 A;;US 19954988 A,1987-06-05,Amine derivatives of anthracycline antibiotics.,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING DALTON H;;COUGHLIN DANIEL J;;RODWELL JOHN DENNIS;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT DAVID,,https://lens.org/137-063-714-950-419,Granted Patent,no,0,0,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,0,0,,,,EXPIRED
254,US,B2,US 9007037 B2,140-748-598-861-629,2015-04-14,2015,US 201313782983 A,2013-03-01,US 201313782983 A;;US 201261605627 P,2012-03-01,Multi-phase operation with single phase control,"A multi-phase control system having multi-phase operation with single phase control includes a main control module, a lineman module, and an add-on lineman module. The main control module and the lineman module control, automatically or manually, the first phase and first phase tap changer of a multi-phase system. The add-on lineman module and the main control module control, automatically or manually, additional phases of the multi-phase system. In certain example embodiments, the multi-phase control system detects when a line voltage of an additional phase is de-energized and allows the tap changer of the additional phase to be powered by a line voltage of the first phase. In certain example embodiments, the tap changer of a de-energized phase is powered by an external power supply.",DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;BRENNY TIMOTHY P;;KROMREY TIMOTHY M;;COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;BRENNY TIMOTHY P;;KROMREY TIMOTHY M,EATON INTELLIGENT POWER LIMITED (2017-12-31);;COOPER TECHNOLOGIES COMPANY (2013-03-04),https://lens.org/140-748-598-861-629,Granted Patent,yes,14,4,11,11,0,H02J3/1878;;G05F1/14;;Y02E40/30;;G05F1/12;;G05F1/153;;G05F1/12;;G05F1/14;;H02J3/1878;;Y02E40/30,G05F1/14;;G05F1/12;;G05F1/147,323/255;;323/256,3,0,,,"Yang-Sun Jang, Machine Translation of ""System for Controlling O.L.T. of Transformer"" publication, Mar. 3, 2013.;;Tapeletro, TAP Eletro Sistemas Ltda., ""Single Phase Voltage Regulator Sychronizer"", R.U.A. 01, User's Manual, Rev Jan. 2011, 33 pages.;;International Search Report and Written Opinion for Corresponding PCT Application No. PCT/US2013/026723, mailed Jun. 26, 2013 (11 pages).",ACTIVE
255,ES,T3,ES 2341127 T3,072-301-989-889-519,2010-06-15,2010,ES 06751667 T,2006-04-26,US 67520205 P,2005-04-26,COMPUESTOS DE BENCISOXAZOL-PIPERAZINA Y PROCEDIMIENTO DE USO.,"Un compuesto de fórmula IV: **(Ver fórmula)** o una sal farmacéuticamente eficaz del mismo en la que t es 1 ó 2; R1, R2, R3 y R4 son independientemente H, F, Cl, Br, CF3, CH3, OH, OCH3, CH2OCH3, o CH2OCH2CH3; R5-R6 son H, CH3, CH2CH3 o R5 y R6, junto con el átomo de carbono al que están unidos, están conectados para formar un anillo espiro con un tamaño de 3 a 7; y Z se selecciona entre CO2H, CONHS(O)2-alquilo, CONHS(O)2-cicloalquilo, CONHS(O)2-heteroalquilo y tetrazol; en que alquilo es alquilo de cadena linea de C1-C6 o alquilo ramificado de C3-C6; cicloalquilo es un grupo cicloalquilo que tiene 3 a 8 átomos de carbono en su estructura anular; heteroalquilo es un grupo alquilo o cicloalquilo como se definieron anteriormente que contiene al menos un heteroátomo seleccionado entre nitrógeno, oxígeno, azufre y fósforo; y tetrazol es **(Ver fórmula)**",HYPNION INC,WHITE JAMES F;;COUGHLIN DANIEL;;EDGAR DALE M;;SOLOMON MICHAEL;;HANGAUER DAVID G;;SHIOSAKI KAZUMI,,https://lens.org/072-301-989-889-519,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,ACTIVE
256,BR,A2,BR PI0610258 A2,157-724-846-219-75X,2012-09-25,2012,BR PI0610258 A,2006-04-26,US 67520205 P;;US 2006/0016059 W,2005-04-26,"composto ou um sal farmaceuticamente eficaz do mesmo, composição farmacêutica, e, uso de um composto","COMPOSTO OU UM SAL FARMACEUTICAMENTE EFICAZ DO MESMO, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO. A invenção diz respeito a composições de benzisoxazol piperazina e métodos de usá-las para modular o sono.",HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,"HYPNION, INC. (US) (2012-10-09)",https://lens.org/157-724-846-219-75X,Patent Application,no,0,0,3,37,0,C07D413/04,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,DISCONTINUED
257,FI,A0,FI 890559 A0,076-684-927-504-050,1989-02-06,1989,FI 890559 A,1989-02-06,US 5844087 A;;US 19954988 A;;US 8801909 W,1987-06-05,AMINDERIVATER AV ANTRACYKLINANTIBIOTIKA OCH ANTIKROPPKONJUGATER AV DESSA.,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING H DALTON;;LOPES ANTHONY DWIGHT;;COUGHLIN DANIEL J;;RADCLIFFE ROBERT D;;RODWELL JOHN DENNIS,,https://lens.org/076-684-927-504-050,Patent Application,no,0,0,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,0,0,,,,DISCONTINUED
258,HK,A1,HK 1122796 A1,101-546-214-772-505,2009-05-29,2009,HK 08113763 A,2008-12-18,US 2006/0016059 W;;US 67520205 P,2005-04-26,BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF,,HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,,https://lens.org/101-546-214-772-505,Patent Application,no,0,0,3,37,0,C07D413/04,A61K/;;C07D/,,0,0,,,,DISCONTINUED
259,AU,B2,AU 2017/324150 B2,198-568-928-420-321,2022-03-10,2022,AU 2017/324150 A,2017-08-29,US 201662385069 P;;US 201615260588 A;;US 2017/0049013 W,2016-09-08,Variable angle bone plate,"A bone plate having at least one variable angle locking hole is described. The variable angle locking hole allows a bone anchor having a threaded head to be driven into underlying bone while oriented at an angle with respect to a central hole axis of the hole that is within a range of angles at which the head is configured to threadedly mate with the at least one thread of the bone plate. Accordingly, the bone anchor can be driven into the underlying bone until the threaded head threadedly purchases with the bone plate inside the variable angle locking hole.",DEPUY SYNTHES PRODUCTS INC,LOPEZ ERASMO A;;SNYDER KRISTINA;;KWAK SEUNG-KYU DANIEL;;JONES DYLAN;;COUGHLIN ROBERT;;NICOLETTI TIMOTHY,,https://lens.org/198-568-928-420-321,Granted Patent,no,1,0,12,12,0,A61B17/8014;;A61B17/8061;;A61B17/8605;;A61B17/8057;;A61B17/8061;;A61B17/8605;;A61B17/8014;;A61B17/8033;;A61B17/8057,A61B17/80,,0,0,,,,ACTIVE
260,DE,D1,DE 602006013115 D1,024-239-928-768-830,2010-05-06,2010,DE 602006013115 T,2006-04-26,US 67520205 P;;US 2006/0016059 W,2005-04-26,BENZISOXAZOLPIPERIDINVERBINDUNGEN UND VERFAHREN ZU DEREN ANWENDUNG,,HYPNION INC,WHITE JAMES F;;COUGHLIN DANIEL;;EDGAR DALE M;;SOLOMON MICHAEL;;HANGAUER DAVID G;;SHIOSAKI KAZUMI,,https://lens.org/024-239-928-768-830,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,ACTIVE
261,FI,A,FI 890559 A,043-810-485-261-510,1989-02-06,1989,FI 890559 A,1989-02-06,US 5844087 A;;US 19954988 A;;US 8801909 W,1987-06-05,AMINDERIVATER AV ANTRACYKLINANTIBIOTIKA OCH ANTIKROPPKONJUGATER AV DESSA.,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING H DALTON;;LOPES ANTHONY DWIGHT;;COUGHLIN DANIEL J;;RADCLIFFE ROBERT D;;RODWELL JOHN DENNIS,,https://lens.org/043-810-485-261-510,Patent Application,no,0,0,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,0,0,,,,DISCONTINUED
262,WO,A1,WO 2013/131037 A1,119-434-438-887-341,2013-09-06,2013,US 2013/0028723 W,2013-03-01,US 201261605627 P,2012-03-01,MULTI-PHASE OPERATION WITH SINGLE PHASE CONTROL,"A multi-phase control system having multi-phase operation with single phase control includes a main control module, a lineman module, and an add-on lineman module. The main control module and the lineman module control, automatically or manually, the first phase and first phase tap changer of a multi-phase system. The add-on lineman module and the main control module control, automatically or manually, additional phases of the multi-phase system. In certain example embodiments, the multi-phase control system detects when a line voltage of an additional phase is de-energized and allows the tap changer of the additional phase to be powered by a line voltage of the first phase. In certain example embodiments, the tap changer of a de-energized phase is powered by an external power supply.",COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;BRENNY TIMOTHY P;;KROMREY TIMOTHY M,,https://lens.org/119-434-438-887-341,Patent Application,yes,5,0,11,11,0,H02J3/1878;;G05F1/14;;Y02E40/30;;G05F1/12;;G05F1/153;;G05F1/12;;G05F1/14;;H02J3/1878;;Y02E40/30,G05F1/10;;G05F1/66,,0,0,,,,PENDING
263,CN,B,CN 101208314 B,139-612-493-223-999,2010-12-08,2010,CN 200680023047 A,2006-04-26,US 2006/0016059 W;;US 67520205 P,2005-04-26,Benzisoxazole piperazine compounds and methods of use thereof,The invention includes benzisoxazole piperidine compositions and methods of using them for modulating sleep.,HYPNION INC,EDGAR DALE M;;KAZUMI SHIOSAKI;;HANGAUER DAVID G;;WHITE JAMES F;;MICHAEL SOLOMON;;DANIEL COUGHLIN,,https://lens.org/139-612-493-223-999,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,ACTIVE
264,EP,A1,EP 3509518 A1,147-868-145-175-758,2019-07-17,2019,EP 17764734 A,2017-08-29,US 201662385069 P;;US 201615260588 A;;US 2017/0049013 W,2016-09-08,VARIABLE ANGLE BONE PLATE,,DEPUY SYNTHES PRODUCTS INC,LOPEZ ERASMO A;;SNYDER KRISTINA;;KWAK SEUNG-KYU DANIEL;;JONES DYLAN;;COUGHLIN ROBERT;;NICOLETTI TIMOTHY,,https://lens.org/147-868-145-175-758,Patent Application,yes,0,0,12,12,0,A61B17/8014;;A61B17/8061;;A61B17/8605;;A61B17/8057;;A61B17/8061;;A61B17/8605;;A61B17/8014;;A61B17/8033;;A61B17/8057,A61B17/80,,0,0,,,,DISCONTINUED
265,WO,A1,WO 2009/039494 A1,162-296-243-337-40X,2009-03-26,2009,US 2008/0077222 W,2008-09-22,US 97431907 P,2007-09-21,"DIAGNOSTICS BENEFITS MANAGEMENT AND DECISION SUPPORT SYSTEM, AND ASSOCIATED METHOD AND COMPUTER-READABLE STORAGE MEDIUM","A system may receive a proposed medical diagnosis of a patient, and automatically identify potential medical services to be performed with respect to the patient. The identified medical services may be deemed relevant to the proposed medical diagnosis, which the system may determine from a customizable decision table. Further, the system may receive selection of a potential medical service from the identified potential medical services, and present an automated, real-time indication regarding paying entity/plan coverage and estimated cost and/or quality metrics for the selected medical service based on the patient and paying entity/plan of the patient. In addition, the system may facilitate selection of a lab/facility to perform the selected medical service. To communicate across clinicians, labs/facilities and paying entities, the system may employ a catalog of medical services spanning multiple clinicians, labs/facilities or paying entities/plans to thereby integrate their nomenclatures, and may employ a coding system in this regard.",MCKESSON FINANCIAL HOLDINGS LT;;ZUBILLER MATTHEW;;COUGHLIN LAURA LATA;;HENSLEY RICHARD;;KNIER CRAIG ALLEN;;LYAKOVETSKY DANIEL;;MOELLER DOUGLAS JAMES,ZUBILLER MATTHEW;;COUGHLIN LAURA LATA;;HENSLEY RICHARD;;KNIER CRAIG ALLEN;;LYAKOVETSKY DANIEL;;MOELLER DOUGLAS JAMES,,https://lens.org/162-296-243-337-40X,Patent Application,yes,3,0,5,5,0,G06Q20/102;;G06Q30/0283;;G06Q40/08;;G16H70/20;;G16H40/67;;G06Q20/102;;G06Q40/08;;G06Q30/0283;;G16H40/67;;G16H70/20,G06Q10/00;;G16H40/67;;G16H70/20,,0,0,,,,PENDING
266,US,B2,US 7494998 B2,000-376-865-498-043,2009-02-24,2009,US 41285606 A,2006-04-26,US 41285606 A;;US 67520205 P,2005-04-26,Benzisoxazole piperazine compounds and methods of use thereof,The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep.,HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,HYPNION INC (2007-04-03),https://lens.org/000-376-865-498-043,Granted Patent,yes,13,9,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,A61K31/497;;C07D413/00;;C07D417/00;;C07D419/00,514/254.02;;544/368,8,2,063-269-544-809-607;;043-548-573-904-650,16983056;;10.1001/archinte.166.16.1763;;15588097;;10.1021/jm049702f,"Roizenblatt, S., et al., A Double-blind, Placebo-Controlled, Crossover Study of Sildenafil in Obstructive Sleep Apnea, Arch Intern Med., 166: 1763-1767 (2006).;;West, Anthony R., Solid State Chemistry and Its Applications, Wiley, New York, 1988, 358.;;Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Ed., vol. 1: Principles and Practice, John Wiley & Sons, 1995, 975.;;Banker, Gilbert S. et al., Modem Pharmaceutics, Marcel Dekker, New York, 1996.;;Hansen et al. Eur. J. Med. Chem., 33:839-858 (1998).;;International Search Report for PCT/US2006/016057, mailed Aug. 21, 2006.;;Leopoldo et al., ""Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-y1)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents"", J. Med. Chem., 47:6616-6624 (2004).;;International Search Report for PCT/US2006/016059, mailed Aug. 30, 2006.",INACTIVE
267,US,A1,US 2011/0153357 A1,015-978-724-000-048,2011-06-23,2011,US 201113038903 A,2011-03-02,US 201113038903 A;;US 23516708 A;;US 97431907 P,2007-09-21,"DIAGNOSTICS BENEFITS MANAGEMENT AND DECISION SUPPORT SYSTEM, AND ASSOCIATED METHOD AND COMPUTER-READABLE STORAGE MEDIUM","A system may receive a proposed medical diagnosis of a patient, and automatically identify potential medical services to be performed with respect to the patient. The identified medical services may be deemed relevant to the proposed medical diagnosis, which the system may determine from a customizable decision table. Further, the system may receive selection of a potential medical service from the identified potential medical services, and present an automated, real-time indication regarding paying entity/plan coverage and estimated cost and/or quality metrics for the selected medical service based on the patient and paying entity/plan of the patient. In addition, the system may facilitate selection of a lab/facility to perform the selected medical service. To communicate across clinicians, labs/facilities and paying entities, the system may employ a catalog of medical services spanning multiple clinicians, labs/facilities or paying entities/plans to thereby integrate their nomenclatures, and may employ a coding system in this regard.",MCKESSON FINANCIAL HOLDINGS,ZUBILLER MATTHEW;;COUGHLIN LAURA LATA;;HENSLEY RICHARD;;KNIER CRAIG ALLEN;;LYAKOVETSKY DANIEL;;MOELLER DOUGLAS JAMES,MCKESSON FINANCIAL HOLDINGS (2010-12-16),https://lens.org/015-978-724-000-048,Patent Application,yes,13,9,5,5,0,G06Q20/102;;G06Q30/0283;;G06Q40/08;;G16H70/20;;G16H40/67;;G06Q20/102;;G06Q40/08;;G06Q30/0283;;G16H40/67;;G16H70/20,G06Q50/00;;G16H40/67;;G16H70/20,705/2,2,0,,,"Utah Department of Health page directed to ICD coding, as published 26 September 2006, available at http://web.archive.org/web/20060926201919/ http://health.utah.gov/opha/ IBIShelp/codes/ICD9Diagnosis06.htm.;;Averill, R. et al. (April 1998). Development of the ICD-10 Procedure Coding System. 3M HIS Research Report. Available at http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1225920750000&assetId=1180606514475&assetType=MMM_Image&blobAttribute=ImageFile",DISCONTINUED
268,CA,C,CA 2606471 C,083-404-523-177-422,2014-02-11,2014,CA 2606471 A,2006-04-26,US 67520205 P;;US 2006/0016057 W,2005-04-26,BENZISOXAZOLE PIPERIDINE COMPOUNDS AND METHODS OF USE THEREOF,The invention includes benzisoxazole piperidine of Formula (IV) (see formula IV) and compositions and methods of using them for modulating sleep.,HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,,https://lens.org/083-404-523-177-422,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D413/04;;A61K31/423;;A61K31/445,,0,0,,,,ACTIVE
269,DE,D1,DE 602006012650 D1,080-433-339-814-448,2010-04-15,2010,DE 602006012650 T,2006-04-26,US 67520205 P;;US 2006/0016057 W,2005-04-26,BENZISOXAZOLPIPERIDINVERBINDUNGEN UND VERFAHREN ZU DEREN ANWENDUNG,,HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,,https://lens.org/080-433-339-814-448,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D413/04;;A61K31/423;;A61K31/445,,0,0,,,,ACTIVE
270,CA,A1,CA 2700341 A1,151-155-454-597-756,2009-03-26,2009,CA 2700341 A,2008-09-22,US 97431907 P;;US 2008/0077222 W,2007-09-21,"DIAGNOSTICS BENEFITS MANAGEMENT AND DECISION SUPPORT SYSTEM, AND ASSOCIATED METHOD AND COMPUTER-READABLE STORAGE MEDIUM","A system may receive a proposed medical diagnosis of a patient, and automatically identify potential medical services to be performed with respect to the patient. The identified medical services may be deemed relevant to the proposed medical diagnosis, which the system may determine from a customizable decision table. Further, the system may receive selection of a potential medical service from the identified potential medical services, and present an automated, real-time indication regarding paying entity/plan coverage and estimated cost and/or quality metrics for the selected medical service based on the patient and paying entity/plan of the patient. In addition, the system may facilitate selection of a lab/facility to perform the selected medical service. To communicate across clinicians, labs/facilities and paying entities, the system may employ a catalog of medical services spanning multiple clinicians, labs/facilities or paying entities/plans to thereby integrate their nomenclatures, and may employ a coding system in this regard.",MCKESSON FINANCIAL HOLDINGS,ZUBILLER MATTHEW;;COUGHLIN LAURA LATA;;HENSLEY RICHARD;;KNIER CRAIG ALLEN;;LYAKOVETSKY DANIEL;;MOELLER DOUGLAS JAMES,,https://lens.org/151-155-454-597-756,Patent Application,no,0,0,5,5,0,G06Q20/102;;G06Q30/0283;;G06Q40/08;;G16H70/20;;G16H40/67;;G06Q20/102;;G06Q40/08;;G06Q30/0283;;G16H40/67;;G16H70/20,G16H40/67;;G06Q10/00;;G16H70/20,,0,0,,,,DISCONTINUED
271,CN,A,CN 109688952 A,151-116-226-776-507,2019-04-26,2019,CN 201780055365 A,2017-08-29,US 201662385069 P;;US 201615260588 A;;US 2017/0049013 W,2016-09-08,VARIABLE ANGLE BONE PLATE,"A bone plate having at least one variable angle locking hole is described. The variable angle locking hole allows a bone anchor having a threaded head to be driven into underlying bone while orientedat an angle with respect to a central hole axis of the hole that is within a range of angles at which the head is configured to threadedly mate with the at least one thread of the bone plate. Accordingly, the bone anchor can be driven into the underlying bone until the threaded head threadedly purchases with the bone plate inside the variable angle locking hole.",DEPUY SYNTHES PRODUCTS INC,LOPEZ ERASMO A;;SNYDER KRISTINA;;KWAK SEUNG-KYU DANIEL;;JONES DYLAN;;COUGHLIN ROBERT;;NICOLETTI TIMOTHY,,https://lens.org/151-116-226-776-507,Patent Application,no,8,0,12,12,0,A61B17/8014;;A61B17/8061;;A61B17/8605;;A61B17/8057;;A61B17/8061;;A61B17/8605;;A61B17/8014;;A61B17/8033;;A61B17/8057,A61B17/80,,0,0,,,,ACTIVE
272,WO,A1,WO 2006/116614 A1,189-651-841-981-370,2006-11-02,2006,US 2006/0016057 W,2006-04-26,US 67520205 P,2005-04-26,BENZISOXAZOLE PIPERIDINE COMPOUNDS AND METHODS OF USE THEREOF,The invention includes benzisoxazole piperidine compositions and methods of using them for modulating sleep.,HYPNION INC;;COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,,https://lens.org/189-651-841-981-370,Patent Application,yes,6,27,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,A61K31/423;;C07D413/04;;A61K31/445,,4,0,,,"HANSEN J B ET AL: ""Mesolimbic selective antipsychotic arylcarbamates"", November 1998, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, PAGE(S) 839-858, ISSN: 0223-5234, XP004160917;;HANSEN J B ET AL.: ""European Journal of Medicinal Chemistry"", November 1998, ED. SCIENTIFIQUE ELSEVIER, pages: 839 - 858;;R. B. SILVERMAN: ""The Organic Chemistry of Drug Design and Drug Action"", 1992, ACADEMIC PRESS;;""Remington: the Science and Practice of Pharmacy"", 1995, MACK PUBLISHING CO.",PENDING
273,PL,T3,PL 1877390 T3,197-483-232-661-320,2010-08-31,2010,PL 06751667 T,2006-04-26,US 67520205 P;;EP 06751667 A;;US 2006/0016059 W,2005-04-26,BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF,,HYPNION INC,WHITE JAMES F;;COUGHLIN DANIEL;;EDGAR DALE M;;SOLOMON MICHAEL;;HANGAUER DAVID G;;SHIOSAKI KAZUMI,,https://lens.org/197-483-232-661-320,Patent Application,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,PENDING
274,US,A,US 5162512 A,093-934-666-624-200,1992-11-10,1992,US 19954988 A,1988-05-27,US 19954988 A;;US 5844087 A;;US 35631582 A;;US 65037584 A;;US 65075484 A,1982-03-09,Amine derivatives of anthracycline antibodies,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING H DALTON;;LOPES ANTHONY D;;RADCLIFFE ROBERT D;;RODWELL JOHN D;;COUGHLIN DANIEL J,CYTOGEN CORPORATION (1988-08-01),https://lens.org/093-934-666-624-200,Granted Patent,yes,6,52,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,536/6.4;;530/322,25,18,010-449-654-489-697;;039-989-967-700-262;;028-096-971-938-954;;001-854-060-668-703;;034-144-941-661-246;;125-735-714-799-644;;053-544-923-465-585;;005-642-438-757-320;;033-659-795-248-870;;058-195-077-686-715;;031-743-344-116-27X;;133-054-406-389-885;;119-843-969-352-247;;005-334-346-125-348;;093-238-503-753-850;;010-368-100-291-65X;;029-269-446-589-556;;104-592-570-848-795,10.1007/978-3-642-95227-2_2;;10.1111/j.1600-065x.1982.tb00387.x;;7042540;;10.1016/s0079-6468(08)70255-8;;400611;;10.1021/jm00359a004;;6302253;;10.1016/s0021-9258(18)70223-8;;13641238;;2428468;;3803566;;164279;;738327;;10.1016/0014-2964(78)90227-x;;10.1002/ijc.2910210612;;669855;;6201208;;10.1002/bip.360220168;;2578191;;10.1021/jm00379a023;;6142673;;10.1111/j.1749-6632.1983.tb32857.x;;7191812;;10.1016/0014-5793(80)81026-x;;10.1016/s0021-9673(01)93687-8;;6586727;;10.1021/jm00206a003;;690999;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;2948729;;10.1007/bf00273384,"Arcamone et al., Int. Symp. on Adriamycin, pp. 9 22 (1972).;;Arnon et al., Immunological Rev. 62:5 27 (1982).;;Brown, Progress in Med. Chem. 15:125 164 (1978).;;Brownlee et al., J. Chem. Soc. Chem. Comm. 1986:659 661 (1986).;;Bunton, in Oxidation in Organic Chemistry, vol. I, Wiberg, ed., Academic Press, New York, pp. 367 407 (1965).;;Chakravarty et al., J. Med. Chem. 26:638 644 (1983).;;Copper et al., J. Biol. Chem. 234:445 448 (1959).;;Danon et al., Chem. Abstracts 104:323y (1986).;;Dillman et al., Cancer Research 46:4886 4891 (1986).;;Dzieduszycka et al., Il Farmaco Ed. Sc. fasc. 11 41:881 891 (1986).;;Hurwitz et al., Cancer Research 35:1175 1181 (1975).;;Hurwitz et al., Europ. J. Cancer 14:1213 1220 (1978).;;Hurwitz et al., Int. J. Cancer 21:747 755 (1978).;;Hurwitz Biopolymers 22:557 567 (1983).;;Hurwitz et al., J. Med. Chem. 28:137 140 (1985).;;Hurwitz et al., J. App. Biochem. 2:25 35 (1980).;;Hurwitz et al., Chem. Abstracts 100:167792e (1984).;;Ann. N.Y. Aca. Sci. 417:125 136 (1983).;;Jackson, in Organic Reactions 2, pp. 341 375 (1944).;;March in Advanced Organic Chemistry: Reaction Mechansms and Structure, McGraw Hill Co., New York, pp. 824 827 (1978).;;Monsigny et al., FEBS Lett. 119:181 186 (1980).;;Scourides et al., J. of Chromatography 288:127 136 (1984).;;Tong et al., J. Med. Chem. 21:732 737 (1978).;;Trouet et al., Proc. Nat l Acad. Sci. 79:626 629 (1982).;;Weiss et al., Cancer Chemother. Pharmacol. 18:185 197 (1986).",EXPIRED
275,SI,T1,SI 1877390 T1,107-433-879-151-719,2010-09-30,2010,SI 200630692 T,2006-04-26,US 67520205 P;;US 2006/0016059 W;;EP 06751667 A,2005-04-26,BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF,,HYPNION INC,WHITE JAMES F;;COUGHLIN DANIEL;;EDGAR DALE M;;SOLOMON MICHAEL;;HANGAUER DAVID G;;SHIOSAKI KAZUMI,,https://lens.org/107-433-879-151-719,Granted Patent,no,0,0,1,37,0,,C07D261/00;;A61K31/00,,0,0,,,,ACTIVE
276,US,A1,US 2009/0163514 A1,106-841-194-775-744,2009-06-25,2009,US 36947709 A,2009-02-11,US 36947709 A;;US 41285606 A;;US 67520205 P,2005-04-26,BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF,The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep.,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,,https://lens.org/106-841-194-775-744,Patent Application,yes,7,1,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,A61K31/496;;A61P25/20;;C07D413/02,514/254.04;;544/368,0,0,,,,INACTIVE
277,US,A,US 4950738 A,165-666-543-199-031,1990-08-21,1990,US 5844087 A,1987-06-05,US 5844087 A;;US 65037584 A,1984-09-13,Amine derivatives of anthracycline antibiotics,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracyline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING H DALTON;;LOPES ANTHONY D;;RADCLIFFE ROBERT D;;RODWELL JOHN D;;COUGHLIN DANIEL J,CYTOGEN CORPORATION A CORP. OF DE (1987-07-23),https://lens.org/165-666-543-199-031,Granted Patent,yes,5,79,1,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;A61K47/6809;;C07H15/252;;C07K5/0804;;A61K41/0042;;A61K51/10;;A61K51/1093;;A61K2121/00;;A61K41/0057;;A61K47/6809,A61K41/00;;A61K47/48;;A61K51/10;;C07H15/252;;C07K5/083,530/322;;536/6.4,24,16,010-449-654-489-697;;039-989-967-700-262;;028-096-971-938-954;;001-854-060-668-703;;034-144-941-661-246;;125-735-714-799-644;;005-642-438-757-320;;033-659-795-248-870;;058-195-077-686-715;;031-743-344-116-27X;;133-054-406-389-885;;005-334-346-125-348;;093-238-503-753-850;;010-368-100-291-65X;;029-269-446-589-556;;104-592-570-848-795,10.1007/978-3-642-95227-2_2;;10.1111/j.1600-065x.1982.tb00387.x;;7042540;;10.1016/s0079-6468(08)70255-8;;400611;;10.1021/jm00359a004;;6302253;;10.1016/s0021-9258(18)70223-8;;13641238;;2428468;;164279;;738327;;10.1016/0014-2964(78)90227-x;;10.1002/ijc.2910210612;;669855;;6201208;;10.1002/bip.360220168;;2578191;;10.1021/jm00379a023;;7191812;;10.1016/0014-5793(80)81026-x;;10.1016/s0021-9673(01)93687-8;;6586727;;10.1021/jm00206a003;;690999;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;2948729;;10.1007/bf00273384,"Arcamone et al., Int. Symp. on Adriamycin, pp. 9 22 (1972).;;Arnon et al., Immunological Rev. 62:5 27 (1982).;;Brown, Progress in Med. Chem. 15:125 164 (1978).;;Brownlee et al., J. Chem. Soc. Chem. Comm. 1986: 659 661 (1986).;;Bunton, in Oxidation in Organic Chemistry, vol. I, Wiberg, ed., Academic Press, New York, p. 367 (1965).;;Chakravarty et al., J. Med. Chem. 26:638 644 (1983).;;Cooper et al., J. Biol. Chem. 234:445 448 (1959).;;Danon et al., Chem. Abstracts 104:323y (1986).;;Dillman et al., Cancer Research 46:4886 4891 (1986).;;Dzieduszycka et al., Il Farmaco Ed. Sc. fasc. 11 41:732 737 (1986).;;Hurwitz et al., Cancer Research 35:1175 1181 (1975).;;Hurwitz et al., Europ. J. Cancer 14:1213 1220 (1978).;;Hurwitz et al., Int. J. Cancer 21:747 755 (1978).;;Hurwitz Biopolymers 22:557 567 (1983).;;Hurwitz et al., J. Med. Chem. 28:137 140 (1985).;;Hurwitz et al., J. App. Biochem. 2:25 35 (1980).;;Hurwitz et al., Chem. Abstracts 100:167792e (1984).;;Jackson, in Organic Reactions 2, p. 341 (1944).;;March in Advanced Organic Chemistry: Reaction Mechanisms and Structure, McGraw Hill Co., New York, pp. 824 825 (1978).;;Monsigny et al., FEBS Lett. 119:181 186 (1980).;;Scourides et al., J. of Chromatography 288:127 136 (1984).;;Tong et al., J. Med. Chem. 21:732 737 (1978).;;Trouet et al., Proc. Nat l Acad. Sci. 79:626 629 (1982).;;Weiss et al., Cancer Chemother. Pharmacol. 18:185 197 (1986).",EXPIRED
278,EP,B1,EP 0294294 B1,169-696-622-875-694,1995-05-17,1995,EP 88401353 A,1988-06-03,US 5844087 A;;US 19954988 A,1987-06-05,Amine derivatives of anthracycline antibiotics.,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING DALTON H;;COUGHLIN DANIEL J;;RODWELL JOHN DENNIS;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT DAVID,,https://lens.org/169-696-622-875-694,Granted Patent,yes,3,8,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,7,0,,,"JOURNAL OF CHROMATOGRAPHY, vol. 288, 1984, pages 127-136, Elsevier Science Publishers B.V., Amsterdam, NL; P.A. SCOURIDES et al.: ""Application of analytical and semi-preparative high-performance liquid chromatography to anthracyclines and bisanthracycline derivatives"";;J. CHEM. SOC., CHEM. COMMUN., 1986, pages 659-661; R.T.C. BROWNLEE et al.: ""The synthesis and characterization of a series of bis-intercalating bisanthracyclines"";;CHEMICAL ABSTRACTS, vol. 87, no. 11, September 12, 1977, page 32-33,abstract no. 78376t, Columbus, Ohio, US; A. GOLDIN et al.: ""Antitumor effect of adriamycin in comparison with related drugs, and in combination chemotherapy"" & ADRIAMYCIN REV., EORTC INT. SYMP., 2nd 1974 (Pub. 1975), 37-54;;CHEMICAL ABSTRACTS, vol. 106, no. 2, January 12, 1987, page 280, abstract no. 9420b, Columbus, Ohio, US; & JP-A-61155334 (TEIJIN LTD.);;CHEMICAL ABSTRACTS, vol. 106, no. 13, March 30, 1987, page 695, abstract no. 102645p, Columbus, Ohio, US; & JP-A-61254598 (GREEN CROSS CORP.);;INT. J. CANCER, vol. 33, 1984, pages 737-744; J. GALLEGO et al.: ""Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumor activity"";;CHEMICAL ABSTRACTS, vol. 93, no. 24, December 15, 1980, page 313, abstr. nr.: 225585q, Columbus, Ohio, US; E. HURWITZ et al.: ""Soluble macromolecules as carriers for daunorubicin & J. APPL. BIOCHEM. 1980, 2(1)25-35",EXPIRED
279,EP,A2,EP 0294294 A2,036-763-121-402-025,1988-12-07,1988,EP 88401353 A,1988-06-03,US 5844087 A;;US 19954988 A,1987-06-05,Amine derivatives of anthracycline antibiotics and antibody conjugates thereof.,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING DALTON H;;COUGHLIN DANIEL J;;RODWELL JOHN DENNIS;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT DAVID,,https://lens.org/036-763-121-402-025,Patent Application,yes,0,37,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,0,0,,,,EXPIRED
280,US,B2,US 8088778 B2,083-304-475-292-750,2012-01-03,2012,US 36947709 A,2009-02-11,US 36947709 A;;US 41285606 A;;US 67520205 P,2005-04-26,Benzisoxazole piperazine compounds and methods of use thereof,The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep.,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M;;HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,,https://lens.org/083-304-475-292-750,Granted Patent,yes,13,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,A61K31/497;;C07D413/00,514/254.04;;544/368,6,2,043-548-573-904-650;;063-269-544-809-607,15588097;;10.1021/jm049702f;;16983056;;10.1001/archinte.166.16.1763,"Hansen et al. Eur. J. Med Chem, 33:839-858 (1998).;;Leopoldo et al., ""Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-l-yl )-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents"", J. Med Chem., 47:6616-6624 (2004).;;Roizenblatt, S., et al. A Double-blind Placebo-Controlled, Crossover Study of Sildenafil in Obstructive Sleep Apnea, Arch Intern Med., 166: 1763-1767 (2006).;;West, Anthony R., Solid State Chemistry and Its Applications, Wiley, New York, 1988, 358.;;Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Ed., vol. 1: Principles and Practice, John Wiley & Sons, 1995, 975.;;Banker, Gilbert S. et al., Modern Pharmaceuticals, Marcel Dekker, New York 1996.",INACTIVE
281,WO,A4,WO 2018/048664 A4,111-926-029-863-12X,2018-05-24,2018,US 2017/0049013 W,2017-08-29,US 201662385069 P;;US 201615260588 A,2016-09-08,VARIABLE ANGLE BONE PLATE,"A bone plate having at least one variable angle locking hole is described. The variable angle locking hole allows a bone anchor having a threaded head to be driven into underlying bone while oriented at an angle with respect to a central hole axis of the hole that is within a range of angles at which the head is configured to threadedly mate with the at least one thread of the bone plate. Accordingly, the bone anchor can be driven into the underlying bone until the threaded head threadedly purchases with the bone plate inside the variable angle locking hole.",DEPUY SYNTHES PRODUCTS INC,LOPEZ ERASMO A;;SNYDER KRISTINA;;KWAK SEUNG-KYU DANIEL;;JONES DYLAN;;COUGHLIN ROBERT;;NICOLETTI TIMOTHY,,https://lens.org/111-926-029-863-12X,Patent Application,yes,0,0,12,12,0,A61B17/8014;;A61B17/8061;;A61B17/8605;;A61B17/8057;;A61B17/8061;;A61B17/8605;;A61B17/8014;;A61B17/8033;;A61B17/8057,A61B17/80,,0,0,,,,PENDING
282,US,A1,US 2009/0144088 A1,121-297-643-288-632,2009-06-04,2009,US 23516708 A,2008-09-22,US 23516708 A;;US 97431907 P,2007-09-21,"DIAGNOSTICS BENEFITS MANAGEMENT AND DECISION SUPPORT SYSTEM, AND ASSOCIATED METHOD AND COMPUTER-READABLE STORAGE MEDIUM","A system may receive a proposed medical diagnosis of a patient, and automatically identify potential medical services to be performed with respect to the patient. The identified medical services may be deemed relevant to the proposed medical diagnosis, which the system may determine from a customizable decision table. Further, the system may receive selection of a potential medical service from the identified potential medical services, and present an automated, real-time indication regarding paying entity/plan coverage and estimated cost and/or quality metrics for the selected medical service based on the patient and paying entity/plan of the patient. In addition, the system may facilitate selection of a lab/facility to perform the selected medical service. To communicate across clinicians, labs/facilities and paying entities, the system may employ a catalog of medical services spanning multiple clinicians, labs/facilities or paying entities/plans to thereby integrate their nomenclatures, and may employ a coding system in this regard.",MCKESSON FINANCIAL HOLDINGS LT,ZUBILLER MATTHEW;;COUGHLIN LAURA LATA;;HENSLEY RICHARD;;KNIER CRAIG ALLEN;;LYAKOVETSKY DANIEL;;MOELLER DOUGLAS JAMES,MCKESSON FINANCIAL HOLDINGS (2008-12-30),https://lens.org/121-297-643-288-632,Patent Application,yes,13,45,5,5,0,G06Q20/102;;G06Q30/0283;;G06Q40/08;;G16H70/20;;G16H40/67;;G06Q20/102;;G06Q40/08;;G06Q30/0283;;G16H40/67;;G16H70/20,G06Q50/00;;G06Q20/00;;G06Q40/00;;G06Q90/00;;G16H40/67;;G16H70/20,705/3;;705/2;;705/4;;705/40;;705/400,0,0,,,,DISCONTINUED
283,CA,A1,CA 2606473 A1,008-908-388-926-214,2006-11-02,2006,CA 2606473 A,2006-04-26,US 67520205 P;;US 2006/0016059 W,2005-04-26,BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF,,HYPNION INC,EDGAR DALE M;;SOLOMON MICHAEL;;COUGHLIN DANIEL;;HANGAUER DAVID G;;WHITE JAMES F;;SHIOSAKI KAZUMI,,https://lens.org/008-908-388-926-214,Patent Application,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,ACTIVE
284,CA,C,CA 2606473 C,025-886-156-240-67X,2013-08-13,2013,CA 2606473 A,2006-04-26,US 67520205 P;;US 2006/0016059 W,2005-04-26,BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF,The invention includes compositions of benzisoxazole piperazine (see formula IV) and methods of using them for modulating sleep.,HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,,https://lens.org/025-886-156-240-67X,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/496;;A61P25/20,,0,0,,,,ACTIVE
285,EP,A1,EP 1877405 A1,144-336-335-492-803,2008-01-16,2008,EP 06751665 A,2006-04-26,US 2006/0016057 W;;US 67520205 P,2005-04-26,BENZISOXAZOLE PIPERIDINE COMPOUNDS AND METHODS OF USE THEREOF,,HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,"HYPNION, INC. (2009-10-21)",https://lens.org/144-336-335-492-803,Patent Application,yes,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D413/04;;A61K31/423;;A61K31/445,,0,0,,,,ACTIVE
286,CA,A1,CA 3036229 A1,159-966-448-830-662,2018-03-15,2018,CA 3036229 A,2017-08-29,US 201662385069 P;;US 201615260588 A;;US 2017/0049013 W,2016-09-08,VARIABLE ANGLE BONE PLATE,"A bone plate having at least one variable angle locking hole is described. The variable angle locking hole allows a bone anchor having a threaded head to be driven into underlying bone while oriented at an angle with respect to a central hole axis of the hole that is within a range of angles at which the head is configured to threadedly mate with the at least one thread of the bone plate. Accordingly, the bone anchor can be driven into the underlying bone until the threaded head threadedly purchases with the bone plate inside the variable angle locking hole.",DEPUY SYNTHES PRODUCTS INC,LOPEZ ERASMO A;;SNYDER KRISTINA;;KWAK SEUNG-KYU DANIEL;;JONES DYLAN;;COUGHLIN ROBERT;;NICOLETTI TIMOTHY,,https://lens.org/159-966-448-830-662,Patent Application,no,0,0,12,12,0,A61B17/8014;;A61B17/8061;;A61B17/8605;;A61B17/8057;;A61B17/8061;;A61B17/8605;;A61B17/8014;;A61B17/8033;;A61B17/8057,A61B17/80,,0,0,,,,PENDING
287,AU,A,AU 1988/019549 A,051-253-700-135-404,1989-01-04,1989,AU 1988/019549 A,1988-06-03,US 5844087 A;;US 19954988 A,1987-06-05,AMINE DERIVATIVES OF ANTHRACYCLINE ANTIBIOTICS AND ANTIBODY CONJUGATES THEREOF,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING H DALTON;;LOPES ANTHONY DWIGHT;;COUGHLIN DANIEL J;;RADCLIFFE ROBERT DAVID;;RODWELL JOHN DENNIS,,https://lens.org/051-253-700-135-404,Patent Application,no,0,0,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,0,0,,,,DISCONTINUED
288,CY,T1,CY 1110026 T1,114-086-020-462-215,2015-01-14,2015,CY 101100403 T,2010-05-07,EP 06751667 A;;US 67520205 P,2005-04-26,ΕΝΩΣΕΙΣ ΠΙΠΕΡΑΖΙΝΗΣ ΒΕΝΖΙΣΟΞΑΖΟΛΗΣ ΚΑΙ ΜΕΘΟΔΟΙ ΧΡΗΣΗΣ ΕΞ ΑΥΤΩΝ,Η εφεύρεση συμπεριλαμβάνει συνθέσεις πιπεραζίνης βενζισοξαζόλης και μεθόδους της χρήσης αυτών για την τροποποίηση του ύπνου.,HYPNION INC,WHITE JAMES F;;COUGHLIN DANIEL;;EDGAR DALE M;;SOLOMON MICHAEL;;HANGAUER DAVID G;;SHIOSAKI KAZUMI,,https://lens.org/114-086-020-462-215,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,ACTIVE
289,EP,A1,EP 1877390 A1,111-085-075-126-653,2008-01-16,2008,EP 06751667 A,2006-04-26,US 2006/0016059 W;;US 67520205 P,2005-04-26,BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF,,HYPNION INC,WHITE JAMES F;;COUGHLIN DANIEL;;EDGAR DALE M;;SOLOMON MICHAEL;;HANGAUER DAVID G;;SHIOSAKI KAZUMI,"HYPNION, INC. (2009-10-21)",https://lens.org/111-085-075-126-653,Patent Application,yes,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,ACTIVE
290,EP,B1,EP 1877405 B1,135-187-126-587-993,2010-03-03,2010,EP 06751665 A,2006-04-26,US 2006/0016057 W;;US 67520205 P,2005-04-26,BENZISOXAZOLE PIPERIDINE COMPOUNDS AND METHODS OF USE THEREOF,,HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,"HYPNION, INC. (2009-10-21)",https://lens.org/135-187-126-587-993,Granted Patent,yes,3,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D413/04;;A61K31/423;;A61K31/445,,1,0,,,"HANSEN J B ET AL: ""Mesolimbic selective antipsychotic arylcarbamates"" November 1998 (1998-11), EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, PAGE(S) 839-858 , XP004160917 ISSN: 0223-5234 the whole document",ACTIVE
291,ES,T3,ES 2340066 T3,024-199-052-820-994,2010-05-28,2010,ES 06751665 T,2006-04-26,US 67520205 P,2005-04-26,COMPUESTOS DE BENZISOXAZOL PIPERIDINA Y PROCEDIMIENTO DE USO DE LOS MISMOS.,"Un compuesto de fórmula IV: **(Ver fórmula)** o una sal del mismo farmacéuticamente eficaz, en la que t es 1 ó 2; R1, R2, R3, y R4 son, de forma independiente, H, F, Cl, Br, CF3, CH3, OH, OCH3, CH2OCH3, o CH2OCH2CH3; R5-R6 son H, CH3, CH2CH3, o R5 y R6, junto con el carbono al que están unidos, están conectados para formar un anillo espiro de tamaño 3 a 7; y Z se selecciona de CO2H, CONHS(O)2-alquilo, CONHS(O)2-cicloalquilo, CONHS(O)2-heteroalquilo y tetrazol; en la que alquilo es alquilo C1-C6 de cadena lineal o alquilo C3-C6 ramificado. Cicloalquilo es un grupo cicloalquilo que tiene de 3 a 8 átomos de carbono en su estructura de anillo, heteroalquilo es un grupo alquilo o cicloalquilo tal como se ha definido en lo que antecede, que contiene al menos un heteroátomo seleccionado de nitrógeno, oxígeno, azufre y fósforo; y tetrazol es: **(Ver fórmula)**",HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,,https://lens.org/024-199-052-820-994,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D413/04;;A61K31/423;;A61K31/445,,0,0,,,,ACTIVE
292,US,B2,US 8129410 B2,067-393-344-722-105,2012-03-06,2012,US 91274106 A,2006-04-26,US 91274106 A;;US 67520205 P;;US 2006/0016057 W,2005-04-26,Benzisoxazole piperidine compounds and methods of use thereof,The invention includes benzisoxazole piperidine compositions and methods of using them for modulating sleep.,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M;;HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,HYPNION INC (2007-04-03),https://lens.org/067-393-344-722-105,Granted Patent,yes,11,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D413/04;;A61K31/445,514/321;;514/233.8;;544/129;;546/321,6,4,077-553-305-299-562;;135-882-149-630-24X;;025-990-744-906-503;;156-831-530-466-786,12037145;;10.1124/pr.54.2.323;;10.1021/jm060300c;;17154504;;10.1016/s0960-894x(00)00166-9;;10843226;;9391162;;pmc28442;;10.1073/pnas.94.25.14115,"Kikuchi et al. ""Preparation of 2a-(piperidino or piperzainoa . . . "" Ca131:87926 (1999).;;Chrostopoulos et al. ""G Protein . . . "" Pharmacol. rev. v.54, p. 323-374 (2002).;;Kolazkowski et al. ""Receptor based pharmnacophore . . . "" J. Med. Chem. v. 49, p. 6732-6741 (2006).;;Lopez-Rodriguez et al. ""First pharmacophoric . . . "" Bioorg. Med. Chem. Lett. v. 10, p. 1097-1100 (2000).;;Thomas et al. ""Unique allosteri . . . "" Pro. Natl. Acad. Sci. v.94, p. 14115-14119 (1997).;;Hansen J B et al: ""Mesolimbic selective antipsychotic arylcarbamates"" Nov. 1998, European Journal of Medicinal Chemistry, Editions Scientifique Elsevier, Parts, FR, pp. 839-858.",INACTIVE
293,EP,A3,EP 0294294 A3,135-495-593-124-407,1990-05-30,1990,EP 88401353 A,1988-06-03,US 5844087 A;;US 19954988 A,1987-06-05,AMINE DERIVATIVES OF ANTHRACYCLINE ANTIBIOTICS AND ANTIBODY CONJUGATES THEREOF,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORPORATION,"KING, DALTON H.;;COUGHLIN, DANIEL J.;;RODWELL, JOHN DENNIS;;LOPES, ANTHONY DWIGHT;;RADCLIFFE, ROBERT DAVID",,https://lens.org/135-495-593-124-407,Search Report,yes,3,0,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,7,2,093-238-503-753-850;;000-432-575-467-71X,10.1016/s0021-9673(01)93687-8;;6586727;;6376376;;10.1002/ijc.2910330605,"Journal of Chromatography, Vol. 288, 1984, pages 127-136, Elsevier Science Publishers B.V., Amsterdam, NL; P.A. SCOURIDES et al.: ""Application of analytical and semi-preparative high-performance liquid chromatography to anthracyclines and bis-anthracycline derivatives"".;;J. Chem. Soc., Chem. Commun., 1986, pages 659-661; R.T.C. BROWNLEE et al.: ""The Synthesis and characterization of a series of bis-intercalating bis-anthracyclines"".;;CHEMICAL ABSTRACTS, Vol. 87, No. 11, September 12, 1977, pages 32-33, Abstract No. 78376t, Columbus, Ohio, US; A. GOLDIN et al.: ""Antitumor effect of adriamycin in comparison with related drugs, and in combination chemotherapy"", & Adriamycin Rev., Eortc Int. Symp. 2nd 1974 (Pub. 1975), 37-54, Abstract & Formula Index 1977-1981, Vol. 86-95, pages 16374-16375, C28H33N5O10, Carbonic dihydrazide.;;CHEMICAL ABSTRACTS, Vol. 106, No. 2, January 12, 1987, page 280, Abstract No. 9420b, Columbus, Ohio, US; & JP-A-61 155 334 (TEIJIN LTD.) 15-07-1986;;CHEMICAL ABSTRACTS, Vol. 106, No. 13, March 30, 1987, page 695, Abstract No. 102645p, Columbus, Ohio, US; & JP-A-61 254 598 (GREEN CROSS CORP.) 12-11-1986;;Int. J. Cancer, Vol. 33, 1984, pages 737-744; J. GALLEGO et al.: ""Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumour activity"".;;CHEMICAL ABSTRACTS, Vol. 93, No. 24, December 15, 1980, page 313, Abstr. No. 225585q, Columbus, Ohio, US; E. HURWITZ et al.: ""Soluble macromolecules as carriers for daunorubicin"", & J. Appl. Biochem. 1980, 2(1), 25-35",EXPIRED
294,AU,A1,AU 2008/302027 A1,078-948-248-023-203,2009-03-26,2009,AU 2008/302027 A,2008-09-22,US 97431907 P;;US 2008/0077222 W,2007-09-21,"Diagnostics benefits management and decision support system, and associated method and computer-readable storage medium",,MCKESSON FINANCIAL HOLDINGS,ZUBILLER MATTHEW;;LYAKOVETSKY DANIEL;;HENSLEY RICHARD;;KNIER CRAIG ALLEN;;MOELLER DOUGLAS JAMES;;COUGHLIN LAURA LATA,,https://lens.org/078-948-248-023-203,Patent Application,no,0,0,5,5,0,G06Q20/102;;G06Q30/0283;;G06Q40/08;;G16H70/20;;G16H40/67;;G06Q20/102;;G06Q40/08;;G06Q30/0283;;G16H40/67;;G16H70/20,G06Q10/00;;G16H40/67;;G16H70/20,,0,0,,,,DISCONTINUED
295,AU,A1,AU 2006/239302 A1,090-938-194-828-289,2006-11-02,2006,AU 2006/239302 A,2006-04-26,US 67520205 P;;US 2006/0016059 W,2005-04-26,Benzisoxazole piperazine compounds and methods of use thereof,,HYPNION INC,SOLOMON MICHAEL;;WHITE JAMES F;;HANGAUER DAVID G;;SHIOSAKI KAZUMI;;EDGAR DALE M;;COUGHLIN DANIEL,,https://lens.org/090-938-194-828-289,Patent Application,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,INACTIVE
296,DE,T2,DE 3853792 T2,124-156-720-924-955,1995-11-30,1995,DE 3853792 T,1988-06-03,US 5844087 A;;US 19954988 A,1987-06-05,Amin-Derivate von Anthracyclin-Antibiotika.,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING DALTON H;;COUGHLIN DANIEL J;;RODWELL JOHN DENNIS;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT DAVID,,https://lens.org/124-156-720-924-955,Granted Patent,no,0,0,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,0,0,,,,EXPIRED
297,AU,B2,AU 2006/239302 B2,135-657-132-598-430,2011-07-07,2011,AU 2006/239302 A,2006-04-26,US 67520205 P;;US 2006/0016059 W,2005-04-26,Benzisoxazole piperazine compounds and methods of use thereof,The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep.,HYPNION INC,MICHAEL SOLOMON;;WHITE JAMES F;;HANGAUER DAVID G;;KAZUMI SHIOSAKI;;EDGAR DALE M;;DANIEL COUGHLIN,,https://lens.org/135-657-132-598-430,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,INACTIVE
298,DK,T3,DK 1877390 T3,140-804-809-027-145,2010-05-31,2010,DK 06751667 T,2006-04-26,US 67520205 P;;US 2006/0016059 W,2005-04-26,Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf,,HYPNION INC,WHITE JAMES F;;COUGHLIN DANIEL;;EDGAR DALE M;;SOLOMON MICHAEL;;HANGAUER DAVID G;;SHIOSAKI KAZUMI,,https://lens.org/140-804-809-027-145,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,ACTIVE
299,MX,A,MX 2007013352 A,152-209-716-134-856,2008-03-26,2008,MX 2007013352 A,2006-04-26,US 67520205 P;;US 2006/0016059 W,2005-04-26,BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF.,The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep.,HYPNION INC,COUGHLIN DANIEL;;WHITE JAMES F;;SHIOSAKI KAZUMI;;HANGAUER DAVID G;;SOLOMON MICHAEL;;EDGAR DALE M,,https://lens.org/152-209-716-134-856,Patent Application,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,ACTIVE
300,AU,B2,AU 2013/225713 B2,169-979-103-803-621,2016-08-04,2016,AU 2013/225713 A,2013-03-01,US 201261605627 P;;US 2013/0028723 W,2012-03-01,Multi-phase operation with single phase control,"A multi-phase control system having multi-phase operation with single phase control includes a main control module, a lineman module, and an add-on lineman module. The main control module and the lineman module control, automatically or manually, the first phase and first phase tap changer of a multi-phase system. The add-on lineman module and the main control module control, automatically or manually, additional phases of the multi-phase system. In certain example embodiments, the multi-phase control system detects when a line voltage of an additional phase is de-energized and allows the tap changer of the additional phase to be powered by a line voltage of the first phase. In certain example embodiments, the tap changer of a de-energized phase is powered by an external power supply.",EATON INTELLIGENT POWER LTD,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;BRENNY TIMOTHY P;;KROMREY TIMOTHY M,EATON INTELLIGENT POWER LIMITED (2018-11-15),https://lens.org/169-979-103-803-621,Granted Patent,no,1,0,11,11,0,H02J3/1878;;G05F1/14;;Y02E40/30;;G05F1/12;;G05F1/153;;G05F1/12;;G05F1/14;;H02J3/1878;;Y02E40/30,G05F1/66;;G05F1/10,,0,0,,,,ACTIVE
301,WO,A1,WO 1988/009823 A1,038-506-896-652-711,1988-12-15,1988,US 8801909 W,1988-06-03,US 5844087 A;;US 19954988 A,1987-06-05,AMINE DERIVATIVES OF ANTHRACYCLINE ANTIBIOTICS AND ANTIBODY CONJUGATES THEREOF,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING H DALTON;;LOPES ANTHONY DWIGHT;;COUGHLIN DANIEL J;;RADCLIFFE ROBERT DAVID;;RODWELL JOHN DENNIS,,https://lens.org/038-506-896-652-711,Patent Application,yes,1,3,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,C2C CAA;;C3H HHX2          HHX2;;C3H H530          HHX2;;U1S S1313,5,3,119-843-969-352-247;;005-642-438-757-320;;029-269-446-589-556,6142673;;10.1111/j.1749-6632.1983.tb32857.x;;164279;;pmc345799;;6952214;;10.1073/pnas.79.2.626,"CHEMICAL ABSTRACTS, Volume 93, Abstract No. 225585q, issued January 1981, (Columbus Ohio, USA), HURWITZ et al., ""Soluble Macro-Molecules as Cacciers for Daunorubicin"" page 124.;;CHEMICAL ABSTRACTS, Volume 104, Abstract No. 323y, issued January 1986, (Columbus, Ohio, USA), DANON et al., ""A Monoclonal Antibody to Thv-1 Antigen Cojugated to Adriamycin Inhibits Human Neuroblastoma Cells"", page 327.;;CHEMICAL ABSTRACTS, Volume 100, Abstracts, No. 167792e, issued January 1984, (Columbus, Ohio, USA), HURWITZ et al., ""A Conjugate of Adriamycin and Monoclonal Antibodies to Thy-1 Antigen Inhibits Human Neuroblastoma Cells in Vitro"", page 27.;;CANCER RESEARCH, Volume 35, issued May 1975, (Baltimore, MD, USA), HURWITZ et al., ""The Covalent Binding of Daunorubicin and Adriamycin to Antibodies with Retention of Both Drug and Antibody Activities"", pages 1175-1181.;;PROC. NATL. ACAD. SCI. U.S.A., Volume 79, isseud January 1982, (Washington, D.C., USA), TROUET et al., ""A Covalent Linkage Between Daunorubicin and Proteins that is Stable in Serum and Reversible by Lysosomal hydrolases, as Required for a Lysomotropic drug-Carrier Conjugate: In Vitro and in Vivo Studies"", page 626-627.",PENDING
302,ES,T3,ES 2074055 T3,064-457-724-456-057,1995-09-01,1995,ES 88401353 T,1988-06-03,US 5844087 A;;US 19954988 A,1987-06-05,DERIVADOS DE AMINA DE ANTIBIOTICOS DE ANTRACICLINA.,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING DALTON H;;COUGHLIN DANIEL J;;RODWELL JOHN DENNIS;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT DAVID,,https://lens.org/064-457-724-456-057,Granted Patent,no,0,0,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,0,0,,,,EXPIRED
303,US,A1,US 2013/0229159 A1,085-547-310-118-374,2013-09-05,2013,US 201313782983 A,2013-03-01,US 201313782983 A;;US 201261605627 P,2012-03-01,Multi-Phase Operation with Single Phase Control,"A multi-phase control system having multi-phase operation with single phase control includes a main control module, a lineman module, and an add-on lineman module. The main control module and the lineman module control, automatically or manually, the first phase and first phase tap changer of a multi-phase system. The add-on lineman module and the main control module control, automatically or manually, additional phases of the multi-phase system. In certain example embodiments, the multi-phase control system detects when a line voltage of an additional phase is de-energized and allows the tap changer of the additional phase to be powered by a line voltage of the first phase. In certain example embodiments, the tap changer of a de-energized phase is powered by an external power supply.",DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;BRENNY TIMOTHY P;;KROMREY TIMOTHY M;;COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;BRENNY TIMOTHY P;;KROMREY TIMOTHY M,EATON INTELLIGENT POWER LIMITED (2017-12-31);;COOPER TECHNOLOGIES COMPANY (2013-03-04),https://lens.org/085-547-310-118-374,Patent Application,yes,9,6,11,11,0,H02J3/1878;;G05F1/14;;Y02E40/30;;G05F1/12;;G05F1/153;;G05F1/12;;G05F1/14;;H02J3/1878;;Y02E40/30,G05F1/12,323/255,1,0,,,"Yang-Sun Jang, Machine Translation of ""System for Controlling O.L.T. of Transformer"" publication, March 3 of 2013.",ACTIVE
304,US,B2,US 10820930 B2,102-126-358-244-117,2020-11-03,2020,US 201615260588 A,2016-09-09,US 201615260588 A;;US 201662385069 P,2016-09-08,Variable angle bone plate,"A bone plate having at least one variable angle locking hole is described. The variable angle locking hole allows a bone anchor having a threaded head to be driven into underlying bone while oriented at an angle with respect to a central hole axis of the hole that is within a range of angles at which the head is configured to threadedly mate with the at least one thread of the bone plate. Accordingly, the bone anchor can be driven into the underlying bone until the threaded head threadedly purchases with the bone plate inside the variable angle locking hole.",DEPUY SYNTHES PRODUCTS INC,LOPEZ ERASMO A;;SNYDER KRISTINA;;KWAK SEUNG-KYU DANIEL;;JONES DYLAN;;COUGHLIN ROBERT;;NICOLETTI TIMOTHY,DEPUY ORTHOPAEDICS INC (2016-10-28);;DEPUY SYNTHES PRODUCTS LLC (2016-11-01);;SYNTHES USA PRODUCTS LLC (2016-10-31),https://lens.org/102-126-358-244-117,Granted Patent,yes,717,0,12,12,0,A61B17/8014;;A61B17/8061;;A61B17/8605;;A61B17/8057;;A61B17/8061;;A61B17/8605;;A61B17/8014;;A61B17/8033;;A61B17/8057,A61B17/80;;A61B17/86,,150,13,017-215-993-388-586;;017-215-993-388-586;;024-357-615-717-263;;077-982-058-309-06X;;066-301-370-123-838;;153-695-488-090-312;;094-097-440-474-802;;134-301-582-092-433;;140-237-946-073-246;;092-940-191-723-671;;038-155-376-146-995;;019-706-351-278-640;;061-561-217-343-307,8854313;;10.1097/00005131-199608000-00002;;8854313;;10.1097/00005131-199608000-00002;;6510088;;11888195;;10.1016/s0020-1383(01)00184-x;;10.1016/s0363-5023(97)80069-x;;9330133;;10.1097/00003086-198807000-00018;;2073447;;10.1007/bf00636166;;10.3917/savo.010.0073;;6111187;;9887674;;10.1097/00005131-199710000-00010;;9334954;;10.1097/00003086-199802000-00010;;9520877;;9520878;;10.1097/00003086-199802000-00011,"Stryker, “VariAx Distal Radius: Locking Plate System”, wwvv.osteosynthesis.stryker.com, 2006, 12 pages.;;International Patent Application No. PCT/US2008/072894; International Search Report dated Mar. 19, 2009, 18 pages.;;European Patent Application No. 12006617.0: Extended European Search Report dated Jan. 21, 2013, 8 pages.;;European Patent Application No. 12006615.4: Extended European Search Report dated Jan. 21, 2013, 7 pages.;;European Patent Application No. 120066063: Extended European Search Report dated Jan. 21, 2013, 7 pages.;;English translation of International Patent Application No. PCT/CH03/00577: International Search Report dated Apr. 28, 2004, 6 pages.;;ACE SymmetryTM, “Curves in All the Right Places”, 1996, 3 pages.;;ACE Symmetry Trademark Titanium Upper Extremity Plates, ACE Medical Company, 1996, 2 pages.;;“Multiple Offerings of Plates, Screws and Pegs”, Small Bone Innovations, Inc., Dec. 2009, 3 pages.;;“Cone Drive History and Double Enveloping Technology”, http://conedrive.com/history/html, accessed Apr. 20, 2006, 9 pages.;;Docket sheet for the Pennsylvania Action—2:03-cv-0084 (CDJ) (Ex. 4) filed Jan. 7, 2003.;;Docket sheet for the California Action—3:07-cv-00309-L-AJB (Ex. 1) Filed Feb. 14, 2007.;;Defendant's Motion for Leave to Amend Answer to Assert Allegations of Inequitable Conduct, Civil Action No. 03-0084 (E.D. Pa.), dated Aug. 7, 2007.;;Declaration of Robert A. King in Support of their Motion for Partial Summary Judgment of Invalidity of Claims 10-12 of U.S. Pat. No. 6,623,486 (without exhibits), dated Sep. 10, 2008.;;Declaration of J. Russell Parsons, Ph.D. in Support of Synthes Opposition to Smith & Nephew's Motion for Summary Judgement of Invalidity of the '744 patent (w/o Exhibits 1-4) dated Sep. 29, 2008; 15 paqes.;;Declaration of J. Russell Parsons, Ph.D. in Support of Synthes Opposition to Smith & Nephew's Motion for Partial Summary Judgment of Invalidity of Method Claims 10-12 of U.S. Pat. No. 6,623,486 (with Exhibits 1-4), dated Sep. 29, 2008 (Dkt. 160) (Ex. 68).;;Declaration of J. Lawrence Marsh, M.D. dated Nov. 22, 2010.;;Declaration of J. Lawrence Marsh, M.D. dated Jun. 25, 2010.;;Declaration of J. Lawrence Marsh, M.D. dated Jun. 3, 2010.;;Declaration of Dr. Seligson in Support of Smith & Nephew's Motion for Partial Summary Judgment of Invalidity of Claims 10-12 of U.S. Pat. No. 6,623,486 (with exhibits), dated Sep. 10, 2008 (Dkt. 132) (Ex. 65).;;Declaration of Clifford H. Turen, M.D. in Support of Synthes' Opposition to Smith & Nephew's Motion for Partial Summary Judgment of Invalidity of Method Claims 10-12 of U.S. Pat. No. 6,623,486 (with Exhibits 1-4 ), dated Sep. 29, 2008 (Dkt. 161) (Ex. 69).;;Declaration of Charles E. Van Horn, Esq., in Support of Synthes Opposition to Smith & Nephew's Motion for Summary Judgement of Invalidity of the '744 patent (w/o Exhibits 1-6) dated Sep. 29, 2008; 12 pages.;;Court Order denying Synthes' Motion for Reconsideration of Claim Construction for the '486 Patent in the Pennsylvania Action, dated Jun. 30, 2008 (Dkt. 118) (Ex. 13).;;Collins Instruments de Chirurgie, published 1935, as illustrated at http://www.litos.com/pages/winkelstabilitaet_e.html (Sep. 26, 2007) (“Collin Catalog”) [SNI-0258552-556] (Ex. 20).;;Claim Construction Order in Pennsylvania Action, dated Feb. 4, 2008.;;Brief in Support of Defendants' Motion for Leave to Amend Answer to Assert Allegations of Inequitable Conduct, Civil Action No. 03-0084 (E..D. Pa.), dated Aug. 7, 2007.;;Bone Plating System, U.S. Appl. No. 09/660,287.;;Bone Fixation Method, U.S. Appl. No. 09/848,251.;;Bolhofner, et al., The Results of Open Reduction and Internal Fixation of Distal Femur Fractures Using a Biologic (Indirect) Reduction Technique; Journal of Orthopedic Trauma, vol. 10, No. 6, pp. 372-377, Liooincort-Raven Publishers, Copyright 1996.;;Bolhofner, et al., “The Results of Open Reduction and Internal Fixation of Distal Femur Fractures Using a Biologic (Indirect) Reduction Technique,” J. of Orthopaedic Trauma, 1996, vol. 10, No. 6, 372-377.;;AO/ASIF Instruments and Implants, a Technical Manual, Springer-Verlag, 1994 (the “AO-ASIF Manual”).;;Answer to Amended Complaint and Counterclaims, Civil Action No. 03-0084 (E .. D. Pa), filed Dec. 5, 2006.;;Amended Complaint for Patent Infringement, Civil Action No. 03-0084 (E.D. Pa.), filed Nov. 13, 2006.;;Ace Symmetry (Trademark), “Curves in All the Right Places”, Titanium Upper Extremity Plates, Ace Medical Company, 1996, 6 pages.;;Ace Symmetry (Trademark) Titanium Upper Extremity Plates, Ace Medical Company, 6 pages.;;510(k) Summary for Synthes (USA)'s Distal Femur Plate (DFP) System (K982222), dated Jul. 29, 1998 (attached as Exhibit O to Amended Answer).;;510(k) Summary for Synthes (USA)'s Anatomical Locking Plate System (K961413), dated Aug. 7, 1996 (attached as Exhibit Q to Amended Answer).;;510(k) Summary for Synthes (USA)'s 2.4 mm Universal Locking Plate System (K961421 ), dated Jun. 26, 1996 (attached as Exhibit S to Amended Answer).;;510(k) Disclosure K982732, Oct. 8, 1998 (Synthes) (“K982732”) [SNI-0259741-744] (Ex. 39).;;510(k) Disclosure K963798, Nov. 27, 1996 (Synthes) (“K963798”) [SNI-0258398] (Ex. 38).;;510(k) Disclosure K962616, Sep. 3, 1996 (Synthes) (“K962616”) [SNI-0258397] (Ex. 37).;;510(k) Disclosure K961421, Jun. 26, 1996 (Synthes) (“K961421”) [SNI-0258396] (Ex. 36).;;510(k) Disclosure K961413, Aug. 7, 1996 (Synthes) (“K961413”) [SNI-0259751] (Ex. 35).;;4.5 mm Cannulated Screw Technique Guide, published 1995 (Synthes) [SNI-0259703-714] (Ex. 21).;;35 U.S.C. .sctn.282 Notice in the Pennsylvania Action, dated Oct. 10, 2008.;;“VariAx TM Distal Radius Locking Plate System”, Stryker R, Copyright 2009, 12 pages.;;“The New Comprehensive Stryker R VariAx TM Distal Radius Locking Plate System”, Copyright 2009, 20 pages.;;“Less Invasive Stabilization System (LISS) Technique Guide,” Synthes (USA) Copyright 2000 (attached as Exhibit K to Amended Answer).;;Zimmer Advertisement, J. of Orthopaedic Trauma, vol. 12, No. 5, Jun./Jul. 1998.;;Vattolo, M., Thesis, “The Effect of Grooves in Osteosynthesis Plates on the Restructuring of the Corticalis,” Laboratory for Experimental Surgery, Swiss Research Institute, 1986 (original in German, translation to English attached with Certification).;;Update, Titanium LC-DCP Condylar Buttress Plate, Jun. 15, 1995 (Synthes) (“The LC-DCP update”).;;Universelle Rekonstruktionsplatte URP 2.4-3.2 (UniRecon-Registered), Swiss Dent, 17, 1996, pp. 19-25.;;The Titanium Distal Radius Plate Technique Guide, published by Synthes, 1997.;;The Titanium Distal Radius Plate Technique Guide, (the “DRP Guide”) published by Synthes in 1996.;;The Locking Reconstruction Plate Technique Guide, published by Synthes, 1997.;;The Distal Radius Plate Instrument and Implant Set Technique Guide, (Synthes) (“1999 Radius Plate Guide”).;;The Distal Radius Plate Instrument and Implant Set Technique Guide, (Synthes) (“1998 Radius Plate Guide”).;;The 1998 Schuhli Guide.;;Technique Guide: 2.4 mm Variable Angle LCP Distal Radius System. Synthes, 2008, 43 pages.;;Technique Guide, Less Invasive Stabilization (LISS), Oct. 2003.;;Synthes' Supporting Memorandum for Reconsideration of Claim Construction (without supporting Declaration) in the Pennsylvania Action, dated Feb. 19, 2008.;;Synthes' Summary Judgment Motion of No Invalidity Based on K982222 Summary including supporting memorandum, and declarations of A. Silversti and B. Liu (with supporting exhibits), dated Sep. 10, 2008.;;Synthes' Responsive Claim Construction Brief (without exhibits) for the Pennsylvania Action, dated Apr. 20, 2007.;;Synthes' Response to Smith & Nephew's Statement of Facts in Support of Smith & Nephew's Motion for Summary Judgment of Invalidity of the '744 patent; dated Sep. 29, 2008; 19 pages.;;Synthes' Response to Motion for Leave to Amend Answer, Civil Action No. 03-0084 (E.D. Pa.), dated Aug. 9, 2007.;;Synthes' Reply to Smith & Nephew's Opposition to Synthes Motion for Reconsideration of Claim Construction for the '486 patent in the Pennsylvania Action, dated Mar. 14, 2008.;;Synthes' Opposition to Smith & Nephew's Motion for Summary Judgment of Invalidity of the '744 patent; dated Sep. 29, 2008; 22 pages.;;Synthes' Opening Claim Construction Brief (without supporting declaration and attached exhibits but including Appendix A & B) for the Pennsylvania Action, dated Mar. 16, 2007 (Dkt. 54) (Ex. 5).;;Synthes' 1996 Titanium Modular Hand System brochure (the “Hand System Brochure”) [SNI-0290287-294] (Ex. 47).;;Synthes Titanium Modular Hand System, 1996.;;Synthes Opposition to Smith & Nephew's Motion for Summary Judgment of Invalidity of Claims 10-12 of the '486 Patent, dated Sep. 29, 2008 (Dkt. 159) (Ex. 67).;;Synthes 1997 Catalog, published by Synthes, Mar. 1997; part 2, 261 pgs.;;Synthes 1997 Catalog, published by Synthes, Mar. 1997; part 1, 200 pgs.;;Sutter, F., et al., “Titanplasma-beschichtetes Hohlschrauben—und Rekonstructions-platten—System (THRP) zur Oberbriickung van Kieferdefekten,” Chirurg No. 55, pp. 741-748, 1984 [SNI-0006164-171], and translation thereof [SNI-0006152-163] (Ex. 33).;;Surgical Instruments Catalog, Collin & Co., 1935 (original in French, translation to English of pp. 392-397 attached with certification).;;Supplemental Expert Report of Clifford H. Turen, M.D., May 2009 (with Exhibit 1), dated Aug. 8, 2008(Ex.60).;;Supplement to Apr. 9, 2008 Expert Report of John F. Witherspoon (without exhibits), dated May 14, 2008 (Ex. 74).;;Supplement to Apr. 9, 2008 Expert Report of J. Lawrence Marsh in the Pennsylvania Action (with Exhibit 1), dated May 14, 2008 (Ex. 46).;;Summary of Safety and Effectiveness Information [510(k) Summary], K982222, Jul. 29, 1998.;;Stay Order in Pennsylvania Action, dated Jul. 13, 2009.;;Smith and Nephew's Opposition to Synthes Motion for Summary Judgment of No Invalidity Based on K982222(including Opposition Memorandum, Statement of Undisputed Facts, K. Doyle Declaration with Exhibits A-F and R. King's Declaration with Exhibits A-D), dated Sep. 29, 2008( Dkt. 154) (Ex. 63).;;Smith & Newphew Statement of Undisputed Facts in Support of its Motion for Summary Judgment of Invalidity of U.S. Pat. No. 7,128,744; dated Sep. 29, 2008; 8 pages.;;Smith & Nephew, Inc. v. Rea, Federal Circuit Opinion dated Jul. 9, 2013, 18 pages.;;Smith & Nephew's Third Supplemental Response to Interrogatories Nos. 4, 5, 6, 8 and 9; Second Supplemental Responses to Interrogatories Nos. 1, 2, 3, 10, 11 and 12; and First Supplemental Responses to Interrogatories Nos. 13, 15 and 17 (with Smith & Nephew Exhibit 1 thereto), dated Aug. 11, 2008 (Ex. 14).;;Smith & Nephew's Responsive Claim Construction Brief (without exhibits) for the Pennsylvania Action, dated Apr. 20, 2007 (Dkt. 60) (Ex. 8).;;Smith & Nephew's Responses and Objections to Plaintiffs Fourth Set of Interrogatories Nos. 15-16, dated May 21, 2008 (Ex. 55).;;Smith & Nephew's Opposition to Synthes' Motion for Reconsideration of Claim Construction for the '486 Patent in the Pennsylvania Action, dated Mar. 4, 2008 (Dkt. 108) (Ex. 11).;;Smith & Nephew's Opening Claim Construction Brief (without exhibits) for the Pennsylvania Action, dated Mar. 16, 2007 (Dkt. 53) (Ex. 6).;;Smith & Nephew's Memorandum in Support of Motion for Leave to file Amended Answer in the Pennsylvania Action, dated Aug. 7, 2007 (Dkt. 77) (Ex. 70).;;Smith & Nephew's Memorandum in Support of its Motion for Summary Judgment of Invalidly of U.S. Pat. No. 7,128,744; dated Sep. 10, 2008; 22 pages.;;Smith & Nephew's Memorandum in Support of its Motion for Partial Summary Judgment of Invalidity of Claims 10-12 of the '486 patent, dated Sep. 10, 2008.;;Smith & Nephew's Amended Answer in the Pennsylvania Action (without Exhibits A-S ) in the Pennsylvania Action, dated Aug. 7, 2007.;;Smith & Nephew Amended Answer and Counterclaims of Defendant, Civil Action No. 03-0084 (E.D. Pa.), dated Aug. 7, 2007.;;Second Supplement to Apr. 9, 2008 Expert Report of J. Lawrence Marsh (with Exhibit 1), dated Sep. 3, 2008.;;Second Supplement to Apr. 9, 2008 Expert Report of David Seligson, M.D., dated Sep. 3, 2008.;;Schuhli Technique Guide, published by Synthes, 1995.;;Schuhli Technique Guide 1998, (Synthes) (“Schuhli Guide”).;;Schmoker, The Locking Reconstruction Plate 2.4-3.2, originally published in Swiss Dent 17, 1996.;;U.S. Appl. No. 15/940,761, Locking Structures for Affixing Bone Anchors to a Bone Plate, and Related Systems and Methods, Mar. 29, 2018.;;U.S. Appl. No. 15/926,390, Bone Plate With Form-Fitting Variable-Angle Locking Hole, filed Mar. 20, 2018.;;Schandelmaier, et al., Distal Femur Fractures and LISS Stabilization, Injury, Int. J. Care Injured, vol. 32, Suppl. 3, 55-63, 2001.;;Ring, D., et al. “Prospective Multicenter Trial of a Plate for Distal Fixation of Distal Radius Fractures,” J. of Hand Surgery, vol. 22a(5), pp. 777-784, Sep. 1997.;;Ring, D., et al,“A New Plate for Internal Fixation of the Distal Radius,” AO.ASIF Dialogue, vol. IX, issue I, Jun. 1996 [SNI-0254971-973] (Ex. 53).;;Reply to Counterclaims, Civil Action No. 03-0084 (E.D. Pa.). filed Jan. 2, 2007.;;Rebuttal Expert Report of Russell Parsons, Ph.D., (with Exhibit 1), dated Jul. 15, 2008.;;Rebuttal Expert Report of Mari Truman, P.E., (with Exhibit 2), dated May 14, 2008 (Ex. 79).;;Rebuttal Expert Report of Eric R. Gozna, M.D., P.Eng., (with Exhibit 1), dated May 13, 2008 (Ex. 56).;;Rebuttal Expert Report of Clifford H. Turen, M.D., (with Exhibit 1 ), dated May 14, 2008.;;Rebuttal Expert Report of Charles E. Van Horn (without Exhibits), dated May 12, 2008 (Ex. 77).;;Pure Titanium Implants Catalog, published Dec. 1993 (Synthes) (“PTI”) [SNI0259670-673] (Ex. 23).;;Printout of http://www.aofoundation.org web site, dated May 23, 2007 (attached as Exhibit L to Amended Answer).;;Printout from USFDA 510(k) Premarket Notification Database, dated May 23, 2007, listing Synthes Distal Femur Plate (DFP) System, and bearing 510(k) No. K982222 (attached as Exhibit N to Amended Answer.;;Printout from USFDA 510(k) Premarket Notification Database, dated May 22, 2007, listing Synthes 24 mm Universal Locking Plate System, and bearing 510(k) No. K961421 (attached as Exhibit R to Amended Answer).;;Printout from US FDA 510(k) Premarket Notification Database, dated May 22, 2007, listing Synthes Anatomical Locking Plate System, and bearing 510(k) No. K961413 (attached as Exhibit P to Amended Answer).;;Photographs of the Pi plate marked as Little Deposition Exhibit 84.;;Photographs of the Bolhofner Distal Femur Plating System (Bolhofner DFPS), Apr. 14, 2008.;;Photographs of Synthes Titanium Distal Femur LISS Plate, 9 holes/236 mm—Right, 42.344 (the sample LISS)(SYN-PHY-0000002).;;Photographs of Synthes Less Invasive Stabilization System (LISS), screw; (SYN-PHY0000004).;;Photographs of Sample Synthes LC-DCP Tibia Plate produced as SYN-PHY-0000014.;;Photographs of Sample Synthes LC-DCP CBP produced as SYN-PHY-0000011.;;Photographs of sample LC-DCP Condylar Buttress Plate (“CBP”) [SYN-PHY-0000001] (Ex. 42).;;Perren, S., et al., “Early Temporary Porosis of Bone Induced by Internal Fixation Implants,” Clinical Orthopaedics and Related Research, No. 232, Jul. 1988, 139-151.;;Perren, et al., “The Limited Contact Dynamic Compression Plate (LC-DCP),” Arch. Orthopaedic & Trauma Surg., 1990, vol. 109, 304-310.;;Ms. Truman's Jul. 24, 2008 deposition transcript in the Pennsylvania Action (Ex. 81).;;Mr. Van Horn's Jul. 15, 2008 deposition transcript in the Pennsylvania Action (Ex. 78).;;Marsh Exhibit C, Declaration of J. Lawrence Marsh, MD., in support of Smith & Nephew's, Inc's Motion for Partial Summary Judgement of Invalidity of Claims 10-12 of U.S. Pat. No. 6,623,486, dated Sep. 9, 2008, pp. 1-20.;;Marsh Exhibit B, Supplement to Apr. 9, 2008 Expert Report of J. Lawrence Marsh, MD, Civil Action No. 03-0084, dated May 14, 2008 , pp. 1-19.;;Marsh Exhibit A, Releasable 510(k) Search, Aug. 7, 2000, http://web.archive.org/web/19970615015534/www.fda.gov/egibin/htmlscript?5-IOk.hts+showcat-OR.;;Marsh Exhibit A, Initial Expert Report of J. Lawrence Marsh, MD, Civil Action No. 03-0084, dated Apr. 9, 2008 , pp. 1-181.;;Marsh Exhibit 1, Curriculum Vitae, Dec. 2006, pp. 1-34.;;Marsh Exhibit 1, Affidavit of Christopher Butler dated Aug. 24, 2010.;;Manual of Internal Fixation, Techniques Recommended by the AO-ASIG Group, Springer-Verlag, 1991, 200-251.;;Luthi, U., et al., “Kontackflache zwischen Osteosyntheseplatte und Knochen,” Aktuel. Traumatol. 10:131-136, 1980 (“Luthi”) [SNI-0258572-577] (Ex. 31).;;Less Invasive Stabilization System LISS Surgical Technique Proximal Tibia, (Draft), 2000, 11 pgs.;;Krettek et al.; “Distale Femurfrakturen”; Swiss Surg.; 1998; 4; p. 263-278 (no English Translation).;;Krettek et al, “LISS less Invasive Stabilization System,” AO International Dialogue, vol. 12, Issue I, Jun. 1999.;;Koval, k., et al., “Distal Femoral Fixation: A Biomechanical Comparison of the Standard Condylar Buttress Plate, a Locked Buttress Plate, and the 95-Degree Blade Plate,” J. of Orthopaedic Trauma, val. 11(7), pp. 521-524, Lippencott-Raven Publishers, Oct. 1997.;;Kolodziej, P., et al. “Biomechanical Evaluation of the Schuhli Nut,” Clinical Orthopaedics and Related Research, No. 34 7, pp. 79-85, Lippencott-Raven Publishers, Feb. 1988 (“Kolodziej”) [SNI-0256042-048] (Ex. 28).;;Kassab, et al., “Patients Treated for Nonunions with Plate and Screw Fixation and Adjunctive Locking Nuts,” Clinical Orthopaedics and Related Research, 1998, 347, 86-92.;;Joint submission selling forth agreed claim construction in the Pennsylvania Action, dated Jul. 31, 2007.;;Initial Expert Report of J. Lawrence Marsh, M.D., Apr. 9, 2008 (with Exhibits 1-2 and Appendices A-L), dated Apr. 9, 2008 (Ex. 41).;;Initial Disclosures of Defendant, Civil Action No. 03-0084 (E.D. Pa), dated Jan. 12, 2007.;;Information Disclosure Statement in U.S. Appl. No. 09/660,287, dated Nov. 13, 2000 (attached as Exhibit G to Amended Answer).;;Information Disclosure Statement bearing, dated May 4, 2001 (attached as Exhibit F to Amended Answer).;;Haas, N.P., et al., “LISS—Less Invasive Stabilization System—A New Internal Fixator for Distal Femur Fractures,” OP J., vol. 13(3), pp. 340-344, Georg Thieme Verlag, Dec. 1997 (in English).;;Gautier, E., et al., “Porosity and Remodelling of Plated Bone After Internal Fixation: Result of Stress Shielding of Vascular Damage?”, Biomaterials and Biomechanics 1983, Elsevier Science Publishers B.V. 1984 (“Gautier”).;;Expert Report of John F. Witherspoon (w/o Exhibits A-C) in the Pennsylvania Action, dated Apr. 9, 2008; 36 pages.;;Dr. Turen's Aug. 15, 2008 deposition transcript in the Pennsylvania Action (Ex. 61).;;Dr. Parsons Aug. 7, 2008 deposition transcript in the Pennsylvania Action (Ex. 58).;;Dr. Marsh's Jul. 26, 2008 Deposition transcript in the Pennsylvania Action (Ex. 52).",ACTIVE
305,US,A1,US 2018/0064477 A1,150-913-000-819-602,2018-03-08,2018,US 201615260588 A,2016-09-09,US 201615260588 A;;US 201662385069 P,2016-09-08,Variable Angle Bone Plate,"A bone plate having at least one variable angle locking hole is described. The variable angle locking hole allows a bone anchor having a threaded head to be driven into underlying bone while oriented at an angle with respect to a central hole axis of the hole that is within a range of angles at which the head is configured to threadedly mate with the at least one thread of the bone plate. Accordingly, the bone anchor can be driven into the underlying bone until the threaded head threadedly purchases with the bone plate inside the variable angle locking hole.",DEPUY SYNTHES PRODUCTS INC,LOPEZ ERASMO A;;SNYDER KRISTINA;;KWAK SEUNG-KYU DANIEL;;JONES DYLAN;;COUGHLIN ROBERT;;NICOLETTI TIMOTHY,DEPUY ORTHOPAEDICS INC (2016-10-28);;DEPUY SYNTHES PRODUCTS LLC (2016-11-01);;SYNTHES USA PRODUCTS LLC (2016-10-31),https://lens.org/150-913-000-819-602,Patent Application,yes,5,24,12,12,0,A61B17/8014;;A61B17/8061;;A61B17/8605;;A61B17/8057;;A61B17/8061;;A61B17/8605;;A61B17/8014;;A61B17/8033;;A61B17/8057,A61B17/80,,0,0,,,,ACTIVE
306,AU,A1,AU 2017/324150 A1,161-164-229-536-313,2019-03-07,2019,AU 2017/324150 A,2017-08-29,US 201662385069 P;;US 201615260588 A;;US 2017/0049013 W,2016-09-08,Variable angle bone plate,"A bone plate having at least one variable angle locking hole is described. The variable angle locking hole allows a bone anchor having a threaded head to be driven into underlying bone while oriented at an angle with respect to a central hole axis of the hole that is within a range of angles at which the head is configured to threadedly mate with the at least one thread of the bone plate. Accordingly, the bone anchor can be driven into the underlying bone until the threaded head threadedly purchases with the bone plate inside the variable angle locking hole.",DEPUY SYNTHES PRODUCTS INC,LOPEZ ERASMO A;;SNYDER KRISTINA;;KWAK SEUNG-KYU DANIEL;;JONES DYLAN;;COUGHLIN ROBERT;;NICOLETTI TIMOTHY,,https://lens.org/161-164-229-536-313,Patent Application,no,0,0,12,12,0,A61B17/8014;;A61B17/8061;;A61B17/8605;;A61B17/8057;;A61B17/8061;;A61B17/8605;;A61B17/8014;;A61B17/8033;;A61B17/8057,A61B17/80,,0,0,,,,ACTIVE
307,DE,D1,DE 3853792 D1,167-163-759-510-923,1995-06-22,1995,DE 3853792 T,1988-06-03,US 5844087 A;;US 19954988 A,1987-06-05,Amin-Derivate von Anthracyclin-Antibiotika.,"Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.",CYTOGEN CORP,KING DALTON H;;COUGHLIN DANIEL J;;RODWELL JOHN DENNIS;;LOPES ANTHONY DWIGHT;;RADCLIFFE ROBERT DAVID,,https://lens.org/167-163-759-510-923,Granted Patent,no,0,0,16,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07H15/252;;C07K5/0804;;G01N33/531;;G01N33/54353;;A61K47/6889;;A61K47/68;;A61K47/6809;;A61P31/04;;C07H15/252;;G01N33/531;;A61K51/10;;C07K5/0804;;G01N33/54353;;A61K2121/00;;A61K41/0057;;A61K41/0042;;A61K51/1093;;A61K47/6809;;A61K47/68;;A61K47/6889,A61K31/70;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K39/395;;A61K41/00;;A61K47/48;;A61K51/10;;A61P31/04;;C07H15/252;;C07K5/083;;G01N33/531;;G01N33/543,,0,0,,,,EXPIRED
308,WO,A1,WO 2018/048664 A1,181-514-764-253-940,2018-03-15,2018,US 2017/0049013 W,2017-08-29,US 201662385069 P;;US 201615260588 A,2016-09-08,VARIABLE ANGLE BONE PLATE,"A bone plate having at least one variable angle locking hole is described. The variable angle locking hole allows a bone anchor having a threaded head to be driven into underlying bone while oriented at an angle with respect to a central hole axis of the hole that is within a range of angles at which the head is configured to threadedly mate with the at least one thread of the bone plate. Accordingly, the bone anchor can be driven into the underlying bone until the threaded head threadedly purchases with the bone plate inside the variable angle locking hole.",DEPUY SYNTHES PRODUCTS INC,LOPEZ ERASMO A;;SNYDER KRISTINA;;KWAK SEUNG-KYU DANIEL;;JONES DYLAN;;COUGHLIN ROBERT;;NICOLETTI TIMOTHY,,https://lens.org/181-514-764-253-940,Patent Application,yes,5,1,12,12,0,A61B17/8014;;A61B17/8061;;A61B17/8605;;A61B17/8057;;A61B17/8061;;A61B17/8605;;A61B17/8014;;A61B17/8033;;A61B17/8057,A61B17/80,,0,0,,,,PENDING
309,WO,A1,WO 2019/173379 A1,198-161-292-584-990,2019-09-12,2019,US 2019/0020809 W,2019-03-05,US 201862639326 P;;US 201862728585 P;;US 201962798379 P,2018-03-06,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,"Devices and methods for managing chest drainage include a drainage system with a chest tube having a chest tube drainage lumen and a drainage reservoir in fluid communication with the chest tube drainage lumen. A pump may be in fluid communication with the chest tube drainage lumen and a pressure sensor may be positioned proximal to the chest tube and in communication with the chest tube drainage lumen. A controller may be in communication with the pressure sensor and the pump, wherein the controller is configured to actuate the pump at a first suction level sufficient to drain a fluid from the chest tube drainage lumen. The controller is further configured to actuate the pump at a second suction level which is different from the first suction level such that an absence of attenuation in the second suction level over time is indicative of an obstruction in the chest tube.",CENTESE INC,LUXON EVAN S;;COUGHLIN RYAN;;BEHRINGER RYAN;;FITCH KYLE;;PRESTON RANDY;;BURNETT DANIEL R;;ZIEGLER MARK,,https://lens.org/198-161-292-584-990,Patent Application,yes,9,1,7,7,0,A61M2205/3331;;A61M2205/18;;A61M2205/15;;A61M2210/101;;A61M2205/502;;A61M2205/70;;A61M2205/8206;;A61M1/742;;A61M1/74;;A61M1/04;;A61M2205/15;;A61M2205/18;;A61M2205/32;;A61M2205/3324;;A61M2205/3337;;A61M2205/3344;;A61M2205/3379;;A61M2205/505;;A61M2205/581;;A61M2210/101;;A61M1/742;;A61M1/84;;A61M1/743;;A61M1/732,A61M1/00;;A61M27/00,,1,0,,,See also references of EP 3752213A4,PENDING
310,AU,A1,AU 2019/232735 A1,097-846-148-400-712,2020-10-22,2020,AU 2019/232735 A,2019-03-05,US 201862728585 P;;US 201862639326 P;;US 201962798379 P;;US 2019/0020809 W,2018-03-06,Devices and methods for managing chest drainage,"Devices and methods for managing chest drainage include a drainage system with a chest tube having a chest tube drainage lumen and a drainage reservoir in fluid communication with the chest tube drainage lumen. A pump may be in fluid communication with the chest tube drainage lumen and a pressure sensor may be positioned proximal to the chest tube and in communication with the chest tube drainage lumen. A controller may be in communication with the pressure sensor and the pump, wherein the controller is configured to actuate the pump at a first suction level sufficient to drain a fluid from the chest tube drainage lumen. The controller is further configured to actuate the pump at a second suction level which is different from the first suction level such that an absence of attenuation in the second suction level over time is indicative of an obstruction in the chest tube.",CENTESE INC,LUXON EVAN S;;COUGHLIN RYAN;;BEHRINGER RYAN;;FITCH KYLE;;PRESTON RANDY;;BURNETT DANIEL R;;ZIEGLER MARK,,https://lens.org/097-846-148-400-712,Patent Application,no,0,0,7,7,0,A61M2205/3331;;A61M2205/18;;A61M2205/15;;A61M2210/101;;A61M2205/502;;A61M2205/70;;A61M2205/8206;;A61M1/742;;A61M1/74;;A61M1/04;;A61M2205/15;;A61M2205/18;;A61M2205/32;;A61M2205/3324;;A61M2205/3337;;A61M2205/3344;;A61M2205/3379;;A61M2205/505;;A61M2205/581;;A61M2210/101;;A61M1/742;;A61M1/84;;A61M1/743;;A61M1/732,A61M1/00;;A61M27/00,,0,0,,,,PENDING
311,GB,A,GB 2514296 A,117-778-064-908-537,2014-11-19,2014,GB 201415294 A,2013-03-01,US 201261605643 P;;US 2013/0028719 W,2012-03-01,Managed Multi-phase Operation,"Systems and methods for maximum deviation multi-phase operation provide techniques for controlling voltage regulators and tap changers in a multi-phase system to operate within a maximum deviation window. The maximum deviation window comprises a low boundary value and a high boundary value. In an example embodiment, systems and methods provide techniques for setting the low boundary value and the high boundary value. In another example embodiment, systems and methods provide techniques for optimized power factor correction in a multi-phase system.",COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;KUMAR HANISH;;KINSLEY GAVIN R;;DU ZHONGMIN,,https://lens.org/117-778-064-908-537,Patent Application,no,5,0,13,13,0,H02M1/4216;;H02M5/10;;G05F1/14;;Y02B70/10;;Y02P80/10;;G05F1/14;;H02P13/06;;H02M1/4216;;G05F1/14;;H02M1/4216;;H02M5/10;;Y02B70/10;;Y02P80/10;;H02M1/42,G05F1/14;;H02P13/06,,0,0,,,,ACTIVE
312,EP,A1,EP 3752213 A1,012-120-648-497-489,2020-12-23,2020,EP 19764862 A,2019-03-05,US 201862639326 P;;US 201862728585 P;;US 201962798379 P;;US 2019/0020809 W,2018-03-06,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,,CENTESE INC,LUXON EVAN S;;COUGHLIN RYAN;;BEHRINGER RYAN;;FITCH KYLE;;PRESTON RANDY;;BURNETT DANIEL R;;ZIEGLER MARK,,https://lens.org/012-120-648-497-489,Patent Application,yes,0,0,7,7,0,A61M2205/3331;;A61M2205/18;;A61M2205/15;;A61M2210/101;;A61M2205/502;;A61M2205/70;;A61M2205/8206;;A61M1/742;;A61M1/74;;A61M1/04;;A61M2205/15;;A61M2205/18;;A61M2205/32;;A61M2205/3324;;A61M2205/3337;;A61M2205/3344;;A61M2205/3379;;A61M2205/505;;A61M2205/581;;A61M2210/101;;A61M1/742;;A61M1/84;;A61M1/743;;A61M1/732,A61M1/00;;A61M27/00,,0,0,,,,PENDING
313,BR,A8,BR 112014021669 A8,090-831-696-398-434,2021-02-23,2021,BR 112014021669 A,2013-03-01,US 2013/0028719 W;;US 201261605643 P,2012-03-01,operação de múltiplas fases gerenciada,"operação de múltiplas fases gerenciada. sistemas e métodos para operação de múltiplas fases de desvio máximo fornecem técnicas para controle de reguladores de tensão e comutadores em um sistema de múltiplas fases para operar dentro de uma janela de desvio máximo. a janela de desvio máximo compreende um valor de limite inferior e um valor de limite superior. em um exemplo de modalidade, os sistemas e métodos fornecem técnicas para definir o valor de limite inferior e o valor de limite superior. em outra exempla modalidade, sistemas e métodos fornecem técnicas para correção de fator de potência otimizada em um sistema de múltiplas fases.",COOPER TECHNOLOGIES CO,CHRISTOPHER J COUGHLIN;;CRAIG A COLOPY;;DANIEL J DALEY;;GAVIN R KINSLEY;;HANISH KUMAR;;ZHONGMIN DU,,https://lens.org/090-831-696-398-434,Patent Application,no,0,0,13,13,0,H02M1/4216;;H02M5/10;;G05F1/14;;Y02B70/10;;Y02P80/10;;G05F1/14;;H02P13/06;;H02M1/4216;;G05F1/14;;H02M1/4216;;H02M5/10;;Y02B70/10;;Y02P80/10;;H02M1/42,G06F1/26,,0,0,,,,ACTIVE
314,AU,B2,AU 2013/225710 B2,168-648-128-434-022,2017-09-28,2017,AU 2013/225710 A,2013-03-01,US 201261605643 P;;US 2013/0028719 W,2012-03-01,Managed multi-phase operation,"Systems and methods for maximum deviation multi-phase operation provide techniques for controlling voltage regulators and tap changers in a multi-phase system to operate within a maximum deviation window. The maximum deviation window comprises a low boundary value and a high boundary value. In an example embodiment, systems and methods provide techniques for setting the low boundary value and the high boundary value. In another example embodiment, systems and methods provide techniques for optimized power factor correction in a multi-phase system.",EATON INTELLIGENT POWER LTD,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;KUMAR HANISH;;KINSLEY GAVIN R;;DU ZHONGMIN,EATON INTELLIGENT POWER LIMITED (2018-11-15),https://lens.org/168-648-128-434-022,Granted Patent,no,5,0,13,13,0,H02M1/4216;;H02M5/10;;G05F1/14;;Y02B70/10;;Y02P80/10;;G05F1/14;;H02P13/06;;H02M1/4216;;G05F1/14;;H02M1/4216;;H02M5/10;;Y02B70/10;;Y02P80/10;;H02M1/42,G06F1/26,,0,0,,,,ACTIVE
315,AU,A1,AU 2013/225710 A1,170-530-473-268-246,2014-09-18,2014,AU 2013/225710 A,2013-03-01,US 201261605643 P;;US 2013/0028719 W,2012-03-01,Managed multi-phase operation,"Systems and methods for maximum deviation multi-phase operation provide techniques for controlling voltage regulators and tap changers in a multi-phase system to operate within a maximum deviation window. The maximum deviation window comprises a low boundary value and a high boundary value. In an example embodiment, systems and methods provide techniques for setting the low boundary value and the high boundary value. In another example embodiment, systems and methods provide techniques for optimized power factor correction in a multi-phase system.",COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;KUMAR HANISH;;KINSLEY GAVIN R;;DU ZHONGMIN,EATON INTELLIGENT POWER LIMITED (2018-11-15),https://lens.org/170-530-473-268-246,Patent Application,no,0,0,13,13,0,H02M1/4216;;H02M5/10;;G05F1/14;;Y02B70/10;;Y02P80/10;;G05F1/14;;H02P13/06;;H02M1/4216;;G05F1/14;;H02M1/4216;;H02M5/10;;Y02B70/10;;Y02P80/10;;H02M1/42,G06F1/26,,0,0,,,,ACTIVE
316,US,A1,US 2020/0397956 A1,044-066-546-728-641,2020-12-24,2020,US 202017007314 A,2020-08-31,US 202017007314 A;;US 2019/0020809 W;;US 201862639326 P;;US 201862728585 P;;US 201962798379 P,2018-03-06,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,"Devices and methods for managing chest drainage include a drainage system with a chest tube having a chest tube drainage lumen and a drainage reservoir in fluid communication with the chest tube drainage lumen. A pump may be in fluid communication with the chest tube drainage lumen and a pressure sensor may be positioned proximal to the chest tube and in communication with the chest tube drainage lumen. A controller may be in communication with the pressure sensor and the pump, wherein the controller is configured to actuate the pump at a first suction level sufficient to drain a fluid from the chest tube drainage lumen. The controller is further configured to actuate the pump at a second suction level which is different from the first suction level such that an absence of attenuation in the second suction level over time is indicative of an obstruction in the chest tube.",CENTESE INC,LUXON EVAN S;;COUGHLIN RYAN;;BEHRINGER RYAN;;FITCH KYLE;;PRESTON RANDY;;BURNETT DANIEL R;;ZIEGLER MARK,CENTESE INC (2019-03-05),https://lens.org/044-066-546-728-641,Patent Application,yes,1,6,7,7,0,A61M2205/3331;;A61M2205/18;;A61M2205/15;;A61M2210/101;;A61M2205/502;;A61M2205/70;;A61M2205/8206;;A61M1/742;;A61M1/74;;A61M1/04;;A61M2205/15;;A61M2205/18;;A61M2205/32;;A61M2205/3324;;A61M2205/3337;;A61M2205/3344;;A61M2205/3379;;A61M2205/505;;A61M2205/581;;A61M2210/101;;A61M1/742;;A61M1/84;;A61M1/743;;A61M1/732,A61M1/00,,0,0,,,,PENDING
317,TW,A,TW 201436417 A,040-748-110-157-414,2014-09-16,2014,TW 102118281 A,2013-05-23,US 201313782962 A,2013-03-01,Managed multi-phase operation,"Systems and methods for maximum deviation multi-phase operation provide techniques for controlling voltage regulators and tap changers in a multi-phase system to operate within a maximum deviation window. The maximum deviation window comprises a low boundary value and a high boundary value. In an example embodiment, systems and methods provide techniques for setting the low boundary value and the high boundary value. In another example embodiment, systems and methods provide techniques for optimized power factor correction in a multi-phase system.",COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;KUMAR HANISH;;KINSLEY GAVIN R;;DU ZHONGMIN,,https://lens.org/040-748-110-157-414,Patent of Addition,no,0,0,1,1,0,Y02E40/50,H02J3/26;;G05F1/70;;H02J13/00,,0,0,,,,PENDING
318,ES,T3,ES 2682108 T3,099-337-666-015-539,2018-09-18,2018,ES 08754559 T,2008-05-19,US 93075807 P;;US 579207 A;;US 2008/0006419 W,2007-05-17,Proceso para la preparación de composiciones para modular una cascada de quinasas y métodos de uso de estas,"Una composición que comprende sal de mesilato de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-N-bencilacetamida (KX2-391), en donde la sal de mesilato de KX2-391 tiene una pureza superior al 98,0 %, 99,0 %, 99,5 %, 99,6 % o 99,7 % según se determina mediante HPLC.",ATHENEX INC,HANGAUER DAVID;;COUGHLIN DANIEL;;CODY JEREMY;;GALE JONATHAN;;PATRA DEBASIS;;PALMER GRANT;;SALSBURY JONATHON;;ISBESTER PAUL,,https://lens.org/099-337-666-015-539,Granted Patent,no,0,0,16,64,0,A61P3/04;;A61P3/10;;A61P9/00;;A61P19/10;;A61P27/16;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D213/56,C07D213/56;;A61K31/44;;A61P35/00,,0,0,,,,ACTIVE
319,EP,A1,EP 3575413 A1,163-359-616-700-833,2019-12-04,2019,EP 19170821 A,2010-12-06,US 28582109 P;;US 28787209 P;;EP 10805335 A;;IB 2010055604 W,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"The invention provides a composition comprising neratinib for use in a method for treatment of breast cancer in a subject, wherein the subject is positive for the presence of one or more of: PIK3ACA gene amplification, a mutation in PIK3CA and a decrease in PTEN protein expression; and wherein the method further comprises administration of capecitabine.",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES,,https://lens.org/163-359-616-700-833,Patent Application,yes,5,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,C12Q1/68;;C12Q1/6886,,56,54,006-463-679-652-100;;120-851-557-979-364;;049-837-860-038-088;;004-440-190-883-777;;052-403-150-111-447;;050-162-297-194-235;;082-057-478-967-176;;002-748-316-087-521;;058-924-894-496-724;;027-400-516-551-608;;030-329-378-068-384;;031-670-462-407-209;;020-297-825-165-551;;012-690-701-696-458;;000-327-302-949-25X;;038-127-123-523-803;;052-073-293-082-752;;006-463-679-652-100;;130-438-174-305-294;;076-059-062-130-42X;;035-590-445-678-854;;016-346-978-857-894;;093-710-732-335-237;;001-001-952-506-49X;;078-072-244-606-504;;086-888-204-946-581;;044-889-105-134-60X;;053-306-130-281-707;;028-000-528-837-594;;018-991-099-378-330;;082-600-475-212-300;;006-099-664-220-163;;120-851-557-979-364;;066-114-990-428-479;;020-120-360-884-359;;036-021-326-611-784;;056-680-529-882-810;;054-273-704-326-192;;076-564-633-692-352;;055-707-345-132-645;;040-863-075-524-621;;009-493-898-884-338;;015-172-131-105-677;;079-971-647-932-297;;034-310-033-915-336;;029-296-191-561-722;;117-584-273-518-919;;105-954-631-721-416;;072-333-676-585-57X;;045-800-725-597-720;;065-470-438-699-384;;051-864-320-804-47X;;105-178-144-548-143;;036-169-739-820-585,10.1016/j.ccr.2007.08.030;;17936563;;16168105;;10.1186/bcr1262;;pmc1242128;;19318484;;10.1158/1078-0432.ccr-08-1978;;10.1158/1078-0432.ccr-07-1698;;17908952;;15710946;;10.1200/jco.2005.02.167;;10449619;;10.1002/(sici)1097-0215(19990924)83:1<127::aid-ijc22>3.0.co;2-6;;19188670;;10.1200/jco.2009.21.9170;;10.1038/nrc1609;;15864276;;17102595;;10.4161/cbt.5.11.3457;;15095477;;10.1002/path.1542;;19629070;;10.1038/nrc2664;;19573809;;pmc2752826;;10.1016/j.ccr.2009.04.012;;17341655;;10.1093/carcin/bgm052;;10.1006/abio.2000.4497;;10706796;;10.1016/j.devcel.2006.10.007;;17141160;;9228007;;10.1126/science.277.5325.567;;18794884;;10.1038/onc.2008.245;;pmc3398461;;10.1016/j.ccr.2007.08.030;;17936563;;10.1158/0008-5472.can-08-1740;;pmc2587064;;19010894;;10.1016/j.ccr.2004.06.022;;15324695;;10.1007/s10911-009-9116-x;;19259796;;10.1053/hupa.2002.124721;;12055674;;10.1002/gcc.20560;;18383208;;10.1248/bpb.30.1624;;17827710;;19345329;;10.1016/j.ccr.2009.02.012;;pmc2673492;;10.1373/clinchem.2007.098376;;18375489;;19261849;;10.1073/pnas.0806514106;;pmc2660768;;17377809;;10.1007/s00428-006-0358-3;;15928251;;10.1210/jc.2004-2281;;11358835;;9916799;;10.1038/5042;;10851074;;10.1038/sj.onc.1203597;;16168105;;10.1186/bcr1262;;pmc1242128;;18089785;;10.1158/0008-5472.can-07-2536;;10.1038/ng0497-356;;09090379;;9090379;;9072974;;10.1126/science.275.5308.1943;;9187108;;9860981;;10.1073/pnas.95.26.15406;;pmc28055;;10.1053/hp.2000.6713;;10821499;;10.1038/modpathol.3880371;;11454999;;10.1038/sj.onc.1203183;;10597304;;9671321;;10.1038/sj.onc.1201940;;10.1158/0008-5472-can-04-3913;;15805248;;17575221;;10.1158/1078-0432.ccr-06-1609;;10514407;;10.1016/s0002-9440(10)65227-3;;pmc1867038;;10.1146/annurev.biochem.70.1.247;;11395408;;10564676;;10.1093/jnci/91.22.1922;;15287024;;10.1002/gcc.20062;;17681183;;10.1053/j.gastro.2007.05.022;;pmc4285346;;10.1074/jbc.m109.006676;;pmc2709372;;19419954;;18676830;;pmc2680495;;10.1158/0008-5472.can-07-6854;;pmc2042178;;17911267;;10.1073/pnas.0702596104;;10.1158/0008-5472.can-07-2488;;18199536;;20501798;;10.1158/1535-7163.mct-09-1171,"BERNS KATRIEN ET AL: ""A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer"", CANCER CELL, CELL PRESS, US, vol. 12, no. 4, 16 October 2007 (2007-10-16), pages 395 - 402, XP002592491, ISSN: 1535-6108, [retrieved on 20071015], DOI: 10.1016/J.CCR.2007.08.030;;WU GUOJUN ET AL: ""Somatic mutation and gain of copy number of PIK3CA in human breast cancer"", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 7, no. 5, 31 May 2005 (2005-05-31), pages R609 - R616, XP021011863, ISSN: 1465-5411, DOI: 10.1186/BCR1262;;WONG K-K ET AL: ""A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors"", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 15, no. 7, 1 April 2009 (2009-04-01), pages 2552 - 2558, XP002591681, ISSN: 1078-0432, [retrieved on 20090324], DOI: 10.1158/1078-0432.CCR-08-1978;;ELLIS MATTHEW J ET AL: ""PIKing the Winner for Phosphatidylinositol 3-Kinase Inhibitors in ErbB2-Positive Breast Cancer: Let's Not PTENed It's Easy!"", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 19, 1 October 2007 (2007-10-01), pages 5661 - 5662, XP008104382, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1698;;BAJETTA ET AL: ""Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women"", JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 10, 1 April 2005 (2005-04-01), pages 2155 - 2161, XP055404459, DOI: 10.1200/JCO.2005.02.167;;ENDO M ET AL: ""Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models"", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 83, no. 1, 24 September 1999 (1999-09-24), pages 127 - 134, XP002459167, ISSN: 0020-7136, DOI: 10.1002/(SICI)1097-0215(19990924)83:1<127::AID-IJC22>3.0.CO;2-6;;BERNS K ET AL., CANCER CELL, vol. 12, no. 4, October 2007 (2007-10-01), pages 395 - 402;;ALLEGRA CJ; JESSUP JM; SOMERFIELD MR ET AL.: ""American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy"", J CLIN ONCOL, vol. 27, 2009, pages 2091 - 2096, XP002597052, DOI: doi:10.1200/JCO.2009.21.9170;;HYNES NE; LANE HA: ""ERBB receptors and cancer: the complexity of targeted inhibitors"", NAT REV CANCER, vol. 5, 2005, pages 341 - 354, XP002362804, DOI: doi:10.1038/nrc1609;;ZHOU Q; CHEUNG YB; JADA SR ET AL.: ""EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues"", CANCER BIOL THER, vol. 5, 2006, pages 1445 - 1449;;BUERGER H; PACKEISEN J; BOECKER A ET AL.: ""Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study"", J PATHOL, vol. 203, 2004, pages 545 - 550;;ENGELMAN JA: ""Targeting PI3K signalling in cancer: opportunities, challenges and limitations"", NAT REV CANCER, vol. 9, 2009, pages 550 - 562, XP002693047, DOI: doi:10.1038/NRC.2664;;VASUDEVAN KM; BARBIE DA; DAVIES MA ET AL.: ""AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer"", CANCER CELL, vol. 16, 2009, pages 21 - 32, XP002693048, DOI: doi:10.1016/J.CCR.2009.04.012;;BLANCO-APARICIO C; RENNER O; LEAL JF ET AL.: ""PTEN, more than the AKT pathway"", CARCINOGENESIS, vol. 28, 2007, pages 1379 - 1386;;MAEHAMA T; TAYLOR GS; SLAMA JT ET AL.: ""A sensitive assay for phosphoinositide phosphatases"", ANAL BIOCHEM, vol. 279, 2000, pages 248 - 250;;GUERTIN DA; STEVENS DM; THOREEN CC ET AL.: ""Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1"", DEV CELL, vol. 11, 2006, pages 859 - 871;;STOKOE D; TEPHENS LR; COPELAND T ET AL.: ""Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B"", SCIENCE, vol. 277, 1997, pages 567 - 570, XP002070055, DOI: doi:10.1126/science.277.5325.567;;YUAN TL; CANTLEY LC: ""PI3K pathway alterations in cancer: variations on a theme"", ONCOGENE, vol. 27, 2008, pages 5497 - 5510, XP055082753, DOI: doi:10.1038/onc.2008.245;;BERNS K; HORLINGS HM; HENNESSY BT ET AL.: ""A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer"", CANCER CELL, vol. 12, 2007, pages 395 - 402;;EICHHORN PJ; GILI M; SCALTRITI M ET AL.: ""Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235"", CANCER RES, vol. 68, 2008, pages 9221 - 9230, XP055052225, DOI: doi:10.1158/0008-5472.CAN-08-1740;;NAGATA Y; LAN KH; ZHOU X ET AL.: ""PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.[see comment"", CANCER CELL, vol. 6, 2004, pages 117 - 127;;BEDARD PL; CARDOSO F; PICCART-GEBHART MJ: ""Stemming resistance to HER-2 targeted therapy"", J MAMMARY GLAND BIOL NEOPLASIA, vol. 14, 2009, pages 55 - 66, XP019681554;;BOSE S; CRANE A; HIBSHOOSH H ET AL.: ""Reduced expression of PTEN correlates with breast cancer progression"", HUM PATHOL, vol. 33, 2002, pages 405 - 409;;BETTENDORF O; SCHMIDT H; STAEBLER A ET AL.: ""Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate"", GENES CHROMOSOMES CANCER, vol. 47, 2008, pages 565 - 572;;MAEHAMA T: ""PTEN: its deregulation and tumorigenesis"", BIOL PHARM BULL, vol. 30, 2007, pages 1624 - 1627;;YIM EK; PENG G; DAI H ET AL.: ""Rak functions as a tumor suppressor by regulating PTEN protein stability and function"", CANCER CELL, vol. 15, 2009, pages 304 - 314;;BOARD RE; THELWELL NJ; RAVETTO PF ET AL.: ""Multiplexed assays for detection of mutations in PIK3CA"", CLIN CHEM, vol. 54, 2008, pages 757 - 760, XP009109926, DOI: doi:10.1373/clinchem.2007.098376;;SALVESEN HB; CARTER SL; MANNELQVIST M ET AL.: ""Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation"", PROC NATL ACAD SCI USA, vol. 106, 2009, pages 4834 - 4839, XP055020507, DOI: doi:10.1073/pnas.0806514106;;WOENCKHAUS J; STEGER K; STURM K ET AL.: ""Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer"", VIRCHOWS ARCH, vol. 450, 2007, pages 387 - 395, XP019491825, DOI: doi:10.1007/s00428-006-0358-3;;WU G; MAMBO E; GUO Z ET AL.: ""Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors"", J CLIN ENDOCRINOL METAB, vol. 90, 2005, pages 4688 - 4693;;REDON R; MULLER D; CAULEE K ET AL.: ""A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains"", CANCER RES, vol. 61, 2001, pages 4122 - 4129, XP002745039;;SHAYESTEH L; LU Y; KUO WL ET AL.: ""PIK3CA is implicated as an oncogene in ovarian cancer"", NAT GENET, vol. 21, 1999, pages 99 - 102, XP002539225, DOI: doi:10.1038/5042;;MA YY; WEI SJ; LIN YC ET AL.: ""PIK3CA as an oncogene in cervical cancer"", ONCOGENE, vol. 19, 2000, pages 2739 - 2744;;WU G; XING M; MAMBO E ET AL.: ""Somatic mutation and gain of copy number of PIK3CA in human breast cancer"", BREAST CANCER RES, vol. 7, 2005, pages R609 - 616, XP021011863, DOI: doi:10.1186/bcr1262;;ADELAIDE J; FINETTI P; BEKHOUCHE I ET AL.: ""Integrated profiling of basal and luminal breast cancers"", CANCER RES, vol. 67, 2007, pages 11565 - 11575, XP002668606, DOI: doi:10.1158/0008-5472.can-07-2536;;STECK PA; PERSHOUSE MA; JASSER SA ET AL.: ""Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers"", NATURE GENETICS, vol. 15, 1997, pages 356 - 362, XP002066156, DOI: doi:10.1038/ng0497-356;;LI J; YEN C; LIAW D ET AL.: ""PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.[see comment"", SCIENCE, vol. 275, 1997, pages 1943 - 1947;;LI DM; SUN H: ""TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta"", CANCER RES, vol. 57, 1997, pages 2124 - 2129, XP002066157;;LI DM; SUN H: ""PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells"", PROC NATL ACAD SCI USA, vol. 95, 1998, pages 15406 - 15411, XP002956409, DOI: doi:10.1073/pnas.95.26.15406;;RUBIN MA; GERSTEIN A; REID K ET AL.: ""10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,NO) prostate cancer"", HUM PATHOL, vol. 31, 2000, pages 504 - 508, XP004833889, DOI: doi:10.1053/hp.2000.6713;;DEPOWSKI PL; ROSENTHAL SI; ROSS JS: ""Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer"", MOD PATHOL, vol. 14, 2001, pages 672 - 676;;LU Y; LIN YZ; LAPUSHIN R ET AL.: ""The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells"", ONCOGENE, vol. 18, 1999, pages 7034 - 7045, XP002283536, DOI: doi:10.1038/sj.onc.1203183;;SAMUELS Y; ERICSON K: ""Oncogenic PI3K and its role in cancer"", CURR OPIN ONCOL, vol. 18, 2006, pages 77 - 82, XP009172157, DOI: doi:10.1097/01.cco.0000198021.99347.b9;;BOSE S; WANG SI; TERRY MB ET AL.: ""Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas"", ONCOGENE, vol. 17, 1998, pages 123 - 127;;SAAL LH; HOLM K; MAURER M ET AL.: ""PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma"", CANCER RES, vol. 65, 2005, pages 2554 - 2559, XP055070087, DOI: doi:10.1158/0008-5472-CAN-04-3913;;PEREZ-TENORIO G; ALKHORI L; OLSSON B ET AL.: ""PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer"", CLIN CANCER RES, vol. 13, 2007, pages 3577 - 3584;;PERREN A; WENG LP; BOAG AH ET AL.: ""Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast"", AM J PATHOL, vol. 155, 1999, pages 1253 - 1260;;MAEHAMA T; TAYLOR GS; DIXON JE: ""PTEN and myotubularin: novel phosphoinositide phosphatases"", ANNU REV BIOCHEM, vol. 70, 2001, pages 247 - 279;;ALI IU; SCHRIML LM; DEAN M: ""Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity"", J NATL CANCER INST, vol. 91, 1999, pages 1922 - 1932;;GARCIA JM; SILVA J; PENA C ET AL.: ""Promoter methylation of the PTEN gene is a common molecular change in breast cancer"", GENES CHROMOSOMES CANCER, vol. 41, 2004, pages 117 - 124;;MENG F; HENSON R; WEHBE-JANEK H ET AL.: ""MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer"", GASTROENTEROLOGY, vol. 133, 2007, pages 647 - 658, XP022198889, DOI: doi:10.1053/j.gastro.2007.05.022;;HUANG TH; WU F; LOEB GB ET AL.: ""Upregulation of miR-21 by HER2/neu signaling promotes cell invasion"", J BIOL CHEM., 2009;;STEMKE-HALE K; GONZALEZ-ANGULO AM; LLUCH A ET AL.: ""An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer"", CANCER RES, vol. 68, 2008, pages 6084 - 6091, XP002534389, DOI: doi:10.1158/0008-5472.CAN-07-6854;;ZHOU J; WULFKUHLE J; ZHANG H ET AL.: ""Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance"", PROC NATL ACAD SCI USA, vol. 104, 2007, pages 16158 - 16163, XP002661526, DOI: doi:10.1073/PNAS.0702596104;;YANG H; KONG W; HE L ET AL.: ""MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN"", CANCER RESEARCH, vol. 68, 2008, pages 425 - 433, XP002545743, DOI: doi:10.1158/0008-5472.can-07-2488;;O'BRIEN N ET AL.: ""Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib"", MOL CANCER THER, vol. 9, no. 6, 2010, pages 1489 - 1502",PENDING
320,PT,E,PT 1877390 E,055-991-701-309-656,2010-05-31,2010,PT 06751667 T,2006-04-26,US 67520205 P,2005-04-26,BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF,,HYPNION INC,HANGAUER DAVID GARRY JR;;WHITE JAMES F;;COUGHLIN DANIEL;;EDGAR DALE M;;SOLOMON MICHAEL;;SHIOSAKI KAZUMI,,https://lens.org/055-991-701-309-656,Granted Patent,no,0,0,33,37,0,C07D261/20;;C07D413/04;;A61P25/20;;A61P43/00;;C07D413/04;;C07D261/20,C07D261/20;;A61K31/423;;A61K31/496,,0,0,,,,ACTIVE
321,EP,A4,EP 3752213 A4,159-199-390-837-217,2021-11-24,2021,EP 19764862 A,2019-03-05,US 201862639326 P;;US 201862728585 P;;US 201962798379 P;;US 2019/0020809 W,2018-03-06,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,,CENTESE INC,LUXON EVAN S;;COUGHLIN RYAN;;BEHRINGER RYAN;;FITCH KYLE;;PRESTON RANDY;;BURNETT DANIEL R;;ZIEGLER MARK,,https://lens.org/159-199-390-837-217,Search Report,no,1,0,7,7,0,A61M2205/3331;;A61M2205/18;;A61M2205/15;;A61M2210/101;;A61M2205/502;;A61M2205/70;;A61M2205/8206;;A61M1/742;;A61M1/74;;A61M1/04;;A61M2205/15;;A61M2205/18;;A61M2205/32;;A61M2205/3324;;A61M2205/3337;;A61M2205/3344;;A61M2205/3379;;A61M2205/505;;A61M2205/581;;A61M2210/101;;A61M1/742;;A61M1/84;;A61M1/743;;A61M1/732,A61M1/00;;A61M27/00,,0,0,,,,PENDING
322,WO,A1,WO 2013/131034 A1,019-083-456-171-489,2013-09-06,2013,US 2013/0028719 W,2013-03-01,US 201261605643 P,2012-03-01,MANAGED MULTI-PHASE OPERATION,"Systems and methods for maximum deviation multi-phase operation provide techniques for controlling voltage regulators and tap changers in a multi-phase system to operate within a maximum deviation window. The maximum deviation window comprises a low boundary value and a high boundary value. In an example embodiment, systems and methods provide techniques for setting the low boundary value and the high boundary value. In another example embodiment, systems and methods provide techniques for optimized power factor correction in a multi-phase system.",COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;KUMAR HANISH;;KINSLEY GAVIN R;;DU ZHONGMIN,,https://lens.org/019-083-456-171-489,Patent Application,yes,5,0,13,13,0,H02M1/4216;;H02M5/10;;G05F1/14;;Y02B70/10;;Y02P80/10;;G05F1/14;;H02P13/06;;H02M1/4216;;G05F1/14;;H02M1/4216;;H02M5/10;;Y02B70/10;;Y02P80/10;;H02M1/42,G06F1/26,,0,0,,,,PENDING
323,GB,B,GB 2514296 B,192-233-845-936-581,2020-02-19,2020,GB 201415294 A,2013-03-01,US 201261605643 P;;US 2013/0028719 W,2012-03-01,Managed Multi-phase Operation,,EATON INTELLIGENT POWER LTD,DANIEL J DALEY;;CRAIG A COLOPY;;CHRISTOPHER J COUGHLIN;;HANISH KUMAR;;GAVIN R KINSLEY;;ZHONGMIN DU,,https://lens.org/192-233-845-936-581,Granted Patent,no,7,0,13,13,0,H02M1/4216;;H02M5/10;;G05F1/14;;Y02B70/10;;Y02P80/10;;G05F1/14;;H02P13/06;;H02M1/4216;;G05F1/14;;H02M1/4216;;H02M5/10;;Y02B70/10;;Y02P80/10;;H02M1/42,G05F1/14;;H02M1/42;;H02P13/06,,0,0,,,,ACTIVE
324,CA,A1,CA 3092858 A1,087-503-278-115-71X,2019-09-12,2019,CA 3092858 A,2019-03-05,US 201862639326 P;;US 201862728585 P;;US 201962798379 P;;US 2019/0020809 W,2018-03-06,DEVICES AND METHODS FOR MANAGING CHEST DRAINAGE,"Devices and methods for managing chest drainage include a drainage system with a chest tube having a chest tube drainage lumen and a drainage reservoir in fluid communication with the chest tube drainage lumen. A pump may be in fluid communication with the chest tube drainage lumen and a pressure sensor may be positioned proximal to the chest tube and in communication with the chest tube drainage lumen. A controller may be in communication with the pressure sensor and the pump, wherein the controller is configured to actuate the pump at a first suction level sufficient to drain a fluid from the chest tube drainage lumen. The controller is further configured to actuate the pump at a second suction level which is different from the first suction level such that an absence of attenuation in the second suction level over time is indicative of an obstruction in the chest tube.",CENTESE INC,LUXON EVAN S;;COUGHLIN RYAN;;BEHRINGER RYAN;;FITCH KYLE;;PRESTON RANDY;;BURNETT DANIEL R;;ZIEGLER MARK,,https://lens.org/087-503-278-115-71X,Patent Application,no,0,0,7,7,0,A61M2205/3331;;A61M2205/18;;A61M2205/15;;A61M2210/101;;A61M2205/502;;A61M2205/70;;A61M2205/8206;;A61M1/742;;A61M1/74;;A61M1/04;;A61M2205/15;;A61M2205/18;;A61M2205/32;;A61M2205/3324;;A61M2205/3337;;A61M2205/3344;;A61M2205/3379;;A61M2205/505;;A61M2205/581;;A61M2210/101;;A61M1/742;;A61M1/84;;A61M1/743;;A61M1/732,A61M1/00;;A61M27/00,,0,0,,,,PENDING
325,US,A1,US 2013/0229158 A1,098-904-024-716-386,2013-09-05,2013,US 201313782962 A,2013-03-01,US 201313782962 A;;US 201261605643 P,2012-03-01,Managed Multi-Phase Operation,"Systems and methods for maximum deviation multi-phase operation provide techniques for controlling voltage regulators and tap changers in a multi-phase system to operate within a maximum deviation window. The maximum deviation window comprises a low boundary value and a high boundary value. In an example embodiment, systems and methods provide techniques for setting the low boundary value and the high boundary value. In another example embodiment, systems and methods provide techniques for optimized power factor correction in a multi-phase system",DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;KUMAR HANISH;;KINSLEY GAVIN R;;DU ZHONGMIN;;COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;KUMAR HANISH;;KINSLEY GAVIN R;;DU ZHONGMIN,EATON INTELLIGENT POWER LIMITED (2017-12-31);;COOPER TECHNOLOGIES COMPANY (2013-06-18),https://lens.org/098-904-024-716-386,Patent Application,yes,8,5,13,13,0,H02M1/4216;;H02M5/10;;G05F1/14;;Y02B70/10;;Y02P80/10;;G05F1/14;;H02P13/06;;H02M1/4216;;G05F1/14;;H02M1/4216;;H02M5/10;;Y02B70/10;;Y02P80/10;;H02M1/42,G05F1/14,323/255,0,0,,,,ACTIVE
326,US,B2,US 9513645 B2,136-159-920-714-505,2016-12-06,2016,US 201313782962 A,2013-03-01,US 201313782962 A;;US 201261605643 P,2012-03-01,Managed multi-phase operation,"Systems and methods for maximum deviation multi-phase operation provide techniques for controlling voltage regulators and tap changers in a multi-phase system to operate within a maximum deviation window. The maximum deviation window comprises a low boundary value and a high boundary value. In an example embodiment, systems and methods provide techniques for setting the low boundary value and the high boundary value. In another example embodiment, systems and methods provide techniques for optimized power factor correction in a multi-phase system.",DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;KUMAR HANISH;;KINSLEY GAVIN R;;DU ZHONGMIN;;COOPER TECHNOLOGIES CO,DALEY DANIEL J;;COLOPY CRAIG A;;COUGHLIN CHRISTOPHER J;;KUMAR HANISH;;KINSLEY GAVIN R;;DU ZHONGMIN,EATON INTELLIGENT POWER LIMITED (2017-12-31);;COOPER TECHNOLOGIES COMPANY (2013-06-18),https://lens.org/136-159-920-714-505,Granted Patent,yes,25,0,13,13,0,H02M1/4216;;H02M5/10;;G05F1/14;;Y02B70/10;;Y02P80/10;;G05F1/14;;H02P13/06;;H02M1/4216;;G05F1/14;;H02M1/4216;;H02M5/10;;Y02B70/10;;Y02P80/10;;H02M1/42,G05F1/70;;G05F1/14;;H02M1/42;;H02M5/10,,2,0,,,"The International Search Report and Written Opinion for Corresponding Application PCT/US2013/028719, mailed Jun. 30, 2013, 11 pages.;;Tapeletro, TAP Eletro Sistemas Ltda., ""Single Phase Voltage Regulator Sychronizer"", R.U.A. 01, User's Manual, REV Jan. 2011, 33 pages.",ACTIVE
327,US,B2,US 8338456 B2,018-203-057-570-893,2012-12-25,2012,US 98404311 A,2011-01-04,US 98404311 A;;US 29461510 P,2010-01-13,Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor,A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.,COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;BERKENBLIT ANNA;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL;;WYETH LLC,COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;BERKENBLIT ANNA;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,WYETH LLC (2010-11-12),https://lens.org/018-203-057-570-893,Granted Patent,yes,8,11,11,11,0,G01N33/57415;;A61P35/00;;A61P43/00;;G01N33/57415,A61K31/4709;;A61P35/00;;G01N1/30;;G01N33/53,514/313;;514/506.9;;435/7.41;;435/21,18,18,082-057-478-967-176;;006-463-679-652-100;;093-710-732-335-237;;009-493-898-884-338;;016-346-978-857-894;;055-707-345-132-645;;030-329-378-068-384;;027-486-134-657-503;;001-001-952-506-49X;;076-059-062-130-42X;;007-484-703-651-028;;079-971-647-932-297;;034-310-033-915-336;;076-564-633-692-352;;015-172-131-105-677;;065-470-438-699-384;;078-072-244-606-504;;051-864-320-804-47X,19188670;;10.1200/jco.2009.21.9170;;10.1016/j.ccr.2007.08.030;;17936563;;10.1002/gcc.20560;;18383208;;9671321;;10.1038/sj.onc.1201940;;10.1053/hupa.2002.124721;;12055674;;10.1038/modpathol.3880371;;11454999;;19629070;;10.1038/nrc2664;;10.1080/00313020701570012;;17886097;;10.1248/bpb.30.1624;;17827710;;10.1016/j.ccr.2004.06.022;;15324695;;10.1002/cncr.22677;;17440983;;17575221;;10.1158/1078-0432.ccr-06-1609;;10514407;;10.1016/s0002-9440(10)65227-3;;pmc1867038;;10.1053/hp.2000.6713;;10821499;;10.1158/0008-5472-can-04-3913;;15805248;;18676830;;pmc2680495;;10.1158/0008-5472.can-07-6854;;19345329;;10.1016/j.ccr.2009.02.012;;pmc2673492;;pmc2042178;;17911267;;10.1073/pnas.0702596104,"Allegra, C., et al., ""American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy,"" Journal of Clinical Oncology, 2009, vol. 27, No. 12, 2091-2096.;;Berns, K., et al., ""A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer,"" Cancer Cell, 2007, vol. 12, 395-402.;;Bettendorf, O., et al., ""Chromosomal Imbalances, Loss of Heterozygosity, and Immunohistochemical Expression of TP53, RBI, and PTEN in Intraductal Cancer, Intraepithelial Neoplasia, and Invasive Adenocarcinoma of the Prostate,"" Genes, Chromosomes & Cancer, 2008, vol. 47, 565-572.;;Bose, S., ""Allelic Loss of Chromosome 10q23 is Associated With Tumor Progression in Breast Carcinomas,"" Oncogene, 1998, vol. 17, No. 123-127.;;Bose, S., et al., ""Reduced Expression of PTEN Correlates With Breast Cancer Progression,"" Human Pathology, 2002, vol. 33, 405-409.;;Depowski, P., ""Loss of Expression of the PTEN Gene Protein Product is Associated With Poor Outcome in Breast Cancer,"" Modern Pathology, 2001,vol. 14, No. 7, 672-676.;;Engelman, J., ""Targeting PI3K Signalling in Cancer: Opportunities, Challenges and Limitations,"" Nature Reviews of Cancer, 2009, vol. 9, 550-562.;;Hager, M., et al., ""PTEN Expression in Renal Cell Carcinoma and Oncocytoma and Prognosis,"" Pathology, 2007, vol. 39, No. 5, 482-485. (Abstract only).;;Maehama, T., ""PTEN: Its Deregulations and Tumorigenesis,"" Biol. Pharm. Bull., 2007, vol. 30, 1624-1627.;;Nagata, Y., et al., ""PTEN Activation Contributes to Tumor Inhibition by Trastuzumab, and Loss of PTEN Predicts Trastuzumab Resistance in Patients,"" Cancer Cell, 2004, vol. 6, 117-127.;;Pantuck, A., ""Prognostic Relevance of the mTOR Pathway in Renal Cell Carcinoma,"" Cancer, 2007, vol. 109, No. 11, 2257-2267.;;Perez-Tenorio, G., et al., PIK3CA Mutations and PTEN Loss Correlate With Similar Prognostic Factors and are not Mutually Exclusive in Breast Cancer, Clinical Cancer Research, 2007, vol. 13, No. 3577-3584.;;Perren, A., et al., ""Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast,"" American Journal of Pathology, 1999, vol. 155, 1253-1260.;;Rubin, M., et al., ""10q23.3 Loss of Heterozygosity Is Higher in Lymph Node-Positive (pT2-3,N+) Versus Lymph Node-Negative (pT2-3, NO) Prostate Cancer,"" Human Pathology, 2000, vol. 31, 504-508.;;Saal, L., et al., ""PIK3CA Mutations Correlate With Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive With PTEN Loss in Human Breast Carcinoma,"" Cancer Research, 2005, vol. 65, No. 7, 2554-2559.;;Stemke-Hale, K., et al., ""An Integrative Genomic and Proteomic Analysis of PIK3Ca, PTEN, and AKT Mutations in Breast Cancer,"" Cancer Research, 2008, vol. 68, No. 15, 6084-6091.;;Yim, E., et al., ""Rak Functions As a Tumor Suppressor by Regulating PTEN Protein Stability and Function,"" Cancer Cell, 2009, vol. 15, 304-314.;;Zhou, J., et al., ""Activation of the PTEN/mTOR/STAT3 Pathway in Breast Cancer Stem-like Cells Is Required for Viability and Maintenance,"" Proceedings of the National Academy of Science U. S. A., 2007, vol. 104, No. 4116158-16163.",ACTIVE
328,MX,A,MX 2009008288 A,047-191-552-523-310,2009-12-01,2009,MX 2009008288 A,2008-02-04,US 89911107 P;;US 95990107 P;;US 2008/0001516 W,2007-02-02,COMPOUNDS THAT INHIBIT CHOLINESTERASE.,"Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.",COLUCID PHARMACEUTICALS INC,SHIOSAKI KAZUMI;;WHITE JAMES F;;RUPNIAK NADIA M J;;DU SHOUCHENG;;LEANDER J DAVID;;COUGHLIN DANIEL J,,https://lens.org/047-191-552-523-310,Patent Application,no,0,0,11,12,0,C07C271/44;;C07C271/48;;C07C271/54;;C07C271/56;;C07D211/90;;C07D213/40;;C07D215/56;;C07D243/38;;C07D267/20;;C07D333/20;;C07D401/04;;C07D405/12;;C07D487/04;;C07D499/68;;C07C2601/02;;C07C2601/14;;C07C2603/32;;C07C2603/74;;A61P1/08;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/28;;A61P25/30;;A61P25/34;;A61P27/06;;A61P27/16;;A61P31/04;;A61P31/12;;A61P37/08;;A61P43/00;;A61P9/10;;C07D211/90;;C07D215/56;;C07C271/54;;C07D405/12;;C07D267/20;;C07D213/40;;C07C271/48;;C07D401/04;;C07C271/56;;C07C271/44;;C07D243/38;;C07D333/20;;C07D487/04;;C07D499/68;;C07C2601/14;;C07C2603/74;;C07C2601/02;;C07C2603/32,C07C271/44;;A61K31/27;;A61K31/4402;;A61K31/4422;;A61K31/496;;A61P25/28;;C07C271/48;;C07C271/52;;C07C271/56;;C07D223/24;;C07D403/14;;C07D413/04,,0,0,,,,PENDING
329,AU,A2,AU 2008/214380 A2,120-835-942-488-019,2009-09-24,2009,AU 2008/214380 A,2008-02-04,US 95990107 P;;US 89911107 P;;US 2008/0001516 W,2007-02-02,Compounds that inhibit cholinesterase,,COLUCID PHARMACEUTICALS INC,COUGHLIN DANIEL J;;LEANDER J DAVID;;DU SHOUCHENG;;WHITE JAMES F;;RUPNIAK NADIA M J;;SHIOSAKI KAZUMI,,https://lens.org/120-835-942-488-019,Patent Application,no,0,0,11,12,0,C07C271/44;;C07C271/48;;C07C271/54;;C07C271/56;;C07D211/90;;C07D213/40;;C07D215/56;;C07D243/38;;C07D267/20;;C07D333/20;;C07D401/04;;C07D405/12;;C07D487/04;;C07D499/68;;C07C2601/02;;C07C2601/14;;C07C2603/32;;C07C2603/74;;A61P1/08;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/28;;A61P25/30;;A61P25/34;;A61P27/06;;A61P27/16;;A61P31/04;;A61P31/12;;A61P37/08;;A61P43/00;;A61P9/10;;C07D211/90;;C07D215/56;;C07C271/54;;C07D405/12;;C07D267/20;;C07D213/40;;C07C271/48;;C07D401/04;;C07C271/56;;C07C271/44;;C07D243/38;;C07D333/20;;C07D487/04;;C07D499/68;;C07C2601/14;;C07C2603/74;;C07C2601/02;;C07C2603/32,C07C271/44;;A61K31/27;;A61K31/4402;;A61K31/4422;;A61K31/496;;A61P25/28;;C07C271/48;;C07C271/52;;C07C271/56;;C07D211/86;;C07D223/24;;C07D403/14;;C07D413/04,,0,0,,,,DISCONTINUED
330,CA,A1,CA 2783743 A1,172-732-872-058-834,2011-06-16,2011,CA 2783743 A,2010-12-06,US 28582109 P;;US 28787209 P;;IB 2010055604 W,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/172-732-872-058-834,Patent Application,no,0,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,C12Q1/68,,0,0,,,,PENDING
331,JP,A,JP 2020169212 A,182-870-619-330-978,2020-10-15,2020,JP 2020119091 A,2020-07-10,US 28582109 P;;US 28787209 P,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"To provide methods for treating breast cancer, in particular, cancers resistant to treatment with one or more known breast cancer treating agents, as well as patient selection strategies for predicting patient response to chemotherapies.SOLUTION: The invention provides methods for treating breast cancer, in particular, cancers resistant to treatment with one or more known breast cancer treating agents, as well as strategies of patient selection for predicting patient response to chemotherapy, where the strategies comprise the steps of: detecting presence or absence in a patient of one or more of PIK3CA gene amplification, PIK3CA mutation, and decrease in PTEN protein expression; and treating a subject positive for the presence of one or more of the biomarkers by administering a pan-ErbB tyrosine kinase inhibitor to the subject.SELECTED DRAWING: None",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/182-870-619-330-978,Patent Application,no,1,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,A61K31/4709;;A61K31/337;;A61K31/4196;;A61K31/436;;A61K31/473;;A61K31/513;;A61K31/517;;A61K31/675;;A61K31/704;;A61K31/7068;;A61K38/22;;A61K39/395;;A61K45/00;;A61P15/00;;A61P35/00;;A61P43/00,,3,0,,,"CLIN CANCER RES, vol. 15, no. 7, JPN6014053471, 1 April 2009 (2009-04-01), pages 2552 - 2558, ISSN: 0004584143;;CANCER CELL, vol. 12, no. 4, JPN6014053467, 2007, pages 395 - 402, ISSN: 0004584144;;「今日の治療指針」１９９９年（ポケット判）, JPN6019019045, 1999, JP, pages 1025 - 1026, ISSN: 0004584145",PENDING
332,EP,A1,EP 2524231 A1,012-021-629-601-240,2012-11-21,2012,EP 11700467 A,2011-01-04,US 29461510 P;;US 2011/0020080 W,2010-01-13,A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR,,WYETH LLC,COUGHLIN CHRISTINA MARIE;;BERKENBLIT ANNA;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,WYETH LLC (2014-05-14),https://lens.org/012-021-629-601-240,Patent Application,yes,0,0,11,11,0,G01N33/57415;;A61P35/00;;A61P43/00;;G01N33/57415,G01N33/574,,0,0,,,,ACTIVE
333,CA,C,CA 2787048 C,011-047-101-651-02X,2021-06-22,2021,CA 2787048 A,2011-01-04,US 29461510 P;;US 2011/0020080 W,2010-01-13,A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ERBB INHIBITOR,A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.,WYETH LLC,COUGHLIN CHRISTINA MARIE;;BERKENBLIT ANNA;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/011-047-101-651-02X,Granted Patent,no,0,0,11,11,0,G01N33/57415;;A61P35/00;;A61P43/00;;G01N33/57415,G01N33/574,,0,0,,,,ACTIVE
334,US,A1,US 2013/0189274 A1,116-675-711-897-611,2013-07-25,2013,US 201013514556 A,2010-12-06,US 201013514556 A;;US 28582109 P;;US 28787209 P;;IB 2010055604 W,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.",BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/116-675-711-897-611,Patent Application,yes,0,15,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,A61K39/395;;A61K31/4709;;A61K45/06,424/145.1;;435/6.12;;435/6.14;;506/9;;514/313,2,1,030-657-359-634-822,24782652;;10.7150/ijms.8251;;pmc4003548,"Burstein et al; Cancer Research, Vol 69, abstract 37, meeting 2008;;Firoozinia et al; International Journal of Medical Sciences, vol 11, 2014, pages 620-625",DISCONTINUED
335,JP,A,JP 2017101072 A,113-870-657-122-712,2017-06-08,2017,JP 2017038956 A,2017-03-02,US 28582109 P;;US 28787209 P,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"PROBLEM TO BE SOLVED: To provide methods for treating breast cancer, in particular, cancers resistant to treatment with one or more known breast cancer treating agents, as well as patient selection strategies for predicting patient response to chemotherapies.SOLUTION: The invention provides methods for treating breast cancer, in particular, cancers resistant to treatment with one or more known breast cancer treating agents, as well as strategies of patient selection for predicting patient response to chemotherapy, where the strategies comprise the steps of: detecting presence or absence in a patient of one or more of PIK3CA gene amplification, PIK3CA mutation, and decrease in PTEN protein expression; and treating a subject positive for the presence of one or more of the biomarkers by administering a pan-ErbB tyrosine kinase inhibitor to the subject.SELECTED DRAWING: None",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/113-870-657-122-712,Patent Application,no,0,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,A61K45/00;;A61K31/337;;A61K31/4196;;A61K31/436;;A61K31/4709;;A61K31/475;;A61K31/513;;A61K31/517;;A61K31/565;;A61K31/675;;A61K31/704;;A61K31/7068;;A61K38/00;;A61K39/395;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q1/68;;G01N33/53,,0,0,,,,DISCONTINUED
336,US,A1,US 2021/0370082 A1,003-272-022-899-781,2021-12-02,2021,US 202117319937 A,2021-05-13,US 202117319937 A;;US 202063024483 P,2020-05-13,SYSTEM AND METHOD FOR SKIN REJUVENATION USING IMPEDANCE MONITORING,"In part, the disclosure relates to a method of cosmetic tissue treatment. The method includes disposing a treatment applicator comprising an electrode array comprising a plurality of needles on a portion of tissue such that a region of the electrode array contacts the portion of tissue, wherein each needle is an electrode in electrical communication with a control system; applying a pulse of radio frequency (RF) energy to the portion of tissue through the electrode array; measuring impedance of electrode array over time; detecting a drop in the measured impedance while electrode array is in contact with the portion of tissue; and upon detection of the reduction in impedance by a threshold value, terminating application of the pulse of RF energy after a treatment time period.",CYNOSURE LLC,BOLL JAMES;;MIRKOV MIRKO GEORGIEV;;MASSE DANIEL;;BRUCE SAMUEL;;ALBERTELLI CHRISTIAN;;COUGHLIN JAMES;;SONNENSHEIN DAVID;;SIMON JEFFREY,CYNOSURE LLC (2022-03-31),https://lens.org/003-272-022-899-781,Patent Application,yes,3,1,9,9,0,A61B2018/00577;;A61B2018/0047;;A61B2018/0016;;A61B2018/143;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B18/12;;A61B18/12;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B2018/00708;;A61B2018/143;;A61B2018/0047;;A61B2018/00577;;A61N1/40,A61N1/40,,0,0,,,,PENDING
337,JP,A,JP 2015110669 A,096-047-519-206-824,2015-06-18,2015,JP 2015051863 A,2015-03-16,US 28582109 P;;US 28787209 P,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"PROBLEM TO BE SOLVED: To provide a method for treating breast cancer, in particular, cancers resistant to treatment with one or more of known breast cancer treating agents, and to provide patient selection strategies to predict the patient's response to drug therapy.SOLUTION: The invention provides a method for treating breast cancer, in particular, cancers resistant to treatment with one or more of known breast cancer treating agents, and to provide patient selection strategies to predict the patient response to drug therapy, which strategies comprise the steps of: detecting the presence or absence of one or more of: PIK3CA gene amplification, a mutation in PIK3CA, and decrease in PTEN protein expression; and treating a patient being positive for the presence of one or more of those by administering a pan-ErbB tyrosine kinase inhibitor to the subject.",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/096-047-519-206-824,Patent Application,no,0,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,A61K31/4709;;A61K31/337;;A61K31/4196;;A61K31/475;;A61K31/513;;A61K31/517;;A61K31/565;;A61K31/5685;;A61K31/675;;A61K31/704;;A61K31/7068;;A61K38/00;;A61K39/395;;A61K45/00;;A61P15/00;;A61P35/00;;A61P43/00;;C12N15/09;;C12Q1/04;;C12Q1/68;;G01N33/53,,3,0,,,"JPN6014053467; Ｃａｎｃｅｒ Ｃｅｌｌ ｖｏｌ．１２， ｎｏ．４, 2007, ｐ．３９５-４０２;;JPN6014053471; Ｃｌｉｎ Ｃａｎｃｅｒ Ｒｅｓ ｖｏｌ．１５， ｎｏ．７, 20090401, ｐ．２５５２-２５５８;;JPN6014053469; Ｂｒｅａｓｔ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ ｖｏｌ．７， ｎｏ．５, 2005, ｐ．Ｒ６０９-Ｒ６１６",PENDING
338,AU,A1,AU 2008/214380 A1,132-735-819-131-871,2008-08-14,2008,AU 2008/214380 A,2008-02-04,US 95990107 P;;US 89911107 P;;US 2008/0001516 W,2007-02-02,Compounds that inhibit cholinesterase,,COLUCID PHARMACEUTICALS INC,COUGHLIN DANIEL J;;LEANDER J DAVID;;DU SHOUCHENG;;WHITE JAMES F;;RUPNIAK NADIA M J;;SHIOSAKI KAZUMI,,https://lens.org/132-735-819-131-871,Patent Application,no,0,0,11,12,0,C07C271/44;;C07C271/48;;C07C271/54;;C07C271/56;;C07D211/90;;C07D213/40;;C07D215/56;;C07D243/38;;C07D267/20;;C07D333/20;;C07D401/04;;C07D405/12;;C07D487/04;;C07D499/68;;C07C2601/02;;C07C2601/14;;C07C2603/32;;C07C2603/74;;A61P1/08;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/28;;A61P25/30;;A61P25/34;;A61P27/06;;A61P27/16;;A61P31/04;;A61P31/12;;A61P37/08;;A61P43/00;;A61P9/10;;C07D211/90;;C07D215/56;;C07C271/54;;C07D405/12;;C07D267/20;;C07D213/40;;C07C271/48;;C07D401/04;;C07C271/56;;C07C271/44;;C07D243/38;;C07D333/20;;C07D487/04;;C07D499/68;;C07C2601/14;;C07C2603/74;;C07C2601/02;;C07C2603/32,C07C271/44;;A61K31/27;;A61K31/4402;;A61K31/4422;;A61K31/496;;A61P25/28;;C07C271/48;;C07C271/52;;C07C271/56;;C07D211/86;;C07D223/24;;C07D403/14;;C07D413/04,,0,0,,,,DISCONTINUED
339,WO,A2,WO 2008/097546 A2,074-365-560-653-103,2008-08-14,2008,US 2008/0001516 W,2008-02-04,US 89911107 P;;US 95990107 P,2007-02-02,COMPOUNDS THAT INHIBIT CHOLINESTERASE,"Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.",COLUCID PHARMACEUTICALS INC;;RUPNIAK NADIA M J;;WHITE JAMES F;;SHIOSAKI KAZUMI;;LEANDER J DAVID;;DU SHOUCHENG;;COUGHLIN DANIEL J,RUPNIAK NADIA M J;;WHITE JAMES F;;SHIOSAKI KAZUMI;;LEANDER J DAVID;;DU SHOUCHENG;;COUGHLIN DANIEL J,,https://lens.org/074-365-560-653-103,Patent Application,yes,2,23,11,12,0,C07C271/44;;C07C271/48;;C07C271/54;;C07C271/56;;C07D211/90;;C07D213/40;;C07D215/56;;C07D243/38;;C07D267/20;;C07D333/20;;C07D401/04;;C07D405/12;;C07D487/04;;C07D499/68;;C07C2601/02;;C07C2601/14;;C07C2603/32;;C07C2603/74;;A61P1/08;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/28;;A61P25/30;;A61P25/34;;A61P27/06;;A61P27/16;;A61P31/04;;A61P31/12;;A61P37/08;;A61P43/00;;A61P9/10;;C07D211/90;;C07D215/56;;C07C271/54;;C07D405/12;;C07D267/20;;C07D213/40;;C07C271/48;;C07D401/04;;C07C271/56;;C07C271/44;;C07D243/38;;C07D333/20;;C07D487/04;;C07D499/68;;C07C2601/14;;C07C2603/74;;C07C2601/02;;C07C2603/32,C07C271/44;;A61K31/27;;A61K31/4402;;A61K31/4422;;A61K31/496;;A61P25/28;;C07C271/48;;C07C271/52;;C07C271/56;;C07D223/24;;C07D403/14;;C07D413/04,,2,2,022-328-512-956-362;;006-393-565-303-85X,1522715;;10.1093/jat/16.3.192;;2272360;;10.1016/0014-2999(90)90006-r,"NADARAJAH B, J. ANAL. TOXICOL., vol. 16, 1992, pages 192 - 193;;FREEDMAN ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 187, 1990, pages 193 - 199",PENDING
340,EP,B1,EP 2524231 B1,109-236-293-052-828,2017-06-28,2017,EP 11700467 A,2011-01-04,US 29461510 P;;US 2011/0020080 W,2010-01-13,A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR,,WYETH LLC,COUGHLIN CHRISTINA MARIE;;BERKENBLIT ANNA;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,WYETH LLC (2014-05-14),https://lens.org/109-236-293-052-828,Granted Patent,yes,6,0,11,11,0,G01N33/57415;;A61P35/00;;A61P43/00;;G01N33/57415,G01N33/574,,1,0,,,"NAGATA Y ET AL: ""PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients"", CANCER CELL, CELL PRESS, US, vol. 6, 1 August 2004 (2004-08-01), pages 117-127, XP002998579, ISSN: 1535-6108, DOI: DOI:10.1016/J.CCR.2004.06.022 cited in the application",ACTIVE
341,US,B2,US 8101782 B2,125-419-076-777-541,2012-01-24,2012,US 1263608 A,2008-02-04,US 1263608 A;;US 89911107 P;;US 95990107 P,2007-02-02,Compounds that inhibit cholinesterase,"Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.",RUPNIAK NADIA M J;;WHITE JAMES F;;SHIOSAKI KAZUMI;;LEANDER J DAVID;;DU SHOUCHENG;;COUGHLIN DANIEL J;;COLUCID PHARMACEUTICALS INC,RUPNIAK NADIA M J;;WHITE JAMES F;;SHIOSAKI KAZUMI;;LEANDER J DAVID;;DU SHOUCHENG;;COUGHLIN DANIEL J,COLUCID PHARMACEUTICALS INC (2008-04-10),https://lens.org/125-419-076-777-541,Granted Patent,yes,32,16,11,12,0,C07C271/44;;C07C271/48;;C07C271/54;;C07C271/56;;C07D211/90;;C07D213/40;;C07D215/56;;C07D243/38;;C07D267/20;;C07D333/20;;C07D401/04;;C07D405/12;;C07D487/04;;C07D499/68;;C07C2601/02;;C07C2601/14;;C07C2603/32;;C07C2603/74;;A61P1/08;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/28;;A61P25/30;;A61P25/34;;A61P27/06;;A61P27/16;;A61P31/04;;A61P31/12;;A61P37/08;;A61P43/00;;A61P9/10;;C07D211/90;;C07D215/56;;C07C271/54;;C07D405/12;;C07D267/20;;C07D213/40;;C07C271/48;;C07D401/04;;C07C271/56;;C07C271/44;;C07D243/38;;C07D333/20;;C07D487/04;;C07D499/68;;C07C2601/14;;C07C2603/74;;C07C2601/02;;C07C2603/32,C07D267/16;;C07D333/22,549/22;;540/551,42,32,018-481-310-187-389;;047-981-897-076-540;;047-736-525-780-992;;093-146-860-573-657;;131-034-051-221-336;;033-182-931-950-950;;068-722-302-536-92X;;100-560-497-056-457;;025-990-647-034-272;;026-407-258-845-085;;026-929-019-093-929;;022-587-852-806-295;;077-726-634-854-419;;070-107-339-138-957;;007-579-574-269-640;;052-581-911-033-183;;090-724-685-212-880;;005-585-552-496-816;;023-444-131-262-994;;023-444-131-262-994;;035-808-991-163-099;;035-230-547-171-641;;018-481-310-187-389;;046-129-061-176-533;;020-706-511-331-670;;066-769-018-969-520;;050-872-681-204-449;;041-981-211-194-932;;002-415-681-780-142;;113-719-915-625-143;;000-942-801-709-327;;015-137-991-967-185,10.1021/jm010914b;;11689067;;10.1016/s0968-0896(99)00309-0;;10819156;;10.1007/978-1-4613-2179-8_61;;10.1002/hlca.19900730323;;10.1071/ch9960171;;10.2165/00023210-199503060-00006;;2608162;;10.1007/bf00965931;;10.1016/0028-3908(91)90134-w;;1758586;;10.1034/j.1600-0404.2003.00081.x;;12675697;;15451390;;10.1016/j.bcp.2004.07.030;;pmc6741718;;15179444;;10.1111/j.1527-3458.2004.tb00010.x;;10.1002/1099-1166(200011)15:11<1028::aid-gps227>3.0.co;2-e;;11113983;;9243353;;10.1002/j.1552-4604.1997.tb04342.x;;10.1017/s1461145799001522;;11281991;;7494864;;10.1016/0163-7258(95)00016-a;;10.1517/13543784.9.10.2259;;11060805;;12090555;;10.1006/nlme.1998.3897;;10536095;;12369266;;10.1016/s0278-5846(02)00205-1;;12369266;;10.1016/s0278-5846(02)00205-1;;10465680;;10.1016/s0028-3908(99)00019-2;;10.1021/cr950066q;;11848856;;10.1021/jm010914b;;11689067;;10.1016/s0531-5565(00)00077-2;;10767583;;12431053;;10.1021/jm020120c;;10.1111/j.1527-3458.2002.tb00215.x;;12070526;;pmc6741681;;4748552;;10.1159/000090630;;16391473;;16340187;;10.1159/000090210;;10.1002/jhet.5570370216;;12323018;;10.1021/ol026418e;;11858843;;10.1016/s0223-5234(01)01324-1;;12670645;;10.1016/s0968-0896(03)00091-9,"Tumiatti et al. (J. Bioorg. Med. Chem., 8 (2000), 681-89).;;Rampa et al. (J. Med. Chem., 2001, 44, p. 3810-20).;;Kubinyi (3D QSAR in Drug Design: Ligand-Protein Interactions and Molecular Similarity, vol. 2-3, Springer, 1998, 800 pages) TOC and pp. 243-244 provided.;;Wermuth, The Practice of Medicinal Chemsitry, 2d ed. (2003), 768 pages; chapters 9-10 provided.;;Tumiatti et al., ""[4[[N-(3-Chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium (McN-A-343)-Related Compounds. Effect of the Butynyl Chain Inclusion into an Aromatic Unit on the Potency for Muscarinic Receptors"", Bioorg. Med. Chem., 8(4):681-689 (2000).;;Weinstock et al., ""Pharmacological activity of novel anticholinesterase agents of potential use in the treatment of Alzheimer's disease"", Advances Behavioral Biol., 29:539-549 (1986).;;Amstutz et al., ""Cyclische Phenyl-carbamate des Miotin-Typs und ihre Wirkung auf die Acetylcholinesterase"", Helvetica Chimica Acta, 73:739-753 (1990) (English Abstract Only).;;Brossi et al., ""Invited Review. Phenserine, a Novel Anticholinesterase Related to Physostigmine: Total Synthesis and Biological Properties"", Aust. J. Chem., 49:171-181 (1996).;;Cutler et al., ""Muscarinic M1-Receptor Agonists: Potential in the Treatment of Alzheimer's Disease"", CNS Drugs, 3(6):467-481 (1995).;;Database Beilstein, Beilstein Institut Fuer Chemische Wissenschaften, Frankfurt Am Main, DE, XP002331880.;;Database CA [Online] Chemical Abstracts Service, Columbus, Ohio, Koyama et al., ""Pharmaceuticals Containing (hydroxybenzyl) Amines as Acetylcholine Esterase Inhibitors and Selective Serotonin Reuptake Inhibitors"", XP002331878 Retrieved from STN Database Accession No. 2004:291183 Abstract & JP 2004 107322 A2 (BTG International Ltd., UK) Apr. 8, 2004.;;Database CA [Online] Chemical Abstracts Service, Columbus, Ohio, Goto et al., ""Preparation of Aromatic Carbamates as Choline Esterase Inhibitors for Improvement of Cerebral Function"", XP002331879 Retrieved from STN Database Accession No. 1991:206818 Abstract & JP 03 002155 A2 (Takeda Chemical Industries, Ltd., Japan) Jan. 8, 1991.;;De Sarno et al., ""The Effect of Heptyl-Physostigmine, a New Cholinesterase Inhibitor, on the Central Cholinergic System of the Rat"", Neurochem. Res., 14(10):971-977 (1989).;;Elmalem et al., ""Antagonism of Morphine-Induced Respiratory Depression by Novel Anticholinesterase Agents"", Neuropharmacol., 30(10):1059-1064 (1991).;;Fogelson et al., ""Effects of Rivastigmine on the Quantitative EEG in Demented Parkinsonian Patients"", Acta Neurol. Scand., 107(4):252-255 (2003).;;Froestl et al., ""SGS742: The first GABAB Receptor Antagonist in Clinical Trials"", Biochem. Pharmacol., 68:1479-1487 (2004).;;Gatto et al., ""TC-1734: An Orally Active Neuronal Nicotinic Acetylcholine Receptor Modulator with Antidepressant, Neuroprotective and Long-Lasting Cognitive Effects"", CNS Drug Reviews, 10(2):147-166 (2004).;;Grace et al., ""A Comparison of Sleep Profiles in Patients with Dementia with Lewy Bodies and Alzheimer's Disease"", Int J. Geriatr. Psychiatry, 15(11):1028-1033 (2000).;;Heinonen et al., ""Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of Monoamine Oxidase Type B in Humans"", J. Clin. Pharmacol., 37:602-609 (1997).;;Janssen et al., ""Does phenylethylamine Act as an Endogenous Amphetamine in Some Patients?"", Int. J. Neuropsychopharmacol., 2:229-240 (1999).;;Kerr et al., ""GABAB Receptors"", Pharmac. Ther., 67(2):187-246 (1995).;;Korczyn, A.D., ""Muscarinic M1 Agonist in the Treatment of Alzheimer's Disease"", Exp. Opin. Invest. Drugs, 9(10):2259-2267 (2000).;;Kupsch, A., ""Rasagiline Teva Pharmaceutical"", Curr. Opin. Investig. Drugs, 3(5):794-797 (2002).;;Land et al., ""D-Cycloserine: Effects on Long-Term Retention of a Conditioned Response and on Memory for Contextual Attributes"", Neurobiol. Learning Mem., 72(3):158-168 (1999).;;Lipiello et al., ""RJR-2403 is an Efficacious Agonist for Human alpha4beta2 Neuronal Nicotinic Acetylcholine Receptors with Lower Efficacy for Other Human Receptor Subtypes"", Soc. Neurosci., 24:88 (Abstract 39.26) (1998).;;Obinu et al., ""Brain Selective Stimulation of Nicotinic Receptors by RJR 1734 Enhances ACH Transmission From Frontoparietal Cortex and Enhances Memory in Rodents"", Internatl. J. Neuropyschopharamology, 3(Suppl. 1):S361 (2003) (Abstract Only).;;Obinu et al., ""Brain Selective Stimulation of Nicotinic Receptors by TC-1734 Enhances Ach Transmission from Frontoparietal Cortex and Enhances Memory in Rodents"", Progress Neuropsychopharmacol. Biol. Psychiatry, 26:913-918 (2002).;;Parsons et al., ""Memantine is a Clinically Well Tolerated N-Methyl-D-Aspartate (NMDA) Receptor Antagonist-A Review of Preclinical Data"", Neuropharmacol., 38(5):735-767 (1999).;;Patani et al., ""Bioisosterism: A Rational Approach in Drug Design"", Chemical Reviews, vol. 96, 3147-3176 (1996).;;Rampa et al., ""Acetylcholinesterase Inhibitors: SAR and Kinetic Studies on omega-[N-Methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl Derivatives"", J. Med. Chem., 44:3810-3820 (2001).;;Schredl et al., ""The Effect of Rivastigmine on Sleep in Elderly healthy Subjects"", Experimental Gerontol., 35(2):243-249 (2000).;;Siatra-Papastaikoudi, T., et al., ""Synthesis of Carbamate Esters of Phenethylamines and their Pharmacological Action on the Central Nervous System"", Chimika Chronika, 10(4), 307-13 (1981).;;Sterling et al., ""Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease"", J. Med. Chem., 45:5260-5279 (2002).;;Trabace et al., ""CHF2819: Pharmacological Profile of a Novel Acetylcholinesterase Inhibitor"", CNS Drug Reviews, 8(1):53-69 (1992).;;White et al., ""On the Physostigmine-Like Action of Certain Synthetic Urethanes,"" J. Pharmacol., vol. 41, 259-288 (1931).;;Yang et al., ""beta-Phenylethylamine: A Specific Substrate for Type B Monoamine Oxidase of Brain"", J. Pharmacol. Exp. Ther., 187(2):365-371 (1973).;;Davis et al. ""Circadian Cholinergic Rhythyms: Implications cof Cholinesterase Inhibitor Therapy."" Dement. Geriatr. Cogn. Disord. 21.2(2006):120-129.;;Gao et al. ""An Efficient O-Dealkylation Procedure for the Synthesis of (3aS,cis)-1,2,3,3a,8,8a-hexahyrdo-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl-3,4-dihydro-2(1H)-isoquinolinecarboxylate."" J. Heterocyclic. Chem. 37(2000):331-333.;;Kogen et al. ""Design and Synthesis of Dual Inhibitors of Acetylcholinesterase and Serotonin Transporter Targeting Potential Agents for Alzheimer's Diseases."" Org. Lett. 4.20(2002):3359-3362.;;Mustazza et al. ""Synthesis and Cholinesterase Activity of Phenylcarbamates Related to Tivastigmine, a Therapeutic Agent for Alzheimer's Disease."" Eur. J. Med. Chem. 37(2002):91-109.;;Schimelpfening, N., About.com:Depression. Top 9 Depression Symptoms, (available online at http://depression.about.com) updated Jun. 11, 2009.;;Toda et al. ""Design, Synthesis and Structure-Activity Relationships of Dual Inhibitors of Acetylcholinesterase and Serotonin Transporter as Potential Agents for Alzheimer's Disease."" Bioorg. Med. Chem. 11(2003):1935-1955.",INACTIVE
342,AU,A1,AU 2021/273493 A1,005-849-313-820-443,2022-12-01,2022,AU 2021/273493 A,2021-05-13,US 202063024483 P;;US 2021/0032279 W,2020-05-13,System and method for skin rejuvenation using impedance monitoring,"In part, the disclosure relates to a method of cosmetic tissue treatment. The method includes disposing a treatment applicator comprising an electrode array comprising a plurality of needles on a portion of tissue such that a region of the electrode array contacts the portion of tissue, wherein each needle is an electrode in electrical communication with a control system; applying a pulse of radio frequency (RF) energy to the portion of tissue through the electrode array; measuring impedance of electrode array over time; detecting a drop in the measured impedance while electrode array is in contact with the portion of tissue; and upon detection of the reduction in impedance by a threshold value, terminating application of the pulse of RF energy after a treatment time period.",CYNOSURE LLC,BOLL JAMES;;MIRKOV MIRKO GEORGIEV;;MASSE DANIEL;;BRUCE SAMUEL;;ALBERTELLI CHRISTIAN;;COUGHLIN JAMES;;SONNENSHEIN DAVID;;SIMON JEFFREY,,https://lens.org/005-849-313-820-443,Patent Application,no,0,0,9,9,0,A61B2018/00577;;A61B2018/0047;;A61B2018/0016;;A61B2018/143;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B18/12;;A61B18/12;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B2018/00708;;A61B2018/143;;A61B2018/0047;;A61B2018/00577;;A61N1/40,A61N1/32;;A61B18/12;;A61N1/04;;A61N1/36,,0,0,,,,PENDING
343,CN,A,CN 101631770 A,135-223-232-908-557,2010-01-20,2010,CN 200880007756 A,2008-02-04,US 89911107 P,2007-02-02,Compounds that inhibit cholinesterase,"Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.",COLUCID PHARMACEUTICALS INC,RUPNIAK NADIA M J;;WHITE JAMES F;;KAZUMI SHIOSAKI;;DAVID LEANDER J;;SHOUCHENG DU;;COUGHLIN DANIEL J,,https://lens.org/135-223-232-908-557,Patent Application,no,0,7,1,12,0,,C07C271/44,,0,0,,,,DISCONTINUED
344,EP,A2,EP 2125709 A2,130-312-320-751-484,2009-12-02,2009,EP 08725187 A,2008-02-04,US 2008/0001516 W;;US 89911107 P;;US 95990107 P,2007-02-02,COMPOUNDS THAT INHIBIT CHOLINESTERASE,,COLUCID PHARMACEUTICALS INC,RUPNIAK NADIA M J;;WHITE JAMES F;;SHIOSAKI KAZUMI;;LEANDER J DAVID;;DU SHOUCHENG;;COUGHLIN DANIEL J,,https://lens.org/130-312-320-751-484,Patent Application,yes,0,0,11,12,0,C07C271/44;;C07C271/48;;C07C271/54;;C07C271/56;;C07D211/90;;C07D213/40;;C07D215/56;;C07D243/38;;C07D267/20;;C07D333/20;;C07D401/04;;C07D405/12;;C07D487/04;;C07D499/68;;C07C2601/02;;C07C2601/14;;C07C2603/32;;C07C2603/74;;A61P1/08;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/28;;A61P25/30;;A61P25/34;;A61P27/06;;A61P27/16;;A61P31/04;;A61P31/12;;A61P37/08;;A61P43/00;;A61P9/10;;C07D211/90;;C07D215/56;;C07C271/54;;C07D405/12;;C07D267/20;;C07D213/40;;C07C271/48;;C07D401/04;;C07C271/56;;C07C271/44;;C07D243/38;;C07D333/20;;C07D487/04;;C07D499/68;;C07C2601/14;;C07C2603/74;;C07C2601/02;;C07C2603/32,A61K31/27;;C07C271/44;;A61K31/4402;;A61K31/4422;;A61K31/496;;A61P25/28;;C07C271/48;;C07C271/52;;C07C271/56;;C07D211/86;;C07D223/24;;C07D403/14;;C07D413/04,,0,0,,,,DISCONTINUED
345,BR,A2,BR 112022022678 A2,023-404-400-411-569,2022-12-13,2022,BR 112022022678 A,2021-05-13,US 2021/0032279 W;;US 202063024483 P,2020-05-13,SISTEMA E MÉTODO PARA REJUVENESCIMENTO DA PELE USANDO MONITORAMENTO DE IMPEDÂNCIA,"SISTEMA E MÉTODO PARA REJUVENESCIMENTO DA PELE USANDO MONITORAMENTO DE IMPEDÂNCIA. A presente invenção refere-se, em parte, a um método de tratamento cosmético de tecido. O método inclui dispor um aplicador de tratamento compreendendo uma matriz de eletrodos compreendendo uma pluralidade de agulhas em uma porção de tecido, de modo que uma região da matriz de eletrodos entre em contato com a porção de tecido, em que cada agulha é um eletrodo em comunicação elétrica com um sistema de controle; aplicar um pulso de energia de radiofrequência (RF) à porção de tecido através da matriz de eletrodos; medir a impedância da matriz de eletrodos ao longo do tempo; detectar uma queda na impedância medida enquanto a matriz de eletrodos está em contato com a porção de tecido e, após a detecção da redução na impedância por um valor limite, terminar a aplicação do pulso de energia de RF depois de um período de tempo do tratamento.",CYNOSURE LLC,JAMES BOLL;;MIRKO GEORGIEV MIRKOV;;DANIEL MASSE;;SAMUEL BRUCE;;CHRISTIAN ALBERTELLI;;JAMES COUGHLIN;;DAVID SONNENSHEIN;;JEFFREY SIMON,,https://lens.org/023-404-400-411-569,Patent Application,no,0,0,9,9,0,A61B2018/00577;;A61B2018/0047;;A61B2018/0016;;A61B2018/143;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B18/12;;A61B18/12;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B2018/00708;;A61B2018/143;;A61B2018/0047;;A61B2018/00577;;A61N1/40,A61N1/32;;A61B18/12;;A61N1/04;;A61N1/36,,0,0,,,,PENDING
346,WO,A3,WO 2008/097546 A3,080-517-076-299-04X,2009-01-15,2009,US 2008/0001516 W,2008-02-04,US 89911107 P;;US 95990107 P,2007-02-02,COMPOUNDS THAT INHIBIT CHOLINESTERASE,"Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.",COLUCID PHARMACEUTICALS INC;;RUPNIAK NADIA M J;;WHITE JAMES F;;SHIOSAKI KAZUMI;;LEANDER J DAVID;;DU SHOUCHENG;;COUGHLIN DANIEL J,RUPNIAK NADIA M J;;WHITE JAMES F;;SHIOSAKI KAZUMI;;LEANDER J DAVID;;DU SHOUCHENG;;COUGHLIN DANIEL J,,https://lens.org/080-517-076-299-04X,Search Report,yes,3,0,11,12,0,C07C271/44;;C07C271/48;;C07C271/54;;C07C271/56;;C07D211/90;;C07D213/40;;C07D215/56;;C07D243/38;;C07D267/20;;C07D333/20;;C07D401/04;;C07D405/12;;C07D487/04;;C07D499/68;;C07C2601/02;;C07C2601/14;;C07C2603/32;;C07C2603/74;;A61P1/08;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/28;;A61P25/30;;A61P25/34;;A61P27/06;;A61P27/16;;A61P31/04;;A61P31/12;;A61P37/08;;A61P43/00;;A61P9/10;;C07D211/90;;C07D215/56;;C07C271/54;;C07D405/12;;C07D267/20;;C07D213/40;;C07C271/48;;C07D401/04;;C07C271/56;;C07C271/44;;C07D243/38;;C07D333/20;;C07D487/04;;C07D499/68;;C07C2601/14;;C07C2603/74;;C07C2601/02;;C07C2603/32,C07C271/44;;A61K31/27;;A61K31/4402;;A61K31/4422;;A61K31/496;;A61P25/28;;C07C271/48;;C07C271/52;;C07C271/56;;C07D211/86;;C07D223/24;;C07D403/14;;C07D413/04,,2,2,047-981-897-076-540;;047-736-525-780-992,10.1016/s0968-0896(99)00309-0;;10819156;;10.1007/978-1-4613-2179-8_61,"TUMIATTI, V. ET AL: ""[4-[[N-(3-Chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium (McN-A-343)-related compounds. Effect of the butynyl chain inclusion into an aromatic unit on the potency for muscarinic receptors"", BIOORGANIC & MEDICINAL CHEMISTRY , 8(4), 681-689 CODEN: BMECEP; ISSN: 0968-0896, 2000, XP002485818;;WEINSTOCK, MARTA ET AL: ""Pharmacological activity of novel anticholinesterase agents of potential use in the treatment of Alzheimer's disease"", ADVANCES IN BEHAVIORAL BIOLOGY , 29(ALZHEIMER'S PARKINSON'S DIS.), 539-49 CODEN: ADBBBW; ISSN: 0099-6246, 1986, XP009101833",PENDING
347,CA,A1,CA 3178202 A1,101-141-083-328-125,2021-11-18,2021,CA 3178202 A,2021-05-13,US 202063024483 P;;US 2021/0032279 W,2020-05-13,SYSTEM AND METHOD FOR SKIN REJUVENATION USING IMPEDANCE MONITORING,"In part, the disclosure relates to a method of cosmetic tissue treatment. The method includes disposing a treatment applicator comprising an electrode array comprising a plurality of needles on a portion of tissue such that a region of the electrode array contacts the portion of tissue, wherein each needle is an electrode in electrical communication with a control system; applying a pulse of radio frequency (RF) energy to the portion of tissue through the electrode array; measuring impedance of electrode array over time; detecting a drop in the measured impedance while electrode array is in contact with the portion of tissue; and upon detection of the reduction in impedance by a threshold value, terminating application of the pulse of RF energy after a treatment time period.",CYNOSURE LLC,BOLL JAMES;;MIRKOV MIRKO GEORGIEV;;MASSE DANIEL;;BRUCE SAMUEL;;ALBERTELLI CHRISTIAN;;COUGHLIN JAMES;;SONNENSHEIN DAVID;;SIMON JEFFREY,,https://lens.org/101-141-083-328-125,Patent Application,no,0,0,9,9,0,A61B2018/00577;;A61B2018/0047;;A61B2018/0016;;A61B2018/143;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B18/12;;A61B18/12;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B2018/00708;;A61B2018/143;;A61B2018/0047;;A61B2018/00577;;A61N1/40,A61B18/12;;A61N1/04;;A61N1/32;;A61N1/36,,0,0,,,,PENDING
348,CA,C,CA 2783743 C,123-390-936-864-647,2022-10-04,2022,CA 2783743 A,2010-12-06,US 28582109 P;;US 28787209 P;;IB 2010055604 W,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/123-390-936-864-647,Granted Patent,no,0,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,C12Q1/68;;A61K31/436;;A61K31/4709;;A61P35/00;;C12Q1/6876,,0,0,,,,PENDING
349,CA,A1,CA 2677241 A1,073-452-483-183-919,2008-08-14,2008,CA 2677241 A,2008-02-04,US 89911107 P;;US 95990107 P;;US 2008/0001516 W,2007-02-02,COMPOUNDS THAT INHIBIT CHOLINESTERASE,"Compounds that inhibit cholinesterase activity and, upon hydrolysis relea se a pharmacologically active agent. The pharmacologically active agent obta ined by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated wi th a deficiency in a pharmacologically active agent, such as acetylcholine.",COLUCID PHARMACEUTICALS INC,LEANDER J DAVID;;DU SHOUCHENG;;SHIOSAKI KAZUMI;;COUGHLIN DANIEL J;;RUPNIAK NADIA M J;;WHITE JAMES F,,https://lens.org/073-452-483-183-919,Patent Application,no,0,0,11,12,0,C07C271/44;;C07C271/48;;C07C271/54;;C07C271/56;;C07D211/90;;C07D213/40;;C07D215/56;;C07D243/38;;C07D267/20;;C07D333/20;;C07D401/04;;C07D405/12;;C07D487/04;;C07D499/68;;C07C2601/02;;C07C2601/14;;C07C2603/32;;C07C2603/74;;A61P1/08;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/28;;A61P25/30;;A61P25/34;;A61P27/06;;A61P27/16;;A61P31/04;;A61P31/12;;A61P37/08;;A61P43/00;;A61P9/10;;C07D211/90;;C07D215/56;;C07C271/54;;C07D405/12;;C07D267/20;;C07D213/40;;C07C271/48;;C07D401/04;;C07C271/56;;C07C271/44;;C07D243/38;;C07D333/20;;C07D487/04;;C07D499/68;;C07C2601/14;;C07C2603/74;;C07C2601/02;;C07C2603/32,C07C271/44;;A61K31/27;;A61K31/4402;;A61K31/4422;;A61K31/496;;A61P25/28;;C07C271/48;;C07C271/52;;C07C271/56;;C07D211/86;;C07D223/24;;C07D403/14;;C07D413/04,,0,0,,,,DISCONTINUED
350,US,A1,US 2012/0010240 A1,047-687-889-422-784,2012-01-12,2012,US 98404311 A,2011-01-04,US 98404311 A;;US 29461510 P,2010-01-13,CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR,A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.,COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEVEN;;BERKENBLIT ANNA;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL;;WYETH LLC,COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEVEN;;BERKENBLIT ANNA;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,WYETH LLC (2010-11-12),https://lens.org/047-687-889-422-784,Patent Application,yes,0,1,11,11,0,G01N33/57415;;A61P35/00;;A61P43/00;;G01N33/57415,A61K31/4709;;A61P35/00;;C40B30/04;;G01N1/30;;G01N33/53,514/313;;506/9;;435/7.4;;435/21,0,0,,,,ACTIVE
351,WO,A1,WO 2021/231748 A1,119-036-306-011-571,2021-11-18,2021,US 2021/0032279 W,2021-05-13,US 202063024483 P,2020-05-13,SYSTEM AND METHOD FOR SKIN REJUVENATION USING IMPEDANCE MONITORING,"In part, the disclosure relates to a method of cosmetic tissue treatment. The method includes disposing a treatment applicator comprising an electrode array comprising a plurality of needles on a portion of tissue such that a region of the electrode array contacts the portion of tissue, wherein each needle is an electrode in electrical communication with a control system; applying a pulse of radio frequency (RF) energy to the portion of tissue through the electrode array; measuring impedance of electrode array over time; detecting a drop in the measured impedance while electrode array is in contact with the portion of tissue; and upon detection of the reduction in impedance by a threshold value, terminating application of the pulse of RF energy after a treatment time period.",CYNOSURE LLC,BOLL JAMES;;MIRKOV MIRKO GEORGIEV;;MASSE DANIEL;;BRUCE SAMUEL;;ALBERTELLI CHRISTIAN;;COUGHLIN JAMES;;SONNENSHEIN DAVID;;SIMON JEFFREY,,https://lens.org/119-036-306-011-571,Patent Application,yes,7,0,9,9,0,A61B2018/00577;;A61B2018/0047;;A61B2018/0016;;A61B2018/143;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B18/12;;A61B18/12;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B2018/00708;;A61B2018/143;;A61B2018/0047;;A61B2018/00577;;A61N1/40,A61N1/32;;A61B18/12;;A61N1/04;;A61N1/36,,4,4,003-749-865-544-159;;085-417-172-729-226;;157-248-148-279-785;;027-062-225-465-540,20166154;;10.1002/lsm.20860;;24490743;;10.1517/17425247.2014.885501;;16305405;;10.2174/1567201052772915;;16305373;;10.2174/1567201043480045,"HCEDERSDAL, MERETE ET AL.: ""Fractional C02 laser-assisted drug delivery"", LASERS IN SURGERY AND MEDICINE, vol. 42, no. 2, 2010, pages 113 - 122;;LIN, CHIH-HUNG ET AL.: ""Lasers as an approach for promoting drug delivery via skin"", EXPERT OPINION ON DRUG DELIVERY, vol. 11, no. 4, 2014, pages 599 - 614;;BENSON, HEATHER AE: ""Transdermal drug delivery: penetration enhancement techniques"", CURRENT DRUG DELIVERY, vol. 2, no. 1, 2005, pages 23 - 33, XP008049099, DOI: 10.2174/1567201052772915;;CROSS ET AL.: ""Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development?"", CURRENT DRUG DELIVERY, vol. 1, no. 1, 2004, pages 81 - 92",PENDING
352,KR,A,KR 20230009436 A,181-396-017-678-967,2023-01-17,2023,KR 20227042945 A,2021-05-13,US 202063024483 P;;US 2021/0032279 W,2020-05-13,임피던스 모니터링을 이용한 피부 회복을 위한 시스템 및 방법,"부분적으로, 본 개시내용은 미용 조직 치료의 방법에 관한 것이다. 방법은 복수의 바늘을 포함하는 전극 어레이를 포함하는 치료 애플리케이터를 조직의 부분 상에 배치하여 전극 어레이의 영역이 조직의 부분과 접촉하게 하는 단계 - 각각의 바늘은 제어 시스템과 전기 통신하는 전극임 -; 전극 어레이를 통해 조직의 부분에 라디오 주파수(RF) 에너지의 펄스를 인가하는 단계; 시간에 따라 전극 어레이의 임피던스를 측정하는 단계; 전극 어레이가 조직의 부분과 접촉하고 있는 동안 측정된 임피던스의 강하를 검출하는 단계; 및 임계값만큼 임피던스에서의 감소의 검출시에, 치료 시간 기간 이후에 RF 에너지의 펄스의 인가를 종료하는 단계를 포함한다.",CYNOSURE LLC,BOLL JAMES;;MIRKOV MIRKO GEORGIEV;;MASSE DANIEL;;BRUCE SAMUEL;;ALBERTELLI CHRISTIAN;;COUGHLIN JAMES;;SONNENSHEIN DAVID;;SIMON JEFFREY,,https://lens.org/181-396-017-678-967,Patent Application,no,0,0,9,9,0,A61B2018/00577;;A61B2018/0047;;A61B2018/0016;;A61B2018/143;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B18/12;;A61B18/12;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B2018/00708;;A61B2018/143;;A61B2018/0047;;A61B2018/00577;;A61N1/40,A61B18/12;;A61B18/00;;A61B18/14,,0,0,,,,PENDING
353,ES,T3,ES 2638821 T3,012-381-980-958-764,2017-10-24,2017,ES 11700467 T,2011-01-04,US 29461510 P;;US 2011/0020080 W,2010-01-13,Un punto de corte en la expresión de la proteína PTEN que identifica tumores con precisión y es predictivo de la respuesta a fármacos a un inhibidor pan-ErbB,"Un método para determinar el tratamiento para un paciente con cáncer de mama que comprende: obtener una célula tumoral y una célula no tumorigénica del paciente; determinar una medida cuantitativa de la expresión de la proteína PTEN en la célula tumoral y en la célula no tumorigénica; calcular un valor de expresión de proteína PTEN normalizado comparando la medida cuantitativa de la expresión de proteína PTEN en la célula tumoral con la medida cuantitativa de la expresión de proteína PTEN en la célula no tumorigénica; y determinar tratar al paciente con un inhibidor de la tirosina quinasa pan-ErbB si el valor de expresión de proteína PTEN es menor de 0,15.",WYETH LLC,COUGHLIN CHRISTINA MARIE;;BERKENBLIT ANNA;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/012-381-980-958-764,Granted Patent,no,0,0,11,11,0,G01N33/57415;;A61P35/00;;A61P43/00;;G01N33/57415,G01N33/574,,0,0,,,,ACTIVE
354,US,A1,US 2022/0170107 A1,027-750-624-626-726,2022-06-02,2022,US 202117522637 A,2021-11-09,US 202117522637 A;;US 201916416083 A;;US 201615099429 A;;US 201213514556 A;;IB 2010055604 W;;US 28787209 P;;US 28582109 P,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"Methods for treating breast cancer, specifically cancers resistant to treatment With one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting tile presence or absence in a patient of one or more of PIK3CA gene amplification a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tifrosine kinase inhibitor.",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/027-750-624-626-726,Patent Application,yes,0,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,C12Q1/6886;;A61K31/4709;;A61K39/395;;A61K45/06;;C07K16/28;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
355,WO,A1,WO 2011/087926 A1,104-242-171-125-629,2011-07-21,2011,US 2011/0020080 W,2011-01-04,US 29461510 P,2010-01-13,A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR,A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.,WYETH LLC;;COUGHLIN CHRISTINIA MARIE;;BERKENBLIT ANNA;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEVEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,COUGHLIN CHRISTINIA MARIE;;BERKENBLIT ANNA;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEVEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/104-242-171-125-629,Patent Application,yes,9,3,11,11,0,G01N33/57415;;A61P35/00;;A61P43/00;;G01N33/57415,G01N33/574,,21,21,076-059-062-130-42X;;016-346-978-857-894;;076-564-633-692-352;;055-707-345-132-645;;006-463-679-652-100;;076-059-062-130-42X;;082-057-478-967-176;;030-329-378-068-384;;006-463-679-652-100;;093-710-732-335-237;;001-001-952-506-49X;;078-072-244-606-504;;007-484-703-651-028;;027-486-134-657-503;;009-493-898-884-338;;079-971-647-932-297;;015-172-131-105-677;;034-310-033-915-336;;078-072-244-606-504;;065-470-438-699-384;;051-864-320-804-47X,10.1016/j.ccr.2004.06.022;;15324695;;10.1053/hupa.2002.124721;;12055674;;10.1053/hp.2000.6713;;10821499;;10.1038/modpathol.3880371;;11454999;;10.1016/j.ccr.2007.08.030;;17936563;;10.1016/j.ccr.2004.06.022;;15324695;;19188670;;10.1200/jco.2009.21.9170;;19629070;;10.1038/nrc2664;;10.1016/j.ccr.2007.08.030;;17936563;;10.1002/gcc.20560;;18383208;;10.1248/bpb.30.1624;;17827710;;19345329;;10.1016/j.ccr.2009.02.012;;pmc2673492;;10.1002/cncr.22677;;17440983;;10.1080/00313020701570012;;17886097;;9671321;;10.1038/sj.onc.1201940;;17575221;;10.1158/1078-0432.ccr-06-1609;;10.1158/0008-5472-can-04-3913;;15805248;;10514407;;10.1016/s0002-9440(10)65227-3;;pmc1867038;;19345329;;10.1016/j.ccr.2009.02.012;;pmc2673492;;18676830;;pmc2680495;;10.1158/0008-5472.can-07-6854;;pmc2042178;;17911267;;10.1073/pnas.0702596104,"NAGATA Y ET AL: ""PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients"", CANCER CELL, CELL PRESS, US, vol. 6, 1 August 2004 (2004-08-01), pages 117 - 127, XP002998579, ISSN: 1535-6108, DOI: DOI:10.1016/J.CCR.2004.06.022;;BOSE S ET AL.: ""Reduced expression of PTEN correlates with breast cancer progression"", HUM. PATHOL., vol. 33, 2002, pages 405 - 409;;RUBIN MA ET AL.: ""10q23.3 loss of heterozygosity is higher in lymph node- positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer"", HUM. PATHOL., vol. 31, 2000, pages 504 - 508, XP004833889, DOI: doi:10.1053/hp.2000.6713;;DEPOWSKI PL; ROSENTHAL SI; ROSS JS: ""Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer"", MOD. PATHOL., vol. 14, 2001, pages 672 - 676;;BERNS K ET AL.: ""A functional genetic approach identifies the P13K pathway as a major determinant of trastuzumab resistance in breast cancer"", CANCER CELL, vol. 12, 2007, pages 395 - 402, XP002592491, DOI: doi:10.1016/j.ccr.2007.08.030;;NAGATA Y ET AL.: ""PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients"", CANCER CELL, vol. 6, 2004, pages 117 - 127, XP002449979, DOI: doi:10.1016/j.ccr.2004.06.022;;ALLEGRA CJ; JESSUP JM; SOMERFIELD MR ET AL.: ""American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy"", J. CLIN. ONCOL., vol. 27, 2009, pages 2091 - 2096, XP002597052, DOI: doi:10.1200/JCO.2009.21.9170;;ENGELMAN JA: ""Targeting P13K signalling in cancer: opportunities, challenges and limitations"", NAT. REV. CANCER, vol. 9, 2009, pages 550 - 562, XP002693047, DOI: doi:10.1038/NRC.2664;;BERNS K ET AL., CANCER CELL, 2007, pages 395 - 402;;BETTENDORF O ET AL.: ""Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate"", GENES CHROMOSOMES CANCER, vol. 47, 2008, pages 565 - 572;;MAEHAMA T: ""PTEN: its deregulation and tumorigenesis"", BIOL. PHARM. BULL., vol. 30, 2007, pages 1624 - 1627;;YIM EK; PENG G; DAI H ET AL.: ""Rak functions as a tumor suppressor by regulating PTEN protein stability and function"", CANCER CELL, vol. 15, 2009, pages 304 - 314;;PANTUCK AJ ET AL.: ""Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy"", CANCER, vol. 109, no. 11, 2007, pages 2257 - 2267;;HAGER M ET AL.: ""PTEN expression in renal cell carcinoma and oncocytoma and prognosis"", PATHOLOGY, vol. 39, no. 5, 2007, pages 482 - 485;;BOSE S ET AL.: ""Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas"", ONCOGENE, vol. 17, 1998, pages 123 - 127.34;;PEREZ-TENORIO G ET AL.: ""PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer"", CLIN. CANCER RES., vol. 13, 2007, pages 3577 - 3584;;SAAL LH ET AL.: ""PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma"", CANCER RES., vol. 65, 2005, pages 2554 - 2559, XP055070087, DOI: doi:10.1158/0008-5472-CAN-04-3913;;PERREN A ET AL.: ""Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast"", AM. J. PATHOL., vol. 155, 1999, pages 1253 - 1260;;YIM EK ET AL.: ""Rak functions as a tumor suppressor by regulating PTEN protein stability and function"", CANCER CELL, vol. 15, 2009, pages 304 - 314;;STEMKE-HALE K ET AL.: ""An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer"", CANCER RES., vol. 68, 2008, pages 6084 - 6091, XP002534389, DOI: doi:10.1158/0008-5472.CAN-07-6854;;ZHOU J ET AL.: ""Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance"", PROC. NATL. ACAD. SCI. U.S.A., vol. 104, 2007, pages 16158 - 16163, XP002661526, DOI: doi:10.1073/PNAS.0702596104",PENDING
356,US,A1,US 2016/0222467 A1,125-072-122-929-105,2016-08-04,2016,US 201615099429 A,2016-04-14,US 201615099429 A;;US 201213514556 A;;IB 2010055604 W;;US 28582109 P;;US 28787209 P,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"Methods for treating breast cancer, specifically cancers resistant to treatment With one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence n a patient o one or inure of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/125-072-122-929-105,Patent Application,yes,1,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,C12Q1/68;;A61K31/4709;;A61K45/06;;C07K16/28;;C07K16/30;;G01N33/574,,1,1,039-517-628-932-733,18721898;;10.1016/j.coph.2008.08.004,"Yap (Yap et al; Current Opinions in Pharcology, vol 8, 393-412, 8/27/2008)",DISCONTINUED
357,EP,A1,EP 2510121 A1,152-346-929-347-776,2012-10-17,2012,EP 10805335 A,2010-12-06,US 28582109 P;;US 28787209 P;;IB 2010055604 W,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,,WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,WYETH LLC (2014-05-14),https://lens.org/152-346-929-347-776,Patent Application,yes,1,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,C12Q1/68,,0,0,,,,DISCONTINUED
358,CA,A1,CA 2787048 A1,059-027-220-079-736,2011-07-21,2011,CA 2787048 A,2011-01-04,US 29461510 P;;US 2011/0020080 W,2010-01-13,A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ERBB INHIBITOR,A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.,WYETH LLC,COUGHLIN CHRISTINIA MARIE;;BERKENBLIT ANNA;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEVEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/059-027-220-079-736,Patent Application,no,0,0,11,11,0,G01N33/57415;;A61P35/00;;A61P43/00;;G01N33/57415,G01N33/574,,0,0,,,,ACTIVE
359,JP,A,JP 2016169229 A,092-857-128-354-706,2016-09-23,2016,JP 2016120503 A,2016-06-17,US 28582109 P;;US 28787209 P,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"PROBLEM TO BE SOLVED: To provide methods for treating breast cancer, in particular, cancers resistant to treatment with one or more known breast cancer treating agents, as well as patient selection strategies for predicting patient response to chemotherapies.SOLUTION: The invention provides methods for treating breast cancer, in particular, cancers resistant to treatment with one or more known breast cancer treating agents, as well as strategies of patient selection for predicting patient response to chemotherapy, where the strategies comprise the steps of: detecting presence or absence in a patient of one or more of PIK3CA gene amplification, PIK3CA mutation, and decrease in PTEN protein expression; and treating a subject positive for the presence of one or more of the biomarkers by administering a pan-ErbB tyrosine kinase inhibitor to the subject.SELECTED DRAWING: None",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/092-857-128-354-706,Patent Application,no,0,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,A61K45/00;;A61K31/337;;A61K31/4196;;A61K31/436;;A61K31/4704;;A61K31/475;;A61K31/513;;A61K31/565;;A61K31/704;;A61K31/7068;;A61K38/00;;A61K39/395;;A61P15/00;;A61P35/00,,3,2,006-463-679-652-100;;049-837-860-038-088,10.1016/j.ccr.2007.08.030;;17936563;;19318484;;10.1158/1078-0432.ccr-08-1978,"CANCER CELL, vol. 12, no. 4, JPN6014053467, 2007, pages 395 - 402, ISSN: 0003701804;;CLIN CANCER RES, vol. 15, no. 7, JPN6014053471, 1 April 2009 (2009-04-01), pages 2552 - 2558, ISSN: 0003701805;;BREAST CANCER RESEARCH, vol. 7, no. 5, JPN6014053469, 2005, pages 609 - 616, ISSN: 0003575336",DISCONTINUED
360,US,A1,US 2008/0261950 A1,059-505-762-512-235,2008-10-23,2008,US 1263608 A,2008-02-04,US 1263608 A;;US 89911107 P;;US 95990107 P,2007-02-02,Compounds that inhibit cholinesterase,"Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.",COLUCID PHARMACEUTICALS INC,RUPNIAK NADIA M J;;WHITE JAMES F;;SHIOSAKI KAZUMI;;LEANDER J DAVID;;DU SHOUCHENG;;COUGHLIN DANIEL J,COLUCID PHARMACEUTICALS INC (2008-04-10),https://lens.org/059-505-762-512-235,Patent Application,yes,15,10,11,12,0,C07C271/44;;C07C271/48;;C07C271/54;;C07C271/56;;C07D211/90;;C07D213/40;;C07D215/56;;C07D243/38;;C07D267/20;;C07D333/20;;C07D401/04;;C07D405/12;;C07D487/04;;C07D499/68;;C07C2601/02;;C07C2601/14;;C07C2603/32;;C07C2603/74;;A61P1/08;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/28;;A61P25/30;;A61P25/34;;A61P27/06;;A61P27/16;;A61P31/04;;A61P31/12;;A61P37/08;;A61P43/00;;A61P9/10;;C07D211/90;;C07D215/56;;C07C271/54;;C07D405/12;;C07D267/20;;C07D213/40;;C07C271/48;;C07D401/04;;C07C271/56;;C07C271/44;;C07D243/38;;C07D333/20;;C07D487/04;;C07D499/68;;C07C2601/14;;C07C2603/74;;C07C2601/02;;C07C2603/32,A61K31/553;;A61K31/27;;A61K31/407;;A61K31/4525;;A61K31/55;;A61P25/00;;A61P25/28;;A61P25/34;;C07C271/44;;C07D223/24;;C07D405/12;;C07D413/04;;C07D487/04,514/211.11;;560/163;;514/551;;514/412;;548/453;;540/547;;514/217;;540/590;;546/197;;514/321,0,0,,,,INACTIVE
361,WO,A1,WO 2011/070499 A1,118-889-825-306-855,2011-06-16,2011,IB 2010055604 W,2010-12-06,US 28582109 P;;US 28787209 P,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.",WYETH LLC;;BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/118-889-825-306-855,Patent Application,yes,5,12,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,C12Q1/68,,54,53,006-463-679-652-100;;120-851-557-979-364;;049-837-860-038-088;;004-440-190-883-777;;082-057-478-967-176;;002-748-316-087-521;;058-924-894-496-724;;027-400-516-551-608;;030-329-378-068-384;;031-670-462-407-209;;020-297-825-165-551;;012-690-701-696-458;;000-327-302-949-25X;;038-127-123-523-803;;052-073-293-082-752;;006-463-679-652-100;;130-438-174-305-294;;076-059-062-130-42X;;035-590-445-678-854;;016-346-978-857-894;;093-710-732-335-237;;001-001-952-506-49X;;078-072-244-606-504;;086-888-204-946-581;;044-889-105-134-60X;;053-306-130-281-707;;028-000-528-837-594;;018-991-099-378-330;;082-600-475-212-300;;006-099-664-220-163;;120-851-557-979-364;;066-114-990-428-479;;020-120-360-884-359;;036-021-326-611-784;;056-680-529-882-810;;054-273-704-326-192;;076-564-633-692-352;;055-707-345-132-645;;040-863-075-524-621;;019-647-747-474-157;;009-493-898-884-338;;015-172-131-105-677;;079-971-647-932-297;;034-310-033-915-336;;029-296-191-561-722;;117-584-273-518-919;;105-954-631-721-416;;072-333-676-585-57X;;045-800-725-597-720;;065-470-438-699-384;;051-864-320-804-47X;;105-178-144-548-143;;036-169-739-820-585,10.1016/j.ccr.2007.08.030;;17936563;;16168105;;10.1186/bcr1262;;pmc1242128;;19318484;;10.1158/1078-0432.ccr-08-1978;;10.1158/1078-0432.ccr-07-1698;;17908952;;19188670;;10.1200/jco.2009.21.9170;;10.1038/nrc1609;;15864276;;17102595;;10.4161/cbt.5.11.3457;;15095477;;10.1002/path.1542;;19629070;;10.1038/nrc2664;;19573809;;pmc2752826;;10.1016/j.ccr.2009.04.012;;17341655;;10.1093/carcin/bgm052;;10.1006/abio.2000.4497;;10706796;;10.1016/j.devcel.2006.10.007;;17141160;;9228007;;10.1126/science.277.5325.567;;18794884;;10.1038/onc.2008.245;;pmc3398461;;10.1016/j.ccr.2007.08.030;;17936563;;10.1158/0008-5472.can-08-1740;;pmc2587064;;19010894;;10.1016/j.ccr.2004.06.022;;15324695;;10.1007/s10911-009-9116-x;;19259796;;10.1053/hupa.2002.124721;;12055674;;10.1002/gcc.20560;;18383208;;10.1248/bpb.30.1624;;17827710;;19345329;;10.1016/j.ccr.2009.02.012;;pmc2673492;;10.1373/clinchem.2007.098376;;18375489;;19261849;;10.1073/pnas.0806514106;;pmc2660768;;17377809;;10.1007/s00428-006-0358-3;;15928251;;10.1210/jc.2004-2281;;11358835;;9916799;;10.1038/5042;;10851074;;10.1038/sj.onc.1203597;;16168105;;10.1186/bcr1262;;pmc1242128;;18089785;;10.1158/0008-5472.can-07-2536;;10.1038/ng0497-356;;09090379;;9090379;;9072974;;10.1126/science.275.5308.1943;;9187108;;9860981;;10.1073/pnas.95.26.15406;;pmc28055;;10.1053/hp.2000.6713;;10821499;;10.1038/modpathol.3880371;;11454999;;10.1038/sj.onc.1203183;;10597304;;10.1097/01.cco.0000198021.99347.b9;;16357568;;9671321;;10.1038/sj.onc.1201940;;10.1158/0008-5472-can-04-3913;;15805248;;17575221;;10.1158/1078-0432.ccr-06-1609;;10514407;;10.1016/s0002-9440(10)65227-3;;pmc1867038;;10.1146/annurev.biochem.70.1.247;;11395408;;10564676;;10.1093/jnci/91.22.1922;;15287024;;10.1002/gcc.20062;;17681183;;10.1053/j.gastro.2007.05.022;;pmc4285346;;10.1074/jbc.m109.006676;;pmc2709372;;19419954;;18676830;;pmc2680495;;10.1158/0008-5472.can-07-6854;;pmc2042178;;17911267;;10.1073/pnas.0702596104;;10.1158/0008-5472.can-07-2488;;18199536;;20501798;;10.1158/1535-7163.mct-09-1171,"BERNS KATRIEN ET AL: ""A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer"", CANCER CELL, CELL PRESS, US, vol. 12, no. 4, 16 October 2007 (2007-10-16), pages 395 - 402, XP002592491, ISSN: 1535-6108, [retrieved on 20071015], DOI: DOI:10.1016/J.CCR.2007.08.030;;WU GUOJUN ET AL: ""Somatic mutation and gain of copy number of PIK3CA in human breast cancer"", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 7, no. 5, 31 May 2005 (2005-05-31), pages R609 - R616, XP021011863, ISSN: 1465-5411, DOI: DOI:10.1186/BCR1262;;WONG K-K ET AL: ""A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors"", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 15, no. 7, 1 April 2009 (2009-04-01), pages 2552 - 2558, XP002591681, ISSN: 1078-0432, [retrieved on 20090324], DOI: DOI:10.1158/1078-0432.CCR-08-1978;;ELLIS MATTHEW J ET AL: ""PIKing the Winner for Phosphatidylinositol 3-Kinase Inhibitors in ErbB2-Positive Breast Cancer: Let's Not PTENed It's Easy!"", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 19, 1 October 2007 (2007-10-01), pages 5661 - 5662, XP008104382, ISSN: 1078-0432, DOI: DOI:10.1158/1078-0432.CCR-07-1698;;BERNS K ET AL., CANCER CELL, vol. 12, no. 4, October 2007 (2007-10-01), pages 395 - 402;;ALLEGRA CJ; JESSUP JM; SOMERFIELD MR ET AL.: ""American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy"", J CLIN ONCOL, vol. 27, 2009, pages 2091 - 2096;;HYNES NE; LANE HA: ""ERBB receptors and cancer: the complexity of targeted inhibitors"", NAT REV CANCER, vol. 5, 2005, pages 341 - 354;;ZHOU Q; CHEUNG YB; JADA SR ET AL.: ""EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues"", CANCER BIOL THER, vol. 5, 2006, pages 1445 - 1449;;BUERGER H; PACKEISEN J; BOECKER A ET AL.: ""Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study"", J PATHOL, vol. 203, 2004, pages 545 - 550;;ENGELMAN JA: ""Targeting P13K signalling in cancer: opportunities, challenges and limitations"", NAT REV CANCER, vol. 9, 2009, pages 550 - 562;;VASUDEVAN KM; BARBIE DA; DAVIES MA ET AL.: ""AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer"", CANCER CELL, vol. 16, 2009, pages 21 - 32;;BLANCO-APARICIO C; RENNER O; LEAL JF ET AL.: ""PTEN, more than the AKT pathway"", CARCINOGENESIS, vol. 28, 2007, pages 1379 - 1386;;MAEHAMA T; TAYLOR GS; SLAMA JT ET AL.: ""A sensitive assay for phosphoinositide phosphatases"", ANAL BIOCHEM, vol. 279, 2000, pages 248 - 250;;GUERTIN DA; STEVENS DM; THOREEN CC ET AL.: ""Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1"", DEV CELL, vol. 11, 2006, pages 859 - 871;;STOKOE D; STEPHENS LR; COPELAND T ET AL.: ""Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B"", SCIENCE, vol. 277, 1997, pages 567 - 570;;YUAN TL; CANTLEY LC: ""P13K pathway alterations in cancer: variations on a theme"", ONCOGENE, vol. 27, 2008, pages 5497 - 5510;;BERNS K; HORLINGS HM; HENNESSY BT ET AL.: ""A functional genetic approach identifies the P13K pathway as a major determinant of trastuzumab resistance in breast cancer"", CANCER CELL, vol. 12, 2007, pages 395 - 402;;EICHHORN PJ; GILI M; SCALTRITI M ET AL.: ""Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235"", CANCER RES, vol. 68, 2008, pages 9221 - 9230;;NAGATA Y; LAN KH; ZHOU X ET AL.: ""PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.[see comment]"", CANCER CELL, vol. 6, 2004, pages 117 - 127;;BEDARD PL; CARDOSO F; PICCART-GEBHART MJ: ""Stemming resistance to HER-2 targeted therapy"", J MAMMARY GLAND BIOL NEOPLASIA, vol. 14, 2009, pages 55 - 66;;BOSE S; CRANE A; HIBSHOOSH H ET AL.: ""Reduced expression of PTEN correlates with breast cancer progression"", HUM PATHOL, vol. 33, 2002, pages 405 - 409;;BETTENDORF O; SCHMIDT H; STAEBLER A ET AL.: ""Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate"", GENES CHROMOSOMES CANCER, vol. 47, 2008, pages 565 - 572;;MAEHAMA T: ""PTEN: its deregulation and tumorigenesis"", BIOL PHARM BULL, vol. 30, 2007, pages 1624 - 1627;;YIM EK; PENG G; DAI H ET AL.: ""Rak functions as a tumor suppressor by regulating PTEN protein stability and function"", CANCER CELL, vol. 15, 2009, pages 304 - 314;;BOARD RE; THELWELL NJ; RAVETTO PF ET AL.: ""Multiplexed assays for detection of mutations in PIK3CA"", CLIN CHEM, vol. 54, 2008, pages 757 - 760;;SALVESEN HB; CARTER SL; MANNELQVIST M ET AL.: ""Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of P13 kinase activation"", PROC NATL ACAD SCI USA, vol. 106, 2009, pages 4834 - 4839;;WOENCKHAUS J; STEGER K; STURM K ET AL.: ""Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer"", VIRCHOWS ARCH, vol. 450, 2007, pages 387 - 395;;WU G; MAMBO E; GUO Z ET AL.: ""Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors"", J CLIN ENDOCRINOL METAB, vol. 90, 2005, pages 4688 - 4693;;REDON R; MULLER D; CAULEE K ET AL.: ""A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains"", CANCER RES, vol. 61, 2001, pages 4122 - 4129;;SHAYESTEH L; LU Y; KUO WL ET AL.: ""PIK3CA is implicated as an oncogene in ovarian cancer"", NAT GENET, vol. 21, 1999, pages 99 - 102;;MA YY; WEI SJ; LIN YC ET AL.: ""PIK3CA as an oncoqene in cervical cancer"", ONCOGENE, vol. 19, 2000, pages 2739 - 2744;;WU G; XING M; MAMBO E ET AL.: ""Somatic mutation and gain of copy number of PIK3CA in human breast cancer"", BREAST CANCER RES, vol. 7, 2005, pages R609 - 616;;ADELAIDE J; FINETTI P; BEKHOUCHE I ET AL.: ""Integrated profiling of basal and luminal breast cancers"", CANCER RES, vol. 67, 2007, pages 11565 - 11575;;STECK PA; PERSHOUSE MA; JASSER SA ET AL.: ""Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers"", NATURE GENETICS, vol. 15, 1997, pages 356 - 362;;LI J; YEN C; LIAW D ET AL.: ""PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.[see comment]"", SCIENCE, vol. 275, 1997, pages 1943 - 1947;;LI DM; SUN H: ""TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta"", CANCER RES, vol. 57, 1997, pages 2124 - 2129;;LI DM; SUN H: ""PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells"", PROC NATL ACAD SCI USA, vol. 95, 1998, pages 15406 - 15411;;RUBIN MA; GERSTEIN A; REID K ET AL.: ""10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,NO) prostate cancer"", HUM PATHOL, vol. 31, 2000, pages 504 - 508;;DEPOWSKI PL; ROSENTHAL SI; ROSS JS: ""Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer"", MOD PATHOL, vol. 14, 2001, pages 672 - 676;;LU Y; LIN YZ; LAPUSHIN R ET AL.: ""The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells"", ONCOGENE, vol. 18, 1999, pages 7034 - 7045;;SAMUELS Y; ERICSON K: ""Oncogenic P13K and its role in cancer"", CURR OPIN ONCOL, vol. 18, 2006, pages 77 - 82;;BOSE S; WANG SI; TERRY MB ET AL.: ""Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas"", ONCOGENE, vol. 17, 1998, pages 123 - 127;;SAAL LH; HOLM K; MAURER M ET AL.: ""PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma"", CANCER RES, vol. 65, 2005, pages 2554 - 2559;;PEREZ-TENORIO G; ALKHORI L; OLSSON B ET AL.: ""PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer"", CLIN CANCER RES, vol. 13, 2007, pages 3577 - 3584;;PERREN A; WENG LP; BOAG AH ET AL.: ""Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast"", AM J PATHOL, vol. 155, 1999, pages 1253 - 1260;;MAEHAMA T; TAYLOR GS; DIXON JE: ""PTEN and myotubularin: novel phosphoinositide phosphatases"", ANNU REV BIOCHEM, vol. 70, 2001, pages 247 - 279;;ALI IU; SCHRIML LM; DEAN M: ""Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity"", J NATL CANCER INST, vol. 91, 1999, pages 1922 - 1932;;GARCIA JM; SILVA J; PENA C ET AL.: ""Promoter methylation of the PTEN gene is a common molecular change in breast cancer"", GENES CHROMOSOMES CANCER, vol. 41, 2004, pages 117 - 124;;MENG F; HENSON R; WEHBE-JANEK H ET AL.: ""MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer"", GASTROENTEROLOGY, vol. 133, 2007, pages 647 - 658;;HUANG TH; WU F; LOEB GB ET AL.: ""Upregulation of miR-21 by HER2/neu signaling promotes cell invasion"", J BIOL CHEM., 2009;;STEMKE-HALE K; GONZALEZ-ANGULO AM; LLUCH A ET AL.: ""An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer"", CANCER RES, vol. 68, 2008, pages 6084 - 6091;;ZHOU J; WULFKUHLE J; ZHANG H ET AL.: ""Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance"", PROC NATL ACAD SCI USA, vol. 104, 2007, pages 16158 - 16163;;YANG H; KONG W; HE L ET AL.: ""MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN"", CANCER RESEARCH, vol. 68, 2008, pages 425 - 433;;O'BRIEN N ET AL.: ""Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib"", MOL CANCER THER, vol. 9, no. 6, 2010, pages 1489 - 1502",PENDING
362,EP,A1,EP 4149609 A1,120-792-580-656-929,2023-03-22,2023,EP 21730725 A,2021-05-13,US 202063024483 P;;US 2021/0032279 W,2020-05-13,SYSTEM AND METHOD FOR SKIN REJUVENATION USING IMPEDANCE MONITORING,,CYNOSURE LLC,BOLL JAMES;;MIRKOV MIRKO GEORGIEV;;MASSE DANIEL;;BRUCE SAMUEL;;ALBERTELLI CHRISTIAN;;COUGHLIN JAMES;;SONNENSHEIN DAVID;;SIMON JEFFREY,,https://lens.org/120-792-580-656-929,Patent Application,yes,0,0,9,9,0,A61B2018/00577;;A61B2018/0047;;A61B2018/0016;;A61B2018/143;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B18/12;;A61B18/12;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B2018/00708;;A61B2018/143;;A61B2018/0047;;A61B2018/00577;;A61N1/40,A61N1/32;;A61B18/12;;A61N1/04;;A61N1/36,,0,0,,,,PENDING
363,JP,A,JP 2019052187 A,143-973-937-564-136,2019-04-04,2019,JP 2018246698 A,2018-12-28,US 28582109 P;;US 28787209 P,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"To provide methods for treating breast cancer, in particular, cancers resistant to treatment with one or more known breast cancer treating agents, as well as patient selection strategies for predicting patient response to chemotherapies.SOLUTION: The invention provides methods for treating breast cancer, in particular, cancers resistant to treatment with one or more known breast cancer treating agents, as well as strategies of patient selection for predicting patient response to chemotherapy, where the strategies comprise the steps of: detecting presence or absence in a patient of one or more of PIK3CA gene amplification, PIK3CA mutation, and decrease in PTEN protein expression; and treating a subject positive for the presence of one or more of the biomarkers by administering a pan-ErbB tyrosine kinase inhibitor to the subject.SELECTED DRAWING: None",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/143-973-937-564-136,Patent Application,no,1,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,A61K45/00;;A61K31/472;;A61K39/395;;G01N33/53;;G01N33/574;;G01N33/68,,3,0,,,"CLIN CANCER RES, vol. 15, no. 7, JPN6014053471, 1 April 2009 (2009-04-01), pages 2552 - 2558, ISSN: 0004210781;;CANCER CELL, vol. 12, no. 4, JPN6014053467, 2007, pages 395 - 402, ISSN: 0004210782;;BREAST CANCER RESEARCH, vol. 7, no. 5, JPN6014053469, 2005, pages 609 - 616, ISSN: 0004210783",DISCONTINUED
364,JP,A,JP 2016053579 A,162-349-610-506-292,2016-04-14,2016,JP 2015226299 A,2015-11-19,US 29461510 P,2010-01-13,CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND PREDICTS DRUG RESPONSE TO PAN-ErbB INHIBITOR,PROBLEM TO BE SOLVED: To provide a cut point in PTEN protein expression that accurately identifies breast cancers and predicts a drug response to a PAN-ErbB inhibitor.SOLUTION: A method comprises: obtaining a tumor cell and a non-tumorigenic cell from a breast cancer patient; performing quantitative measurement of PTEN protein expression in the tumor cell and the non-tumorigenic cell; calculating a normalized PTEN protein expression score by comparing these two quantitative measurements of PTEN protein expression.SELECTED DRAWING: None,WYETH LLC,CHRISTINIA MARIE COUGHLIN;;ANNA BERKENBLIT;;JAY MARSHALL FEINGOLD;;DANIEL STEVEN JOHNSTON;;STRAHS ANDREW LOUIS;;CHARLES MICHAEL ZACHARCHUK,,https://lens.org/162-349-610-506-292,Patent Application,no,4,0,11,11,0,G01N33/57415;;A61P35/00;;A61P43/00;;G01N33/57415,G01N33/68;;A61K39/395;;A61K45/00;;A61P35/00;;A61P43/00;;C12Q1/06;;C12Q1/42;;G01N33/574;;G01N37/00,,0,0,,,,PENDING
365,US,A1,US 2019/0271047 A1,012-662-776-965-917,2019-09-05,2019,US 201916416083 A,2019-05-17,US 201916416083 A;;US 201615099429 A;;US 201213514556 A;;IB 2010055604 W;;US 28787209 P;;US 28582109 P,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS,"Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/012-662-776-965-917,Patent Application,yes,0,0,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,C12Q1/6886;;A61K31/4709;;A61K39/395;;A61K45/06;;C07K16/28;;C07K16/30;;G01N33/574,,0,0,,,,DISCONTINUED
366,JP,A,JP 2011121944 A,184-084-061-531-707,2011-06-23,2011,JP 2010273484 A,2010-12-08,US 28582109 P;;US 28787209 P,2009-12-11,PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKER,"<P>PROBLEM TO BE SOLVED: To provide methods for treating breast cancer specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy. <P>SOLUTION: The methods and strategies for treating breast cancer includes steps for: detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression; and treating a patient positive for the presence of one or more thereof by administering to the subject a pan-ErbB tyrosine kinase inhibitor. <P>COPYRIGHT: (C)2011,JPO&INPIT",WYETH LLC,BERKENBLIT ANNA;;COUGHLIN CHRISTINA MARIE;;FEINGOLD JAY MARSHALL;;JOHNSTON DANIEL STEPHEN;;STRAHS ANDREW LOUIS;;ZACHARCHUK CHARLES MICHAEL,,https://lens.org/184-084-061-531-707,Patent Application,no,0,2,16,16,0,C12Q2600/106;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P15/00;;A61P35/00;;A61P43/00;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q1/6886;;A61K31/4709;;A61K39/3955;;A61K45/06;;C07K16/2863;;C07K16/3015;;C07K2317/24;;C07K2317/76;;G01N33/57415;;G01N2333/47,A61K45/00;;A61K31/337;;A61K31/4196;;A61K31/436;;A61K31/4704;;A61K31/475;;A61K31/513;;A61K31/565;;A61K31/675;;A61K31/704;;A61K31/7068;;A61K38/00;;A61K39/395;;A61P15/00;;A61P35/00;;G01N33/53;;G01N33/68,,3,0,,,"CANCER CELL, vol. 12, no. 4, JPN6014053467, 2007, pages 395 - 402, ISSN: 0002967856;;CLIN CANCER RES, vol. 15, no. 7, JPN6014053471, 1 April 2009 (2009-04-01), pages 2552 - 2558, ISSN: 0002967857;;BREAST CANCER RESEARCH, vol. 7, no. 5, JPN6014053469, 2005, pages 609 - 616, ISSN: 0002967858",DISCONTINUED
367,AU,A,AU 2001/024532 A,169-367-349-702-76X,2001-07-09,2001,AU 2001/024532 A,2000-12-21,US 47421399 A;;US 0035093 W,1999-12-29,Conformal load bearing antenna structure,,NORTHROP GRUMMAN CORP,ALT KEVIN HERMAN;;DURHAM MICHAEL DAVID;;LOCKYER ALLEN JOHN;;COUGHLIN DANIEL PATRICK;;GATH JAMES KENNETH;;KUDVA JAYANTH NANDALKE,,https://lens.org/169-367-349-702-76X,Patent Application,no,0,0,8,8,0,H01Q9/0407;;H01Q9/0407;;H01Q1/28;;H01Q1/28;;H01Q1/282;;H01Q1/282,H01Q1/28;;H01Q9/04,,0,0,,,,DISCONTINUED
368,CA,A1,CA 2470156 A1,010-446-777-922-178,2003-06-26,2003,CA 2470156 A,2002-12-17,EP 0214355 W;;US 34095301 P,2001-12-19,.BETA.-AMINO-.ALPHA.-CYANOACRYLATES AND THEIR USE AS HERBICIDES,".beta.-Amino-.alpha.-Cyanoacrylates of formula I where the variables have the following meanings: R1 is n-alkyl, n-alkenyl or alkoxyalkyl; R2,R3 are alkyl, which may be partially or fully halogenated and/or may carry a substituent from the group consisting of cyano, alkoxy, haloalkoxy, alkylthio, haloalkylthio, C1-C6-alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl and haloalkylsulfonyl, are alkenyl or alkynyl; or R2 and R3 together with the carbon atom to which they are attached form a cycloalkyl ring in which one or two nonadjacent CH2 groups may be replaced by oxygen or sulfur, and where the cycloalkyl ring may be substituted by halogen or alkyl; R4 is hydrogen, halogen, cyano or alkyl, where the substituents R2, R3 and R4 or two of the radicals R2, R3 and R4 are not simultaneously methyl, and their agriculturally useful salts, processes and intermediates for their preparation; and the use of these compounds or of compositions comprising these compounds for controlling undesirable plants are described.",BASF AG,COUGHLIN DANIEL J;;FLEMING LINDA B;;GUACIARO MICHAEL A;;HUPPATZ JOHN L;;MARAVETZ LESTER L;;EVERSON ALBERT C,,https://lens.org/010-446-777-922-178,Patent Application,no,0,0,13,13,0,A01N37/42;;A01N37/44;;A01N43/08;;A01N43/16;;A01N43/18;;C07C255/23;;C07C255/30;;C07C255/31;;C07C323/60;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C255/23;;A01N43/18;;C07D307/16;;C07C323/60;;C07D309/04;;A01N37/42;;C07D309/06;;A01N37/44;;C07C255/31;;C07D307/14;;A01N43/16;;C07C255/30;;A01N43/08;;C07C2601/02;;C07C2601/14;;C07C2601/08,C07D335/02;;A01N37/42;;A01N37/44;;A01N41/12;;A01N43/08;;A01N43/16;;A01N43/18;;C07C253/30;;C07C255/23;;C07C255/30;;C07C323/58;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06,,0,0,,,,DISCONTINUED
369,WO,A1,WO 2001/048863 A1,046-275-643-532-716,2001-07-05,2001,US 0035093 W,2000-12-21,US 47421399 A,1999-12-29,CONFORMAL LOAD BEARING ANTENNA STRUCTURE,"A conformal load bearing antenna structure (10) for attachment to an aircraft having an outer skin. The conformal load bearing antenna structure comprises a top face sheet (12) and an end fed radiating element (14) disposed thereon. Disposed adjacent to the top face sheet is a dielectric (16) and a structural core (18) disposed adjacent to the dielectric. In the preferred embodiment, a bottom face sheet (22) is disposed adjacent to the structural core and an absorber (24) is disposed adjacent to the bottom face sheet. Accordingly, the top face sheet, the dielectric, the structural core, and the bottom face sheet are configured to provide structural strength to the aircraft when the antenna is attached to the outer skin thereof.",NORTHROP GRUMMAN CORP,ALT KEVIN HERMAN;;DURHAM MICHAEL DAVID;;LOCKYER ALLEN JOHN;;COUGHLIN DANIEL PATRICK;;GATH JAMES KENNETH;;KUDVA JAYANTH NANDALKE,,https://lens.org/046-275-643-532-716,Patent Application,yes,2,0,8,8,0,H01Q9/0407;;H01Q9/0407;;H01Q1/28;;H01Q1/28;;H01Q1/282;;H01Q1/282,H01Q1/28;;H01Q9/04,,1,0,,,See also references of EP 1261997A4,PATENTED
370,EP,A1,EP 1261997 A1,079-153-757-193-187,2002-12-04,2002,EP 00988310 A,2000-12-21,US 0035093 W;;US 47421399 A,1999-12-29,CONFORMAL LOAD BEARING ANTENNA STRUCTURE,,NORTHROP GRUMMAN CORP,ALT KEVIN HERMAN;;DURHAM MICHAEL DAVID;;LOCKYER ALLEN JOHN;;COUGHLIN DANIEL PATRICK;;GATH JAMES KENNETH;;KUDVA JAYANTH NANDALKE,,https://lens.org/079-153-757-193-187,Patent Application,yes,0,0,8,8,0,H01Q9/0407;;H01Q9/0407;;H01Q1/28;;H01Q1/28;;H01Q1/282;;H01Q1/282,H01Q1/28;;H01Q9/04,,0,0,,,,EXPIRED
371,EP,A1,EP 1458674 A1,087-739-497-468-559,2004-09-22,2004,EP 02804907 A,2002-12-17,EP 0214355 W;;US 34095301 P,2001-12-19,BETA-AMINO-ALPHA-CYANOACRYLATES AND THEIR USE AS HERBICIDES,,BASF AG,EVERSON ALBERT C;;COUGHLIN DANIEL J;;GUACIARO MICHAEL A;;FLEMING LINDA B;;MARAVETZ LESTER L;;HUPPATZ JOHN L,BASF SE (2008-03-05),https://lens.org/087-739-497-468-559,Patent Application,yes,0,0,13,13,0,A01N37/42;;A01N37/44;;A01N43/08;;A01N43/16;;A01N43/18;;C07C255/23;;C07C255/30;;C07C255/31;;C07C323/60;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C255/23;;A01N43/18;;C07D307/16;;C07C323/60;;C07D309/04;;A01N37/42;;C07D309/06;;A01N37/44;;C07C255/31;;C07D307/14;;A01N43/16;;C07C255/30;;A01N43/08;;C07C2601/02;;C07C2601/14;;C07C2601/08,C07D335/02;;A01N37/42;;A01N37/44;;A01N41/12;;A01N43/08;;A01N43/16;;A01N43/18;;C07C253/30;;C07C255/23;;C07C255/30;;C07C323/58;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06,,0,0,,,,EXPIRED
372,AU,A,AU 1985/048071 A,119-127-931-764-660,1986-04-08,1986,AU 1985/048071 A,1985-09-10,US 65037584 A;;US 65075484 A,1984-09-13,ANTIBODY THERAPEUTIC AGENT CONJUGATES,,CYTOGEN CORP,FRANK GOERS JOHN WALTER;;DALTON KING HURLEY;;CHYI LEE;;JAMES COUGHLIN DANIEL;;CHARLES SIEGEL RICHARD;;DENNIS RODWELL JOHN,,https://lens.org/119-127-931-764-660,Patent Application,no,0,1,12,90,0,A61K51/1093;;A61K41/0042;;A61K41/0057;;A61K41/0071;;A61K51/10;;A61K2121/00,A61K41/00;;A61K51/10,,0,0,,,,EXPIRED
373,US,B2,US 7842832 B2,048-179-823-535-255,2010-11-30,2010,US 49956804 A,2004-06-21,US 49956804 A;;EP 0214355 W;;US 34095301 P,2001-12-19,β-amino-α-cyanoacrylates and their use as herbicides,"β-Amino-α-Cyanoacrylates of formula I where the variables have the following meanings: R 1 is n-alkyl, n-alkenyl or alkoxyalkyl; R 2 ,R 3 are alkyl, which may be partially or fully halogenated and/or may carry a substituent from the group consisting of cyano, alkoxy, haloalkoxy, alkylthio, haloalkylthio, C 1 -C 6 -alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl and haloalkylsulfonyl, are alkenyl or alkynyl; or R 2 and R 3 together with the carbon atom to which they are attached form a cycloalkyl ring in which one or two nonadjacent CH 2 groups may be replaced by oxygen or sulfur, and where the cycloalkyl ring may be substituted by halogen or alkyl; R 4 is hydrogen, halogen, cyano or alkyl, where the substituents R 2 , R 3 and R 4 or two of the radicals R 2 , R 3 and R 4 are not simultaneously methyl, and their agriculturally useful salts, processes and intermediates for their preparation; and the use of these compounds or of compositions comprising these compounds for controlling undesirable plants are described.",BASF SE,EVERSON ALBERT C;;COUGHLIN DANIEL J;;GUACIARO MICHAEL A;;FLEMING LINDA B;;MARAVETZ LESTER L;;HUPPATZ JOHN L,BASF SE (2003-01-08),https://lens.org/048-179-823-535-255,Granted Patent,yes,5,0,13,13,0,A01N37/42;;A01N37/44;;A01N43/08;;A01N43/16;;A01N43/18;;C07C255/23;;C07C255/30;;C07C255/31;;C07C323/60;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C255/23;;A01N43/18;;C07D307/16;;C07C323/60;;C07D309/04;;A01N37/42;;C07D309/06;;A01N37/44;;C07C255/31;;C07D307/14;;A01N43/16;;C07C255/30;;A01N43/08;;C07C2601/02;;C07C2601/14;;C07C2601/08,C07C255/07;;A01N37/34;;C07D335/02;;A01N37/42;;A01N37/44;;A01N41/12;;A01N43/08;;A01N43/16;;A01N43/18;;C07C253/30;;C07C255/23;;C07C255/30;;C07C323/58;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06,558/443;;504/312,8,1,057-408-697-130-70X,10.1515/znc-1991-1-215,"Hayashi, et al. (AN 1968:82967 ZCAPLUS, abstract of Bulletin of Chemical SOciety of Japan (1967), 40(9), 2160-3).;;GLickman et al. (AN 1945:20676, ZCAPLUS, abstract of J. of Am. Chem Soc. (1945), 67, 1012-16).;;Campbell et al. (AN 1911:8811, ZCAPLUS, abstract of Proc. Chem. Soc. (1911), 26, 2296).;;Campbell et al. (AN 1911:8812, ZCAPLUS, abstract of J. of the Chem. Soc. Transcation (1910), 97, 2418-25).;;Baba et al. (Bull. Chem. Soc. Japan, 42 (1969) 1653-59).;;Hiramatsu et al., ""Herbicide"" English Abstract of document.;;Hiramatsu et al., ""Herbicide, Weed Killing Method and Plant-Growth Regulator"" English Abstract of document.;;McFadden et al,. ""X-Ray Structure Analysis of a Cyanoacrylate Inhibitor of Photosystem II Electron Transport"" Zeitschrift für Naturforschung C, Journal of Biosciences 46(1-2), 93-98 (1991).",INACTIVE
374,EP,A4,EP 1261997 A4,180-633-211-994-963,2004-08-18,2004,EP 00988310 A,2000-12-21,US 0035093 W;;US 47421399 A,1999-12-29,CONFORMAL LOAD BEARING ANTENNA STRUCTURE,,NORTHROP GRUMMAN CORP,ALT KEVIN HERMAN;;DURHAM MICHAEL DAVID;;LOCKYER ALLEN JOHN;;COUGHLIN DANIEL PATRICK;;GATH JAMES KENNETH;;KUDVA JAYANTH NANDALKE,,https://lens.org/180-633-211-994-963,Search Report,no,2,0,8,8,0,H01Q9/0407;;H01Q9/0407;;H01Q1/28;;H01Q1/28;;H01Q1/282;;H01Q1/282,H01Q1/28;;H01Q9/04,,1,0,,,See also references of WO 0148863A1,EXPIRED
375,EP,B1,EP 1261997 B1,121-104-822-351-920,2006-10-18,2006,EP 00988310 A,2000-12-21,US 0035093 W;;US 47421399 A,1999-12-29,CONFORMAL LOAD BEARING ANTENNA STRUCTURE,,NORTHROP GRUMMAN CORP,ALT KEVIN HERMAN;;DURHAM MICHAEL DAVID;;LOCKYER ALLEN JOHN;;COUGHLIN DANIEL PATRICK;;GATH JAMES KENNETH;;KUDVA JAYANTH NANDALKE,,https://lens.org/121-104-822-351-920,Granted Patent,yes,4,2,8,8,0,H01Q9/0407;;H01Q9/0407;;H01Q1/28;;H01Q1/28;;H01Q1/282;;H01Q1/282,H01Q1/28;;H01Q9/04,,0,0,,,,EXPIRED
376,EP,B1,EP 1458674 B1,006-114-640-040-451,2010-02-24,2010,EP 02804907 A,2002-12-17,EP 0214355 W;;US 34095301 P,2001-12-19,BETA-AMINO-ALPHA-CYANOACRYLATES AND THEIR USE AS HERBICIDES,,BASF SE,EVERSON ALBERT C;;COUGHLIN DANIEL J;;GUACIARO MICHAEL A;;FLEMING LINDA B;;MARAVETZ LESTER L;;HUPPATZ JOHN L,BASF SE (2008-03-05),https://lens.org/006-114-640-040-451,Granted Patent,yes,3,0,13,13,0,A01N37/42;;A01N37/44;;A01N43/08;;A01N43/16;;A01N43/18;;C07C255/23;;C07C255/30;;C07C255/31;;C07C323/60;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C255/23;;A01N43/18;;C07D307/16;;C07C323/60;;C07D309/04;;A01N37/42;;C07D309/06;;A01N37/44;;C07C255/31;;C07D307/14;;A01N43/16;;C07C255/30;;A01N43/08;;C07C2601/02;;C07C2601/14;;C07C2601/08,C07C255/23;;C07D335/02;;A01N37/34;;A01N37/42;;A01N37/44;;A01N41/12;;A01N43/08;;A01N43/16;;A01N43/18;;C07C253/30;;C07C255/30;;C07C255/31;;C07C323/58;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07D309/20,,3,0,,,"A.F. CAMPBELL ET AL.: ""An Instance Illustrating the Stability of the Four-Carbon Ring"" JOURNAL OF THE CHEMICAL SOCIETY., 1910, pages 2418-2425, XP008016046 LETCHWORTH GB;;TOSHIO HAYASHI ET AL.: ""Studies on Geometric Isomerism by Nuclear Magnetic Resonance. IV. Structure of alpha-Cyano-beta-amino-beta-alkylacrylic Esters"" BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN., vol. 40, no. 9, September 1967 (1967-09), pages 2160-2162, XP002237804 TOKYO JP cited in the application;;TOSHIO HAYASHI ET AL. : ""Studies on Geometric Isomerism by Nuclear Magnetic Resonance. I. Stereochemistry of alpha-Cyano-beta-alkoxy-beta-alkylacrylic Esters"" JOURNAL OF ORGANIC CHEMISTRY, vol. 30, no. 3, 12 March 1965 (1965-03-12), pages 695-699, XP002237805 EASTON US",EXPIRED
377,US,B1,US 6198445 B1,047-884-132-680-936,2001-03-06,2001,US 47421399 A,1999-12-29,US 47421399 A,1999-12-29,Conformal load bearing antenna structure,"A conformal load bearing antenna structure for attachment to an aircraft having an outer skin. The conformal load bearing antenna structure comprises a top face sheet and an end fed radiating element disposed thereon. Disposed adjacent to the top face sheet is a dielectric and a structural core disposed adjacent to the dielectric. In the preferred embodiment, a bottom face sheet is disposed adjacent to the structural core and an absorber is disposed adjacent to the bottom face sheet. Accordingly, the top face sheet, the dielectric, the structural core, and the bottom face sheet are configured to provide structural strength to the aircraft when the antenna is attached to the outer skin thereof.",NORTHROP GRUMMAN CORP,ALT KEVIN HERMAN;;DURHAM MICHAEL DAVID;;LOCKYER ALLEN JOHN;;COUGHLIN DANIEL PATRICK;;GATH JAMES KENNETH;;KUDVA JAYANTH NANDALKE,NORTHROP GRUMMAN CORPORATION (2000-03-07),https://lens.org/047-884-132-680-936,Granted Patent,yes,25,70,8,8,0,H01Q9/0407;;H01Q9/0407;;H01Q1/28;;H01Q1/28;;H01Q1/282;;H01Q1/282,H01Q1/28;;H01Q9/04,343/705;;343/872;;343/895,0,0,,,,EXPIRED
378,US,A,US 5156840 A,084-851-274-301-525,1992-10-20,1992,US 32788189 A,1989-03-23,US 32788189 A;;US 35631582 A;;US 44205082 A;;US 65037584 A,1982-03-09,Amine-containing porphyrin derivatives,The invention relates to amine-containing porphyrin derivatives. Theporphyrins can be used as photosensitizers which are useful as therapeutic agents. Also described are methods for preparing conjugates in which a porphyrin derivative is covalently attached to an antibody or antibody fragment. In vivo therapeutic methods utilizing the conjugates are also desired.,CYTOGEN CORP,GOERS JOHN W F;;LEE CHYI;;COUGHLIN DANIEL J;;ALVAREZ VERNON L;;RODWELL JOHN D;;MCKEARN THOMAS J,CYTOGEN CORPORATION 600 COLLEGE ROAD EAST FORRESTAL RESEARCH CENTER PRINCETON NJ 08540 A CORP. OF DE (1989-03-13),https://lens.org/084-851-274-301-525,Granted Patent,yes,0,153,1,90,0,A61K41/0042;;A61K41/0042;;A61K41/0071;;A61K41/0071;;A61K47/68;;A61K47/68;;A61K47/6889;;A61K47/6889;;A61K51/10;;A61K51/10;;A61K51/1093;;A61K51/1093;;A61K2121/00;;A61K2121/00;;C07K5/0804;;C07K5/0804;;G01N33/531;;G01N33/531;;G01N33/54353;;G01N33/54353,A61K41/00;;A61K47/48;;A61K51/10;;C07K5/083;;G01N33/531;;G01N33/543,424/85.91;;514/410,5,2,090-802-635-099-729;;038-806-033-169-358,6185591;;10.4049/jimmunol.130.3.1473;;6241684,"Dougherty, 1983, in Porphyrin Photosensization, New York Plenum Publishing Corp. pp. 3 13.;;Hasegawa et al., 1978, Chem. Abstracts 89(13): 29 Abstract No 1107732.;;Mew et al., 1983, J. Immunol. 130(3): 1473 1477.;;Ocampo et al., 1985, J. Chem. Soc. Commun. 4: 198 200.;;Wat et al., 1984, Prog. Clin. Biol. Res. 170: 351 359.",EXPIRED
379,DE,D1,DE 60235492 D1,125-717-348-683-430,2010-04-08,2010,DE 60235492 T,2002-12-17,US 34095301 P;;EP 0214355 W,2001-12-19,BETA-AMINO-ALPHA-CYANOACRYLATE UND DEREN VERWENDUNG ALS HERBIZIDE,,BASF SE,EVERSON ALBERT C;;COUGHLIN DANIEL J;;GUACIARO MICHAEL A;;FLEMING LINDA B;;MARAVETZ LESTER L;;HUPPATZ JOHN L,,https://lens.org/125-717-348-683-430,Granted Patent,no,0,0,13,13,0,A01N37/42;;A01N37/44;;A01N43/08;;A01N43/16;;A01N43/18;;C07C255/23;;C07C255/30;;C07C255/31;;C07C323/60;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C255/23;;A01N43/18;;C07D307/16;;C07C323/60;;C07D309/04;;A01N37/42;;C07D309/06;;A01N37/44;;C07C255/31;;C07D307/14;;A01N43/16;;C07C255/30;;A01N43/08;;C07C2601/02;;C07C2601/14;;C07C2601/08,C07C255/23;;C07D335/02;;A01N37/34;;A01N37/42;;A01N37/44;;A01N41/12;;A01N43/08;;A01N43/16;;A01N43/18;;C07C253/30;;C07C255/30;;C07C255/31;;C07C323/58;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07D309/20,,0,0,,,,EXPIRED
380,CN,A,CN 115605258 A,029-536-795-414-686,2023-01-13,2023,CN 202180034983 A,2021-05-13,US 202063024483 P;;US 2021/0032279 W,2020-05-13,System and method for rejuvenating skin using impedance monitoring,"The present disclosure relates, in part, to methods of cosmetic tissue treatment. The method comprises disposing a treatment applicator comprising an electrode array comprising a plurality of needles, each needle being an electrode in electrical communication with a control system, on a portion of the tissue such that a region of the electrode array contacts the portion of the tissue; applying a radio frequency (RF) energy pulse to the portion of tissue through the electrode array; measuring the impedance of the electrode array over time; detecting a drop in the measured impedance when the electrode array is in contact with a portion of the tissue; and terminating application of the RF energy pulse after a processing period upon detecting an impedance reduction threshold.",CYNOSURE INC,BOHL JOHANNES;;MIRKOV MIKHAIL GRIGORIEVICH;;MASSE DOMINIQUE;;BRUCE SARA;;ALBERTELLI CLAUDIO;;COUGHLIN JOHN;;SONASHIN DANIEL;;SIMON JU RG,,https://lens.org/029-536-795-414-686,Patent Application,no,0,0,9,9,0,A61B2018/00577;;A61B2018/0047;;A61B2018/0016;;A61B2018/143;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B18/12;;A61B18/12;;A61B2018/00642;;A61B2018/00672;;A61B2018/00875;;A61B2018/00708;;A61B2018/143;;A61B2018/0047;;A61B2018/00577;;A61N1/40,A61N1/32;;A61B18/12;;A61N1/04;;A61N1/36,,0,0,,,,PENDING
381,AU,A1,AU 2002/356664 A1,118-349-474-616-028,2003-06-30,2003,AU 2002/356664 A,2002-12-17,EP 0214355 W;;US 34095301 P,2001-12-19,BETA-AMINO-ALPHA-CYANOACRYLATES AND THEIR USE AS HERBICIDES,,BASF AG,EVERSON ALBERT C;;COUGHLIN DANIEL J;;GUACIARO MICHAEL A;;FLEMING LINDA B;;MARAVETZ LESTER L;;HUPPATZ JOHN L,,https://lens.org/118-349-474-616-028,Patent Application,no,0,0,13,13,0,A01N37/42;;A01N37/44;;A01N43/08;;A01N43/16;;A01N43/18;;C07C255/23;;C07C255/30;;C07C255/31;;C07C323/60;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C255/23;;A01N43/18;;C07D307/16;;C07C323/60;;C07D309/04;;A01N37/42;;C07D309/06;;A01N37/44;;C07C255/31;;C07D307/14;;A01N43/16;;C07C255/30;;A01N43/08;;C07C2601/02;;C07C2601/14;;C07C2601/08,C07D335/02;;A01N37/42;;A01N37/44;;A01N41/12;;A01N43/08;;A01N43/16;;A01N43/18;;C07C253/30;;C07C255/23;;C07C255/30;;C07C323/58;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06,,0,0,,,,DISCONTINUED
382,CA,A1,CA 2793758 A1,196-788-460-477-147,2013-05-03,2013,CA 2793758 A,2012-10-26,US 201113288494 A,2011-11-03,FUSER COATING COMPOSITION AND METHOD OF MANUFACTURE,"The present teachings include a coating composition of a powder of fluorine containing particles, aerogel particles and poly(alkylene carbonate). A method of making a fuser member and the fuser member resulting therefrom is also provided.",XEROX CORP,QI YU;;ZHANG QI;;IRVING DAVID C;;COUGHLIN DANIEL L JR;;MOORLAG CAROLYN;;DOOLEY BRYNN;;HU NAN-XING,,https://lens.org/196-788-460-477-147,Patent Application,no,0,0,7,7,0,G03G15/2057;;C09D127/12;;C09D127/18;;C09D127/12;;G03G15/2057;;C09D127/18,C09D169/00;;C09D7/12;;C09D127/12;;C09D129/10;;G03G15/20,,0,0,,,,INACTIVE
383,WO,A1,WO 2003/051823 A1,114-259-773-129-09X,2003-06-26,2003,EP 0214355 W,2002-12-17,US 34095301 P,2001-12-19,BETA-AMINO-ALPHA-CYANOACRYLATES AND THEIR USE AS HERBICIDES,"&bgr;-Amino-&agr;-Cyanoacrylates of formula I where the variables have the following meanings: R1 is n-alkyl, n-alkenyl or alkoxyalkyl; R2,R3 are alkyl, which may be partially or fully halogenated and/or may carry a substituent from the group consisting of cyano, alkoxy, haloalkoxy, alkylthio, haloalkylthio, C1-C6-alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl and haloalkylsulfonyl, are alkenyl or alkynyl; or R2 and R3 together with the carbon atom to which they are attached form a cycloalkyl ring in which one or two nonadjacent CH2 groups may be replaced by oxygen or sulfur, and where the cycloalkyl ring may be substituted by halogen or alkyl; R4 is hydrogen, halogen, cyano or alkyl, where the substituents R2, R3 and R4 or two of the radicals R2, R3 and R4 are not simultaneously methyl, and their agriculturally useful salts, processes and intermediates for their preparation; and the use of these compounds or of compositions comprising these compounds for controlling undesirable plants are described.",BASF AG;;EVERSON ALBERT C;;COUGHLIN DANIEL J;;GUACIARO MICHAEL A;;FLEMING LINDA B;;MARAVETZ LESTER L;;HUPPATZ JOHN L,EVERSON ALBERT C;;COUGHLIN DANIEL J;;GUACIARO MICHAEL A;;FLEMING LINDA B;;MARAVETZ LESTER L;;HUPPATZ JOHN L,,https://lens.org/114-259-773-129-09X,Patent Application,yes,3,0,13,13,0,A01N37/42;;A01N37/44;;A01N43/08;;A01N43/16;;A01N43/18;;C07C255/23;;C07C255/30;;C07C255/31;;C07C323/60;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C255/23;;A01N43/18;;C07D307/16;;C07C323/60;;C07D309/04;;A01N37/42;;C07D309/06;;A01N37/44;;C07C255/31;;C07D307/14;;A01N43/16;;C07C255/30;;A01N43/08;;C07C2601/02;;C07C2601/14;;C07C2601/08,A01N37/42;;A01N37/44;;A01N41/12;;A01N43/08;;A01N43/16;;A01N43/18;;C07C253/30;;C07C255/23;;C07D335/02;;C07C255/30;;C07C323/58;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06,,3,2,037-281-784-543-19X;;098-541-683-558-158,10.1246/bcsj.40.2160;;10.1021/jo01014a009,"A.F. CAMPBELL ET AL.: ""An Instance Illustrating the Stability of the Four-Carbon Ring"", JOURNAL OF THE CHEMICAL SOCIETY., 1910, LETCHWORTH GB, pages 2418 - 2425, XP008016046;;TOSHIO HAYASHI ET AL.: ""Studies on Geometric Isomerism by Nuclear Magnetic Resonance. IV. Structure of alpha-Cyano-beta-amino-beta-alkylacrylic Esters"", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN., vol. 40, no. 9, September 1967 (1967-09-01), TOKYO JP, pages 2160 - 2162, XP002237804;;TOSHIO HAYASHI ET AL.: ""Studies on Geometric Isomerism by Nuclear Magnetic Resonance. I. Stereochemistry of alpha-Cyano-beta-alkoxy-beta-alkylacrylic Esters"", JOURNAL OF ORGANIC CHEMISTRY, vol. 30, no. 3, 12 March 1965 (1965-03-12), EASTON US, pages 695 - 699, XP002237805",PENDING
384,US,A1,US 2005/0054536 A1,150-090-178-043-501,2005-03-10,2005,US 49956804 A,2004-06-21,US 49956804 A;;EP 0214355 W;;US 34095301 P,2001-12-19,Beta-amino-alpha-cyanoacrylates and their use as herbicides,"β-Amino-α-Cyanoacrylates of formula I where the variables have the following meanings: R 1 is n-alkyl, n-alkenyl or alkoxyalkyl; R 2 ,R 3 are alkyl, which may be partially or fully halogenated and/or may carry a substituent from the group consisting of cyano, alkoxy, haloalkoxy, alkylthio, haloalkylthio, C 1 -C 6 -alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl and haloalkylsulfonyl, are alkenyl or alkynyl; or R 2 and R 3 together with the carbon atom to which they are attached form a cycloalkyl ring in which one or two nonadjacent CH 2 groups may be replaced by oxygen or sulfur, and where the cycloalkyl ring may be substituted by halogen or alkyl; R 4 is hydrogen, halogen, cyano or alkyl, where the substituents R 2 , R 3 and R 4 or two of the radicals R 2 , R 3 and R 4 are not simultaneously methyl, and their agriculturally useful salts, processes and intermediates for their preparation; and the use of these compounds or of compositions comprising these compounds for controlling undesirable plants are described.",EVERSON ALBERT C;;COUGHLIN DANIEL J.;;GUACIARO MICHAEL A.;;FLEMING LINDA B.;;MARAVETZ LESTER L.;;HUPPATZ JOHN L.,EVERSON ALBERT C;;COUGHLIN DANIEL J;;GUACIARO MICHAEL A;;FLEMING LINDA B;;MARAVETZ LESTER L;;HUPPATZ JOHN L,BASF SE (2003-01-08),https://lens.org/150-090-178-043-501,Patent Application,yes,2,0,13,13,0,A01N37/42;;A01N37/44;;A01N43/08;;A01N43/16;;A01N43/18;;C07C255/23;;C07C255/30;;C07C255/31;;C07C323/60;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C255/23;;A01N43/18;;C07D307/16;;C07C323/60;;C07D309/04;;A01N37/42;;C07D309/06;;A01N37/44;;C07C255/31;;C07D307/14;;A01N43/16;;C07C255/30;;A01N43/08;;C07C2601/02;;C07C2601/14;;C07C2601/08,A01N37/42;;A01N37/44;;C07D335/02;;A01N41/12;;A01N43/08;;A01N43/16;;A01N43/18;;C07C253/30;;C07C255/23;;C07C255/30;;C07C323/58;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06,504/312;;558/437,0,0,,,,EXPIRED
385,CA,C,CA 2793758 C,100-818-249-824-387,2016-06-21,2016,CA 2793758 A,2012-10-26,US 201113288494 A,2011-11-03,FUSER COATING COMPOSITION AND METHOD OF MANUFACTURE,"The present teachings include a coating composition of a powder of fluorine containing particles, aerogel particles and poly(alkylene carbonate). A method of making a fuser member and the fuser member resulting therefrom is also provided.",XEROX CORP,QI YU;;ZHANG QI;;IRVING DAVID C;;COUGHLIN DANIEL L JR;;MOORLAG CAROLYN;;DOOLEY BRYNN;;HU NAN-XING,,https://lens.org/100-818-249-824-387,Granted Patent,no,0,0,7,7,0,G03G15/2057;;C09D127/12;;C09D127/18;;C09D127/12;;G03G15/2057;;C09D127/18,C09D169/00;;C09D7/12;;C09D127/12;;C09D129/10;;G03G15/20,,0,0,,,,INACTIVE
386,TW,A,TW 200306157 A,035-676-351-657-494,2003-11-16,2003,TW 91136680 A,2002-12-19,US 34095301 P,2001-12-19,β-Amino-α-cyanoacrylates,"β-Amino-α-cyanoacrylates of formula I, where the variables have the following meanings: R1 is n-alkyl, n-alkenyl or alkoxyalkyl; R2, R3 are alkyl, which may be partially or fully halogenated and/or may carry a substituent from the group consisting of cyano, alkoxy, haloalkoxy, alkylthio, haloalkylthio, C1-C6-alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl and haloalkylsulfonyl, are alkenyl or alkynyl; or R2 and R3 together with the carbon atom to which they are attached form a cycloalkyl ring in which one or two nonadjacent CH2 groups may be replaced by oxygen or sulfur, and where the cycloalkyl ring may be substituted by halogen or alkyl; R4 is hydrogen, halogen, cyano or alkyl, where the substituents R2, R3 and R4 or two of the radicals R2, R3 and R4 are not simultaneously methyl, and their agriculturally useful salts, processes and intermediates for their preparation; and the use of these compounds or of compositions comprising these compounds for controlling undesirable plants are described.",BASF AG,EVERSON ALBERT C;;COUGHLIN DANIEL J;;GUACIARO MICHAEL A;;FLEMING LINDA B;;MARAVETZ LESTER L;;JOHN L HUPPATZ,,https://lens.org/035-676-351-657-494,Patent of Addition,no,0,0,13,13,0,A01N37/42;;A01N37/44;;A01N43/08;;A01N43/16;;A01N43/18;;C07C255/23;;C07C255/30;;C07C255/31;;C07C323/60;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C255/23;;A01N43/18;;C07D307/16;;C07C323/60;;C07D309/04;;A01N37/42;;C07D309/06;;A01N37/44;;C07C255/31;;C07D307/14;;A01N43/16;;C07C255/30;;A01N43/08;;C07C2601/02;;C07C2601/14;;C07C2601/08,C07D335/02;;A01N37/42;;A01N37/44;;A01N41/12;;A01N43/08;;A01N43/16;;A01N43/18;;C07C253/30;;C07C255/23;;C07C255/30;;C07C323/58;;C07D307/14;;C07D307/16;;C07D309/04;;C07D309/06,,0,0,,,,PENDING
387,JP,A,JP 2013097382 A,152-430-620-742-112,2013-05-20,2013,JP 2012234151 A,2012-10-23,US 201113288494 A,2011-11-03,FUSER COATING COMPOSITION AND METHOD OF MANUFACTURING,"PROBLEM TO BE SOLVED: To provide a method of manufacturing fuser members having a topcoat or release layer that produces low gloss prints.SOLUTION: A fuser member comprises a resilient layer disposed on a substrate. A powder coating composition of fluorine-containing particles, aerogel particles and poly(alkylene carbonate) is deposited on the resilient layer to form a coated layer. The coated layer is heated to a temperature of about 300°C to about 380°C to form a release layer.",XEROX CORP,YU CHI;;QI ZHANG;;DAVID C ARVIN;;DANIEL L COUGHLIN;;CAROLYN P MOORLAG;;BULLIN MARY DOOLEY;;NUNG SHIN HU,,https://lens.org/152-430-620-742-112,Patent Application,no,3,3,7,7,0,G03G15/2057;;C09D127/12;;C09D127/18;;C09D127/12;;G03G15/2057;;C09D127/18,G03G15/20,,0,0,,,,INACTIVE
388,DE,A1,DE 102012219423 A1,013-610-175-576-82X,2013-05-08,2013,DE 102012219423 A,2012-10-24,US 201113288494 A,2011-11-03,Beschichtungszusammensetzung und Herstellungsverfahren für Fixierelement,"Die vorliegenden Lehren umfassen eine Beschichtungszusammensetzung eines Pulvers von fluorhaltigen Teilchen, Aerogelteilchen und Poly(alkylencarbonat). Außerdem werden ein Verfahren zur Herstellung eines Fixierelements und das daraus resultierende Fixierelement bereitgestellt.",XEROX CORP,QI YU;;ZHANG QI;;IRVING DAVID C;;COUGHLIN DANIEL L;;MOORLAG CAROLYN P;;DOOLEY BRYNN MARY;;HU NAN-XING,,https://lens.org/013-610-175-576-82X,Patent Application,no,0,0,7,7,0,G03G15/2057;;C09D127/12;;C09D127/18;;C09D127/12;;G03G15/2057;;C09D127/18,G03G15/20;;C09D169/00,,0,0,,,,DISCONTINUED
389,JP,A,JP 2017193587 A,066-476-745-078-442,2017-10-26,2017,JP 2017151432 A,2017-08-04,US 93075807 P;;US 579207 A,2007-05-17,"METHOD FOR PREPARING COMPOSITIONS FOR MODULATING KINASE CASCADE, AND METHOD OF USING THE SAME","PROBLEM TO BE SOLVED: To provide a method for preparing a composition for modulating a kinase cascade, and a method of using the same.SOLUTION: The present invention is directed to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and mesylates and dihydrochlorides thereof. More specifically, the present invention provides an efficient method for synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and mesylates and dihydrochlorides thereof, and a method of modulating one or more components of a kinase cascade using the compositions.SELECTED DRAWING: None",ATHENEX INC,HANGAUER DAVID G;;DANIEL COUGHLIN;;JEREMY A CODY;;JONATHAN GALE;;DEBASIS PATRA;;GRANT J PALMER;;ISBESTER PAUL K;;JONATHON SALSBURY,,https://lens.org/066-476-745-078-442,Patent Application,no,0,0,16,64,0,A61P3/04;;A61P3/10;;A61P9/00;;A61P19/10;;A61P27/16;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D213/56,C07D213/56;;A61K31/5377;;A61P3/04;;A61P3/10;;A61P9/00;;A61P19/10;;A61P27/16;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00,,0,0,,,,PENDING
390,US,B2,US 8623954 B2,172-060-434-125-786,2014-01-07,2014,US 201113288494 A,2011-11-03,US 201113288494 A,2011-11-03,Fuser coating composition and method of manufacture,"The present teachings include a coating composition of a powder of fluorine containing particles, aerogel particles and poly(alkylene carbonate). A method of making a fuser member and the fuser member resulting therefrom is also provided.",QI YU;;ZHANG QI;;IRVING DAVID C;;COUGHLIN JR DANIEL L;;MOORLAG CAROLYN P;;DOOLEY BRYNN MARY;;HU NAN-XING;;XEROX CORP,QI YU;;ZHANG QI;;IRVING DAVID C;;COUGHLIN JR DANIEL L;;MOORLAG CAROLYN P;;DOOLEY BRYNN MARY;;HU NAN-XING,XEROX CORPORATION (2011-10-12),https://lens.org/172-060-434-125-786,Granted Patent,yes,30,0,7,7,0,G03G15/2057;;C09D127/12;;C09D127/18;;C09D127/12;;G03G15/2057;;C09D127/18,C08K3/34,524/492;;523/307;;523/309;;524/430;;524/493,15,0,,,"Buie-Hatcher, Final Office Action, U.S. Appl. No. 13/053,418, filed Sep. 19, 2012.;;U.S. Appl. No. 13/251,364, filed Oct. 3, 2011.;;U.S. Appl. No. 13/182,015, filed Jul. 13, 2011.;;U.S. Appl. No. 13/053,730, filed Mar. 22, 2011.;;U.S. Appl. No. 13/053,423, filed Mar. 22, 2011.;;U.S. Appl. No. 13/053,418, filed Mar. 22, 2011.;;U.S. Appl. No. 13/053,423, Office Action dated Feb. 22, 2013.;;U.S. Appl. No. 13/053,418, Notice of Allowance and Fees Due dated Dec. 28, 2012.;;U.S. Appl. No. 13/053,418, filed Mar. 22, 2011, Office Action dated Apr. 17, 2012.;;""DOW Corning VM-2270 Aerogel Fine Particles"" Dow Corning Corporation 2008.;;U.S. Appl. No. 13/251,364, Office Action dated Apr. 11, 2013.;;U.S. Appl. No. 13/448,822, Office Action dated Jun. 7, 2013.;;Roberts, ""Resonant Acoustic Mixing"", Resodyn Acoustic Mixers, Nov. 6, 2011, pp. 1-8.;;""Spectral Series Fumed Alumina for Power Coating Processes"", Cabot Corporation, MA, USA, 2005, pp. 1-2.;;U.S. Appl. No. 13/053,423, Office Action dated Jun. 17, 2013.",ACTIVE
391,US,A1,US 2013/0116369 A1,083-357-835-068-218,2013-05-09,2013,US 201113288494 A,2011-11-03,US 201113288494 A,2011-11-03,FUSER COATING COMPOSITION AND METHOD OF MANUFACTURE,"The present teachings include a coating composition of a powder of fluorine containing particles, aerogel particles and poly(alkylene carbonate). A method of making a fuser member and the fuser member resulting therefrom is also provided.",QI YU;;ZHANG QI;;IRVING DAVID C;;COUGHLIN JR DANIEL L;;MOORLAG CAROLYN P;;DOOLEY BRYNN M;;HU NAN-XING;;XEROX CORP,QI YU;;ZHANG QI;;IRVING DAVID C;;COUGHLIN JR DANIEL L;;MOORLAG CAROLYN P;;DOOLEY BRYNN M;;HU NAN-XING,XEROX CORPORATION (2011-10-12),https://lens.org/083-357-835-068-218,Patent Application,yes,0,12,7,7,0,G03G15/2057;;C09D127/12;;C09D127/18;;C09D127/12;;G03G15/2057;;C09D127/18,C08K5/42;;B05D3/02;;B05D5/00;;B05D7/24;;B82Y30/00;;C08K3/22;;C08K5/095;;C09D127/18;;C09D139/00;;C09D141/00,524/157;;524/502;;524/430;;524/520;;524/516;;524/518;;524/319;;427/226;;977/742,0,0,,,,ACTIVE
392,JP,A,JP 2015028068 A,045-750-902-076-932,2015-02-12,2015,JP 2014206119 A,2014-10-07,US 93075807 P;;US 579207 A,2007-05-17,"METHOD FOR PREPARATION OF COMPOSITION FOR MODULATING KINASE CASCADE, AND METHOD FOR USING THE SAME","PROBLEM TO BE SOLVED: To provide a method for the preparation of a composition for modulating kinase cascade, and to provide a method for using the same.SOLUTION: The invention relates to a composition comprising 2-(5-(4-(2-morpholino ethoxy)phenyl)pyridin-2-yl)-N-benzyl acetamide, or a mesylate or dihydrochloride thereof. In particular, the invention provides a more efficient method for the synthesis of 2-(5-(4-(2-morpholino ethoxy)phenyl)pyridin-2-yl)-N-benzyl acetamide and a mesylate or dihydrochloride thereof, and a method for modulating one or more component in the kinase cascade by using the inventive composition.",KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G;;DANIEL COUGHLIN;;JEREMY A CODY;;JONATHAN GALE;;DEBASIS PATRA;;GRANT J PALMER;;ISBESTER PAUL K;;JONATHON SALSBURY,,https://lens.org/045-750-902-076-932,Patent Application,no,5,0,16,64,0,A61P3/04;;A61P3/10;;A61P9/00;;A61P19/10;;A61P27/16;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D213/56,C07D213/56;;A61K31/5377;;A61P3/04;;A61P3/10;;A61P9/00;;A61P19/10;;A61P27/16;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00,,0,0,,,,ACTIVE
393,US,B1,US 6175336 B1,065-391-208-011-497,2001-01-16,2001,US 47249799 A,1999-12-27,US 47249799 A,1999-12-27,Structural endcap antenna,A structural endcap antenna for a vertical tail of an aircraft. The endcap antenna comprises an outer skin having an inner surface and an antenna element disposed adjacent to the inner surface of the outer skin. The antenna element is in electrical communication with an RF signal source. Disposed adjacent to the antenna element is an inner support structure electrically bonded thereto. The antenna element and the inner support structure are excited by the RF signal source and provide structural support to the endcap antenna.,NORTHROP GRUMMAN CORP,COUGHLIN DANIEL PATRICK;;LOCKYER ALLEN JOHN;;DURHAM MICHAEL DAVID;;ALT KEVIN HERMAN;;LACOMBE PETER;;KUDVA JAYANTH NANDALKE;;OLSEN KEITH ALAN,NORTHROP GRUMMAN CORPORATION (2000-02-15),https://lens.org/065-391-208-011-497,Granted Patent,yes,24,14,1,1,0,H01Q1/38;;H01Q1/38;;H01Q1/28;;H01Q1/28,H01Q1/28;;H01Q1/38,343/708;;343/705,0,0,,,,EXPIRED
394,CN,B,CN 101687798 B,037-380-564-143-032,2012-08-15,2012,CN 200880024401 A,2008-05-19,US 2008/0006419 W;;US 93075807 P;;US 579207 A,2007-05-17,Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof,"The invention relates to compositions comprising 2-(5-(4-(2- morpholinoethoxy)phenyl)pytidin-2-yl)--V-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-<4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-Lambda Lambda benzylacetainide and its mesylate and dihydrochloride salts and methods for modulating oneor more components of a kinase cascade using the compositions of the invention.",KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G JR;;DANIEL COUGHLIN;;CODY JEREMY A;;JONATHAN GALE;;DEBASIS PATRA;;PALMER GRANT J;;ISBESTER PAUL K;;JONATHON SALSBURY,,https://lens.org/037-380-564-143-032,Granted Patent,no,0,0,16,64,0,A61P3/04;;A61P3/10;;A61P9/00;;A61P19/10;;A61P27/16;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D213/56,C07D213/56;;A61K31/44;;A61P35/00,,0,0,,,,ACTIVE
395,AU,B2,AU 2008/254500 B2,032-232-470-981-637,2014-01-23,2014,AU 2008/254500 A,2008-05-19,US 579207 A;;US 93075807 P;;US 2008/0006419 W,2007-05-17,Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof,"The invention relates to compositions comprising 2-(5-(4-(2- morpholinoethoxy)phenyl)pyτidin-2-yl)--V-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-<4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-ΛΛbenzylacetainide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.",ATNX SPV LLC,COUGHLIN DANIEL;;GALE JONATHAN;;HANGAUER JR DAVID G;;CODY JEREMY A;;PATRA DEBASIS;;PALMER GRANT J;;ISBESTER PAUL K;;SALSBURY JONATHON,"ATNX SPV, LLC (2023-03-16)",https://lens.org/032-232-470-981-637,Granted Patent,no,1,0,16,64,0,C07D213/56;;A61P19/10;;A61P27/16;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00,C07D213/56;;A61K31/44;;A61P35/00,,0,0,,,,ACTIVE
396,CA,A1,CA 2686267 A1,029-192-950-543-634,2008-11-27,2008,CA 2686267 A,2008-05-19,US 93075807 P;;US 579207 A;;US 2008/0006419 W,2007-05-17,PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING AKINASE CASCADE AND METHODS OF USE THEREOF,"The invention relates to compositions comprising 2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl)--V- benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5- < 4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-A A benzylacetainide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.",KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G JR;;PALMER GRANT J;;CODY JEREMY A;;COUGHLIN DANIEL;;GALE JONATHAN;;SALSBURY JONATHON;;PATRA DEBASIS;;ISBESTER PAUL K,,https://lens.org/029-192-950-543-634,Patent Application,no,0,0,16,64,0,A61P3/04;;A61P3/10;;A61P9/00;;A61P19/10;;A61P27/16;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D213/56,C07D413/12;;A61K31/5377,,0,0,,,,ACTIVE
397,EP,B1,EP 2155681 B1,076-726-457-907-551,2018-05-02,2018,EP 08754559 A,2008-05-19,US 2008/0006419 W;;US 93075807 P;;US 579207 A,2007-05-17,PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF,,ATHENEX INC,HANGAUER DAVID G JR;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS;;PALMER GRANT J;;SALSBURY JONATHON;;ISBESTER PAUL K,"ATHENEX, INC. (2018-05-16);;ATNX SPV, LLC; US (2023-06-23);;ATNX SPV, LLC, BUFFALO, US (2023-02-28);;ATNX SPV, LLC. (2023-06-08)",https://lens.org/076-726-457-907-551,Granted Patent,yes,1,0,16,64,0,C07D213/56;;A61P19/10;;A61P27/16;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00,C07D213/56;;A61K31/44;;A61P35/00,,0,0,,,,ACTIVE
398,EP,A1,EP 2155681 A1,058-930-037-393-262,2010-02-24,2010,EP 08754559 A,2008-05-19,US 2008/0006419 W;;US 93075807 P;;US 579207 A,2007-05-17,PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF,,KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G JR;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS;;PALMER GRANT J;;SALSBURY JONATHON;;ISBESTER PAUL K,"ATHENEX, INC. (2018-05-16);;ATNX SPV, LLC; US (2023-06-23);;ATNX SPV, LLC, BUFFALO, US (2023-02-28);;ATNX SPV, LLC. (2023-06-08)",https://lens.org/058-930-037-393-262,Patent Application,yes,0,0,16,64,0,A61P3/04;;A61P3/10;;A61P9/00;;A61P19/10;;A61P27/16;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D213/56,C07D213/56;;A61K31/44;;A61P35/00,,1,0,,,See references of WO 2008144045A1,ACTIVE
399,US,A1,US 2011/0201611 A1,139-576-431-723-028,2011-08-18,2011,US 201113094667 A,2011-04-26,US 201113094667 A;;US 15405608 A;;US 579207 A;;US 93075807 P;;US 87776206 P,2006-12-28,Process for the Preparation of Compositions for Modulating a Kinase Cascade and Methods of Use Thereof,"The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.",KINEX PHARMACEUTICALS LLC,HANGAUER JR DAVID G;;COUGHLIN DANIEL;;GALE JONATHAN;;CODY JEREMY A;;PATRA DEBASIS;;PALMER GRANT J;;ISBESTER PAUL K;;SALSBURY JONATHON,ATHENEX INC (2015-08-26);;ATNX SPV LLC (2022-06-29),https://lens.org/139-576-431-723-028,Patent Application,yes,20,2,4,64,0,A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/02;;A61P37/06;;C07D413/12;;C07D413/12,A61K31/5377;;A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/02;;A61P37/06;;C07D413/12,514/235.5;;544/131,0,0,,,,ACTIVE
400,CN,A,CN 101687798 A,156-095-277-742-106,2010-03-31,2010,CN 200880024401 A,2008-05-19,US 2008/0006419 W;;US 93075807 P;;US 579207 A,2007-05-17,Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof,"The invention relates to compositions comprising 2-(5-(4-(2- morpholinoethoxy)phenyl)pytidin-2-yl)--V-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-<4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-Lambda Lambda benzylacetainide and its mesylate and dihydrochloride salts and methods for modulating oneor more components of a kinase cascade using the compositions of the invention.",KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G JR;;DANIEL COUGHLIN;;CODY JEREMY A;;JONATHAN GALE;;DEBASIS PATRA;;PALMER GRANT J;;ISBESTER PAUL K;;JONATHON SALSBURY,,https://lens.org/156-095-277-742-106,Patent Application,no,0,9,16,64,0,A61P3/04;;A61P3/10;;A61P9/00;;A61P19/10;;A61P27/16;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D213/56,C07D213/56;;A61K31/44;;A61P35/00,,0,0,,,,ACTIVE
401,CA,C,CA 2686267 C,003-841-763-384-862,2015-10-06,2015,CA 2686267 A,2008-05-19,US 93075807 P;;US 579207 A;;US 2008/0006419 W,2007-05-17,PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF,"The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)--V-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5- < 4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-AA benzylacetainide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.",KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G JR;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;SALSBURY JONATHON;;PALMER GRANT J;;ISBESTER PAUL K;;PATRA DEBASIS,,https://lens.org/003-841-763-384-862,Granted Patent,no,0,0,16,64,0,C07D213/56;;A61P19/10;;A61P27/16;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00,C07D413/12;;A61K31/5377,,0,0,,,,ACTIVE
402,US,B2,US 7939529 B2,083-173-635-477-168,2011-05-10,2011,US 15405608 A,2008-05-19,US 15405608 A;;US 579207 A;;US 93075807 P,2007-05-17,Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof,"The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.",KINEX PHARMACEUTICALS LLC,HANGAUER JR DAVID G;;COUGHLIN DANIEL;;GALE JONATHAN;;CODY JEREMY A;;PATRA DEBASIS;;PALMER GRANT J;;ISBESTER PAUL K;;SALSBURY JONATHON,ATHENEX INC (2015-08-26);;ATNX SPV LLC (2022-06-29),https://lens.org/083-173-635-477-168,Granted Patent,yes,39,30,4,64,0,A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/02;;A61P37/06;;C07D413/12;;C07D413/12,A61K31/53,514/235.5,21,19,093-514-661-071-28X;;014-892-315-361-770;;024-246-415-334-792;;013-644-197-083-407;;029-742-983-481-795;;133-545-268-130-061;;014-944-545-982-558;;017-937-967-857-021;;041-703-940-947-068;;085-441-379-277-757;;083-766-165-487-727;;016-856-688-460-880;;008-506-871-340-22X;;014-281-294-082-381;;196-137-673-224-806;;045-942-893-332-610;;059-992-524-705-606;;056-481-350-704-182;;002-209-090-598-253,5748697;;10.1021/jm00311a010;;15362850;;10.1021/bi0495073;;11102447;;10.1074/jbc.m008368200;;12020799;;10.1016/s0304-419x(02)00040-9;;10.1126/science.286.5439.531;;10521349;;pmc6757905;;12122079;;10.1523/jneurosci.22-14-06208.2002;;20026599;;10.1021/jm049876x;;15369401;;1875332;;10.1021/jm00112a001;;9544425;;10.1023/a:1005960822365;;10.1002/chin.200429087;;10.1021/jm00023a009;;7473597;;14739300;;10.1074/jbc.m311032200;;10.1517/13543776.15.9.1183;;10.1038/84675;;11175854;;10.1021/cen-v081n008.p032;;pmc33604;;10.1073/pnas.96.14.7697;;10393883;;10.1016/j.bmcl.2003.11.079;;15013006;;10.1021/jm00364a026;;6137568;;17186241;;10.1007/s00280-006-0398-z,"Cain et al., ""Potential Antitumor Agents. IX. Bisquaternary Salts"", J. Med. Chem.,11(5):963-966 (1968).;;Davidson et al., ""Discovery and characterization of a substrate selective p38alpha inhibitor"", Biochemistry, 43:11658-11671 (2004).;;Duong et al., ""Inhibition of osteoclast function by adenovirus expressing Antisense protein-tyrosine kinase 2"", J. Biol. Chem., 276(10):7484-7492 (2001).;;Frame, M.C., ""Src in cancer:deregulation and consequences for cell behaviour"", Biochem. Biophys. Acta, 1602:114-130 (2002).;;Golub et al., ""Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring"", Science, 286:531-537 (1999).;;Guo et al., ""Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia"", J. Neurosci., 22(14):6208-6217 (2002).;;Hadjeri et al., ""Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones"". J. Med. Chem., 47:4964-4970 (2004).;;Huff, J.R., ""HIV Protease: A Novel Chemotherapeutic Target for AIDS"", J. Med. Chem., 34(8):2305-2314 (1991).;;Lala et al., ""Role of nitric oxide in tumor progression: Lessons from experimental tumors"", Cancer Metastasis Rev., 17(1):91-106 (1998).;;Liechti et al., ""Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor"", Eur. J. Med. Chem., 39(1):11-26 (2004).;;Million et al., ""Inhibition of the EGF-stimulated cellular proliferation of ER 22 cells by hydroxybiphenyl derivatives"", J. Med. Chem., 38(23):4693-4703 (1995).;;Miyazaki et al., ""Src kinase activity is essential for osteoclast function"", J. Biol. Chem., 279(17):17660-17666 (2004).;;Parang et al., ""Recent advances in the discovery of Src kinase inhibitors"", Expert Opin. Ther. Patents, 15(9):1183-1207 (2005).;;Paul et al., ""Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke"", Nat. Med., 7(2):222-227 (2001).;;Rouhi, A.M., ""The right stuff: From research and development to the clinic, getting drug crystals right is full of pitfalls"", Chem. Eng. News, pp. 32-35 (2003).;;U.S. Pharmacopia #23, National Formulary #18, pp. 1843-1844 (1995).;;Yu et al., ""Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors"", Proc. Natl. Acad. Sci. USA, 96:7697-7704 (1999).;;Zhang et al., ""Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs"", Bioorg. Med. Chem. Lett., 14(4):983-987 (2004).;;Bryn et al., ""Hydrates and Solvates"", in Solid-State Chem. Drugs, 2nd Ed., SSCI, Inc., IN, Ch. 11, pp. 233-247 (1999).;;Honma et al., ""Antiallergic agents. 2. N-(1H-Tetrazol-5-yl)-6-phenyl-2-pyridinecarboxamides"", J. Med. Chem., 26:1499-1504 (1983).;;Planas-Silva et al., ""Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins"", Cancer Chemotherapy Pharmacol., 60(4):535-543 (2006).",ACTIVE
403,AU,B2,AU 2014/202221 B2,005-795-251-061-507,2016-06-23,2016,AU 2014/202221 A,2014-04-23,AU 2008/254500 A;;AU 2014/202221 A,2008-05-19,Process for the Preparation of Compositions for Modulating a Kinase Cascade and Methods of Use Thereof,"The invention relates to compositions comprising 2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin 2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-)5-<4-)2 morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.",ATNX SPV LLC,HANGAUER JR DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS;;PALMER GRANT J;;ISBESTER PAUL K;;SALSBURY JONATHON,"ATNX SPV, LLC (2023-03-16)",https://lens.org/005-795-251-061-507,Granted Patent,no,2,0,2,2,0,,C07D213/56;;A61K31/44;;A61P35/00,,0,0,,,,ACTIVE
404,DK,T3,DK 2155681 T3,023-764-429-117-493,2018-08-06,2018,DK 08754559 T,2008-05-19,US 93075807 P;;US 579207 A;;US 2008/0006419 W,2007-05-17,FREMGANGSMÅDE TIL FREMSTILLING AF SAMMENSÆTNINGER TIL MODULERING AF KINASEKASKADE OG FREMGANGSMÅDER TIL ANVENDELSE DERAF,,ATHENEX INC,COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;HANGAUER DAVID G JR;;PATRA DEBASIS;;PALMER GRANT J;;SALSBURY JONATHON;;ISBESTER PAUL K,,https://lens.org/023-764-429-117-493,Granted Patent,no,0,0,16,64,0,A61P3/04;;A61P3/10;;A61P9/00;;A61P19/10;;A61P27/16;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D213/56,C07D213/56;;A61K31/44;;A61P35/00,,0,0,,,,ACTIVE
405,AU,A1,AU 2008/254500 A1,115-208-973-130-390,2008-11-27,2008,AU 2008/254500 A,2008-05-19,US 579207 A;;US 93075807 P;;US 2008/0006419 W,2007-05-17,Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof,,KINEX PHARMACEUTICALS LLC,COUGHLIN DANIEL;;CODY JEREMY A;;PALMER GRANT J;;GALE JONATHAN;;PATRA DEBASIS;;SALSBURY JONATHON;;ISBESTER PAUL K;;HANGAUER DAVID G JR,"ATNX SPV, LLC (2023-03-16)",https://lens.org/115-208-973-130-390,Patent Application,no,0,0,16,64,0,A61P3/04;;A61P3/10;;A61P9/00;;A61P19/10;;A61P27/16;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D213/56,C07D213/56;;A61K31/44;;A61P35/00,,0,0,,,,ACTIVE
406,AU,A1,AU 2014/202221 A1,003-271-732-414-756,2014-05-22,2014,AU 2014/202221 A,2014-04-23,AU 2008/254500 A;;AU 2014/202221 A,2008-05-19,Process for the Preparation of Compositions for Modulating a Kinase Cascade and Methods of Use Thereof,"The invention relates to compositions comprising 2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin 2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-)5-<4-)2 morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.",KINEX PHARMACEUTICALS LLC,HANGAUER JR DAVID G;;COUGHLIN DANIEL;;CODY JEREMY A;;GALE JONATHAN;;PATRA DEBASIS;;PALMER GRANT J;;ISBESTER PAUL K;;SALSBURY JONATHON,"ATNX SPV, LLC (2023-03-16)",https://lens.org/003-271-732-414-756,Patent Application,no,0,0,2,2,0,,C07D213/56;;A61K31/44;;A61P35/00,,0,0,,,,ACTIVE
407,US,A,US 4867973 A,183-255-630-879-920,1989-09-19,1989,US 65037584 A,1984-09-13,US 65037584 A;;US 64632884 A,1984-08-31,Antibody-therapeutic agent conjugates,This invention relates to antibody-therapeutic agent conjugates having a therapeutic agent covalently attached to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody conjugates. Therapeutic in vivo methods utilizing such antibody-therapeutic agent conjugates are described.,CYTOGEN CORP,GOERS JOHN W F;;KING HURLEY D;;LEE CHYI;;COUGHLIN DANIEL J;;ALVAREZ VERNON L;;RODWELL JOHN D;;MCKEARN THOMAS J,CYTOGEN CORPORATION A CORP OF DE (1984-10-08),https://lens.org/183-255-630-879-920,Granted Patent,yes,13,416,1,90,0,A61K41/0042;;A61K51/10;;A61K51/1093;;A61K2121/00;;C07K5/0804;;G01N33/532;;G01N33/534;;Y10S530/866;;Y10S530/828;;Y10S530/864;;A61K41/0071;;A61K47/68;;G01N33/532;;G01N33/534;;A61K51/1093;;A61K2121/00;;C07K5/0804;;A61K51/10;;A61K41/0042;;Y10S530/864;;Y10S530/866;;Y10S530/828;;A61K41/0071;;A61K47/68,A61K41/00;;A61K47/48;;A61K51/10;;C07K5/083;;G01N33/532;;G01N33/534,424/85.91;;424/85.8;;424/86;;424/87;;530/387;;530/388;;530/389;;530/390;;530/391;;530/828;;514/2;;514/6;;514/8,34,27,005-334-346-125-348;;029-269-446-589-556;;006-530-116-700-399;;162-766-551-165-818;;029-355-433-223-855;;075-889-605-642-840;;133-572-190-866-899;;053-977-872-012-335;;034-144-941-661-246;;013-367-834-212-265;;016-132-221-527-857;;053-367-492-376-059;;015-905-644-328-679;;037-576-359-715-69X;;044-471-993-527-613;;032-327-260-001-487;;112-350-446-844-955;;026-239-711-372-07X;;037-987-949-965-097;;038-699-074-248-473;;090-802-635-099-729;;100-521-187-523-433;;006-392-791-860-123;;061-708-320-333-821;;055-631-723-799-490;;039-266-207-397-847;;008-338-316-745-754,7191812;;10.1016/0014-5793(80)81026-x;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;6836297;;10.1126/science.6836297;;7397692;;5353111;;10.1021/bi00839a042;;7207595;;10.1038/290145a0;;7217674;;10.1021/bi00690a015;;241376;;10.1016/s0021-9258(18)70223-8;;13641238;;10.1126/science.6115471;;6115471;;10.1093/jnci/61.3.657;;80453;;6996002;;10.1016/0163-7258(80)90010-8;;10.1038/265407a0;;834290;;6163457;;10.1016/0005-2736(81)90532-0;;10.1016/s0021-9258(19)70595-x;;7410345;;10.1002/ijc.2910240414;;393637;;10.1002/0471264180.or002.08;;10.1016/s0021-9258(17)30016-9;;571437;;7442804;;10.1038/288602a0;;7284322;;10.1021/bi00517a043;;6185591;;10.4049/jimmunol.130.3.1473;;10.1021/ja00505a043;;365720;;10.1016/0161-5890(78)90003-2;;7252257;;10.1111/1523-1747.ep12479235;;7023363;;10.1146/annurev.bi.50.070181.002245;;10.1042/bj1630219;;869924;;pmc1164687;;196922;;10.1016/0014-5793(77)80423-7,"Monsigny et al, FEBS Letters , vol. 119 (1), Sep. 1980, pp. 181 186, Preparation and Biological Properties of a Covalent Antitumor Drug Arm Carrier , CDAC Conjugate).;;Trovet et al., Proc Natl Acad Sci , Jan. 1982, vol. 79, pp. 626 629, A Covalent Linkage Between Davnorubicon and Proteins That is Stable in Serum and Reversible by Lysosumal Protease as Required for a Lysosomotropol Drug Carrier Conjugate: In Vitro and In Vivo Studies .;;Paul, Fundamental Immunology , 1984, pp. 132, 149.;;March, Advanced Organic Chemistry , 2nd Ed, 1972, pp. 824 827.;;Anderson and Parrish, Science 220: 524 527 (1983).;;Bale et al., Cancer Research 40: 2965 2972 (1980).;;Bing, Biochemistry 8: 4503 4510 (1969).;;Blythman et al, Nature 290: 145 146 (1981).;;Bunton, in Oxidation in Organic Chemistry, vol. I, Widberg, ed., Academic Press, New York, p. 365 (1965).;;Caporale et al., J. Immunol. 126: 1963 1965 (1981).;;Cooper, Biochemistry 14: 4245 4251 (1975).;;Cooper et al., J. Biol. Chem. 234: 445 448 (1959).;;Davis and Preston, Science 213: 1358 1388 (1981).;;Dougherty et al., in Porphyrin Photosensitization, Kessel and Dougherty eds., Plenum Publishing Corp., New York, (1983) pp. 3 13.;;Ghose et al., J. Natl. Cancer Inst. 61(3): 657 676 (1978).;;Gregoriadis, Pharmac. Ther. 10: 103 118 (1980).;;Gregoriadis, Nature 265: 407 411 (1977).;;Heath et al., Biochim Biophys. Acta. 640: 66 81 (1981).;;Huang et al., J. Biol. Chem. 255(17): 8015 8018 (1980).;;Hurwitz et al., Int. J. Cancer 24: 461 470 (1979).;;Jackson, Periodic Acid Oxidations in Organic Reactions, vol. 2, pp. 341 375 (1944).;;Jentoff and Dearborn, J. Biol. Chem. 254: 4359 4365 (1979).;;Lesserman et al., Nature 288: 602 604 (1980).;;March, in Advanced Organic Chemistry: Reactions, Mechanisms and Structures, McGraw Hill Co., New York, pp. 824 825 (1978).;;Martin et al., Biochem 20: 4229 4238 (1981).;;Mew et al., J. Immunol. 130: 1473 1477 (1983).;;Mitra and Lawton, J. Amer. Chem. Soc. 101: 3097 3110 (1979).;;Murayama et al., Immunochem. 15: 523 528 (1978).;;Parrish, J. Investig. Dermatol. 77: 45 50 (1981).;;Reid and Porter, Ann. Rev. Biochem 50: 433 464 (1981).;;Rowland, in Targeted Drugs, Goldberg ed., Interscience Publications, New York, pp. 57 72 (1983).;;Sim et al., Biochem. J. 163: 219 227 (1977).;;Stanworth and Turner, in Handbook of Experimental Immunology, vol. I, 2d ed. Weir, ed. Blackwell Scientific Publications, London, Chapter 10 (1973).;;Willan et al., FEBS Lett. 80: 133 136 (1977).",EXPIRED
408,US,B2,US 8293739 B2,072-466-480-938-731,2012-10-23,2012,US 201113094667 A,2011-04-26,US 201113094667 A;;US 15405608 A;;US 579207 A;;US 93075807 P;;US 87776206 P,2006-12-28,Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof,"The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy) phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.",HANGAUER JR DAVID G;;COUGHLIN DANIEL;;GALE JONATHAN;;CODY JEREMY A;;PATRA DEBASIS;;PALMER GRANT J;;ISBESTER PAUL K;;SALSBURY JONATHON;;KINEX PHARMACEUTICALS LLC,HANGAUER JR DAVID G;;COUGHLIN DANIEL;;GALE JONATHAN;;CODY JEREMY A;;PATRA DEBASIS;;PALMER GRANT J;;ISBESTER PAUL K;;SALSBURY JONATHON,ATHENEX INC (2015-08-26);;ATNX SPV LLC (2022-06-29),https://lens.org/072-466-480-938-731,Granted Patent,yes,57,16,4,64,0,A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/02;;A61P37/06;;C07D413/12;;C07D413/12,A61K31/535,514/235.2,27,22,093-514-661-071-28X;;014-892-315-361-770;;024-246-415-334-792;;013-644-197-083-407;;029-742-983-481-795;;133-545-268-130-061;;014-944-545-982-558;;056-481-350-704-182;;017-937-967-857-021;;041-703-940-947-068;;085-441-379-277-757;;083-766-165-487-727;;016-856-688-460-880;;008-506-871-340-22X;;014-281-294-082-381;;002-209-090-598-253;;196-137-673-224-806;;045-942-893-332-610;;059-992-524-705-606;;101-726-729-921-07X;;048-203-518-030-581;;001-516-175-552-397,5748697;;10.1021/jm00311a010;;15362850;;10.1021/bi0495073;;11102447;;10.1074/jbc.m008368200;;12020799;;10.1016/s0304-419x(02)00040-9;;10.1126/science.286.5439.531;;10521349;;pmc6757905;;12122079;;10.1523/jneurosci.22-14-06208.2002;;20026599;;10.1021/jm049876x;;15369401;;10.1021/jm00364a026;;6137568;;1875332;;10.1021/jm00112a001;;9544425;;10.1023/a:1005960822365;;10.1002/chin.200429087;;10.1021/jm00023a009;;7473597;;14739300;;10.1074/jbc.m311032200;;10.1517/13543776.15.9.1183;;10.1038/84675;;11175854;;17186241;;10.1007/s00280-006-0398-z;;10.1021/cen-v081n008.p032;;pmc33604;;10.1073/pnas.96.14.7697;;10393883;;10.1016/j.bmcl.2003.11.079;;15013006;;10.1002/chin.200334072;;10.1007/s11864-001-0072-y;;12057096;;10.1016/s0169-409x(01)00097-7;;11325474,"Bryn et al., ""Hydrates and Solvates"", in Solid-State Chem. Drugs, 2nd Ed., SSCI, Inc.,IN, Ch. 11, pp. 233-247 (1999).;;Cain et al., ""Potential Antitumor Agents. IX. Bisquaternary Salts"", J. Med. Chem., 11(5):963-966 (1968).;;Davidson et al., ""Discovery and Characterization of a Substrate Selective p38alpha Inhibitor"", Biochemistry, 43:11658-11671 (2004).;;Duong et al., ""Inhibition of Osteoclast Function by Adenovirus Expressing Antisense Protein-tyrosine Kinase 2"", J. Biol. Chem., 276(10):7484-7492 (2001).;;Frame, M.C., ""Src in cancer:deregulation and consequences for cell behaviour"", Biochem. Biophys. Acta, 1602:114-130 (2002).;;Golub et al., ""Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring"", Science, 286:531-537 (1999).;;Guo et al., ""Tyrosine Phosphorylation of the NR2B Subunit of the NMDA Receptor in the Spinal Cord during the Development and Maintenance of Inflammatory Hyperalgesia"", J. Neurosci., 22(14):6208-6217 (2002).;;Hadjeri et al., ""Antimitotic Activity of 5-Hydroxy-7-methoxy-2-phenyl-4-quinolones"". J. Med. Chem., 47:4964-4970 (2004).;;Honma et al., ""Antiallergic agents. 2. N-(1H-Tetrazol-5-y1)-6-phenyl-2-pyridinecarboxamides"", J. Med. Chem., 26:1499-1504 (1983).;;Huff, J.R., ""HIV Protease: A Novel Chemotherapeutic Target for AIDS"", J. Med. Chem., 34(8):2305-2314 (1991).;;Lala et al., ""Role of nitric oxide in tumor progression: Lessons from experimental tumors"", Cancer Metastasis Rev., 17(1):91-106 (1998).;;Liechti et al., ""Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor"", Eur. J. Med. Chem., 39(1):11-26 (2004).;;Million et al , ""Inhibition of the EGF-Stimulated Cellular Proliferation of ER 22 Cells by Hydroxybiphenyl Derivatives"", J. Med. Chem., 38(23):4693-4703 (1995).;;Miyazaki et al., ""Src Kinase Activity is Essential for Osteoclast Function"", J. Biol. Chem., 279(17):17660-17666 (2004).;;Parang et al., ""Recent advances in the discovery of Src kinase inhibitors"", Expert Opin. Ther. Patents, 15(9):1183-1207 (2005).;;Paul et al., ""Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke"", Nat. Med., 7(2):222-227 (2001).;;Planas-Silva et al., ""Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins"", Cancer Chemother. Pharmacol., 60(4):535-543 (2006).;;Rouhi et al., ""The Right Stuff: From research and development to the clinic, getting drug crystals right is full of pitfalls"", Chem. Eng. News, pp. 32-35 (2003).;;U.S. Pharmacopia #23, National Formulary #18, pp. 1843-1844 (1995).;;Yu et al., ""Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors"", Proc. Natl. Acad. Sci. USA, 96:7697-7704 (1999).;;Zhang et al., ""Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs"", Bioorg. Med. Chem. Lett., 14(4):983-987 (2004).;;An et al. ""Oxidation of N-Benzylaldimines to N-Benzylamides by MCPBA and BF3OEt2."" Synlett. 6(2003):876-878.;;Croteau et al. ""Adults with Newly Diagnosed High-Grade Gliomas."" Current Treatment Options in Oncology. 2(2001):507-515.;;Garrido et al. ""Synthesis of N,N'-Diacy1-1,2-di-(4-pyridyl)ethylenediamines."" J. Het. Chem. 18(1981):1305-1308.;;Han, ""Advances in Characterization of Pharmaceutical Hydrates."" Trends in Bio/Pharmaceutical Industry. 3(2006):25-29.;;Stella et al. ""Prodrugs: Challenges and Rewards."" Biotechnology: Pharmaceutical Aspects. New York:Springer-Verlag. 1(2007):24.;;Vippagunt et al. ""Cyrstalline Solids."" Advanced Drug Delivery Reviews. 48(2001):3-26.",ACTIVE
409,EP,A2,EP 0175617 A2,061-936-480-960-343,1986-03-26,1986,EP 85401776 A,1985-09-13,US 65037584 A;;US 65075484 A,1984-09-13,Antibody-therapeutic agent conjugates.,This invention relates to antibody-therapeutic agent conjugates having a therapeutic agent covalently attached to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody conjugates. Therapeutic in vivo methods utilizing such antibody-therapeutic agent conjugates are described. Additionally novel photosensitizers suitable for use in preparing antibody-therapeutic agents are also described.,CYTOGEN CORP,GOERS JOHN WALTER;;LEE CHYI;;SIEGEL RICHARD CHARLES;;MCKEARN THOMAS JOSEPH;;KING HURLEY DALTON;;COUGHLIN DANIEL JAMES;;RODWELL JOHN DENNIS;;ALVAREZ VERNON LEON,,https://lens.org/061-936-480-960-343,Patent Application,yes,0,43,12,90,0,A61K51/1093;;A61K41/0042;;A61K41/0057;;A61K41/0071;;A61K51/10;;A61K2121/00,A61K41/00;;A61K51/10,,0,0,,,,EXPIRED
410,AT,T1,AT E68974 T1,150-317-946-546-499,1991-11-15,1991,AT 85401776 T,1985-09-13,EP 85401776 A;;US 65075484 A;;US 65037584 A,1984-09-13,THERAPEUTISCHE ANTIKOERPERMITTELKONJUGATE.,,CYTOGEN CORP,GOERS JOHN WALTER;;LEE CHYI;;SIEGEL RICHARD CHARLES;;MCKEARN THOMAS JOSEPH;;KING HURLEY DALTON;;COUGHLIN DANIEL JAMES;;RODWELL JOHN DENNIS;;ALVAREZ VERNON LEON,,https://lens.org/150-317-946-546-499,Granted Patent,no,0,0,1,90,0,,A61K39/395,,0,0,,,,DISCONTINUED
411,EP,B1,EP 0175617 B1,042-354-305-059-452,1991-10-30,1991,EP 85401776 A,1985-09-13,US 65037584 A;;US 65075484 A,1984-09-13,ANTIBODY-THERAPEUTIC AGENT CONJUGATES,,CYTOGEN CORPORATION,"GOERS, JOHN WALTER;;LEE, CHYI;;SIEGEL, RICHARD CHARLES;;MCKEARN, THOMAS JOSEPH;;KING, HURLEY DALTON;;COUGHLIN, DANIEL JAMES;;RODWELL, JOHN DENNIS;;ALVAREZ, VERNON LEON",,https://lens.org/042-354-305-059-452,Granted Patent,yes,0,35,12,90,0,A61K51/1093;;A61K41/0042;;A61K41/0057;;A61K41/0071;;A61K51/10;;A61K2121/00,A61K41/00;;A61K51/10,,1,0,,,"CHEMICAL ABSTRACTS, vol. 89, no. 13, 25 September 1978, Columbus, Ohio, US; abstract no. 110773Z, page 29",EXPIRED
412,DE,D1,DE 3584559 D1,049-223-385-904-20X,1991-12-05,1991,DE 3584559 T,1985-09-13,US 65037584 A;;US 65075484 A,1984-09-13,THERAPEUTISCHE ANTIKOERPERMITTELKONJUGATE.,,CYTOGEN CORP,GOERS JOHN WALTER;;LEE CHYI;;SIEGEL RICHARD CHARLES;;MCKEARN THOMAS JOSEPH;;KING HURLEY DALTON;;COUGHLIN DANIEL JAMES;;RODWELL JOHN DENNIS;;ALVAREZ VERNON LEON,,https://lens.org/049-223-385-904-20X,Granted Patent,no,0,0,12,90,0,A61K51/1093;;A61K41/0042;;A61K41/0057;;A61K41/0071;;A61K51/10;;A61K2121/00,A61K41/00;;A61K51/10,,0,0,,,,EXPIRED
413,EP,A3,EP 0175617 A3,020-077-579-266-44X,1988-06-15,1988,EP 85401776 A,1985-09-13,US 65037584 A;;US 65075484 A,1984-09-13,ANTIBODY-THERAPEUTIC AGENT CONJUGATES,This invention relates to antibody-therapeutic agent conjugates having a therapeutic agent covalently attached to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody conjugates. Therapeutic in vivo methods utilizing such antibody-therapeutic agent conjugates are described. Additionally novel photosensitizers suitable for use in preparing antibody-therapeutic agents are also described.,CYTOGEN CORPORATION,"GOERS, JOHN WALTER;;LEE, CHYI;;SIEGEL, RICHARD CHARLES;;MCKEARN, THOMAS JOSEPH;;KING, HURLEY DALTON;;COUGHLIN, DANIEL JAMES;;RODWELL, JOHN DENNIS;;ALVAREZ, VERNON LEON",,https://lens.org/020-077-579-266-44X,Search Report,yes,1,0,12,90,0,A61K51/1093;;A61K41/0042;;A61K41/0057;;A61K41/0071;;A61K51/10;;A61K2121/00,A61K41/00;;A61K51/10,,9,6,090-802-635-099-729;;051-361-301-178-501;;106-020-965-469-000;;070-088-469-625-840;;171-783-818-492-895;;078-861-637-355-816,6185591;;10.4049/jimmunol.130.3.1473;;10.1002/ijc.2910140414;;4477557;;7410836;;10.1093/ee/11.2.467;;4028022;;10.1039/c39850000198,"THE JOURNAL OF IMMUNOLOGY, vol. 130, no. 3, March 1983, pages 1473-1477, American Association of Immunologists, US; D. MEW et al.: ""Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates"";;CHEMICAL ABSTRACTS, vol. 82, no. 3, 20th January 1975, page 361, abstract no. 15067u, Columbus, Ohio, US; W.T. SHEARER et al.: ""Cytotoxicity with antibody-glucose oxidase conjugates specific for a human colonic cancer and carcioembryonic antigen""; & INT. J. CANCER 1974, 14(4), 539-47;;CHEMICAL ABSTRACTS, vol. 102, no. 15, 15th April 1985, page 283, abstract no. 128005x, Columbus, Ohio, US; Ch. K. WAT et al.: ""Photosensitizerprotein conjugates: potential use as photoimmunotherapeutic agents"", & PROG. CLIN. BIOL. RES. 1984, 170 (Porphyrin localization treat tumors), 351-9;;CHEMICAL ABSTRACTS, vol. 103, no. 15, 14th October 1985, page 558, abstract 121395m, Columbus, Ohio, US; D. Mew et al.: ""Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation""; & CANCER RES. 1985, 45 (9), 4380-6;;THE JOURNAL OF IMMUNOLOGY, vol. 125, no. 3, September 1980, page 1201, WILLIAMS & WILKINS Co., US; G.W. PHILPOTT et al.: ""Selective binding and cytotoxicity of rat basophilic leukemia cells (RBL-1) with immunoglobulin E-biotin and avidin-glucose oxidase conjugates"";;CHEMICAL ABSTRACTS, vol. 89, no. 13, 25th September 1978, page 29, abstract no. 110773z, Columbus, Ohio, US; & JP-A-52 141 882 (E. HASEGAWA et al.) (26-11-1977);;CHEMICAL ABSTRACTS, vol. 97, no. 7, 16th August 1982, page 224, abstract nr. 51193a, Columbus, Ohio, US; H. SAKURAI et al.: ""Growth inhibition and photoxidative toxicity in the housefly. Musca domestica L. caused by xanthene dye in larval growth medium and after injection""; & ENVIRON. ENTOMOL. 1982, 11(2), 467-70;;CANCER RESEARCH, vol. 45, September 1985, pages 4380-4386, D. MEW et al.: ""Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation"".;;CHEMICAL ABSTRACTS, vol. 103, no. 5, 5th August 1985, page 491, abstract no. 37259n, Columbus, Ohio, US; R. OCAMPO et al.: ""Identification of polar porphyrins in oil shale""; & J. CHEM. SOC. CHEM. COMMUN. 1985,(4), 198-200",EXPIRED
414,DK,A,DK 218386 A,021-525-951-566-872,1986-07-11,1986,DK 218386 A,1986-05-12,US 65037584 A;;US 65075484 A;;US 8501700 W,1984-09-13,KONJUGATER AF ANTISTOF OG TERAPEUTISK MIDDEL,,CYTOGEN CORP,GOERS JOHN WALTER FRANK;;KING HURLEY DALTON;;LEE CHYI;;COUGHLIN DANIEL JAMES;;SIEGEL RICHARD CHARLES;;RODWELL JOHN DENNIS;;MCKEARN THOMAS JOSEPH;;ALVAREZ VERNON LEON,,https://lens.org/021-525-951-566-872,Patent Application,no,0,0,12,90,0,A61K51/1093;;A61K41/0042;;A61K41/0057;;A61K41/0071;;A61K51/10;;A61K2121/00,A61K41/00;;A61K51/10,,0,0,,,,DISCONTINUED
415,WO,A1,WO 1986/001720 A1,034-423-098-692-365,1986-03-27,1986,US 8501700 W,1985-09-10,US 65037584 A;;US 65075484 A,1984-09-13,ANTIBODY THERAPEUTIC AGENT CONJUGATES,Antibody-therapeutic agent conjugates having a therapeutic agent covalently attached to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody conjugates. Therapeutic in vivo methods utilizing such antibody-therpautic agent conjugates are described. Additionally novel photosensitizers suitable for use in preparing antibody-therapeutic agents are also described.,CYTOGEN CORP,GOERS JOHN WALTER FRANK;;KING HURLEY DALTON;;LEE CHYI;;COUGHLIN DANIEL JAMES;;SIEGEL RICHARD CHARLES;;RODWELL JOHN DENNIS;;MCKEARN THOMAS JOSEPH;;ALVAREZ VERNON LEON,,https://lens.org/034-423-098-692-365,Patent Application,yes,2,8,12,90,0,A61K51/1093;;A61K41/0042;;A61K41/0057;;A61K41/0071;;A61K51/10;;A61K2121/00,A61K41/00;;A61K51/10,C3H HHX2          HHX2;;C3H H501          HHX2;;C3H H508          HHX2;;C3H H514          HHX2;;C3H H515          HHX2;;C3H H530          HHX2;;U1S S1313,6,5,090-802-635-099-729;;005-334-346-125-348;;029-269-446-589-556;;053-420-688-904-765;;006-392-791-860-123,6185591;;10.4049/jimmunol.130.3.1473;;7191812;;10.1016/0014-5793(80)81026-x;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;6965909;;10.1111/j.1432-1033.1980.tb04438.x;;365720;;10.1016/0161-5890(78)90003-2,"Mew et al: J. Immunology, Vol. 130(3) March 1983, pp. 1473-1477;;Monsigny et al: FEBS Letters, Sept. 1980, Vol. 119(1) pp. 181-186;;Trouet et al: Proc. Natl. Acad. Sci., Vol. 79 (1) January 1982, pp. 626-629;;Ross et al: Eur. J. Biochem., Vol. 104, PP. 381-390, 1980;;Stanworth et al: Handbook of Exp. Immun, Vol. I 2nd Ed. Weir, Editor; Blackwell Scientific Publications, London, Chapter 10, 1973;;Murayama et al: Immunochem., Vol. 15, pp. 523-528, 1978",PENDING
416,CA,C,CA 1326834 C,130-242-361-978-086,1994-02-08,1994,CA 490424 A,1985-09-11,US 65037584 A;;US 65075484 A,1984-09-13,PORPHYRIN DERIVATIVES,ABSTRACT OF THE DISCLOSURE This invention relates to antibody-therapeutic agent conjugates having a therapeutic agent covalently attached to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody conjugates. Therapeutic in vivo methods utilizing such antibody-therapeutic agent conjugates are described. Additionally novel photosensitizers suitable for use in preparing antibody-therapeutic agents are also described.,CYTOGEN CORP,GOERS JOHN W F;;KING HURLEY D;;LEE CHYI;;COUGHLIN DANIEL J;;SIEGEL RICHARD C;;RODWELL JOHN D;;MCKEARN THOMAS J;;ALVAREZ VERNON L,,https://lens.org/130-242-361-978-086,Granted Patent,no,0,0,12,90,0,A61K41/0042;;A61K41/0057;;A61K51/10;;A61K51/1093;;A61K2121/00;;A61K41/0071,A61K41/00;;A61K51/10,D319500011   M;;26002372   S,0,0,,,,EXPIRED
417,ZA,B,ZA 857064 B,142-369-404-325-290,1987-05-27,1987,ZA 857064 A,1985-09-13,US 65037584 A,1984-09-13,ANTIBODY-THERAPEUTIC AGENT CONJUGATES,,CYTOGEN CORP,GOERS JOHN WALTER FRANK;;LEE CHYI;;SIEGEL RICHARD CHARLES;;MCKEARN THOMAS JOSEPH;;KING HURLEY DALTON;;COUGHLIN DANIEL JAMES;;RODWELL JOHN DENNIS;;ALVAREZ VERNON LEON,,https://lens.org/142-369-404-325-290,Granted Patent,no,0,0,2,90,0,,C12N15/00;;A61K/;;A61K39/00;;A61K39/395;;A61K45/00;;C07D/;;C07D487/00;;C07D487/22;;C07D493/00;;C07D493/10;;C07K14/00;;C07K16/00;;C07K19/00;;C12N/;;C12N15/02;;C12P21/00;;C12P21/08,,0,0,,,,EXPIRED
418,AU,A,AU 1989/030161 A,083-498-749-589-219,1989-07-13,1989,AU 1989/030161 A,1989-02-21,US 65037584 A;;US 65075484 A,1984-09-13,ANTIBODY-THERAPEUTIC AGENT CONJUGATE INTERMEDIATES,,CYTOGEN CORP,GOERS JOHN WALTER FRANK;;SIEGEL RICHARD CHARLES;;COUGHLIN DANIEL JAMES;;LEE CHYI;;KING HURLEY DALTON;;RODWELL JOHN DENNIS;;MCKEARN THOMAS JOSEPH;;ALVAREZ VERNON LEON,,https://lens.org/083-498-749-589-219,Patent Application,no,0,1,12,90,0,A61K51/1093;;A61K41/0042;;A61K41/0057;;A61K41/0071;;A61K51/10;;A61K2121/00,A61K41/00;;A61K51/10,,0,0,,,,DISCONTINUED
419,GR,B,GR 852217 B,097-157-225-885-562,1986-01-14,1986,GR 850102217 A,1985-09-12,US 65075484 A;;US 65037584 A,1984-09-13,GR 852217 B,,CYTOGEN CORP,GOERS JOHN WALTER FRANK;;LEE CHYI;;SIEGEL RICHARD CHARLES;;MICKEARN THOMAS JOSEPH;;KING HURLEY DALTON;;COUGHLIN DANIEL JAMES;;RODWELL JOHN DENNIS;;ALVAREZ VERNON LEON,,https://lens.org/097-157-225-885-562,Granted Patent,no,0,0,12,90,0,A61K51/1093;;A61K41/0042;;A61K41/0057;;A61K41/0071;;A61K51/10;;A61K2121/00,A61K41/00;;A61K51/10,,0,0,,,,EXPIRED
420,DK,D0,DK 218386 D0,031-260-101-594-211,1986-05-12,1986,DK 218386 A,1986-05-12,US 65037584 A;;US 65075484 A;;US 8501700 W,1984-09-13,KONJUGATER AF ANTISTOF OG TERAPEUTISK MIDDEL,,CYTOGEN CORP,GOERS JOHN WALTER FRANK;;KING HURLEY DALTON;;LEE CHYI;;COUGHLIN DANIEL JAMES;;SIEGEL RICHARD CHARLES;;RODWELL JOHN DENNIS;;MCKEARN THOMAS JOSEPH;;ALVAREZ VERNON LEON,,https://lens.org/031-260-101-594-211,Patent Application,no,0,0,12,90,0,A61K51/1093;;A61K41/0042;;A61K41/0057;;A61K41/0071;;A61K51/10;;A61K2121/00,A61K41/00;;A61K51/10,,0,0,,,,DISCONTINUED
421,US,A,US 5886224 A,061-330-327-632-224,1999-03-23,1999,US 89140397 A,1997-07-10,US 89140397 A;;US 59065096 A;;US 47359095 A;;US 41528395 A;;US 37804495 A;;US 265495 P;;US 737595 P,1995-01-24,alpha -diimines for polymerization catalysts,"Disclosed herein are processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic esters or carboxylic acids, and other monomers. The polymerizations are catalyzed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described herein is the synthesis of linear .alpha.-olefins by the oligomerization of ethylene using as a catalyst system a combination a nickel compound having a selected .alpha.-diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected .alpha.-diimine nickel complexes with ethylene.",DU PONT;;UNIV NORTH CAROLINA,BROOKHART MAURICE S;;JOHNSON LYNDA KAYE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;KRUETZER KRISTINA ANN;;BENNETT ALISON MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH,,https://lens.org/061-330-327-632-224,Granted Patent,yes,38,75,17,75,0,C08F110/02;;C08F110/02;;C08F10/00;;C08F10/00;;C08F10/02;;C08F10/02;;C08F10/06;;C08F10/06;;C08F110/06;;C08F110/06;;C08F110/14;;C08F110/14;;C08F210/02;;C08F210/02;;C08F210/14;;C08F210/14;;C08F210/16;;C08F210/16;;C08F232/00;;C08F232/00;;C08L23/02;;C08L23/02;;Y10S430/165;;Y10S430/165;;Y10T428/1352;;Y10T428/1352;;Y10T428/1386;;Y10T428/1386;;Y10T428/139;;Y10T428/139;;Y10T428/24942;;Y10T428/24942;;Y10T428/2878;;Y10T428/2878;;Y10T428/31692;;Y10T428/31692;;Y10T428/31855;;Y10T428/31855;;Y10T428/31895;;Y10T428/31895;;Y10T428/31938;;Y10T428/31938;;Y10T442/20;;Y10T442/20;;Y10T442/60;;Y10T442/60;;Y10T442/626;;Y10T442/626,B01J31/00;;B01J37/00;;C07C2/32;;C07C69/52;;C07C251/08;;C07F7/00;;C07F15/00;;C07F19/00;;C08F4/02;;C08F4/06;;C08F4/60;;C08F4/70;;C08F4/80;;C08F10/00;;C08F10/02;;C08F10/06;;C08F10/08;;C08F12/30;;C08F20/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/14;;C08F210/16;;C08F220/10;;C08F232/00;;C08F232/04;;C08F255/00;;C08L23/02,564/272;;564/270;;564/271;;564/277,59,43,177-347-884-688-64X;;101-579-530-746-406;;030-879-648-911-287;;050-373-888-844-623;;063-039-280-300-669;;039-142-183-108-89X;;042-522-701-231-875;;111-111-698-171-49X;;005-063-002-453-864;;076-405-685-873-413;;006-637-028-209-17X;;077-759-882-145-137;;135-659-417-443-693;;045-904-068-319-830;;165-789-127-128-402;;072-647-548-538-586;;031-235-936-595-146;;069-686-239-154-208;;047-388-678-146-759;;006-627-900-407-680;;114-216-909-982-55X;;046-925-223-398-487;;031-235-936-595-146;;027-541-666-632-63X;;141-962-524-305-949;;133-199-484-001-468;;049-434-420-066-011;;164-831-587-786-422;;013-459-583-169-642;;116-598-384-747-643;;051-135-574-887-615;;093-805-713-932-396;;051-135-574-887-615;;093-805-713-932-396;;098-076-046-369-775;;083-137-309-271-641;;099-058-421-181-908;;162-040-217-658-278;;129-574-938-069-043;;022-507-155-586-191;;036-680-143-987-323;;083-064-288-336-703;;029-243-457-817-264,10.1021/ma60067a010;;10.1021/ma00139a022;;10.1002/app.1994.070510102;;10.1021/ma00206a027;;10.1002/anie.198101161;;10.1002/anie.198510011;;10.2116/bunsekikagaku.29.11_774;;10.1002/pol.1968.110060504;;10.1016/s0040-4020(01)80757-2;;10.1039/c39930001203;;10.1021/ja00082a020;;10.1002/recl.19941130204;;10.1021/om00014a049;;10.1016/s0022-328x(00)88576-9;;10.1016/0014-3057(92)90322-s;;10.1002/pol.1969.110070411;;10.1021/ma00238a039;;10.1021/ja00105a088;;10.1002/anie.198003961;;10.1002/cber.19841170222;;10.1021/ma00026a017;;10.1002/recl.19911101207;;10.1021/ma00238a039;;10.1002/macp.1966.020900103;;10.1021/ma60012a027;;10.1002/macp.1989.021900308;;10.1021/ma00094a008;;10.1021/ma00125a010;;10.1016/s0020-1693(00)85976-9;;10.1002/cber.19761090508;;10.1021/ja00128a054;;10.1021/ja953247i;;10.1021/ja00128a054;;10.1021/ja953247i;;10.1021/ja00974a030;;10.1002/marc.1995.030160102;;10.1021/ma00088a007;;10.1021/ja00087a077;;10.1002/cber.19851180203;;10.1016/0304-5102(86)87079-1;;10.1021/ma00027a039;;10.1016/0020-1693(94)03854-6;;10.1016/0022-328x(91)86318-k,"J. March, Advanced Organic Chemistry, 4th Ed., Wiley, New York. 1992, pp. 285 286.;;M. Charton, (1975) J. Am. Chem. Soc. 97, 1552 1556.;;A.Y. Meyers, J. Chem. Soc. Perkins Trans. II, 1567 1572 (1986).;;M.S. Newman, Staric Effects in Organic Chemistry, Wiley, New York, 1956, pp. 598 603.;;RWTaft, Jr. (1952) J. Am. Chem. Soc. 74, 3120 28.;;D. E. Axelson, et al., A Quantitative Analysis of Low Density (Branched) Polyethylenes by Carbon 13 Fourier Transform Nuclear Magnetic Resonance at 67.9 MHz, Macromolecules, 12, 41 52, 1979.;;T. Usami, et al., Fine Branching Structure in High Pressure, Low Density Polyethylenes by 50.10 MHz 13 C NMR Analysis, Macromolecules, 17, 1757 1761, 1984.;;J. P. Blitz, et al., The Characterization of Short Chain Branching in Polyethylene Using Fourier Transform Infrared Spectroscopy, Journal of Applied Polymer Science, 51, 1, 13 20, 1994.;;E. Nordmeier, et al., The Molecular Structure of Low Density Polyethylene. 1. Long Chain Branching and Solution Properties, Macromolecules, 23, 4, 1072 1076, 1990.;;F. A. Bovey, et al., C 13 NMR Observations of Chain Branching in Vinyl Polymers, Polym. Preprs Am Chem Soc Div Polym Chem, 20, 2, 160 163, 1979.;;W. Keim, et al., Novel Nickel and Palladium Complexex with Aminobis(imino)phosphorane Ligands for the Polymerization of Ethylene, Angew. Chem. Int. Ed. Engl., 20, 116 117, 1981.;;V. M. Mohring, et al., Novel Polymerization of Olefins with the Catalyst System Nickel/Aminobis(imino)phosphorane, Angew. Chem. Int. Ed. Engl., 24, 1001 1003, 1985.;;Nishioka, et al., Assignment of Chain Branching . . . , Bunseki Kagaku, 29, 11, 774 780, 1980.;;A. D. Ketley, et al., The 1,3 Polymerization of Propylene by Palladium Cyanide, Polymer Letters, 6, 341 343, 1968.;;R. van Asselt, et al., Palladium Complexes Containing Rigid Bidentate Nitrogen Ligands as Catalysts for Carbon Carbon Bond Formation, Tetrahedron, 50, 2, 323 334, 1994.;;R. van Asselt, et al., Isolation of Alkyl and Acyl palladium Complexes containing Rigid Bidentate Nitrogen Ligands by Stepwise Successive Insertion of CO and Alkenes, J. Chem. Soc. Commun., 15, 1203 1205, 1993.;;R. van Asselt, et al., Insertion of Carbon Monoxide and Alkenes in Palladium Carbon Bonds of Complexes Containing Rigid Bidentate Nitrogen Ligands: The First Example of Isolated Complexes in Stepwise Successive Insertion Reactions on the Way to Polyketones, J. Am. Chem. Soc., 116, 3, 977 985, 1994.;;R. van Asselt, et al., Synthesis and characterization of rigid bidentate nitrogen ligands and some examples of coordination to divalent palladium. X ray crystal structures of bis( tolylimino)acenaphthene and methylchloro bis(o,o diisopropylphenyl imino)acenaphthene palladium(II), Recl. Trav. Chim. Pays Bas, 113, 2, 88 89, 1994.;;R. van Asselt, Stablization of High Oxidation States by Rigid Bidentate Nitrogen Ligands; Synthesis and Characterization of Diorgano and Triorganopalladium(IV) and Cationic Triorganoplatinum (IV) Complexes, Organometallics, 13, 2, 706 720, 1994.;;M. Svoboda, et al., Diazadien Nickel Alkyle, J. Organometal Chem, 191, 1 321 328, 1980.;;N. Alberola, et al., Mechanical and Relaxations in Polyethylene I. Glass Transitions of Polyethylene, Eur. Polym. J., 28, 8, 935 948, 1992.;;E. W. Fischer, et al., Effect of Filtration Conditions on the Apparent Density of the Intercrystalline Layers of Polyethylene Single Crystal Mats, Polymer Letters, 7, 307 311, 1969.;;David R. Burfield, et al., Differential Scanning Calerimetry Characteristics of Polypropylene. Dependence of Tg on Polymer Tacticity and Molecular Weight, Macromolecules, 16, 702 704, 1983.;;Piet W. N. M. van Leeuwen, et al., Migration versus Insertion in Square Planar Platinum and Palladium Complexes, J. Am. Chem. Soc., 116, 12117 12118, 1994.;;Heindirk tom Dieck, et al., Rigid Phenyl Group Conformation in Complexes, Angew. Chem. Intl. Ed. Engl, 19, 396 397, 1980.;;Heindirk tom Dieck, et al., Synthesis of Chiral Diazadienes R* N CR CR N R*, Chem. Ber., 117, 694 701, 1984.;;K. Zemke, et al., Conformational Exchange near the Glass Transition: Two Dimensional 13 C NMR Study of Atactic Polypropylene, Macromolecules, 24, 6874 6876, 1991.;;J. C. Randall, et al., 13 C NMR microstructure determinations of low density polyethylene homopolymers and copolymers, Recl. Trav. Chim. Pays Bas, 110, 543 552, 1991.;;David R. Burfield, et al., Differential Scanning Calorimetry Characterization of Polypropylene. Dependence of Tg on Polymer Tacticity and Molecular Weight, Macromolecules, 16, 702 704, 1983.;;Jan Tecl, Studium vetveni polyethylenu nuklearni magnetickou resonancni spektroskopii, Chemicky prumyal, roc., 37/62, 196 200, 1987.;;G. Natta, et al., Crystalline Alternating Ethylene Cyclopentene Copolymers and Other Ethylene Cycloolefin Copolymers, Makromol. Chem., 54, 95 101, 1962.;;J. Boor, et al., Polymerization of Cyclopentene, 3 Methylcyclopentence, and 3 Methylcyclohexene, Die Makromolekulare Chemie, 90, 26 37, 1966.;;B. C. Anderson, et al., Polymerization of Internal Olefins, Macromolecules, 2, No. 6, 686 687, 1969.;;Walter Kaminsky, et al., Copolymerization of cycloalkenes with ethylene in presence of chiral zirconocene catalysts, Makromol. Chem., 190, 515 526, 1989.;;W. Kaminsky, et al., in T. Keii, et al., Eds., Polymerization of Cyclic Olefins with Homogeneous Catalysts, Catalytic Olefin Polymerization, 929, 425 438, 1990.;;W. Mark Kelly, et al., Polymerization of Cyclopenetene Using Metallocene Catalysts: Polymer Tacticity and Properties, Macromolecule, 27, 4477 4485, 1994.;;Alexej Jerschow, et al., Nuclear Magnetic Resonance Evidence for a New Microstructure in Ethene Cyclopentene Copolymers, Macromolecules, 28, 7095 7099, 1995.;;Heindirk tom Dieck, et al., Diazadiene complexes of Group 4 metals I. Synthesis of mono , bis and tris(diazadiene) titanium complexes and the structure of diazadienedichlorotitanium, Inorganica Chimica Acta., 177, 191 197, 1990.;;Heindirk tom Dieck, et al., Metallierung einer nichtaktivierten Alkyl Gruppe im Nickelkomplex 1, Chem. Ber., 109, 1657 1664, 1976.;;Lynda K. Johnson, et al., New Pd(II) and Ni(II) Based Catalysts for Polymerization of Ethylene and Olefins, J. Am Chem. Soc., 117, 6414 6415, 1995.;;Lynda K. Johnson, et al., Copolymerization of Ethylene and Propylene with Functionalized Vinyl Monomers by Palladium(II) Catalysts, J. Am. Chem. Soc., 118, 267 268, 1996.;;PCT/US 96/01282 Partial International Search.;;Johnson, et al., New Pd(II) and Ni(II) Based Catalysts for Polymerization of Ethylene and Olefins, J. Am. Chem. Soc., 117, 6414 6415, 1995.;;Johnson, et al., Copolymerization of Ethylene and Propylene with Functionalized Vinyl Monomers by Palladium (II) Catalysts, J. Am. Chem. Soc., 118, 267 268, 1996.;;Saito, et al., Diethyldipyridylnickel. Preparation, Characterization, and Reactions, J. Am. Chem. Soc., 88:22, 5198 5201, 1966.;;Bartolini, et al., Enantioselective isotactic alternating copolymerization of styrene and 4 methylstyrene with carbon monoxide catalyzed by a cationic bioxazoline Pd(II) complex, Macromol.Rapid Commun., 16, 9 14, 1995.;;Jiang, et al., Stereo and Enantioselective Alternating Copolymerization of Olefins with Carbon Monoxide. Synthesis of Chiral Polymers, Macromolecules, 27,2694 2700, 1994.;;Brookhart, et al., Polymers with Main Chain Chirality. Synthesis of Highly Isotactic, Optically Active Poly(4 tert butylstyrene alt CO) Using Pd(II) Catalysts Based on C 2 Symmetic Bisoxazoline Ligands, J. Am. Chem. Soc., 116, 3641 3642, 1994.;;Diercks, et al., Katalytische Cyclotetramerisierung von Propiols a ureestern, Chem. Ger., 118, 428 435, 1985.;;Dierck, et al., Diazadienes as Control Ligands in Catalysis Part 12.* The Nickel Catalyzed Cyclotetramerization of Propargylic Alchol to Substituted Cyclooctatetraenes and the Structure of 1,3,5,7 Tetrakis(Hydroxymethyl)Cyclooctatetraene, Journal of Molecular Catalysis, 35, 317 328, 1986.;;PCT International Search Report dated Oct. 21, 1996 for PCT/US96/01282 (CR 9608 D).;;Montecatini Societa Generale Per L Industria Mineria E Chimica: Catalytic Manufacture of Olefin Copolymers with Three or More Monomer Components , Chemical Abstracts, 77, No. 8, 1972, Abstract No. 49803t.;;Scott Collins & W. Mark Kelly, The Microstructure of Poly(cyclopentene) Produced by Polymerization of Cyclopentene with Homogeneous Ziegler Natta Catalysts, Macromolecules, 25, 233 237, 1992.;;Wissing, e et al., Influence of bulky substituents on the regioselective group transfer reactions of diorganozinc compounds with N,N bis(2,6 di isopropenyl) 1,4 diaza 1,3 butadiene, Chemical Abstracts, 121, No. 11, 1055, 1994, Abstract No. 134322g.;;Christina Munz, Constantin Stephan and Heindirk tom Dieck, Diazadiene stablized palladacyclopent 2 enes and the catalytic addition of various allylic systems to dimethyl acetylenedicarboxylate, Journal of Organometallic Chemistry, 407, 413 420, 1991.;;Werner Bonrath, Klaus R. P o rschke, Richard Mynott and Carl Kr u ger, Synthesis and Structure of Ni(2,6 i Pr 2 C 6 H 3 N CH CH NC 6 H 3 2,6 i Pr 2 ) 2 , Zeitschrift F u r Naturforschung, 456, 1647 1650, 1990.;;Emulsion Polymerization to Fibers, Manufacture, Encyclopedia of Polymer Science and Engineering, vol. 6, pp. 385 387, Copyright 1986.;;Editors: Barbara Elvers, Stephen Hawkins, Gail Schulz, Plastics, Properties and Testing to Polyvinyl Compounds Ullmann s Encyclopedia of Industrial Chemistry, vol. A 21, pp. 488 493, 1992.;;Polymer Technology Dictionary, Tony Whelan MSc, Consultant, Chapman & Hall, 1994, pp. 1, 282, 312.",EXPIRED
422,US,A,US 6034259 A,082-997-291-707-489,2000-03-07,2000,US 89139897 A,1997-07-10,US 89139897 A;;US 59065096 A;;US 47359095 A;;US 41528395 A;;US 37804495 A,1995-01-24,alpha -olefins and olefin polymers and processes therefor,"Disclosed herein are processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic esters or carboxylic acids, and other monomers. The polymerizations are catalyzed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described herein is the synthesis of linear .alpha.-olefins by the oligomerization of ethylene using as a catalyst system a combination a nickel compound having a selected .alpha.-diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected .alpha.-diimine nickel complexes with ethylene.",DU PONT;;UNIV NORTH CAROLINA,BROOKHART MAURICE S;;JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT ALISON MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH,,https://lens.org/082-997-291-707-489,Granted Patent,yes,37,34,17,75,0,C08F110/02;;C08F110/02;;C08F10/00;;C08F10/00;;C08F10/02;;C08F10/02;;C08F10/06;;C08F10/06;;C08F110/06;;C08F110/06;;C08F110/14;;C08F110/14;;C08F210/02;;C08F210/02;;C08F210/14;;C08F210/14;;C08F210/16;;C08F210/16;;C08F232/00;;C08F232/00;;C08L23/02;;C08L23/02;;Y10S430/165;;Y10S430/165;;Y10T428/1352;;Y10T428/1352;;Y10T428/1386;;Y10T428/1386;;Y10T428/139;;Y10T428/139;;Y10T428/24942;;Y10T428/24942;;Y10T428/2878;;Y10T428/2878;;Y10T428/31692;;Y10T428/31692;;Y10T428/31855;;Y10T428/31855;;Y10T428/31895;;Y10T428/31895;;Y10T428/31938;;Y10T428/31938;;Y10T442/20;;Y10T442/20;;Y10T442/60;;Y10T442/60;;Y10T442/626;;Y10T442/626,B01J31/00;;B01J37/00;;C07C2/32;;C07C69/52;;C07C251/08;;C07F7/00;;C07F15/00;;C07F19/00;;C08F4/02;;C08F4/06;;C08F4/60;;C08F4/70;;C08F4/80;;C08F10/00;;C08F10/02;;C08F10/06;;C08F10/08;;C08F12/30;;C08F20/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/14;;C08F210/16;;C08F220/10;;C08F232/00;;C08F232/04;;C08F255/00;;C08L23/02,556/137;;556/1;;556/7;;556/13;;556/43;;556/51;;556/52;;556/57;;556/58;;556/140;;556/155;;556/167;;534/15;;502/155;;526/348,54,43,177-347-884-688-64X;;101-579-530-746-406;;030-879-648-911-287;;050-373-888-844-623;;063-039-280-300-669;;039-142-183-108-89X;;042-522-701-231-875;;111-111-698-171-49X;;005-063-002-453-864;;076-405-685-873-413;;006-637-028-209-17X;;077-759-882-145-137;;135-659-417-443-693;;045-904-068-319-830;;165-789-127-128-402;;072-647-548-538-586;;031-235-936-595-146;;069-686-239-154-208;;047-388-678-146-759;;006-627-900-407-680;;114-216-909-982-55X;;046-925-223-398-487;;031-235-936-595-146;;027-541-666-632-63X;;141-962-524-305-949;;133-199-484-001-468;;049-434-420-066-011;;164-831-587-786-422;;013-459-583-169-642;;116-598-384-747-643;;051-135-574-887-615;;093-805-713-932-396;;051-135-574-887-615;;093-805-713-932-396;;098-076-046-369-775;;083-137-309-271-641;;099-058-421-181-908;;162-040-217-658-278;;129-574-938-069-043;;022-507-155-586-191;;036-680-143-987-323;;083-064-288-336-703;;029-243-457-817-264,10.1021/ma60067a010;;10.1021/ma00139a022;;10.1002/app.1994.070510102;;10.1021/ma00206a027;;10.1002/anie.198101161;;10.1002/anie.198510011;;10.2116/bunsekikagaku.29.11_774;;10.1002/pol.1968.110060504;;10.1016/s0040-4020(01)80757-2;;10.1039/c39930001203;;10.1021/ja00082a020;;10.1002/recl.19941130204;;10.1021/om00014a049;;10.1016/s0022-328x(00)88576-9;;10.1016/0014-3057(92)90322-s;;10.1002/pol.1969.110070411;;10.1021/ma00238a039;;10.1021/ja00105a088;;10.1002/anie.198003961;;10.1002/cber.19841170222;;10.1021/ma00026a017;;10.1002/recl.19911101207;;10.1021/ma00238a039;;10.1002/macp.1966.020900103;;10.1021/ma60012a027;;10.1002/macp.1989.021900308;;10.1021/ma00094a008;;10.1021/ma00125a010;;10.1016/s0020-1693(00)85976-9;;10.1002/cber.19761090508;;10.1021/ja00128a054;;10.1021/ja953247i;;10.1021/ja00128a054;;10.1021/ja953247i;;10.1021/ja00974a030;;10.1002/marc.1995.030160102;;10.1021/ma00088a007;;10.1021/ja00087a077;;10.1002/cber.19851180203;;10.1016/0304-5102(86)87079-1;;10.1021/ma00027a039;;10.1016/0020-1693(94)03854-6;;10.1016/0022-328x(91)86318-k,"D. E. Axelson, et al., A Quantitative Analysis of Low Density (Branched) Polyethylenes by Carbon 13 Fourier Transform Nuclear Magnetic Resonance at 67.9 MHz, Macromolecules , 12, 41 52, 1979.;;T. Usami, et al., Fine Branching Structure in High Pressure, Low Density Polyethylenes by 50.10 MHz 13 C NMR Analysis, Macromolecules , 17, 1757 1761, 1984.;;J. P. Blitz, et al., The Characterization of Short Chain Branching in Polyethylene Using Fourier Transform Infrared Spectroscopy, Journal of Applied Polymer Science , 51, 1, 13 20, 1994.;;E. Nordmeier, et al., The Molecular Structure of Low Density Polyethylene. 1. Long Chain Branching and Solution Properties, Macromolecules , 23, 4, 1072 1076, 1990.;;F. A. Bovey, et al., C 13 NMR Observations of Chain Branching in Vinyl Polymers, Polym. Preprs Am Chem Soc Div Polym Chem , 20, 2, 160 163, 1979.;;W. Keim, et al., Novel Nickel and Palladium Complexes with Aminobis(imino)phosphorane Ligands for the Polymerization of Ethylene, Angew. Chem. Int. Ed. Engl. , 20, 116 117, 1981.;;V. M. Mohring, et al., Novel Polymerization of Olefins with the Catalyst System Nickel/Aminobis(imino)phosphorane, Angew. Chem. Int. Ed. Engl. , 24, 1001 1003, 1985.;;Nishioka, et al., Assignment of Chain Branching . . . , Bunseki Kagaku , 29, 11, 774 780, 1980.;;A. D. Ketley, et al., The 1,3 Polymerization of Propylene by Palladium Cyanide, Polymer Letters , 6, 341 343, 1968.;;R. van Asselt, et al., Palladium Complexes Containing Rigid Bidentate Nitrogen Ligands as Catalysts for Carbon Carbon Bond Formation, Tetrahedron , 50, 2, 323 334, 1994.;;R. van Asselt, et al., Isolation of Alkyl and Acyl palladium Complexes containing Rigid Bidentate Nitrogen Ligands by Stepwise Successive Insertion of CO and Alkenes, J. Chem. Soc. Chem. Commun. , 15, 1203 1205, 1993.;;R. van Asselt, et al., Insertion of Carbon Monoxide and Alkenes in Palladium Carbon Bonds of Complexes Containing Rigid Bidentate Nitrogen Ligands: The First Example of Isolated Complexes in Stepwise Successive Insertion Reactions on the Way to Polyketones, J. Am. Chem. Soc. , 116, 3, 977 985, 1994.;;R. van Asselt, et al., Synthesis and characterization of rigid bidentate nitrogen ligands and some examples of coordination to divalent palladium. X ray crystal structures of bis( tolylimino)acenaphthene and methylchloro bis(o,o diisopropylphenyl imino)acenaphthene palladium(II), Recl. Trav. Chim. Pays Bas , 113, 2, 88 98, 1994.;;R. van Asselt, Stabilization of High Oxidation States by Rigid Bidentate Nitrogen Ligands; Synthesis and Characterization of Diorgano and Triorganopalladium(IV) and Cationic Triorganoplatinum(IV) Complexes, Organometallics , 13, 2, 706 720, 1994.;;M. Svoboda, et al., Diazadien Nickel Alkyle, J. Organometal Chem , 191, 1, 321 328, 1980.;;N. Alberola, et al., Mechanical and Relaxations in Polyethylene I. Glass Transitions of Polyethylene, Eur. Polym. J. , 28, 8, 935 948, 1992.;;E. W. Fischer, et al., Effect of Filtration Conditions on the Apparent Density of the Intercrystalline Layers of Polyethylene Single Crystal Mats, Polymer Letters , 7, 307 311, 1969.;;David R. Burfield, et al., Differential Scanning Calerimetry Characteristics of Polypropylene. Dependence of Tg on Polymer Tacticity and Molecular Weight, Macromolecules , 16, 702 704, 1983.;;Piet W. N. M. van Leeuwen, et al., Migration versus Insertion in Square Planar Platinum and Palladium Complexes, J. Am. Chem. Soc. , 116, 12117 12118, 1994.;;Heindirk tom Dieck, et al., Rigid Phenyl Group Conformation in Complexes, Angew. Chem. Int. Ed. Engl , 19, 396 397, 1980.;;Heindirk tom Dieck, et al., Synthesis of Chiral Diazadienes R* N CR CR N R*, Chem. Ber. , 117, 694 701, 1984.;;K. Zemke, et al., Conformational Exchange near the Glass Transition: Two Dimensional 13 C NMR Study of Atactic Polypropylene, Macromolecules , 24, 6874 6876, 1991.;;J. C. Randall, et al., 13 C NMR microstructure determinations of low density polyethylene homopolymers and copolymers, Recl. Trav. Chim. Pays Bas , 110, 543 552, 1991.;;David R. Burfield, et al., Differential Scanning Calorimetry Characterization of Polypropylene. Dependence of Tg on Polymer Tacticity and Molecular Weight, Macromolecules , 16, 702 704, 1983.;;Jan Tecl, Studium vetveni polyethylenu nuklearni magnetickou resonancni spektroskopii, Chemicky prumyal, roc. , 37/62, 196 200, 1987.;;G. Natta, et al., Crystalline Alternating Ethylene Cyclopentene Copolymers and Other Ethylene Cycloolefin Copolymers, Makromol. Chem. , 54, 95 101, 1962.;;J. Boor, et al., Polymerization of Cyclopentene, 3 Methylcyclopentene, and 3 Methylcyclohexene, Die Makromolekulare Chemie , 90, 26 37, 1966.;;B. C. Anderson, et al., Polymerization of Internal Olefins, Macromolecules , 2, No. 6, 686 687, 1969.;;Walter Kaminsky, et al., Copolymerization of cycloalkenes with ethylene in presence of chiral zirconocene catalysts, Makromol. Chem. , 190, 515 526, 1989.;;W. Kaminsky, et al., in T. Keii, et al. Eds., Polymerization of Cyclic Olefins with Homogeneous Catalysts, Catalytic Olefin Polymerization , 929, 425 438, 1990.;;W. Mark Kelly, et al., Polymerization of Cyclopenetene Using Metallocene Catalysts: Polymer Tacticity and Properties, Macromolecule , 27, 4477 4485, 1994.;;Alexej Jerschow, et al., Nuclear Magnetic Resonance Evidence for a New Microstructure in Ethene Cyclopentene Copolymers, Macromolecules , 28, 7095 7099, 1995.;;Heindirk tom Dieck, et al., Diazadiene complexes of Group 4 metals I. Synthesis of mono , bis and tris(diazadiene) titanium complexes and the structure of diazadienedichlorotitanium, Inorganica Chimica Acta. , 177, 191 197, 1990.;;Heindirk tom Dieck, et al., Metallierung einer nichtaktivierten Alkyl Gruppe im Nickelkomplex 1, Chem. Ber. , 109, 1657 1664, 1976.;;Lynda K. Johnson, et al., New Pd(II) and Ni(II) Based Catalysts for Polymerization of Ethylene and Olefins, J. Am. Chem. Soc. , 117, 6414 6415, 1995.;;Lynda K. Johnson, et al., Copolymerization of Ethylene and Propylene with Functionalized Vinyl Monomers by Palladium(II) Catalysts, J. Am. Chem. Soc. , 118, 267 268, 1996.;;PCT/US 96/01282 Partial International Search.;;Johnson, et al., New Pd(II) and Ni(II) Based Catalysts for Polymerization of Ethylene and Olefins, J. Am. Chem. Soc. , 117, 6414 6415, 1995.;;Johnson, et al., Copolymerization of Ethylene and Propylene with Functionalized Vinyl Monomers by Palladium (II) Catalysts, J. Am. Chem. Soc. , 118, 267 268, 1996.;;Saito, et al., Diethyldipyridylnickel. Preparation, Characterization, and Reactions, J. Am. Chem. Soc. , 88:22, 5198 5201, 1966.;;Bartolini, et al., Enantioselective isotactic alternating copolymerization of styrene and 4 methylstyrene with carbon monoxide catalyzed by a cationic bioxazoline Pd(II) complex, Macromol.Rapid Commun. , 16, 9 14, 1995.;;Jiang, et al., Stereo and Enantioselective Alternating Copolymerization of Olefins with Carbon Monoxide. Synthesis of Chiral Polymers, Macromolecules , 27,2694 2700, 1994.;;Brookhart, et al., Polymers with Main Chain Chirality. Synthesis of Highly Isotactic, Optically Active Poly(4 tert butylstyrene alt CO) Using Pd(II) Catalysts Based on C 2 Symmetic Bisoxazoline Ligands, J. Am. Chem. Soc. , 116, 3641 3642, 1994.;;Diercks, et al., Katalytische Cyclotetramerisierung von Propiols a ureestern, Chem. Ger. , 118, 428 435, 1985.;;Dierck, et al., Diazadienes as Control Ligands in Catalysis Part 12.* The Nickel Catalyzed Cyclotetramerization of Propargylic Alcohol to Substituted Cyclooctatetraenes and the Structure of 1,3,5,7 Tetrakis(Hydroxymethyl)Cyclooctatetraene, Journal of Molecular Catalysis , 35, 317 328, 1986.;;PCT International Search Report dated Oct. 21, 1996 for PCT/US96/01282 (CR 9608 D).;;Montecatini Societa Generale per l Industria Mineria e Chimica: Catalytic Manufacture of Olefin Copolymers with Three or More Monomer Components , Chemical Abstracts , 77, No. 8, 1972, Abstract No. 49803t.;;Scott Collins & W. Mark Kelly, The Microstructure of Poly(cyclopentene) Produced by Polymerization of Cyclopentene with Homogeneous Ziegler Natta Catalysts, Macromolecules , 25, 233 237, 1992.;;Wissing, e et al., Influence of bulky substituents on the regioselective group transfer reactions of diorganozinc compounds with N,N bis(2,6 di isopropenyl) 1,4 diaza 1,3 butadiene, Chemical Abstracts , 121, No. 11, 1055, 1994, Abstract No. 134322g.;;Christina Munz, Constantin Stephan and Heindirk tom Dieck, Diazadiene stabilized palladacyclopent 2 enes and the catalytic addition of various allylic systems to dimethyl acetylenedicarboxylate, Journal of Organometallic Chemistry , 407, 413 420, 1991.;;Werner Bonrath, Klaus R. P o rschke, Richard Mynott and Carl Kr u ger, Synthesis and Structure of Ni(2,6 i Pr 2 C 6 H 3 N CH CH NC 6 H 3 2,6 i Pr 2 ) 2 , Zeitschrift F u r Naturforschung , 456, 1647 1650, 1990.;;Emulsion Polymerization to Fibers, Manufacture, Encylopedia of Polymer Science and Engineering , vol. 6, pp. 385 387, Copyright 1986.;;Editors: Barbara Elvers, Stephen Hawkins, Gail Schulz, Plastics, Properties and Testing to Polyvinyl Compounds, Ullmann s Encyclopedia of Industrial Chemistry , vol. A 21, pp. 488 493, 1992.;;Polymer Technology Dictionary, Tony Whelan, MSc, Consultant, Chapman & Hall, 1994, pp1, 282, 312.",EXPIRED
423,AU,A,AU 2000/071835 A,145-848-137-196-523,2001-03-08,2001,AU 2000/071835 A,2000-11-24,AU 2000/071835 A;;AU 1996/050208 A,1996-01-24,Alpha-olefins and olefin polymers and processes therefor,,DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;BROOKHART MAURICE S;;TEMPEL DANIEL JOSEPH;;PARTHASARATHY ANJU;;ITTEL STEVEN DALE;;COUGHLIN EDWARD BRYAN;;BENNETT MARGARET ANNE;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;MCCORD ELIZABETH;;FELDMAN JERALD;;ARTHUR SAMUEL DAVID;;KILLIAN CHRISTOPHER MOORE,,https://lens.org/145-848-137-196-523,Patent Application,no,0,1,2,3,0,,C07C249/02;;C07C251/08;;C07C251/24;;C08F4/602;;C08F4/70;;C08F4/80;;C08F110/02;;C08F110/06;;C08F110/08;;C08F120/22;;C08F132/04;;C08F210/02,,0,0,,,,EXPIRED
424,AU,B2,AU 759997 B2,163-974-423-116-571,2003-05-01,2003,AU 2000/071835 A,2000-11-24,AU 2000/071835 A;;AU 1996/050208 A,1996-01-24,Alpha-olefins and olefin polymers and processes therefor,,DU PONT;;UNIV NORTH CAROLINA CHAPEL HILL,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/163-974-423-116-571,Granted Patent,no,0,0,2,3,0,,C07C249/02;;C07C251/08;;C07C251/24;;C08F4/602;;C08F4/70;;C08F4/80;;C08F110/02;;C08F110/06;;C08F110/08;;C08F120/22;;C08F132/04;;C08F210/02,,3,0,,,"J.AM.CHEM.SOC.VOL 88,NO 22,20 NOV 66, SAITO ET AL,P5198-5201;;MACROMOL.RAP COMM,VOL 16, NO 1, JAN 95,HEIDELBERG, P 9-14;;MACROMOL,VOL 27,NO 10,9 MAY 94,WASHINGTON,JIANG ,P2694-2700",EXPIRED
425,AU,B2,AU 2003/204611 B2,148-155-726-604-932,2006-03-02,2006,AU 2003/204611 A,2003-06-10,AU 2000/071835 A;;AU 1996/050208 A,1996-01-24,Alpha-olefins and olefin polymers and processes therefor,,DU PONT;;UNIV OF NORTH CAROLINA CHAPEL HILL,KILLAN CHRISTOPHER MOORE;;MCLAIN STEPHAN JAMES;;ITTEL STEVEN DALE;;COUGHLIN EDWARD BRYAN;;ARTHUR SAMUEL DAVID;;KREUTZER KRISTINA ANN;;BROOKHART MAURICE S;;BENNETT MARGARET ANNE;;FELDMAN JERALD;;JOHNSON LYNDA KAYE;;TEMPEL DANIEL JOSEPH;;MCCORD ELIZABETH;;PARTHASARATHY ANJU,,https://lens.org/148-155-726-604-932,Granted Patent,no,5,2,1,3,0,,C08F110/02;;C07C249/02;;C07C251/08;;C07C251/24;;C08F4/80;;C08F110/08;;C08F120/22;;C08F132/04;;C08F210/02,,0,0,,,,EXPIRED
426,CA,A1,CA 2338542 A1,048-891-608-712-561,1996-08-01,1996,CA 2338542 A,1996-01-24,CA 2211108 A;;US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,.ALPHA.-OLEFINS AND OLEFIN POLYMERS AND PROCESSES THEREFOR,"Disclosed herein are processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic esters or carboxylic acids, and other monomers. The polymerizations are catalysed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described here in is the synthesis of linear .alpha.-olefins by the oligomerization of ethylene using as a catalyst system a combination of a nickel compound having a selected .alpha.-diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected ~(a)-diimine nickel complexes with ethylene.",DU PONT;;UNIV NORTH CAROLINA,ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;BROOKHART MAURICE S;;TEMPEL DANIEL JOSEPH;;PARTHASARATHY ANJU;;ITTEL STEVEN DALE;;MCLAIN STEPHAN JAMES;;MCCORD ELIZABETH FORRESTER;;KILLIAN CHRISTOPHER MOORE;;JOHNSON LYNDA KAYE;;KREUTZER KRISTINA ANN;;COUGHLIN EDWARD BRYAN;;BENNETT MARGARET ANNE,,https://lens.org/048-891-608-712-561,Patent Application,no,0,4,5,75,0,,C07F15/00;;C08F4/52;;C08F4/60;;C08F4/64;;C08F4/80;;C08F10/00;;C08F110/00;;C08F132/04;;C08F214/18;;C08F220/14;;C08F232/04;;C08L23/02;;C08L33/08;;C09J123/02;;C09J133/08,,0,0,,,,EXPIRED
427,WO,A3,WO 1996/023010 A3,093-513-028-661-167,1996-12-05,1996,US 9601282 W,1996-01-24,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,ALPHA -OLEFINS AND OLEFIN POLYMERS AND PROCESSES TALPHA -OLEFINS AND OLEFIN POLYMERS AND PROCESSES THEREFOR HEREFOR,"Disclosed herein are processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic esters or carboxylic acids, and other monomers. The polymerizations are catalysed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described herein is the synthesis of linear α-olefins by the oligomerization of ethylene using as a catalyst system a combination of a nickel compound having a selected α-diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected $(a)-diimine nickel complexes with ethylene.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/093-513-028-661-167,Search Report,yes,21,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07C251/08;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,14,7,093-805-713-932-396;;083-137-309-271-641;;099-058-421-181-908;;162-040-217-658-278;;036-680-143-987-323;;029-243-457-817-264;;069-936-621-235-710,10.1021/ja953247i;;10.1002/marc.1995.030160102;;10.1021/ma00088a007;;10.1021/ja00087a077;;10.1021/ma00027a039;;10.1016/0022-328x(91)86318-k;;10.1515/znb-1990-1209,"JOHNSON ET AL.: ""New Pd(II)- and Ni(II)-Based catalysts for Polymerization of Ethylene and alpha-Olefins"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 117, no. 23, 14 June 1995 (1995-06-14), WASHINGTON, XP002003543;;JOHNSON ET AL.: ""Copolymerization of Ethylene and Propylene with Funktionalized Vinyl Monomers by Palladium(II)Catalysts"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 1, 10 January 1996 (1996-01-10), WASHINGTON, XP002003542;;SAITO, T. ET AL.: ""Diethyldipyridylnickel. Preparation, Characterization, and Reactions"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 88, no. 22, 20 November 1966 (1966-11-20), WASHINGTON, XP002004034;;BARTOLINI, S. ET AL: ""Enantioselective isotactic alternating copolymerization of styrene and 4-methylstyrene with carbon monoxide catalyzed by a cationic bioxazoline Pd(II) complex"", MACROMOLECULAR RAPID COMMUNICATIONS, vol. 16, no. 1, January 1995 (1995-01-01), HEIDELBERG, XP002004035;;JIANG, Z. ET AL: ""Stereo- and Enantioselective Alternating Copolymerization of alpha-Olefins with Carbon Monoxide. Synthesis of Chiral Polymers"", MACROMOLUCULES, vol. 27, no. 10, 9 May 1994 (1994-05-09), WASHINGTON, pages 2694 - 2700, XP002003921;;BROOKHART, M. ET AL: ""Polymers with Main-Chain Chirality. Synthesis of Highly Isotactic, Optically Active Poly (4-tert.-butylstyrene-alt-CO) Using Pd (II) Catalysts Based on C2-Symmetric Bioxazoline Ligands"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 116, no. 8, 20 April 1994 (1994-04-20), WASHINGTON, pages 3641 - 3642, XP002003922;;R. DIERCKS, H. TOM DIECK: ""Katalytische Cyclotetramerisierung von Propiolsäureestern"", CHEMISCHE BERICHTE, vol. 118, 1985, WEINHEIM, XP002003541;;TOM DIECK ET AL.: ""Diazadienes as Control Ligands in Catalysis Part 12* The Nickel Catalyzed Cyclotetramerization of Propargylic Alcohol to Substituted Cyclooctatetraenes and the Structure of 1,3,5,7-Tetrakis(hydroxymethyl)cyclooctatetraene"", JOURNAL OF MOLECULAR CATALYSTS, vol. 35, no. 3, June 1986 (1986-06-01), LAUSANNE, XP002003923;;DATABASE WPI Section Ch Week 9428, Derwent World Patents Index; Class A18, AN 94-231215, XP002015135;;CHEMICAL ABSTRACTS, vol. 77, no. 8, 21 August 1972, Columbus, Ohio, US; abstract no. 49803, ""MONTECATINI"" SOCIETA GENERALE PER L'INDUSTRIA MINERIA E CHIMICA: ""Catalytic manufacture of olefin copolymers with three or more monomer components"" XP002015133;;COLLINS, S. , KELLY, W.M.: ""The Microstructure of Poly(cyclopentene) Produced by Polymerization of Cyclopentene with Homogeneous Ziegler-Natta Catalysts"", MACROMOLECULES, vol. 25, no. 1, January 1992 (1992-01-01), WASHINGTON, XP002015130;;CHEMICAL ABSTRACTS, vol. 121, no. 11, 12 September 1994, Columbus, Ohio, US; abstract no. 134322, WISSING, E ET AL.: ""Influence of bulky substituents on the regioselective group-transfer reactions of diorganozinc compounds with N,N'-bis(2,6-di-isopropenyl)-1,4-diaza-1,3-butadiene"" XP002015134;;MUNZ, C., STEPHAN, C., TOM DIECK, H.: ""Diazadiene-stabilized palladacyclopent-2-enes and the catalytic addition of various allylic systems to dimethyl acetylenedicarboxylate"", JOURNAL OF ORGANOMETALLIC CHEMISTRY, LAUSANNE, XP002015131;;BONRATH, W. ET AL.: ""Synthese und Struktur von Ni(2,6-iPr2C6H3N=CH-CH=NC6H3-2,6-iPr2)2"", ZEITSCHRIFT FÜR NATURFORSCHUNG, vol. 45b, - 1990, TÜBINGEN, XP002015132",PATENTED
428,CA,A1,CA 2338526 A1,068-402-257-849-990,1996-08-01,1996,CA 2338526 A,1996-01-24,CA 2211108 A;;US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,.ALPHA.-OLEFINS AND OLEFIN POLYMERS AND PROCESSES THEREFOR,"Disclosed heroin arc processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic eaters a carboxylic acids, and other monomers. The polymerizations are catalysed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described here in is the synthesis of linear a.olefins by the oligomerization of ethylene using as a catalyst system a combination of a nickel compound having a selected .alpha.-diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected $(a)diimine nickel complexes with ethylene.",UNIV NORTH CAROLINA;;DU PONT,ITTEL STEVEN DALE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;COUGHLIN EDWARD BRYAN;;KILLIAN CHRISTOPHER MOORE;;BROOKHART MAURICE S;;TEMPEL DANIEL JOSEPH;;PARTHASARATHY ANJU;;MCCORD ELIZABETH FORRESTER;;BENNETT MARGARET ANNE;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;JOHNSON LYNDA KAYE,,https://lens.org/068-402-257-849-990,Patent Application,no,0,0,5,75,0,,C07F15/00;;C08F4/52;;C08F4/60;;C08F4/64;;C08F4/80;;C08F10/00;;C08F110/00;;C08F132/04;;C08F214/18;;C08F220/14;;C08F232/04;;C08L23/02;;C08L33/08;;C09J123/02;;C09J133/08,,0,0,,,,EXPIRED
429,NO,D0,NO 973310 D0,089-074-488-226-864,1997-07-17,1997,NO 973310 A,1997-07-17,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P;;US 9601282 W,1995-01-24,"<alfa>-olefiner og olefinpolymerer, og fremgangsmåte for fremstilling av slike polymerer","Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANN;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARTHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE C,,https://lens.org/089-074-488-226-864,Patent Application,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/00;;C07C251/08;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,DISCONTINUED
430,EP,B1,EP 0805826 B1,001-765-331-344-467,2003-04-23,2003,EP 96907020 A,1996-01-24,US 9601282 W;;US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,OLEFIN POLYMERS,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/001-765-331-344-467,Granted Patent,yes,21,3,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/08;;C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,14,0,,,"JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 117, no. 23, 14 June 1995, WASHINGTON, XP002003543 JOHNSON ET AL.: ""New Pd(II)- and Ni(II)-Based catalysts for Polymerization of Ethylene and alpha-Olefins"";;JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 1, 10 January 1996, WASHINGTON, XP002003542 JOHNSON ET AL.: ""Copolymerization of Ethylene and Propylene with Funktionalized Vinyl Monomers by Palladium(II)Catalysts"";;JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 88, no. 22, 20 November 1966, WASHINGTON, XP002004034 SAITO, T. ET AL.: ""Diethyldipyridylnickel. Preparation, Characterization, and Reactions"";;MACROMOLECULAR RAPID COMMUNICATIONS, vol. 16, no. 1, January 1995, HEIDELBERG, XP002004035 BARTOLINI, S. ET AL: ""Enantioselective isotactic alternating copolymerization of styrene and 4-methylstyrene with carbon monoxide catalyzed by a cationic bioxazoline Pd(II) complex"";;MACROMOLUCULES, vol. 27, no. 10, 9 May 1994, WASHINGTON, pages 2694-2700, XP002003921 JIANG, Z. ET AL: ""Stereo- and Enantioselective Alternating Copolymerization of alpha-Olefins with Carbon Monoxide. Synthesis of Chiral Polymers"";;JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 116, no. 8, 20 April 1994, WASHINGTON, pages 3641-3642, XP002003922 BROOKHART, M. ET AL: ""Polymers with Main-Chain Chirality. Synthesis of Highly Isotactic, Optically Active Poly (4-tert.-butylstyrene-alt-CO) Using Pd (II) Catalysts Based on C2-Symmetric Bioxazoline Ligands"";;CHEMISCHE BERICHTE, vol. 118, 1985, WEINHEIM, XP002003541 R. DIERCKS, H. TOM DIECK: ""Katalytische Cyclotetramerisierung von Propiolsäureestern"";;JOURNAL OF MOLECULAR CATALYSTS, vol. 35, no. 3, June 1986, LAUSANNE, XP002003923 TOM DIECK ET AL.: ""Diazadienes as Control Ligands in Catalysis Part 12* The Nickel Catalyzed Cyclotetramerization of Propargylic Alcohol to Substituted Cyclooctatetraenes and the Structure of 1,3,5,7-Tetrakis(hydroxymethyl)cyclooctate traene"";;DATABASE WPI Section Ch, Week 9428 Derwent Publications Ltd., London, GB; Class A18, AN 94-231215 XP002015135 & JP 06 168 625 A (NIPPON ZEON KK) , 14 June 1994;;CHEMICAL ABSTRACTS, vol. 77, no. 8, 21 August 1972 Columbus, Ohio, US; abstract no. 49803, ""MONTECATINI"" SOCIETA GENERALE PER L'INDUSTRIA MINERIA E CHIMICA: ""Catalytic manufacture of olefin copolymers with three or more monomer components"" XP002015133 & IT 630 410 A;;MACROMOLECULES, vol. 25, no. 1, January 1992, WASHINGTON, XP002015130 COLLINS, S. , KELLY, W.M.: ""The Microstructure of Poly(cyclopentene) Produced by Polymerization of Cyclopentene with Homogeneous Ziegler-Natta Catalysts"";;CHEMICAL ABSTRACTS, vol. 121, no. 11, 12 September 1994 Columbus, Ohio, US; abstract no. 134322, WISSING, E ET AL.: ""Influence of bulky substituents on the regioselective group-transfer reactions of diorganozinc compounds with N,N'-bis(2,6-di-isopropenyl)-1,4-diaza-1,3 -butadiene"" XP002015134 & INORG. CHIM. ACTA, vol. 220, no. 1-2, 1994, pages 55-61,;;JOURNAL OF ORGANOMETALLIC CHEMISTRY, LAUSANNE, XP002015131 MUNZ, C., STEPHAN, C., TOM DIECK, H.: ""Diazadiene-stabilized palladacyclopent-2-enes and the catalytic addition of various allylic systems to dimethyl acetylenedicarboxylate"";;ZEITSCHRIFT FÜR NATURFORSCHUNG, vol. 45b, - 1990 TÜBINGEN, XP002015132 BONRATH, W. ET AL.: ""Synthese und Struktur von Ni(2,6-iPr2C6H3N=CH-CH=NC6H3-2,6-iPr2)2""",EXPIRED
431,CA,A1,CA 2338581 A1,130-254-581-449-627,1996-08-01,1996,CA 2338581 A,1996-01-24,CA 2211108 A;;US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,.ALPHA.-OLEFINS AND OLEFIN POLYMERS AND PROCESSES THEREFOR,"Disclosed herein are processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic esters or carboxylic acids, and other monomers. The polymerizations ate catalysed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described here in is the synthesis of linear .alpha.-olefins by the oligomerization of ethylene using as a catalyst system a combination of a nickel compound having a selected .alpha.-diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected S(a)-diimine nickel complexes with ethylene.",DU PONT;;UNIV NORTH CAROLINA,KREUTZER KRISTINA ANN;;ARTHUR SAMUEL DAVID;;BROOKHART MAURICE S;;TEMPEL DANIEL JOSEPH;;PARTHASARATHY ANJU;;MCCORD ELIZABETH FORRESTER;;KILLIAN CHRISTOPHER MOORE;;FELDMAN JERALD;;COUGHLIN EDWARD BRYAN;;BENNETT MARGARET ANNE;;JOHNSON LYNDA KAYE;;MCLAIN STEPHAN JAMES;;ITTEL STEVEN DALE,,https://lens.org/130-254-581-449-627,Patent Application,no,0,0,5,75,0,,C07F15/00;;C08F4/52;;C08F4/60;;C08F4/64;;C08F4/80;;C08F10/00;;C08F110/00;;C08F132/04;;C08F214/18;;C08F220/14;;C08F232/04;;C08L23/02;;C08L33/08;;C09J123/02;;C09J133/08,,0,0,,,,DISCONTINUED
432,AT,T1,AT E238360 T1,043-703-226-825-277,2003-05-15,2003,AT 96907020 T,1996-01-24,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P;;US 9601282 W,1995-01-24,POLYOLEFINE,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/043-703-226-825-277,Granted Patent,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/08;;C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,DISCONTINUED
433,EP,A2,EP 1348723 A2,198-634-281-117-34X,2003-10-01,2003,EP 03075669 A,1996-01-24,EP 96907020 A;;US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,Ethylen Copolymers,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH 2 =CH(CH 2 ) m CO 2 R 1 , wherein R 1  is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH 2 ) n CO 2 R 1 , in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHEN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/198-634-281-117-34X,Patent Application,yes,0,2,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/08;;C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,DISCONTINUED
434,CA,A1,CA 2211108 A1,148-687-209-663-878,1996-08-01,1996,CA 2211108 A,1996-01-24,US 265495 P;;US 737595 P;;US 47359095 A;;US 41528395 A;;US 37804495 A;;US 9601282 W,1995-01-24,.ALPHA.-OLEFINS AND OLEFIN POLYMERS AND PROCESSES THEREFOR,"Disclosed herein are processes for polymerizing ethylene, acyclic olefins, a nd/or selected cyclic olefins, and optionally selected o lefinic esters or carboxylic acids, and other monomers. The polymerizations are cata lysed by selected transition metal compounds, and someti mes other co-catalysts. Since some of the polymerizations exhibit some character istics of living polymerizations, block copolymers can b e readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of the m unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described here in is the synthesis of linear .alpha.-olefins by the oli gomerization of ethylene using as a catalyst system a combination of a nickel compound ha ving a selected .alpha.-diimine ligand and a selected Le wis or Bronsted acid, or by contacting selected $(a)-diimine nickel complexes with ethylene.",DU PONT;;UNIV NORTH CAROLINA,ITTEL STEVEN DALE;;BROOKHART MAURICE S;;JOHNSON LYNDA KAYE;;MCLAIN STEPHAN JAMES;;MCCORD ELIZABETH FORRESTER;;PARTHASARATHY ANJU;;FELDMAN JERALD;;KILLIAN CHRISTOPHER MOORE;;BENNETT MARGARET ANNE;;KREUTZER KRISTINA ANN;;ARTHUR SAMUEL DAVID;;TEMPEL DANIEL JOSEPH;;COUGHLIN EDWARD BRYAN,,https://lens.org/148-687-209-663-878,Patent Application,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/08;;C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,EXPIRED
435,TR,T1,TR 199700681 T1,170-702-528-257-332,1998-02-21,1998,TR 9700681 T,1996-01-24,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,alfa-olefinler ve olefin polimerleri ve bunlarla ilgili islemler.,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT,JOHNSON LYNDA KYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZADBETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/170-702-528-257-332,Patent Application,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07C251/08;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,PENDING
436,PL,A1,PL 322446 A1,013-405-771-129-759,1998-02-02,1998,PL 32244696 A,1996-01-24,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,ALPHA-OLEFINES AND OLEFINIC POLYMERS AND METHODS OF OBTAINING THEM,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/013-405-771-129-759,Patent Application,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/00;;C07F5/00;;C07F7/00;;C07C251/08;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,PENDING
437,EP,A3,EP 1348723 A3,120-490-245-040-381,2004-09-29,2004,EP 03075669 A,1996-01-24,EP 96907020 A;;US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,Alpha-olefins and olefin polymers and processes for their preparation,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH 2 =CH(CH 2 ) m CO 2 R 1 , wherein R 1  is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH 2 ) n CO 2 R 1 , in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHEN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/120-490-245-040-381,Search Report,yes,4,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/08;;C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,1,1,004-397-567-739-425,10.1016/0304-5102(87)80023-8,"KLABUNDE U ET AL: ""NICKEL CATALYSIS FOR ETHYLENE HOMO- AND CO-POLYMERIZATION"", JOURNAL OF MOLECULAR CATALYSIS, LAUSANNE, CH, vol. 41, no. 1/2, 2 July 1987 (1987-07-02), pages 123 - 134, XP008002524",DISCONTINUED
438,CA,C,CA 2338542 C,168-759-442-723-123,2004-05-18,2004,CA 2338542 A,1996-01-24,CA 2211108 A;;US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,.ALPHA.-OLEFINS AND OLEFIN POLYMERS AND PROCESSES THEREFOR,"Disclosed herein are processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic esters or carboxylic acids, and other monomers. The polymerizations are catalysed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are uxful as elastomers, molding resins, in adhesives, etc. Also described herei n is the synthesis of linear a-olefins by the oligomerization of ethylene using as a catalyst system a combination of a nickel compound having a xlected .alpha.-diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected $(a)-diimine nickel complexes with ethylene.",DU PONT;;UNIV NORTH CAROLINA,FELDMAN JERALD;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S;;MCLAIN STEPHAN JAMES;;MCCORD ELIZABETH FORRESTER;;ARTHUR SAMUEL DAVID;;BENNETT MARGARET ANNE;;ITTEL STEVEN DALE;;KREUTZER KRISTINA ANN;;COUGHLIN EDWARD BRYAN;;KILLIAN CHRISTOPHER MOORE;;JOHNSON LYNDA KAYE,,https://lens.org/168-759-442-723-123,Granted Patent,no,0,0,5,75,0,,C07F15/00;;C08F4/52;;C08F4/60;;C08F4/64;;C08F4/80;;C08F10/00;;C08F110/00;;C08F132/04;;C08F214/18;;C08F220/14;;C08F232/04;;C08L23/02;;C08L33/08;;C09J123/02;;C09J133/08,,0,0,,,,EXPIRED
439,AU,B2,AU 729324 B2,188-828-626-137-200,2001-02-01,2001,AU 1996/050208 A,1996-01-24,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P;;US 9601282 W,1995-01-24,Alpha-olefins and olefin polymers and processes therefor,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/188-828-626-137-200,Granted Patent,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/08;;C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,3,1,099-058-421-181-908,10.1021/ma00088a007,"J.AMERICAN CHEM.SOC,VOL 88,NO.22,1996,SAITO ET AL P5198-5201;;MACROMOL RAPID COMMUN,VOL 16, NO.1, 1995,BARTOLININI, P.9-14;;MACROMOLECULES,VOL.27, NO.10, 1994, JIANG ET AL, P.2694-2700",EXPIRED
440,JP,A,JP 2005307218 A,000-190-551-995-674,2005-11-04,2005,JP 2005151691 A,2005-05-24,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,CATALYST COMPOSITIONS,"<P>PROBLEM TO BE SOLVED: To provide novel catalyst compositions useful for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic esters or carboxylic acids, and other monomers. <P>SOLUTION: Transition metal compounds such as Ni, Co, Fe, and Pd, and two nitrogen atoms, or nitrogen and phosphorus atoms are used as ligands. Compositions on rectangular plane steric configuration for a ligand with two seats having enough three-dimensional bulk on both sides of a coordination plane as a catalyst. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. <P>COPYRIGHT: (C)2006,JPO&NCIPI",DU PONT;;UNIV NORTH CAROLINA CHAPEL HILL,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/000-190-551-995-674,Patent Application,no,0,9,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C07C251/08;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,INACTIVE
441,CZ,A3,CZ 235197 A3,161-293-540-848-062,1997-12-17,1997,CZ 235197 A,1996-01-24,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P;;US 9601282 W,1995-01-24,"ALPHA OLEFINS, OLEFIN POLYMERS AND PROCESS FOR PREPARING THEREOF","Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/161-293-540-848-062,Patent Application,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/08;;C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,PENDING
442,CA,C,CA 2338526 C,121-954-280-749-088,2003-12-09,2003,CA 2338526 A,1996-01-24,CA 2211108 A;;US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,.ALPHA.-OLEFINS AND OLEFIN POLYMERS AND PROCESSES THEREFOR,"Disclosed heroin arc processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic eaters a carboxylic acids, and other monomers. The polymerizations are catalysed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described here in is the synthesis of linear a.olefins by the oligomerization of ethylene using as a catalyst system a combination of a nickel compound having a selected .alpha.-diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected $(a)diimine nickel complexes with ethylene.",DU PONT;;UNIV NORTH CAROLINA,KILLIAN CHRISTOPHER MOORE;;JOHNSON LYNDA KAYE;;COUGHLIN EDWARD BRYAN;;BENNETT MARGARET ANNE;;ITTEL STEVEN DALE;;KREUTZER KRISTINA ANN;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;BROOKHART MAURICE S;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES,,https://lens.org/121-954-280-749-088,Granted Patent,no,0,0,5,75,0,,C07F15/00;;C08F4/52;;C08F4/60;;C08F4/64;;C08F4/80;;C08F10/00;;C08F110/00;;C08F132/04;;C08F214/18;;C08F220/14;;C08F232/04;;C08L23/02;;C08L33/08;;C09J123/02;;C09J133/08,,0,0,,,,EXPIRED
443,NO,L,NO 973310 L,165-917-903-037-161,1997-09-23,1997,NO 973310 A,1997-07-17,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P;;US 9601282 W,1995-01-24,"<alfa>-olefiner og olefinpolymerer, og fremgangsmåte for fremstilling av slike polymerer","Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANN;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARTHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE C,,https://lens.org/165-917-903-037-161,Abstract,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07C251/08;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,DISCONTINUED
444,FI,A,FI 973096 A,057-020-282-251-373,1997-09-23,1997,FI 973096 A,1997-07-23,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P;;US 9601282 W,1995-01-24,Alfa-olefiinejä ja olefiinipolymeereja ja menetelmiä niiden valmistamiseksi,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/057-020-282-251-373,Patent Application,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/00;;C07C251/08;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,DISCONTINUED
445,BR,A,BR 9607485 A,108-413-334-774-21X,1997-12-23,1997,BR 9607485 A,1996-01-24,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P;;US 9601282 W,1995-01-24,Polieolefina polímero processo para a polimeriyação de olefinas processo para a copolimerização de uma olefina fluroada copolímero catalisador composto homopolimero homopolipropileno melhorador de aderência aditivo de óleo resina de base modificador de viscosidade agente de revestimento ou de pentração agente de endurecimento modificador para asfalto isolamento de fio ou revestimento base eliminador película aditivo resina extrusão ou co-extrusãono peça folha laminado fibra espuma composição bolde ponto de congelação tela membrana diluente ionómero plastificador mistura polietileno polipropile adesivo objeto esponjoso pó mangueria rebaixador sa,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHEN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/108-413-334-774-21X,Patent Application,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/08;;C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,EXPIRED
446,WO,A2,WO 1996/023010 A2,042-178-017-894-015,1996-08-01,1996,US 9601282 W,1996-01-24,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,alpha -OLEFINS AND OLEFIN POLYMERS AND PROCESSES THEREFOR,"Disclosed herein are processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic esters or carboxylic acids, and other monomers. The polymerizations are catalysed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described herein is the synthesis of linear alpha -olefins by the oligomerization of ethylene using as a catalyst system a combination of a nickel compound having a selected alpha -diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected DOLLAR (a)-diimine nickel complexes with ethylene.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/042-178-017-894-015,Patent Application,no,0,372,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07C251/08;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,PATENTED
447,EP,A2,EP 0805826 A2,153-069-212-828-496,1997-11-12,1997,EP 96907020 A,1996-01-24,US 9601282 W;;US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P,1995-01-24,ALPHA-OLEFINS AND OLEFIN POLYMERS AND PROCESSES THEREFOR,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/153-069-212-828-496,Patent Application,yes,0,3,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/08;;C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,EXPIRED
448,FI,A0,FI 973096 A0,150-098-139-648-23X,1997-07-23,1997,FI 973096 A,1997-07-23,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P;;US 9601282 W,1995-01-24,Alfa-olefiinejä ja olefiinipolymeereja ja menetelmiä niiden valmistamiseksi,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/150-098-139-648-23X,Patent Application,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/00;;C07C251/08;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,DISCONTINUED
449,AU,A,AU 1996/050208 A,163-235-205-377-758,1996-08-14,1996,AU 1996/050208 A,1996-01-24,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P;;US 9601282 W,1995-01-24,Alpha-olefins and olefin polymers and processes therefor,"Polymers are disclosed consisting essentially of units derived from the monomers ethylene and a compound of the formula CH2=CH(CH2)mCO2R<1>, wherein R<1> is hydrogen, hydrocarbyl or substituted hydrocarbyl, and m is 0 or an integer from 1 to 16, and which contains about 0.01 to about 40 mole percent of repeat units derived from said compound, and provided that said repeat units derived from said compound are in branches of the formula -CH(CH2)nCO2R<1>, in about 30 to about 70 mole percent of said branches n is 5 or more, in about 0 to about 20 mole percent n is 4, in about 3 to 60 mole percent n is 1, 2 and 3, and in about 1 to about 60 mole percent n is 0.The polymers made are useful as elastomers, molding resins, in adhesives, etc.",DU PONT;;UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/163-235-205-377-758,Patent Application,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/08;;C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,EXPIRED
450,CA,C,CA 2211108 C,175-103-768-935-080,2001-05-29,2001,CA 2211108 A,1996-01-24,US 265495 P;;US 737595 P;;US 47359095 A;;US 41528395 A;;US 37804495 A;;US 9601282 W,1995-01-24,.ALPHA.-OLEFINS AND OLEFIN POLYMERS AND PROCESSES THEREFOR,"Disclosed herein are processes for polymerizing ethylene, acyclic olefins, a nd/or selected cyclic olefins, and optionally selected o lefinic esters or carboxylic acids, and other monomers. The polymerizations are cata lysed by selected transition metal compounds, and someti mes other co-catalysts. Since some of the polymerizations exhibit some character istics of living polymerizations, block copolymers can b e readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of the m unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described here in is the synthesis of linear .alpha.-olefins by the oli gomerization of ethylene using as a catalyst system a combination of a nickel compound ha ving a selected .alpha.-diimine ligand and a selected Le wis or Bronsted acid, or by contacting selected $(a)-diimine nickel complexes with ethylene.",DU PONT;;UNIV NORTH CAROLINA,BENNETT MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;KILLIAN CHRISTOPHER MOORE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH;;BROOKHART MAURICE S;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;KREUTZER KRISTINA ANN;;MCLAIN STEPHAN JAMES;;MCCORD ELIZABETH FORRESTER;;JOHNSON LYNDA KAYE,,https://lens.org/175-103-768-935-080,Granted Patent,no,0,1,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/08;;C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,EXPIRED
451,NZ,A,NZ 303800 A,003-000-766-796-946,2000-05-26,2000,NZ 30380096 A,1996-01-24,US 37804495 A;;US 41528395 A;;US 47359095 A;;US 737595 P;;US 265495 P;;US 9601282 W,1995-01-24,"Olefin polymers and block polymers, preparation, use, catalysts and catalyst intermediates","Two polyolefins: i) A polyolefin that contains about 80 to 150 branches per 1000 methylene groups. For every 100 methyl branches, there are about 30-90 ethyl branches, 4-20 propyl branches, 15-50 butyl branches, 3-15 amyl branches and 30-140 hexyl or longer branches. ii) A polyolefin, which contains about 20 to 150 branches per 1000 methylene groups. For every 100 methyl branches, there are about 4-20 ethyl branches, 1-12 propyl branches, 1-12 butyl branches, 1-10 amyl branches and 0-20 hexyl or longer branches. Also claimed is an ethylene homopolymer with a density of 0.86 g/ml or less, a polymer of one or more alpha-olefins of the formula CH2=CH2(CH2)aH which contains the above formula (XXV), wherein R35 is an alkyl group and R36 is an alkyl group containing two or more carbon atoms. In addition, a polypropylene containing one or both of the above formulas (XXVII) and (XXIX), provided that, if (XXIX) is present, it has to be in a greater than or equal amount to 0.5 of (XXIX) per 1000 methylene groups, or the polymer contains at least 0.5 or more of (XXVIII) per 1000 methylene groups.",UNIV NORTH CAROLINA,JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT MARGRET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPLE DANIEL JOSEPH;;BROOKHART MAURICE S,,https://lens.org/003-000-766-796-946,Patent Application,no,0,0,36,75,0,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02;;C09J123/06;;C09J123/20;;C08F110/08;;C08F4/70,C07C251/00;;C07F5/00;;C07F7/00;;C07F9/00;;C07F11/00;;C07F15/00;;C07F15/02;;C07F15/04;;C07C251/08;;C07F15/06;;C08F/;;C08F4/04;;C08F4/42;;C08F4/52;;C08F4/60;;C08F4/622;;C08F4/639;;C08F4/70;;C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/06;;C08F210/14;;C08F210/16;;C08F232/00;;C08F232/04;;C08G61/04;;C08J5/18;;C08L23/02;;C08L23/16;;C09D123/00;;C09J123/00;;C09J123/02;;C10M107/02;;C10M119/00;;C10M143/04,,0,0,,,,PENDING
452,WO,A3,WO 1996/023010 A3,090-412-469-517-054,1996-08-01,1996,US US9601282,1996-01-24,"US 8/378,044;;US 8/415,283;;US 8/473,590;;US 60/0/002,654;;US 60/0/007,375",1995-01-24,'alpha'-OLEFINS AND OLEFIN POLYMERS AND PROCESSES THEREFOR,"Disclosed herein are processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic esters or carboxylic acids, and other monomers. The polymerizations are catalysed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described herein is the synthesis of linear α-olefins by the oligomerization of ethylene using as a catalyst system a combination of a nickel compound having a selected α-diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected $(a)-diimine nickel complexes with ethylene.",E.I. DU PONT DE NEMOURS AND COMPANY;;UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL,"JOHNSON, Lynda, Kaye;;KILLIAN, Christopher, Moore;;ARTHUR, Samuel, David;;FELDMAN, Jerald;;McCORD, Elizabeth, Forrester;;McLAIN, Stephan, James;;KREUTZER, Kristina, Ann;;BENNETT, Margaret, Anne;;COUGHLIN, Edward, Bryan;;ITTEL, Steven, Dale;;PARTHASARATHY, Anju;;TEMPEL, Daniel, Joseph;;BROOKHART, Maurice, S.",,https://lens.org/090-412-469-517-054,Search Report,yes,0,0,1,1,0,,C08F10/00;;C08F10/02;;C08F10/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F210/02;;C08F210/14;;C08F210/16;;C08F232/00;;C08L23/02,,0,0,,,,UNKNOWN
453,US,A1,US 2003/0171508 A1,090-191-335-309-78X,2003-09-11,2003,US 88727301 A,2001-06-22,US 88727301 A;;US 89900297 A;;US 59065096 A;;US 47359095 A;;US 41528395 A;;US 37804495 A;;US 265495 P;;US 737595 P,1995-01-24,Alpha-olefins and olefin polymers and processes therefor,"
   Disclosed herein are processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic esters or carboxylic acids, and other monomers. The polymerizations are catalyzed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure, which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described herein is the synthesis of linear -olefins by the oligomerization of ethylene using as a catalyst system a combination a nickel compound having a selected -diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected -diimine nickel complexes with ethylene. 
",BROOKHART MAURICE S.;;JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT ALISON MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH,BROOKHART MAURICE S;;JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT ALISON MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH,,https://lens.org/090-191-335-309-78X,Patent Application,yes,0,5,17,75,0,C08F110/02;;C08F110/02;;C08F10/00;;C08F10/00;;C08F10/02;;C08F10/02;;C08F10/06;;C08F10/06;;C08F110/06;;C08F110/06;;C08F110/14;;C08F110/14;;C08F210/02;;C08F210/02;;C08F210/14;;C08F210/14;;C08F210/16;;C08F210/16;;C08F232/00;;C08F232/00;;C08L23/02;;C08L23/02;;Y10S430/165;;Y10S430/165;;Y10T428/1352;;Y10T428/1352;;Y10T428/1386;;Y10T428/1386;;Y10T428/139;;Y10T428/139;;Y10T428/24942;;Y10T428/24942;;Y10T428/2878;;Y10T428/2878;;Y10T428/31692;;Y10T428/31692;;Y10T428/31855;;Y10T428/31855;;Y10T428/31895;;Y10T428/31895;;Y10T428/31938;;Y10T428/31938;;Y10T442/20;;Y10T442/20;;Y10T442/60;;Y10T442/60;;Y10T442/626;;Y10T442/626,B01J31/00;;B01J37/00;;C07C2/32;;C07C69/52;;C07C251/08;;C07F7/00;;C07F15/00;;C07F19/00;;C08F4/02;;C08F4/06;;C08F4/60;;C08F4/70;;C08F4/80;;C08F10/00;;C08F10/02;;C08F10/06;;C08F10/08;;C08F12/30;;C08F20/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/14;;C08F210/16;;C08F220/10;;C08F232/00;;C08F232/04;;C08F255/00;;C08L23/02,526 9;;526/348;;526/351;;526/352,0,0,,,,EXPIRED
454,US,B1,US 6310163 B1,049-930-140-021-751,2001-10-30,2001,US 89900297 A,1997-07-10,US 89900297 A;;US 59065096 A;;US 47359095 A;;US 41528395 A;;US 37804495 A;;US 265495 P;;US 737595 P,1995-01-24,alpha-olefins and olefin polymers and processes therefor,"Disclosed herein are processes for polymerizing ethylene, acyclic olefins, and/or selected cyclic olefins, and optionally selected olefinic esters or carboxylic acids, and other monomers. The polymerizations are catalyzed by selected transition metal compounds, and sometimes other co-catalysts. Since some of the polymerizations exhibit some characteristics of living polymerizations, block copolymers can be readily made. Many of the polymers produced are often novel, particularly in regard to their microstructure which gives some of them unusual properties. Numerous novel catalysts are disclosed, as well as some novel processes for making them. The polymers made are useful as elastomers, molding resins, in adhesives, etc. Also described herein is the synthesis of linear .alpha.-olefins by the oligomerization of ethylene using as a catalyst system a combination a nickel compound having a selected .alpha.-diimine ligand and a selected Lewis or Bronsted acid, or by contacting selected .alpha.-diimine nickel complexes with ethylene.",DU PONT,BROOKHART MAURICE S;;JOHNSON LYNDA KAYE;;KILLIAN CHRISTOPHER MOORE;;ARTHUR SAMUEL DAVID;;FELDMAN JERALD;;MCCORD ELIZABETH FORRESTER;;MCLAIN STEPHAN JAMES;;KREUTZER KRISTINA ANN;;BENNETT ALISON MARGARET ANNE;;COUGHLIN EDWARD BRYAN;;ITTEL STEVEN DALE;;PARTHASARATHY ANJU;;TEMPEL DANIEL JOSEPH,,https://lens.org/049-930-140-021-751,Granted Patent,yes,40,27,17,75,0,C08F110/02;;C08F110/02;;C08F10/00;;C08F10/00;;C08F10/02;;C08F10/02;;C08F10/06;;C08F10/06;;C08F110/06;;C08F110/06;;C08F110/14;;C08F110/14;;C08F210/02;;C08F210/02;;C08F210/14;;C08F210/14;;C08F210/16;;C08F210/16;;C08F232/00;;C08F232/00;;C08L23/02;;C08L23/02;;Y10S430/165;;Y10S430/165;;Y10T428/1352;;Y10T428/1352;;Y10T428/1386;;Y10T428/1386;;Y10T428/139;;Y10T428/139;;Y10T428/24942;;Y10T428/24942;;Y10T428/2878;;Y10T428/2878;;Y10T428/31692;;Y10T428/31692;;Y10T428/31855;;Y10T428/31855;;Y10T428/31895;;Y10T428/31895;;Y10T428/31938;;Y10T428/31938;;Y10T442/20;;Y10T442/20;;Y10T442/60;;Y10T442/60;;Y10T442/626;;Y10T442/626,B01J31/00;;B01J37/00;;C07C2/32;;C07C69/52;;C07C251/08;;C07F7/00;;C07F15/00;;C07F19/00;;C08F4/02;;C08F4/06;;C08F4/60;;C08F4/70;;C08F4/80;;C08F10/00;;C08F10/02;;C08F10/06;;C08F10/08;;C08F12/30;;C08F20/06;;C08F110/02;;C08F110/06;;C08F110/14;;C08F132/04;;C08F210/02;;C08F210/14;;C08F210/16;;C08F220/10;;C08F232/00;;C08F232/04;;C08F255/00;;C08L23/02,526/318.6;;526/329;;526/331;;430/199;;430/252;;430/964;;428/36.9;;521/38;;521/149,49,41,177-347-884-688-64X;;101-579-530-746-406;;030-879-648-911-287;;050-373-888-844-623;;063-039-280-300-669;;039-142-183-108-89X;;042-522-701-231-875;;111-111-698-171-49X;;005-063-002-453-864;;076-405-685-873-413;;006-637-028-209-17X;;077-759-882-145-137;;135-659-417-443-693;;045-904-068-319-830;;165-789-127-128-402;;072-647-548-538-586;;031-235-936-595-146;;069-686-239-154-208;;047-388-678-146-759;;006-627-900-407-680;;114-216-909-982-55X;;046-925-223-398-487;;027-541-666-632-63X;;141-962-524-305-949;;133-199-484-001-468;;049-434-420-066-011;;164-831-587-786-422;;013-459-583-169-642;;116-598-384-747-643;;051-135-574-887-615;;093-805-713-932-396;;098-076-046-369-775;;083-137-309-271-641;;099-058-421-181-908;;162-040-217-658-278;;129-574-938-069-043;;022-507-155-586-191;;036-680-143-987-323;;083-064-288-336-703;;029-243-457-817-264;;069-936-621-235-710,10.1021/ma60067a010;;10.1021/ma00139a022;;10.1002/app.1994.070510102;;10.1021/ma00206a027;;10.1002/anie.198101161;;10.1002/anie.198510011;;10.2116/bunsekikagaku.29.11_774;;10.1002/pol.1968.110060504;;10.1016/s0040-4020(01)80757-2;;10.1039/c39930001203;;10.1021/ja00082a020;;10.1002/recl.19941130204;;10.1021/om00014a049;;10.1016/s0022-328x(00)88576-9;;10.1016/0014-3057(92)90322-s;;10.1002/pol.1969.110070411;;10.1021/ma00238a039;;10.1021/ja00105a088;;10.1002/anie.198003961;;10.1002/cber.19841170222;;10.1021/ma00026a017;;10.1002/recl.19911101207;;10.1002/macp.1966.020900103;;10.1021/ma60012a027;;10.1002/macp.1989.021900308;;10.1021/ma00094a008;;10.1021/ma00125a010;;10.1016/s0020-1693(00)85976-9;;10.1002/cber.19761090508;;10.1021/ja00128a054;;10.1021/ja953247i;;10.1021/ja00974a030;;10.1002/marc.1995.030160102;;10.1021/ma00088a007;;10.1021/ja00087a077;;10.1002/cber.19851180203;;10.1016/0304-5102(86)87079-1;;10.1021/ma00027a039;;10.1016/0020-1693(94)03854-6;;10.1016/0022-328x(91)86318-k;;10.1515/znb-1990-1209,"D. E. Axelson, et al., A Quantitative Analysis of Low-Density (Branched) Polyethylenes by Carbon-13 Fourier Transform Nuclear Magnetic Resonance at 67.9 MHz, Macromolecules, 12, 41-52, 1979.;;T. Usami, et al., Fine-Branching Structure in High-Pressure, Low-Density Polyethylenes by 50.10-MHz 13C NMR Analysis, Macromolecules, 17, 1757-1761, 1984.;;J. P. Blitz, et al., The Characterization of Short Chain Branching in Polyethylene Using Fourier Transform Infrared Spectroscopy, Journal of Applied Polymer Science, 51, 1, 13-20, 1994.;;E. Nordmeier, et al., The Molecular Structure of Low-Density Polyethylene. 1. Long-Chain Branching and Solution Properties, Macromolecules, 23, 4, 1072-1076, 1990.;;F. A. Bovey, et al., C-13 NMR Observations of Chain Branching in Vinyl Polymers, Polym. Preprs Am Chem Soc Div Polym Chem, 20, 2, 160-163, 1979.;;W. Keim, et al., Novel Nickel- and Palladium-Complexes with Aminobis(imino)phosphorane Ligands for the Polymerization of Ethylene, Angew. Chem. Int. Ed. Engl., 20, 116-117, 1981.;;V. M. Mohring, et al., Novel Polymerization of alpha-Olefins with the Catalyst System Nickel/Aminobis(imino)phosphorane, Angew. Chem. Int. Ed. Engl., 24, 1001-1003, 1985.;;Nishioka, et al., Assignment of Chain Branching . . . , Bunseki Kagaku, 29, 11, 774-780, 1980.;;A. D. Ketley, et al., The 1,3-Polymerization of Propylene by Palladium Cyanide, Polymer Letters, 6, 341-343, 1968.;;R. van Asselt, et al., Palladium Complexes Containing Rigid Bidentate Nitrogen Ligands as Catalysts for Carbon-Carbon Bond Formation, Tetrahedron, 50, 2, 323-334, 1994.;;R. van Asselt, et al., Isolation of Alkyl- and Acyl-palladium Complexes containing Rigid Bidentate Nitrogen Ligands by Stepwise Successive Insertion of CO and Alkenes, J. Chem. Soc. Chem. Commun., 15, 1203-1205, 1993.;;R. van Asselt, et al., Insertion of Carbon Monoxide and Alkenes in Palladium-Carbon Bonds of Complexes Containing Rigid Bidentate Nitrogen Ligands: The First Example of Isolated Complexes in Stepwise Successive Insertion Reactions on the Way to Polyketones, J. Am. Chem. Soc., 116, 3, 977-985, 1994.;;R. van Asselt, et al., Synthesis and characterization of rigid bidentate nitrogen ligands and some examples of coordination to divalent palladium. X-ray crystal structures of bis(rho-tolylimino)acenaphthene and methylchloro[bis(o,o'-diisopropylphenyl-imino)acenaphthene]palladium(II), Recl. Trav. Chim. Pays-Bas, 113, 2, 88-98, 1994.;;R. van Asselt, Stabilization of High Oxidation States by Rigid Bidentate Bidentate Nitrogen Ligands; Synthesis and Characterization of Diorgano- and Triorganopalladium(IV) and Cationic Triorganoplatinum(IV) Complexes, Organometallics, 13, 2, 706-720, 1994.;;M. Svoboda, et al., Diazadien-Nickel-Alkyle, J. Organometal Chem, 191, 1, 321-328, 1980.;;N. Alberola, et al., Mechanical gamma and beta Relaxations in Polyethylene-I. Glass Transitions of Polyethylene, Eur. Polym. J., 28, 8, 935-948, 1992.;;E. W. Fischer, et al., Effect of Filtration Conditions on the Apparent Density of the Intercrystalline Layers of Polyethylene Single Crystal Mats, Polymer Letters, 7, 307-311, 1969.;;David R. Burfield, et al., Differential Scanning Calerimetry Characteristics of Polypropylene. Dependence of Tg on Polymer Tacticity and Molecular Weight, Macromolecules, 16, 702-704, 1983.;;Piet, W. N. M. van Leeuwen, et al., Migration versus Insertion in Square-Planar Platinum and Palladium Complexes, J. Am. Chem. Soc., 116, 12117-12118, 1994.;;Heindirk tom Dieck, et al., Rigid Phenyl-Group Conformation in Complexes, Angew. Chem. Intl. Ed. Engl, 19, 396-397, 1980.;;Heindirk tom Dieck, et al., Synthesis of Chiral Diazadienes R* -N =CR'-CR'=N -R*, Chem. Ber., 117, 694-701, 1984.;;K. Zemke, et al., Conformational Exchange near the Glass Transition: Two Dimensional 13C NMR Study of Atactic Polypropylene, Macromolecules, 24, 6874-6876, 1991.;;J. C. Randall, et al. 13C NMR microstructure determinations of low-density polyethylene homopolymers and copolymers, Recl. Trav. Chim. Pays-Bas, 110, 543-552, 1991.;;Jan Tecl, Studium vetveni polyethylenu nuklearni magnetickou resonancni spektroskopii, Chemicky prumyal, roc., 37/62, 196-200, 1987.;;G. Natta, et al. Crystalline Alternating Ethylene-Cyclopentene Copolymers and Other Ethylene-Cycloolefin Copolymers, Makromol. Chem., 54, 95-101, 1962.;;J. Boor, et al., Polymerization of Cyclopentene, 3-Methylcyclopentene, and 3-Methylcyclohexene, Die Makromolekulare Chemie, 90, 26-37, 1966.;;B. C. Anderson, et al., Polymerization of Internal Olefins, Macromolecules, 2, No. 6, 686-687, 1969.;;Walter Kaminsky, et al., Copolymerization of cycloalkenes with ethylene in presence of chiral zirconocene catalysts, Makromol. Chem., 190, 515-526, 1989.;;W. Kaminsky, et al., in T. Keii, et al. Eds., Polymerization of Cyclic Olefins with Homogeneous Catalysts, Catalytic Olefin Polymerization, 929, 425-438, 1990.;;W. Mark Kelly, et al., Polymerization of Cyclopenetene Using Metallocene Catalysts: Polymer Tacticity and Properties, Macromolecule, 27, 4477-4485, 1994.;;Alexej Jerschow, et al., Nuclear Magnetic Resonance Evidence for a New Microstructure in Ethene-Cyclopentene Copolymers, Macromolecules, 28, 7095-7099, 1995.;;Heindirk tom Dieck, et al., Diazadiene complexes of Group 4 metals I. Synthesis of mono-, bis- and tris(diazadiene) titanium complexes and the structure of diazadienedichlorotitanium, Inorganica Chimica Acta., 177, 191-197, 1990.;;Heindirk tom Dieck, et al., Metallierung einer nichtaktivierten Alkyl-Gruppe im Nickelkomplex 1, Chem. Ber., 109, 1657-1664, 1976.;;Lynda K. Johnson, et al., New Pd(II)- and Ni(II)-Based Catalysts for Polymerization of Ethylene and alpha-Olefins, J. Am Chem. Soc., 117, 6414-6415, 1995.;;Lynda K. Johnson, et al., Copolymerization of Ethylene and Propylene with Functionalized Vinyl Monomers by Palladium(II) Catalysts, J. Am. Chem. Soc., 118, 267-268, 1996.;;Saito, et al., Diethyldipyridylnickel. Preparation, Characterization, and Reactions, J. Am. Chem. Soc., 88:22, 5198-5201, 1966.;;Bartolini, et al., Enantioselective isotactic alternating copolymerization of styrene and 4-methylstyrene with carbon monoxide catalyzed by a cationic bioxazoline Pd(II) complex,Macromol.Rapid Commun., 16, 9-14, 1995.;;Jiang, et al., Stereo- and Enantioselective Alternating Copolymerization of alpha-Olefins with Carbon Monoxide. Synthesis of Chiral Polymers, Macromolecules, 27,2694-2700, 1994.;;Brookhart, et al., Polymers with Main-Chain Chirality. Synthesis of Highly Isotactic, Optically Active Poly(4-tert-butylstyrene-alt-CO) Using Pd(II) Catalysts Based on C2-Symmetic Bisoxazoline Ligands, J. Am. Chem. Soc., 116, 3641-3642, 1994.;;Diercks, et al., Katalytische Cyclotetramerisierung von Propiolsäureestern, Chem. Ger., 118, 428-435, 1985.;;Dierck, et al., Diazadienes as Control Ligands in Catalysis Part 12.* The Nickel-Catalyzed Cyclotetramerization of Propargylic Alcohol to Substituted Cyclooctatetraenes and the Structure of 1,3,5,7-Tetrakis(Hydroxymethyl)Cyclooctatetraene, Journal of Molecular Catalysis, 35, 317-328, 1986.;;""Montecatini"" Societa Generale Per L'Industria Mineria E Chimica: ""Catalytic Manufacture of Olefin Copolymers with Three or More Monomer Components"", Chemical Abstracts, 77, No. 8, 1972, Abstract No. 49803t.;;Scott Collins & W. Mark Kelly, The Microstructure of Poly(cyclopentene) Produced by Polymerization of Cyclopenetene with Homogeneous Ziegler-Natta Catalysts, Macromolecules, 25, 233-237, 1992.;;Wissing, e et al., Influence of bulky substituents on the regioselective group-transfer reactions of diorganozinc compounds with N,N'-bis(2,6-di-isopropenyl)-1,4-diaza-1,3-butadiene, Chemical Abstracts, 121, No. 11, 1055, 1994, Abstract No. 134322g.;;Christina Munz, Constantin Stephan and Heindirk tom Dieck, Diazadiene-stabilized palladacyclopent-2-enes and the catalytic additon of various allylic systems to dimethyl acetylenedicarboxylate, Journal of Organometallic Chemistry, 407, 413-420, 1991.;;Werner Bonrath, Klaus R. Pörschke, Richard Mynott and Carl Krüger, Synthesis and Structure of Ni(92,6-iPr2C6H3N=CH-CH=NC6H3-2,6-iPr2)2, Zeitschrift Für Naturforschung, 456, 1647-1650, 1990.;;Emulsion Polymerization to Fibers, Manufacture, Encyclopedia of Polymer Science and Engineering, vol. 6, pp. 385-387, Copyright 1986.;;Editors: Barbara Elvers, Stephen Hawkins, Gail Schulz, Plastics, Properties and Testing to Polyvinyl Compounds, Ullmann's Encyclopedia of Industrial Chemistry, vol. A 21, pp. 488-493, 1992.;;Polymer Technology Dictionary, Tony Whelan MSc, Consultant, Chapman & Hall, 1994, pp1, 282, 312.",EXPIRED
455,US,B1,US 11133999 B1,014-802-608-116-275,2021-09-28,2021,US 202016874962 A,2020-05-15,US 202016874962 A;;US 201962910745 P,2019-10-04,Network sensor deployment for deep packet inspection,"Disclosed herein are methods, systems, and processes for centralized containerized deployment of network traffic sensors to network sensor hosts for deep packet inspection (DPI) that supports various other cybersecurity operations. A network sensor package containing a pre-configured network sensor container is received by a network sensor host from a network sensor deployment server. Installation of the network sensor package on the network sensor host causes execution of the network sensor container that further causes deployment of an on-premise network sensor along with a network sensor management system, a DPI system, and an intrusion detection/prevention (IDS/IPS) system. The configurable on-premise network sensor is deployed on multiple operating system distributions of the network sensor host and generates actionable network metadata using DPI techniques for optimized log search and management and improved intrusion detection and response (IDR) operations.",RAPID7 INC,BROSNAN JOHN;;MYERS JEFF;;LYUBKA ANDRIY;;DELANEY DARRAGH;;CAREY ERRAN;;HUTCHINGS MARTIN;;MCTEGGART RALPH;;WILLIAMS RYAN;;SKELTON DANIEL;;COUGHLIN LUKE;;TEDESCO GIANNI;;LOPES LUIS RAMOS DOS SANTOS;;SVENOY LARS-KRISTIAN;;MOINESCU DAN-ADRIAN;;COCHRANE NIALL;;DOYLE MORGAN;;ADDIS SARAH,RAPID7 INC (2020-06-11),https://lens.org/014-802-608-116-275,Granted Patent,yes,13,2,9,9,0,H04L67/02;;H04L69/22;;H04L69/325;;H04L69/326;;H04L63/14;;H04L63/0823;;H04L41/12;;H04L41/0843;;H04L41/046;;H04L43/0894;;H04L41/0806;;H04L61/5014;;H04L61/4511;;H04L41/40;;H04L41/0895;;H04L43/0894;;H04L63/14;;H04L41/046;;H04L41/0806;;G06F9/445;;G06F9/455;;H04L43/028;;H04L69/16,H04L47/36;;G06F9/445;;G06F9/455,,0,0,,,,ACTIVE
